

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 June 2001 (07.06.2001)

PCT

(10) International Publication Number  
**WO 01/40269 A2**

(51) International Patent Classification<sup>7</sup>: C07K 14/00

Jennifer, L. [US/US]; 16677 NE 88th Street, Redmond, WA 98052 (US). WANG, Aijun [CN/US]; 3106 213th Place SE, Issaquah, WA 98029 (US).

(21) International Application Number: PCT/US00/32520

(22) International Filing Date:  
29 November 2000 (29.11.2000)

(74) Agents: POTTER, Jane, E., R.; Seed Intellectual Property Law Group PLLC, Suite 6300, 701 Fifth Avenue, Seattle, WA 98104-7092 et al. (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/451,651 30 November 1999 (30.11.1999) US  
09/510,662 22 February 2000 (22.02.2000) US  
09/523,586 10 March 2000 (10.03.2000) US  
09/545,068 7 April 2000 (07.04.2000) US  
09/571,025 15 May 2000 (15.05.2000) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): CORIXA CORPORATION [US/US]; Suite 200, 1124 Columbia Street, Seattle, WA 98104 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): DILLON, Davin, C. [US/US]; 18112 NW Montreux Drive, Issaquah, WA 98027 (US). DAY, Craig, H. [US/US]; 11501 Stone Ave. N., C122, Seattle, WA 98133-8317 (US). JIANG, Yuqiu [CN/US]; 5001 South 232nd Street, Kent, WA 98032 (US). HOUGHTON, Raymond, L. [US/US]; 2636 - 242nd Place SE, Bothell, WA 98021 (US). MITCHAM,

Published:

— Without international search report and to be republished upon receipt of that report.

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: COMPOSITIONS AND METHODS FOR THERAPY AND DIAGNOSIS OF BREAST CANCER

(57) Abstract: Compositions and methods for the therapy and diagnosis of cancer, such as breast cancer, are disclosed. Compositions may comprise one or more breast tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a breast tumor protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of diseases such as breast cancer. Diagnostic methods based on detecting a breast tumor protein, or mRNA encoding such a protein, in a sample are also provided.

WO 01/40269 A2

## COMPOSITIONS AND METHODS FOR THERAPY AND DIAGNOSIS OF BREAST CANCER

### TECHNICAL FIELD

The present invention relates generally to therapy and diagnosis of cancer, such as breast cancer. The invention is more specifically related to polypeptides comprising at least a portion of a breast tumor protein, and to polynucleotides encoding such polypeptides. Such polypeptides and polynucleotides may be used in vaccines and pharmaceutical compositions for prevention and treatment of breast cancer, and for the diagnosis and monitoring of such cancers.

### 10 BACKGROUND OF THE INVENTION

Breast cancer is a significant health problem for women in the United States and throughout the world. Although advances have been made in detection and treatment of the disease, breast cancer remains the second leading cause of cancer-related deaths in women, affecting more than 180,000 women in the United States each year. For women in North America, the life-time odds of getting breast cancer are now one in eight.

No vaccine or other universally successful method for the prevention or treatment of breast cancer is currently available. Management of the disease currently relies on a combination of early diagnosis (through routine breast screening procedures) and aggressive treatment, which may include one or more of a variety of treatments such as surgery, radiotherapy, chemotherapy and hormone therapy. The course of treatment for a particular breast cancer is often selected based on a variety of prognostic parameters, including an analysis of specific tumor markers. See, e.g., Porter-Jordan and Lippman, *Breast Cancer* 8:73-100 (1994). However, the use of established markers often leads to a result that is difficult to interpret, and the high mortality observed in breast cancer patients indicates that improvements are needed in the treatment, diagnosis and prevention of the disease.

Accordingly, there is a need in the art for improved methods for therapy and diagnosis of breast cancer. The present invention fulfills these needs and further provides other related advantages.

#### SUMMARY OF THE INVENTION

5 Briefly stated, the present invention provides compositions and methods for the diagnosis and therapy of cancer, such as breast cancer. In one aspect, the present invention provides polypeptides comprising at least a portion of a breast tumor protein, or a variant thereof. Certain portions and other variants are immunogenic, such that the ability of the variant to react with antigen-specific antisera is not substantially  
10 diminished. Within certain embodiments, the polypeptide comprises a sequence that is encoded by a polynucleotide sequence selected from the group consisting of: (a) sequences recited in SEQ ID NO: 1-38, 42-204, 205, 207 and 210-290; (b) variants of a sequence recited in SEQ ID NO: 1-38, 42-204, 205, 207 and 210-290; and (c) complements of a sequence of (a) or (b).

15 The present invention further provides polynucleotides that encode a polypeptide as described above, or a portion thereof (such as a portion encoding at least 15 amino acid residues of a breast tumor protein), expression vectors comprising such polynucleotides and host cells transformed or transfected with such expression vectors.

Within other aspects, the present invention provides pharmaceutical  
20 compositions comprising a polypeptide or polynucleotide as described above and a physiologically acceptable carrier.

Within a related aspect of the present invention, vaccines for prophylactic or therapeutic use are provided. Such vaccines comprise a polypeptide or polynucleotide as described above and an immunostimulant.

25 The present invention further provides pharmaceutical compositions that comprise: (a) an antibody or antigen-binding fragment thereof that specifically binds to a breast tumor protein; and (b) a physiologically acceptable carrier.

Within further aspects, the present invention provides pharmaceutical compositions comprising: (a) an antigen presenting cell that expresses a polypeptide as  
30 described above and (b) a pharmaceutically acceptable carrier or excipient. Antigen

presenting cells include dendritic cells, macrophages, monocytes, fibroblasts and B cells.

Within related aspects, vaccines are provided that comprise: (a) an antigen presenting cell that expresses a polypeptide as described above and (b) an immunostimulant.

The present invention further provides, in other aspects, fusion proteins that comprise at least one polypeptide as described above, as well as polynucleotides encoding such fusion proteins.

Within related aspects, pharmaceutical compositions comprising a fusion protein, or a polynucleotide encoding a fusion protein, in combination with a physiologically acceptable carrier are provided.

Vaccines are further provided, within other aspects, that comprise a fusion protein, or a polynucleotide encoding a fusion protein, in combination with an immunostimulant.

Within further aspects, the present invention provides methods for inhibiting the development of a cancer in a patient, comprising administering to a patient a pharmaceutical composition or vaccine as recited above.

The present invention further provides, within other aspects, methods for removing tumor cells from a biological sample, comprising contacting a biological sample with T cells that specifically react with a breast tumor protein, wherein the step of contacting is performed under conditions and for a time sufficient to permit the removal of cells expressing the protein from the sample.

Within related aspects, methods are provided for inhibiting the development of a cancer in a patient, comprising administering to a patient a biological sample treated as described above.

Methods are further provided, within other aspects, for stimulating and/or expanding T cells specific for a breast tumor protein, comprising contacting T cells with one or more of: (i) a polypeptide as described above; (ii) a polynucleotide encoding such a polypeptide; and/or (iii) an antigen presenting cell that expresses such a polypeptide; under conditions and for a time sufficient to permit the stimulation and/or



expansion of T cells. Isolated T cell populations comprising T cells prepared as described above are also provided.

Within further aspects, the present invention provides methods for inhibiting the development of a cancer in a patient, comprising administering to a patient an effective amount of a T cell population as described above.

The present invention further provides methods for inhibiting the development of a cancer in a patient, comprising the steps of: (a) incubating CD4<sup>+</sup> and/or CD8<sup>+</sup> T cells isolated from a patient with one or more of: (i) a polypeptide comprising at least an immunogenic portion of a breast tumor protein; (ii) a polynucleotide encoding such a polypeptide; and (iii) an antigen-presenting cell that expresses such a polypeptide; and (b) administering to the patient an effective amount of the proliferated T cells, and thereby inhibiting the development of a cancer in the patient. Proliferated cells may, but need not, be cloned prior to administration to the patient.

Within further aspects, the present invention provides methods for determining the presence or absence of a cancer in a patient, comprising: (a) contacting a biological sample obtained from a patient with a binding agent that binds to a polypeptide as recited above; (b) detecting in the sample an amount of polypeptide that binds to the binding agent; and (c) comparing the amount of polypeptide with a predetermined cut-off value, and therefrom determining the presence or absence of a cancer in the patient. Within preferred embodiments, the binding agent is an antibody, more preferably a monoclonal antibody. The cancer may be breast cancer.

The present invention also provides, within other aspects, methods for monitoring the progression of a cancer in a patient. Such methods comprise the steps of: (a) contacting a biological sample obtained from a patient at a first point in time with a binding agent that binds to a polypeptide as recited above; (b) detecting in the sample an amount of polypeptide that binds to the binding agent; (c) repeating steps (a) and (b) using a biological sample obtained from the patient at a subsequent point in time; and (d) comparing the amount of polypeptide detected in step (c) with the amount detected in step (b) and therefrom monitoring the progression of the cancer in the patient.

The present invention further provides, within other aspects, methods for determining the presence or absence of a cancer in a patient, comprising the steps of: (a) contacting a biological sample obtained from a patient with an oligonucleotide that hybridizes to a polynucleotide that encodes a breast tumor protein; (b) detecting in the sample a level of a polynucleotide, preferably mRNA, that hybridizes to the oligonucleotide; and (c) comparing the level of polynucleotide that hybridizes to the oligonucleotide with a predetermined cut-off value, and therefrom determining the presence or absence of a cancer in the patient. Within certain embodiments, the amount of mRNA is detected via polymerase chain reaction using, for example, at least one oligonucleotide primer that hybridizes to a polynucleotide encoding a polypeptide as recited above, or a complement of such a polynucleotide. Within other embodiments, the amount of mRNA is detected using a hybridization technique, employing an oligonucleotide probe that hybridizes to a polynucleotide that encodes a polypeptide as recited above, or a complement of such a polynucleotide.

In related aspects, methods are provided for monitoring the progression of a cancer in a patient, comprising the steps of: (a) contacting a biological sample obtained from a patient with an oligonucleotide that hybridizes to a polynucleotide that encodes a breast tumor protein; (b) detecting in the sample an amount of a polynucleotide that hybridizes to the oligonucleotide; (c) repeating steps (a) and (b) using a biological sample obtained from the patient at a subsequent point in time; and (d) comparing the amount of polynucleotide detected in step (c) with the amount detected in step (b) and therefrom monitoring the progression of the cancer in the patient.

Within further aspects, the present invention provides antibodies, such as monoclonal antibodies, that bind to a polypeptide as described above, as well as diagnostic kits comprising such antibodies. Diagnostic kits comprising one or more oligonucleotide probes or primers as described above are also provided.

These and other aspects of the present invention will become apparent upon reference to the following detailed description. All references disclosed herein are hereby incorporated by reference in their entirety as if each was incorporated individually.

**SEQUENCE IDENTIFIERS**

- SEQ ID NO: 1 is the determined cDNA sequence for clone 26915.
- SEQ ID NO: 2 is the determined cDNA sequence for clone 26914.
- SEQ ID NO: 3 is the determined cDNA sequence for clone 26673.
- 5 SEQ ID NO: 4 is the determined cDNA sequence for clone 26672.
- SEQ ID NO: 5 is the determined cDNA sequence for clone 26671.
- SEQ ID NO: 6 is the determined cDNA sequence for clone 26670.
- SEQ ID NO: 7 is the determined cDNA sequence for clone 26669.
- SEQ ID NO: 8 is a first determined cDNA sequence for clone 26668.
- 10 SEQ ID NO: 9 is a second determined cDNA sequence for clone 26668.
- SEQ ID NO: 10 is the determined cDNA sequence for clone 26667.
- SEQ ID NO: 11 is the determined cDNA sequence for clone 26666.
- SEQ ID NO: 12 is the determined cDNA sequence for clone 26665.
- SEQ ID NO: 13 is the determined cDNA sequence for clone 26664.
- 15 SEQ ID NO: 14 is the determined cDNA sequence for clone 26662.
- SEQ ID NO: 15 is the determined cDNA sequence for clone 26661.
- SEQ ID NO: 16 is the determined cDNA sequence for clone 26660.
- SEQ ID NO: 17 is the determined cDNA sequence for clone 26603.
- SEQ ID NO: 18 is the determined cDNA sequence for clone 26601.
- 20 SEQ ID NO: 19 is the determined cDNA sequence for clone 26600.
- SEQ ID NO: 20 is the determined cDNA sequence for clone 26587.
- SEQ ID NO: 21 is the determined cDNA sequence for clone 26586.
- SEQ ID NO: 22 is the determined cDNA sequence for clone 26584.
- SEQ ID NO: 23 is the determined cDNA sequence for clone 26583.
- 25 SEQ ID NO: 24 is the determined cDNA sequence for clone 26580.
- SEQ ID NO: 25 is the determined cDNA sequence for clone 26579.
- SEQ ID NO: 26 is the determined cDNA sequence for clone 26577.
- SEQ ID NO: 27 is the determined cDNA sequence for clone 26575.
- SEQ ID NO: 28 is the determined cDNA sequence for clone 26574.
- 30 SEQ ID NO: 29 is the determined cDNA sequence for clone 26573.
- SEQ ID NO: 30 is the determined cDNA sequence for clone 25612.

- SEQ ID NO: 31 is the determined cDNA sequence for clone 22295.  
SEQ ID NO: 32 is the determined cDNA sequence for clone 22301.  
SEQ ID NO: 33 is the determined cDNA sequence for clone 22298.  
SEQ ID NO: 34 is the determined cDNA sequence for clone 22297.  
5 SEQ ID NO: 35 is the determined cDNA sequence for clone 22303.  
SEQ ID NO: 36 is the determined cDNA sequence for a first GABA<sub>A</sub> receptor clone.  
SEQ ID NO: 37 is the determined cDNA sequence for a second GABA<sub>A</sub> receptor clone.  
10 SEQ ID NO: 38 is the determined cDNA sequence for a third GABA<sub>A</sub> receptor clone.  
SEQ ID NO: 39 is the amino acid sequence encoded by SEQ ID NO: 36.  
SEQ ID NO: 40 is the amino acid sequence encoded by SEQ ID NO: 37.  
SEQ ID NO: 41 is the amino acid sequence encoded by SEQ ID NO: 38.  
15 SEQ ID NO: 42 is the determined cDNA sequence for contig 1.  
SEQ ID NO: 43 is the determined cDNA sequence for contig 2.  
SEQ ID NO: 44 is the determined cDNA sequence for contig 3.  
SEQ ID NO: 45 is the determined cDNA sequence for contig 4.  
SEQ ID NO: 46 is the determined cDNA sequence for contig 5.  
20 SEQ ID NO: 47 is the determined cDNA sequence for contig 6.  
SEQ ID NO: 48 is the determined cDNA sequence for contig 7.  
SEQ ID NO: 49 is the determined cDNA sequence for contig 8.  
SEQ ID NO: 50 is the determined cDNA sequence for contig 9.  
SEQ ID NO: 51 is the determined cDNA sequence for contig 10.  
25 SEQ ID NO: 52 is the determined cDNA sequence for contig 11.  
SEQ ID NO: 53 is the determined cDNA sequence for contig 12.  
SEQ ID NO: 54 is the determined cDNA sequence for contig 13.  
SEQ ID NO: 55 is the determined cDNA sequence for contig 14.  
SEQ ID NO: 56 is the determined cDNA sequence for contig 15.  
30 SEQ ID NO: 57 is the determined cDNA sequence for contig 16.  
SEQ ID NO: 58 is the determined cDNA sequence for contig 17.

SEQ ID NO: 59 is the determined cDNA sequence for contig 18.  
SEQ ID NO: 60 is the determined cDNA sequence for contig 19.  
SEQ ID NO: 61 is the determined cDNA sequence for contig 20.  
SEQ ID NO: 62 is the determined cDNA sequence for contig 21.  
5 SEQ ID NO: 63 is the determined cDNA sequence for contig 22.  
SEQ ID NO: 64 is the determined cDNA sequence for contig 23.  
SEQ ID NO: 65 is the determined cDNA sequence for contig 24.  
SEQ ID NO: 66 is the determined cDNA sequence for contig 25.  
SEQ ID NO: 67 is the determined cDNA sequence for contig 26.  
10 SEQ ID NO: 68 is the determined cDNA sequence for contig 27.  
SEQ ID NO: 69 is the determined cDNA sequence for contig 28.  
SEQ ID NO: 70 is the determined cDNA sequence for contig 29.  
SEQ ID NO: 71 is the determined cDNA sequence for contig 30.  
SEQ ID NO: 72 is the determined cDNA sequence for contig 31.  
15 SEQ ID NO: 73 is the determined cDNA sequence for contig 32.  
SEQ ID NO: 74 is the determined cDNA sequence for contig 33.  
SEQ ID NO: 75 is the determined cDNA sequence for contig 34.  
SEQ ID NO: 76 is the determined cDNA sequence for contig 35.  
SEQ ID NO: 77 is the determined cDNA sequence for contig 36.  
20 SEQ ID NO: 78 is the determined cDNA sequence for contig 37.  
SEQ ID NO: 79 is the determined cDNA sequence for contig 38.  
SEQ ID NO: 80 is the determined cDNA sequence for contig 39.  
SEQ ID NO: 81 is the determined cDNA sequence for contig 40.  
SEQ ID NO: 82 is the determined cDNA sequence for contig 41.  
25 SEQ ID NO: 83 is the determined cDNA sequence for contig 42.  
SEQ ID NO: 84 is the determined cDNA sequence for contig 43.  
SEQ ID NO: 85 is the determined cDNA sequence for contig 44.  
SEQ ID NO: 85 is the determined cDNA sequence for contig 45.  
SEQ ID NO: 85 is the determined cDNA sequence for contig 46.  
30 SEQ ID NO: 88 is the determined cDNA sequence for contig 47.  
SEQ ID NO: 89 is the determined cDNA sequence for contig 48.

SEQ ID NO: 90 is the determined cDNA sequence for contig 49.  
SEQ ID NO: 91 is the determined cDNA sequence for contig 50.  
SEQ ID NO: 92 is the determined cDNA sequence for contig 51.  
SEQ ID NO: 93 is the determined cDNA sequence for contig 52.  
5 SEQ ID NO: 94 is the determined cDNA sequence for contig 53.  
SEQ ID NO: 95 is the determined cDNA sequence for contig 54.  
SEQ ID NO: 96 is the determined cDNA sequence for contig 55.  
SEQ ID NO: 97 is the determined cDNA sequence for contig 56.  
SEQ ID NO: 98 is the determined cDNA sequence for contig 57.  
10 SEQ ID NO: 99 is the determined cDNA sequence for contig 58.  
SEQ ID NO: 100 is the determined cDNA sequence for contig 59.  
SEQ ID NO: 101 is the determined cDNA sequence for contig 60.  
SEQ ID NO: 102 is the determined cDNA sequence for contig 61.  
SEQ ID NO: 103 is the determined cDNA sequence for contig 62.  
15 SEQ ID NO: 104 is the determined cDNA sequence for contig 63.  
SEQ ID NO: 105 is the determined cDNA sequence for contig 64.  
SEQ ID NO: 106 is the determined cDNA sequence for contig 65.  
SEQ ID NO: 107 is the determined cDNA sequence for contig 66.  
SEQ ID NO: 108 is the determined cDNA sequence for contig 67.  
20 SEQ ID NO: 109 is the determined cDNA sequence for contig 68.  
SEQ ID NO: 110 is the determined cDNA sequence for contig 69.  
SEQ ID NO: 111 is the determined cDNA sequence for contig 70.  
SEQ ID NO: 112 is the determined cDNA sequence for contig 71.  
SEQ ID NO: 113 is the determined cDNA sequence for contig 72.  
25 SEQ ID NO: 114 is the determined cDNA sequence for contig 73.  
SEQ ID NO: 115 is the determined cDNA sequence for contig 74.  
SEQ ID NO: 116 is the determined cDNA sequence for contig 75.  
SEQ ID NO: 117 is the determined cDNA sequence for contig 76.  
SEQ ID NO: 118 is the determined cDNA sequence for contig 77.  
30 SEQ ID NO: 119 is the determined cDNA sequence for contig 78.  
SEQ ID NO: 120 is the determined cDNA sequence for contig 79.

SEQ ID NO: 121 is the determined cDNA sequence for contig 80.  
SEQ ID NO: 122 is the determined cDNA sequence for contig 81.  
SEQ ID NO: 123 is the determined cDNA sequence for contig 82.  
SEQ ID NO: 124 is the determined cDNA sequence for contig 83.  
5 SEQ ID NO: 125 is the determined cDNA sequence for contig 84.  
SEQ ID NO: 126 is the determined cDNA sequence for contig 85.  
SEQ ID NO: 127 is the determined cDNA sequence for contig 86.  
SEQ ID NO: 128 is the determined cDNA sequence for contig 87.  
SEQ ID NO: 129 is the determined cDNA sequence for contig 88.  
10 SEQ ID NO: 130 is the determined cDNA sequence for contig 89.  
SEQ ID NO: 131 is the determined cDNA sequence for contig 90.  
SEQ ID NO: 132 is the determined cDNA sequence for contig 91.  
SEQ ID NO: 133 is the determined cDNA sequence for contig 92.  
SEQ ID NO: 134 is the determined cDNA sequence for contig 93.  
15 SEQ ID NO: 135 is the determined cDNA sequence for contig 94.  
SEQ ID NO: 136 is the determined cDNA sequence for contig 95.  
SEQ ID NO: 137 is the determined cDNA sequence for contig 96.  
SEQ ID NO: 138 is the determined cDNA sequence for clone 47589.  
SEQ ID NO: 139 is the determined cDNA sequence for clone 47578.  
20 SEQ ID NO: 140 is the determined cDNA sequence for clone 47602.  
SEQ ID NO: 141 is the determined cDNA sequence for clone 47593.  
SEQ ID NO: 142 is the determined cDNA sequence for clone 47583.  
SEQ ID NO: 143 is the determined cDNA sequence for clone 47624.  
SEQ ID NO: 144 is the determined cDNA sequence for clone 47622.  
25 SEQ ID NO: 145 is the determined cDNA sequence for clone 47649.  
SEQ ID NO: 146 is the determined cDNA sequence for clone 48955.  
SEQ ID NO: 147 is the determined cDNA sequence for clone 48962.  
SEQ ID NO: 148 is the determined cDNA sequence for clone 48964.  
SEQ ID NO: 149 is the determined cDNA sequence for clone 48987.  
30 SEQ ID NO: 150 is the determined cDNA sequence for clone 49002.  
SEQ ID NO: 151 is the determined cDNA sequence for clone 48950.

SEQ ID NO: 152 is the determined cDNA sequence for clone 48934.  
SEQ ID NO: 153 is the determined cDNA sequence for clone 48960.  
SEQ ID NO: 154 is the determined cDNA sequence for clone 48931.  
SEQ ID NO: 155 is the determined cDNA sequence for clone 48935.  
5 SEQ ID NO: 156 is the determined cDNA sequence for clone 48940.  
SEQ ID NO: 157 is the determined cDNA sequence for clone 48936.  
SEQ ID NO: 158 is the determined cDNA sequence for clone 48930.  
SEQ ID NO: 159 is the determined cDNA sequence for clone 48956.  
SEQ ID NO: 160 is the determined cDNA sequence for clone 48959.  
10 SEQ ID NO: 161 is the determined cDNA sequence for clone 48949.  
SEQ ID NO: 162 is the determined cDNA sequence for clone 48965.  
SEQ ID NO: 163 is the determined cDNA sequence for clone 48970.  
SEQ ID NO: 164 is the determined cDNA sequence for clone 48984.  
SEQ ID NO: 165 is the determined cDNA sequence for clone 48969.  
15 SEQ ID NO: 166 is the determined cDNA sequence for clone 48978.  
SEQ ID NO: 167 is the determined cDNA sequence for clone 48968.  
SEQ ID NO: 168 is the determined cDNA sequence for clone 48929.  
SEQ ID NO: 169 is the determined cDNA sequence for clone 48937.  
SEQ ID NO: 170 is the determined cDNA sequence for clone 48982.  
20 SEQ ID NO: 171 is the determined cDNA sequence for clone 48983.  
SEQ ID NO: 172 is the determined cDNA sequence for clone 48997.  
SEQ ID NO: 173 is the determined cDNA sequence for clone 48992.  
SEQ ID NO: 174 is the determined cDNA sequence for clone 49006.  
SEQ ID NO: 175 is the determined cDNA sequence for clone 48994.  
25 SEQ ID NO: 176 is the determined cDNA sequence for clone 49013.  
SEQ ID NO: 177 is the determined cDNA sequence for clone 49008.  
SEQ ID NO: 178 is the determined cDNA sequence for clone 48990.  
SEQ ID NO: 179 is the determined cDNA sequence for clone 48989.  
SEQ ID NO: 180 is the determined cDNA sequence for clone 49014.  
30 SEQ ID NO: 181 is the determined cDNA sequence for clone 48988.  
SEQ ID NO: 182 is the determined cDNA sequence for clone 49018.



SEQ ID NO: 183 is the determined cDNA sequence for clone 6921.  
SEQ ID NO: 184 is the determined cDNA sequence for clone 6837.  
SEQ ID NO: 185 is the determined cDNA sequence for clone 6840.  
SEQ ID NO: 186 is the determined cDNA sequence for clone 6844.  
5 SEQ ID NO: 187 is the determined cDNA sequence for clone 6854.  
SEQ ID NO: 188 is the determined cDNA sequence for clone 6872.  
SEQ ID NO: 189 is the determined cDNA sequence for clone 6906.  
SEQ ID NO: 190 is the determined cDNA sequence for clone 6908.  
SEQ ID NO: 191 is the determined cDNA sequence for clone 6910.  
10 SEQ ID NO: 192 is the determined cDNA sequence for clone 6912.  
SEQ ID NO: 193 is the determined cDNA sequence for clone 6913.  
SEQ ID NO: 194 is the determined cDNA sequence for clone 6914.  
SEQ ID NO: 195 is the determined cDNA sequence for clone 6916.  
SEQ ID NO: 196 is the determined cDNA sequence for clone 6918.  
15 SEQ ID NO: 197 is the determined cDNA sequence for clone 6924.  
SEQ ID NO: 198 is the determined cDNA sequence for clone 6928.  
SEQ ID NO: 199 is the determined cDNA sequence for clone 6978A.  
SEQ ID NO: 200 is the determined cDNA sequence for clone 6978B.  
SEQ ID NO: 201 is the determined cDNA sequence for clone 6982A.  
20 SEQ ID NO: 202 is the determined cDNA sequence for clone 6982B.  
SEQ ID NO: 203 is the determined cDNA sequence for clone 6850.  
SEQ ID NO: 204 is the determined cDNA sequence for clone 6860.  
SEQ ID NO: 205 is the determined cDNA sequence for O772P.  
SEQ ID NO: 206 is the amino acid sequence encoded by SEQ ID NO:  
25 205.  
  
SEQ ID NO: 207 is the full-length cDNA sequence for O8E.  
SEQ ID NO: 208 is a first amino acid sequence encoded by SEQ ID NO:  
207.  
  
SEQ ID NO: 209 is a second amino acid sequence encoded by SEQ ID  
30 NO: 209.

SEQ ID NO: 210-290 are determined cDNA sequence of breast-tumor specific clones.

#### DETAILED DESCRIPTION OF THE INVENTION

As noted above, the present invention is generally directed to compositions and methods for using the compositions, for example in the therapy and diagnosis of cancer, such as breast cancer. Certain illustrative compositions described herein include breast tumor polypeptides, polynucleotides encoding such polypeptides, binding agents such as antibodies, antigen presenting cells (APCs) and/or immune system cells (*e.g.*, T cells). A "breast tumor protein," as the term is used herein, refers generally to a protein that is expressed in breast tumor cells at a level that is at least two fold, and preferably at least five fold, greater than the level of expression in other normal tissues, as determined using a representative assay provided herein. Certain breast tumor proteins are tumor proteins that react detectably (within an immunoassay, such as an ELISA or Western blot) with antisera of a patient afflicted with breast cancer.

Therefore, in accordance with the above, and as described further below, the present invention provides illustrative polynucleotide compositions having sequences set forth in SEQ ID NO:1-38, 42-204, 205, 207 and 210-290, polypeptides encoded by such polynucleotides, antibody compositions capable of binding such polypeptides, and numerous additional embodiments employing such compositions, for example in the detection, diagnosis and/or therapy of human breast cancer.

#### POLYNUCLEOTIDE COMPOSITIONS

As used herein, the terms "DNA segment" and "polynucleotide" refer to a DNA molecule that has been isolated free of total genomic DNA of a particular species. Therefore, a DNA segment encoding a polypeptide refers to a DNA segment that contains one or more coding sequences yet is substantially isolated away from, or purified free from, total genomic DNA of the species from which the DNA segment is obtained. Included within the terms "DNA segment" and "polynucleotide" are DNA

segments and smaller fragments of such segments, and also recombinant vectors, including, for example, plasmids, cosmids, phagemids, phage, viruses, and the like.

As will be understood by those skilled in the art, the DNA segments of this invention can include genomic sequences, extra-genomic and plasmid-encoded  
5 sequences and smaller engineered gene segments that express, or may be adapted to express, proteins, polypeptides, peptides and the like. Such segments may be naturally isolated, or modified synthetically by the hand of man.

"Isolated," as used herein, means that a polynucleotide is substantially away from other coding sequences, and that the DNA segment does not contain large  
10 portions of unrelated coding DNA, such as large chromosomal fragments or other functional genes or polypeptide coding regions. Of course, this refers to the DNA segment as originally isolated, and does not exclude genes or coding regions later added to the segment by the hand of man.

As will be recognized by the skilled artisan, polynucleotides may be  
15 single-stranded (coding or antisense) or double-stranded, and may be DNA (genomic, cDNA or synthetic) or RNA molecules. RNA molecules include HnRNA molecules, which contain introns and correspond to a DNA molecule in a one-to-one manner, and mRNA molecules, which do not contain introns. Additional coding or non-coding sequences may, but need not, be present within a polynucleotide of the present  
20 invention, and a polynucleotide may, but need not, be linked to other molecules and/or support materials.

Polynucleotides may comprise a native sequence (*i.e.*, an endogenous sequence that encodes a breast tumor protein or a portion thereof) or may comprise a variant, or a biological or antigenic functional equivalent of such a sequence.  
25 Polynucleotide variants may contain one or more substitutions, additions, deletions and/or insertions, as further described below, preferably such that the immunogenicity of the encoded polypeptide is not diminished, relative to a native tumor protein. The effect on the immunogenicity of the encoded polypeptide may generally be assessed as described herein. The term "variants" also encompasses homologous genes of  
30 xenogenic origin.

When comparing polynucleotide or polypeptide sequences, two sequences are said to be "identical" if the sequence of nucleotides or amino acids in the two sequences is the same when aligned for maximum correspondence, as described below. Comparisons between two sequences are typically performed by comparing the sequences over a comparison window to identify and compare local regions of sequence similarity. A "comparison window" as used herein, refers to a segment of at least about 20 contiguous positions, usually 30 to about 75, 40 to about 50, in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.

Optimal alignment of sequences for comparison may be conducted using the Megalign program in the Lasergene suite of bioinformatics software (DNASTAR, Inc., Madison, WI), using default parameters. This program embodies several alignment schemes described in the following references: Dayhoff, M.O. (1978) A model of evolutionary change in proteins – Matrices for detecting distant relationships. In Dayhoff, M.O. (ed.) Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, Washington DC Vol. 5, Suppl. 3, pp. 345-358; Hein J. (1990) Unified Approach to Alignment and Phylogenies pp. 626-645 *Methods in Enzymology* vol. 183, Academic Press, Inc., San Diego, CA; Higgins, D.G. and Sharp, P.M. (1989) *CABIOS* 5:151-153; Myers, E.W. and Muller W. (1988) *CABIOS* 4:11-17; Robinson, E.D. (1971) *Comb. Theor* 11:105; Santou, N. Nes, M. (1987) *Mol. Biol. Evol.* 4:406-425; Sneath, P.H.A. and Sokal, R.R. (1973) *Numerical Taxonomy – the Principles and Practice of Numerical Taxonomy*, Freeman Press, San Francisco, CA; Wilbur, W.J. and Lipman, D.J. (1983) *Proc. Natl. Acad. Sci. USA* 80:726-730.

Alternatively, optimal alignment of sequences for comparison may be conducted by the local identity algorithm of Smith and Waterman (1981) *Add. APL. Math* 2:482, by the identity alignment algorithm of Needleman and Wunsch (1970) *J. Mol. Biol.* 48:443, by the search for similarity methods of Pearson and Lipman (1988) *Proc. Natl. Acad. Sci. USA* 85: 2444, by computerized implementations of these algorithms (GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, WI), or by inspection.

One preferred example of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1977) *Nucl. Acids Res.* 25:3389-3402 and Altschul et al. (1990) *J. Mol. Biol.* 215:403-410, respectively. BLAST and BLAST 2.0 can be used, for example with the parameters described herein, to determine percent sequence identity for the polynucleotides and polypeptides of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. In one illustrative example, cumulative scores can be calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatching residues; always <0). For amino acid sequences, a scoring matrix can be used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1989) *Proc. Natl. Acad. Sci. USA* 89:10915) alignments, (B) of 50, expectation (E) of 10, M=5, N=-4 and a comparison of both strands.

Preferably, the "percentage of sequence identity" is determined by comparing two optimally aligned sequences over a window of comparison of at least 20 positions, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions (*i.e.*, gaps) of 20 percent or less, usually 5 to 15 percent, or 10 to 12 percent, as compared to the reference sequences (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid bases or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the reference sequence (*i.e.*, the window size) and multiplying the results by 100 to yield the percentage of sequence identity.

Therefore, the present invention encompasses polynucleotide and polypeptide sequences having substantial identity to the sequences disclosed herein, for example those comprising at least 50% sequence identity, preferably at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or higher, sequence  
5 identity compared to a polynucleotide or polypeptide sequence of this invention using the methods described herein, (e.g., BLAST analysis using standard parameters, as described below). One skilled in this art will recognize that these values can be appropriately adjusted to determine corresponding identity of proteins encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid similarity,  
10 reading frame positioning and the like.

In additional embodiments, the present invention provides isolated polynucleotides and polypeptides comprising various lengths of contiguous stretches of sequence identical to or complementary to one or more of the sequences disclosed herein. For example, polynucleotides are provided by this invention that comprise at  
15 least about 15, 20, 30, 40, 50, 75, 100, 150, 200, 300, 400, 500 or 1000 or more contiguous nucleotides of one or more of the sequences disclosed herein as well as all intermediate lengths there between. It will be readily understood that "intermediate lengths", in this context, means any length between the quoted values, such as 16, 17, 18, 19, *etc.*; 21, 22, 23, *etc.*; 30, 31, 32, *etc.*; 50, 51, 52, 53, *etc.*; 100, 101, 102, 103,  
20 *etc.*; 150, 151, 152, 153, *etc.*; including all integers through 200-500; 500-1,000, and the like.

The polynucleotides of the present invention, or fragments thereof, regardless of the length of the coding sequence itself, may be combined with other DNA sequences, such as promoters, polyadenylation signals, additional restriction  
25 enzyme sites, multiple cloning sites, other coding segments, and the like, such that their overall length may vary considerably. It is therefore contemplated that a nucleic acid fragment of almost any length may be employed, with the total length preferably being limited by the ease of preparation and use in the intended recombinant DNA protocol. For example, illustrative DNA segments with total lengths of about 10,000, about 5000,  
30 about 3000, about 2,000, about 1,000, about 500, about 200, about 100, about 50 base

pairs in length, and the like, (including all intermediate lengths) are contemplated to be useful in many implementations of this invention.

In other embodiments, the present invention is directed to polynucleotides that are capable of hybridizing under moderately stringent conditions to a polynucleotide sequence provided herein, or a fragment thereof, or a complementary sequence thereof. Hybridization techniques are well known in the art of molecular biology. For purposes of illustration, suitable moderately stringent conditions for testing the hybridization of a polynucleotide of this invention with other polynucleotides include prewashing in a solution of 5' X SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0); hybridizing at 50°C-65°C, 5' X SSC, overnight; followed by washing twice at 65°C for 20 minutes with each of 2X, 0.5X and 0.2X SSC containing 0.1% SDS.

Moreover, it will be appreciated by those of ordinary skill in the art that, as a result of the degeneracy of the genetic code, there are many nucleotide sequences that encode a polypeptide as described herein. Some of these polynucleotides bear minimal homology to the nucleotide sequence of any native gene. Nonetheless, polynucleotides that vary due to differences in codon usage are specifically contemplated by the present invention. Further, alleles of the genes comprising the polynucleotide sequences provided herein are within the scope of the present invention. Alleles are endogenous genes that are altered as a result of one or more mutations, such as deletions, additions and/or substitutions of nucleotides. The resulting mRNA and protein may, but need not, have an altered structure or function. Alleles may be identified using standard techniques (such as hybridization, amplification and/or database sequence comparison).

## 25 PROBES AND PRIMERS

In other embodiments of the present invention, the polynucleotide sequences provided herein can be advantageously used as probes or primers for nucleic acid hybridization. As such, it is contemplated that nucleic acid segments that comprise a sequence region of at least about 15 nucleotide long contiguous sequence that has the same sequence as, or is complementary to, a 15 nucleotide long contiguous sequence

disclosed herein will find particular utility. Longer contiguous identical or complementary sequences, *e.g.*, those of about 20, 30, 40, 50, 100, 200, 500, 1000 (including all intermediate lengths) and even up to full length sequences will also be of use in certain embodiments.

5           The ability of such nucleic acid probes to specifically hybridize to a sequence of interest will enable them to be of use in detecting the presence of complementary sequences in a given sample. However, other uses are also envisioned, such as the use of the sequence information for the preparation of mutant species primers, or primers for use in preparing other genetic constructions.

10           Polynucleotide molecules having sequence regions consisting of contiguous nucleotide stretches of 10-14, 15-20, 30, 50, or even of 100-200 nucleotides or so (including intermediate lengths as well), identical or complementary to a polynucleotide sequence disclosed herein, are particularly contemplated as hybridization probes for use in, *e.g.*, Southern and Northern blotting. This would allow  
15 a gene product, or fragment thereof, to be analyzed, both in diverse cell types and also in various bacterial cells. The total size of fragment, as well as the size of the complementary stretch(es), will ultimately depend on the intended use or application of the particular nucleic acid segment. Smaller fragments will generally find use in hybridization embodiments, wherein the length of the contiguous complementary  
20 region may be varied, such as between about 15 and about 100 nucleotides, but larger contiguous complementarity stretches may be used, according to the length complementary sequences one wishes to detect.

          The use of a hybridization probe of about 15-25 nucleotides in length allows the formation of a duplex molecule that is both stable and selective. Molecules  
25 having contiguous complementary sequences over stretches greater than 15 bases in length are generally preferred, though, in order to increase stability and selectivity of the hybrid, and thereby improve the quality and degree of specific hybrid molecules obtained. One will generally prefer to design nucleic acid molecules having gene-complementary stretches of 15 to 25 contiguous nucleotides, or even longer where  
30 desired.



Hybridization probes may be selected from any portion of any of the sequences disclosed herein. All that is required is to review the sequence set forth in SEQ ID NO: 1-38, 42-204, 205, 207 and 210-290, or to any continuous portion of the sequence, from about 15-25 nucleotides in length up to and including the full length  
5 sequence, that one wishes to utilize as a probe or primer. The choice of probe and primer sequences may be governed by various factors. For example, one may wish to employ primers from towards the termini of the total sequence.

Small polynucleotide segments or fragments may be readily prepared by, for example, directly synthesizing the fragment by chemical means, as is commonly  
10 practiced using an automated oligonucleotide synthesizer. Also, fragments may be obtained by application of nucleic acid reproduction technology, such as the PCR<sup>TM</sup> technology of U. S. Patent 4,683,202 (incorporated herein by reference), by introducing selected sequences into recombinant vectors for recombinant production, and by other recombinant DNA techniques generally known to those of skill in the art of molecular  
15 biology.

The nucleotide sequences of the invention may be used for their ability to selectively form duplex molecules with complementary stretches of the entire gene or gene fragments of interest. Depending on the application envisioned, one will typically desire to employ varying conditions of hybridization to achieve varying degrees of  
20 selectivity of probe towards target sequence. For applications requiring high selectivity, one will typically desire to employ relatively stringent conditions to form the hybrids, e.g., one will select relatively low salt and/or high temperature conditions, such as provided by a salt concentration of from about 0.02 M to about 0.15 M salt at temperatures of from about 50°C to about 70°C. Such selective conditions tolerate  
25 little, if any, mismatch between the probe and the template or target strand, and would be particularly suitable for isolating related sequences.

Of course, for some applications, for example, where one desires to prepare mutants employing a mutant primer strand hybridized to an underlying template, less stringent (reduced stringency) hybridization conditions will typically be  
30 needed in order to allow formation of the heteroduplex. In these circumstances, one may desire to employ salt conditions such as those of from about 0.15 M to about 0.9 M

salt, at temperatures ranging from about 20°C to about 55°C. Cross-hybridizing species can thereby be readily identified as positively hybridizing signals with respect to control hybridizations. In any case, it is generally appreciated that conditions can be rendered more stringent by the addition of increasing amounts of formamide, which serves to  
5 destabilize the hybrid duplex in the same manner as increased temperature. Thus, hybridization conditions can be readily manipulated, and thus will generally be a method of choice depending on the desired results.

#### POLYNUCLEOTIDE IDENTIFICATION AND CHARACTERIZATION

Polynucleotides may be identified, prepared and/or manipulated using  
10 any of a variety of well established techniques. For example, a polynucleotide may be identified, as described in more detail below, by screening a microarray of cDNAs for tumor-associated expression (*i.e.*, expression that is at least two fold greater in a tumor than in normal tissue, as determined using a representative assay provided herein). Such screens may be performed, for example, using a Synteni microarray (Palo Alto,  
15 CA) according to the manufacturer's instructions (and essentially as described by Schena et al., *Proc. Natl. Acad. Sci. USA* 93:10614-10619, 1996 and Heller et al., *Proc. Natl. Acad. Sci. USA* 94:2150-2155, 1997). Alternatively, polynucleotides may be amplified from cDNA prepared from cells expressing the proteins described herein, such as breast tumor cells. Such polynucleotides may be amplified via polymerase  
20 chain reaction (PCR). For this approach, sequence-specific primers may be designed based on the sequences provided herein, and may be purchased or synthesized.

An amplified portion of a polynucleotide of the present invention may be used to isolate a full length gene from a suitable library (*e.g.*, a breast tumor cDNA library) using well known techniques. Within such techniques, a library (cDNA or  
25 genomic) is screened using one or more polynucleotide probes or primers suitable for amplification. Preferably, a library is size-selected to include larger molecules. Random primed libraries may also be preferred for identifying 5' and upstream regions of genes. Genomic libraries are preferred for obtaining introns and extending 5' sequences.

For hybridization techniques, a partial sequence may be labeled (*e.g.*, by nick-translation or end-labeling with  $^{32}\text{P}$ ) using well known techniques. A bacterial or bacteriophage library is then generally screened by hybridizing filters containing denatured bacterial colonies (or lawns containing phage plaques) with the labeled probe

5 (see Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY, 1989). Hybridizing colonies or plaques are selected and expanded, and the DNA is isolated for further analysis. cDNA clones may be analyzed to determine the amount of additional sequence by, for example, PCR using a primer from the partial sequence and a primer from the vector. Restriction maps and

10 partial sequences may be generated to identify one or more overlapping clones. The complete sequence may then be determined using standard techniques, which may involve generating a series of deletion clones. The resulting overlapping sequences can then be assembled into a single contiguous sequence. A full length cDNA molecule can be generated by ligating suitable fragments, using well known techniques.

15 Alternatively, there are numerous amplification techniques for obtaining a full length coding sequence from a partial cDNA sequence. Within such techniques, amplification is generally performed via PCR. Any of a variety of commercially available kits may be used to perform the amplification step. Primers may be designed using, for example, software well known in the art. Primers are preferably 22-30

20 nucleotides in length, have a GC content of at least 50% and anneal to the target sequence at temperatures of about 68°C to 72°C. The amplified region may be sequenced as described above, and overlapping sequences assembled into a contiguous sequence.

One such amplification technique is inverse PCR (*see* Triglia et al., *Nucl. Acids Res.* 16:8186, 1988), which uses restriction enzymes to generate a fragment in the

25 known region of the gene. The fragment is then circularized by intramolecular ligation and used as a template for PCR with divergent primers derived from the known region. Within an alternative approach, sequences adjacent to a partial sequence may be retrieved by amplification with a primer to a linker sequence and a primer specific to a

30 known region. The amplified sequences are typically subjected to a second round of amplification with the same linker primer and a second primer specific to the known

region. A variation on this procedure, which employs two primers that initiate extension in opposite directions from the known sequence, is described in WO 96/38591. Another such technique is known as "rapid amplification of cDNA ends" or RACE. This technique involves the use of an internal primer and an external primer, which hybridizes to a polyA region or vector sequence, to identify sequences that are 5' and 3' of a known sequence. Additional techniques include capture PCR (Lagerstrom et al., *PCR Methods Applic. 1*:111-19, 1991) and walking PCR (Parker et al., *Nucl. Acids. Res. 19*:3055-60, 1991). Other methods employing amplification may also be employed to obtain a full length cDNA sequence.

10 In certain instances, it is possible to obtain a full length cDNA sequence by analysis of sequences provided in an expressed sequence tag (EST) database, such as that available from GenBank. Searches for overlapping ESTs may generally be performed using well known programs (*e.g.*, NCBI BLAST searches), and such ESTs may be used to generate a contiguous full length sequence. Full length DNA sequences  
15 may also be obtained by analysis of genomic fragments.

#### POLYNUCLEOTIDE EXPRESSION IN HOST CELLS

In other embodiments of the invention, polynucleotide sequences or fragments thereof which encode polypeptides of the invention, or fusion proteins or functional equivalents thereof, may be used in recombinant DNA molecules to direct  
20 expression of a polypeptide in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences that encode substantially the same or a functionally equivalent amino acid sequence may be produced and these sequences may be used to clone and express a given polypeptide.

As will be understood by those of skill in the art, it may be advantageous  
25 in some instances to produce polypeptide-encoding nucleotide sequences possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce a recombinant RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring  
30 sequence.

Moreover, the polynucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter polypeptide encoding sequences for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the gene product. For example, DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. In addition, site-directed mutagenesis may be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, or introduce mutations, and so forth.

10 In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences may be ligated to a heterologous sequence to encode a fusion protein. For example, to screen peptide libraries for inhibitors of polypeptide activity, it may be useful to encode a chimeric protein that can be recognized by a commercially available antibody. A fusion protein may also be  
15 engineered to contain a cleavage site located between the polypeptide-encoding sequence and the heterologous protein sequence, so that the polypeptide may be cleaved and purified away from the heterologous moiety.

Sequences encoding a desired polypeptide may be synthesized, in whole or in part, using chemical methods well known in the art (see Caruthers, M. H. et al. 20 (1980) *Nucl. Acids Res. Symp. Ser.* 215-223, Horn, T. et al. (1980) *Nucl. Acids Res. Symp. Ser.* 225-232). Alternatively, the protein itself may be produced using chemical methods to synthesize the amino acid sequence of a polypeptide, or a portion thereof. For example, peptide synthesis can be performed using various solid-phase techniques (Roberge, J. Y. et al. (1995) *Science* 269:202-204) and automated synthesis may be  
25 achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin Elmer, Palo Alto, CA).

A newly synthesized peptide may be substantially purified by preparative high performance liquid chromatography (e.g., Creighton, T. (1983) *Proteins, Structures and Molecular Principles*, WH Freeman and Co., New York, N.Y.)  
30 or other comparable techniques available in the art. The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (e.g., the Edman

degradation procedure). Additionally, the amino acid sequence of a polypeptide, or any part thereof, may be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

- 5 In order to express a desired polypeptide, the nucleotide sequences encoding the polypeptide, or functional equivalents, may be inserted into appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence. Methods which are well known to those skilled in the art may be used to construct expression vectors containing
- 10 sequences encoding a polypeptide of interest and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. Such techniques are described in Sambrook, J. et al. (1989) *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Press, Plainview, N.Y., and Ausubel, F. M. et al. (1989) *Current*
- 15 *Protocols in Molecular Biology*, John Wiley & Sons, New York, N.Y.

- A variety of expression vector/host systems may be utilized to contain and express polynucleotide sequences. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors;
- 20 insect cell systems infected with virus expression vectors (e.g., baculovirus); plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems.

- The "control elements" or "regulatory sequences" present in an
- 25 expression vector are those non-translated regions of the vector--enhancers, promoters, 5' and 3' untranslated regions--which interact with host cellular proteins to carry out transcription and translation. Such elements may vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used.
- 30 For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the PBLUESCRIPT phagemid (Stratagene, La Jolla, Calif.) or

PSPORT1 plasmid (Gibco BRL, Gaithersburg, MD) and the like may be used. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are generally preferred. If it is necessary to generate a cell line that contains multiple copies of the sequence encoding a polypeptide, vectors based on SV40 or EBV  
5 may be advantageously used with an appropriate selectable marker.

In bacterial systems, a number of expression vectors may be selected depending upon the use intended for the expressed polypeptide. For example, when large quantities are needed, for example for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be used:  
10 Such vectors include, but are not limited to, the multifunctional *E. coli* cloning and expression vectors such as BLUESCRIPT (Stratagene), in which the sequence encoding the polypeptide of interest may be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of  $\beta$ -galactosidase so that a hybrid protein is produced; pIN vectors (Van Heeke, G. and S. M. Schuster (1989) *J.*  
15 *Biol. Chem.* 264:5503-5509); and the like. pGEX Vectors (Promega, Madison, Wis.) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems may be designed to include  
20 heparin, thrombin, or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

In the yeast, *Saccharomyces cerevisiae*, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH may be used. For reviews, see Ausubel et al. (supra) and Grant et al. (1987) *Methods*  
25 *Enzymol.* 153:516-544.

In cases where plant expression vectors are used, the expression of sequences encoding polypeptides may be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV may be used alone or in combination with the omega leader sequence from TMV (Takamatsu, N.  
30 (1987) *EMBO J.* 6:307-311. Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used (Coruzzi, G. et al. (1984) *EMBO J.*

3:1671-1680; Broglie, R. et al. (1984) *Science* 224:838-843; and Winter, J. et al. (1991) *Results Probl. Cell Differ.* 17:85-105). These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. Such techniques are described in a number of generally available reviews (see, for example, Hobbs, S. or  
5 Murry, L. E. in McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York, N.Y.; pp. 191-196).

An insect system may also be used to express a polypeptide of interest. For example, in one such system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in *Spodoptera frugiperda* cells or  
10 in *Trichoplusia* larvae. The sequences encoding the polypeptide may be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of the polypeptide-encoding sequence will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses may then be used to infect, for example, *S. frugiperda*  
15 cells or *Trichoplusia* larvae in which the polypeptide of interest may be expressed (Engelhard, E. K. et al. (1994) *Proc. Natl. Acad. Sci.* 91 :3224-3227).

In mammalian host cells, a number of viral-based expression systems are generally available. For example, in cases where an adenovirus is used as an expression vector, sequences encoding a polypeptide of interest may be ligated into an adenovirus  
20 transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain a viable virus which is capable of expressing the polypeptide in infected host cells (Logan, J. and Shenk, T. (1984) *Proc. Natl. Acad. Sci.* 81:3655-3659). In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used  
25 to increase expression in mammalian host cells.

Specific initiation signals may also be used to achieve more efficient translation of sequences encoding a polypeptide of interest. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding the polypeptide, its initiation codon, and upstream sequences are inserted into the  
30 appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a portion



thereof, is inserted, exogenous translational control signals including the ATG initiation codon should be provided. Furthermore, the initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic.

- 5 The efficiency of expression may be enhanced by the inclusion of enhancers which are appropriate for the particular cell system which is used, such as those described in the literature (Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162).

In addition, a host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the  
10 desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be used to facilitate correct insertion, folding and/or function. Different host cells such as CHO, HeLa, MDCK, HEK293, and WI38, which have specific cellular machinery and  
15 characteristic mechanisms for such post-translational activities, may be chosen to ensure the correct modification and processing of the foreign protein.

For long-term, high-yield production of recombinant proteins, stable expression is generally preferred. For example, cell lines which stably express a polynucleotide of interest may be transformed using expression vectors which may  
20 contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which  
25 successfully express the introduced sequences. Resistant clones of stably transformed cells may be proliferated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler, M. et al. (1977) *Cell* 11:223-32) and adenine phosphoribosyltransferase  
30 (Lowy, I. et al. (1990) *Cell* 22:817-23) genes which can be employed in tk.sup.- or aprt.sup.- cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can

be used as the basis for selection; for example, dhfr which confers resistance to methotrexate (Wigler, M. et al. (1980) *Proc. Natl. Acad. Sci.* 77:3567-70); npt, which confers resistance to the aminoglycosides, neomycin and G-418 (Colbere-Garapin, F. et al (1981) *J. Mol. Biol.* 150:1-14); and als or pat, which confer resistance to  
5 chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, *supra*). Additional selectable genes have been described, for example, trpB, which allows cells to utilize indole in place of tryptophan, or hisD, which allows cells to utilize histinol in place of histidine (Hartman, S. C. and R. C. Mulligan (1988) *Proc. Natl. Acad. Sci.* 85:8047-51). Recently, the use of visible markers has gained popularity with such  
10 markers as anthocyanins, beta-glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, being widely used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes, C. A. et al. (1995) *Methods Mol. Biol.* 55:121-131).

Although the presence/absence of marker gene expression suggests that  
15 the gene of interest is also present, its presence and expression may need to be confirmed. For example, if the sequence encoding a polypeptide is inserted within a marker gene sequence, recombinant cells containing sequences can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a polypeptide-encoding sequence under the control of a single promoter.  
20 Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

Alternatively, host cells which contain and express a desired polynucleotide sequence may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-  
25 RNA hybridizations and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein.

A variety of protocols for detecting and measuring the expression of polynucleotide-encoded products, using either polyclonal or monoclonal antibodies  
30 specific for the product are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated

cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on a given polypeptide may be preferred for some applications, but a competitive binding assay may also be employed. These and other assays are described, among other places, in Hampton, R. et al. (1990; 5 Serological Methods, a Laboratory Manual, APS Press, St Paul. Minn.) and Maddox, D. E. et al. (1983; *J. Exp. Med.* 158:1211-1216).

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to 10 polynucleotides include oligolabeling, nick translation, end-labeling or PCR amplification using a labeled nucleotide. Alternatively, the sequences, or any portions thereof may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 15 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits. Suitable reporter molecules or labels, which may be used include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with a polynucleotide sequence of interest may be 20 cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a recombinant cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides of the invention may be designed to contain signal sequences which direct secretion of the 25 encoded polypeptide through a prokaryotic or eukaryotic cell membrane. Other recombinant constructions may be used to join sequences encoding a polypeptide of interest to nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow 30 purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity

purification system (Immunex Corp., Seattle, Wash.). The inclusion of cleavable linker sequences such as those specific for Factor XA or enterokinase (Invitrogen, San Diego, Calif.) between the purification domain and the encoded polypeptide may be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing a polypeptide of interest and a nucleic acid encoding 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification on IMIAC (immobilized metal ion affinity chromatography) as described in Porath, J. et al. (1992, *Prot. Exp. Purif.* 3:263-281) while the enterokinase cleavage site provides a means for purifying the desired polypeptide from the fusion protein. A discussion of vectors which contain fusion proteins is provided in Kroll, D. J. et al. (1993; *DNA Cell Biol.* 12:441-453).

In addition to recombinant production methods, polypeptides of the invention, and fragments thereof, may be produced by direct peptide synthesis using solid-phase techniques (Merrifield J. (1963) *J. Am. Chem. Soc.* 85:2149-2154). Protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer). Alternatively, various fragments may be chemically synthesized separately and combined using chemical methods to produce the full length molecule.

## 20 SITE-SPECIFIC MUTAGENESIS

Site-specific mutagenesis is a technique useful in the preparation of individual peptides, or biologically functional equivalent polypeptides, through specific mutagenesis of the underlying polynucleotides that encode them. The technique, well-known to those of skill in the art, further provides a ready ability to prepare and test sequence variants, for example, incorporating one or more of the foregoing considerations, by introducing one or more nucleotide sequence changes into the DNA. Site-specific mutagenesis allows the production of mutants through the use of specific oligonucleotide sequences which encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient size and sequence complexity to form a stable duplex on both sides of the

deletion junction being traversed. Mutations may be employed in a selected polynucleotide sequence to improve, alter, decrease, modify, or otherwise change the properties of the polynucleotide itself, and/or alter the properties, activity, composition, stability, or primary sequence of the encoded polypeptide.

5 In certain embodiments of the present invention, the inventors contemplate the mutagenesis of the disclosed polynucleotide sequences to alter one or more properties of the encoded polypeptide, such as the antigenicity of a polypeptide vaccine. The techniques of site-specific mutagenesis are well-known in the art, and are widely used to create variants of both polypeptides and polynucleotides. For example,  
10 site-specific mutagenesis is often used to alter a specific portion of a DNA molecule. In such embodiments, a primer comprising typically about 14 to about 25 nucleotides or so in length is employed, with about 5 to about 10 residues on both sides of the junction of the sequence being altered.

As will be appreciated by those of skill in the art, site-specific  
15 mutagenesis techniques have often employed a phage vector that exists in both a single stranded and double stranded form. Typical vectors useful in site-directed mutagenesis include vectors such as the M13 phage. These phage are readily commercially-available and their use is generally well-known to those skilled in the art. Double-stranded plasmids are also routinely employed in site directed mutagenesis that  
20 eliminates the step of transferring the gene of interest from a plasmid to a phage.

In general, site-directed mutagenesis in accordance herewith is performed by first obtaining a single-stranded vector or melting apart of two strands of a double-stranded vector that includes within its sequence a DNA sequence that encodes the desired peptide. An oligonucleotide primer bearing the desired mutated sequence is  
25 prepared, generally synthetically. This primer is then annealed with the single-stranded vector, and subjected to DNA polymerizing enzymes such as *E. coli* polymerase I Klenow fragment, in order to complete the synthesis of the mutation-bearing strand. Thus, a heteroduplex is formed wherein one strand encodes the original non-mutated sequence and the second strand bears the desired mutation. This heteroduplex vector is  
30 then used to transform appropriate cells, such as *E. coli* cells, and clones are selected which include recombinant vectors bearing the mutated sequence arrangement.

The preparation of sequence variants of the selected peptide-encoding DNA segments using site-directed mutagenesis provides a means of producing potentially useful species and is not meant to be limiting as there are other ways in which sequence variants of peptides and the DNA sequences encoding them may be obtained. For example, recombinant vectors encoding the desired peptide sequence may be treated with mutagenic agents, such as hydroxylamine, to obtain sequence variants. Specific details regarding these methods and protocols are found in the teachings of Maloy *et al.*, 1994; Segal, 1976; Prokop and Bajpai, 1991; Kuby, 1994; and Maniatis *et al.*, 1982, each incorporated herein by reference, for that purpose.

As used herein, the term "oligonucleotide directed mutagenesis procedure" refers to template-dependent processes and vector-mediated propagation which result in an increase in the concentration of a specific nucleic acid molecule relative to its initial concentration, or in an increase in the concentration of a detectable signal, such as amplification. As used herein, the term "oligonucleotide directed mutagenesis procedure" is intended to refer to a process that involves the template-dependent extension of a primer molecule. The term template dependent process refers to nucleic acid synthesis of an RNA or a DNA molecule wherein the sequence of the newly synthesized strand of nucleic acid is dictated by the well-known rules of complementary base pairing (see, for example, Watson, 1987). Typically, vector mediated methodologies involve the introduction of the nucleic acid fragment into a DNA or RNA vector, the clonal amplification of the vector, and the recovery of the amplified nucleic acid fragment. Examples of such methodologies are provided by U. S. Patent No. 4,237,224, specifically incorporated herein by reference in its entirety.

#### POLYNUCLEOTIDE AMPLIFICATION TECHNIQUES

A number of template dependent processes are available to amplify the target sequences of interest present in a sample. One of the best known amplification methods is the polymerase chain reaction (PCR™) which is described in detail in U.S. Patent Nos. 4,683,195, 4,683,202 and 4,800,159, each of which is incorporated herein by reference in its entirety. Briefly, in PCR™, two primer sequences are prepared which are complementary to regions on opposite complementary strands of the target

sequence. An excess of deoxynucleoside triphosphates is added to a reaction mixture along with a DNA polymerase (e.g., *Taq* polymerase). If the target sequence is present in a sample, the primers will bind to the target and the polymerase will cause the primers to be extended along the target sequence by adding on nucleotides. By raising  
5 and lowering the temperature of the reaction mixture, the extended primers will dissociate from the target to form reaction products, excess primers will bind to the target and to the reaction product and the process is repeated. Preferably reverse transcription and PCR™ amplification procedure may be performed in order to quantify the amount of mRNA amplified. Polymerase chain reaction methodologies are well  
10 known in the art.

Another method for amplification is the ligase chain reaction (referred to as LCR), disclosed in Eur. Pat. Appl. Publ. No. 320,308 (specifically incorporated herein by reference in its entirety). In LCR, two complementary probe pairs are prepared, and in the presence of the target sequence, each pair will bind to opposite  
15 complementary strands of the target such that they abut. In the presence of a ligase, the two probe pairs will link to form a single unit. By temperature cycling, as in PCR™, bound ligated units dissociate from the target and then serve as "target sequences" for ligation of excess probe pairs. U.S. Patent No. 4,883,750, incorporated herein by reference in its entirety, describes an alternative method of amplification similar to LCR  
20 for binding probe pairs to a target sequence.

Qbeta Replicase, described in PCT Intl. Pat. Appl. Publ. No. PCT/US87/00880, incorporated herein by reference in its entirety, may also be used as still another amplification method in the present invention. In this method, a replicative sequence of RNA that has a region complementary to that of a target is added to a  
25 sample in the presence of an RNA polymerase. The polymerase will copy the replicative sequence that can then be detected.

An isothermal amplification method, in which restriction endonucleases and ligases are used to achieve the amplification of target molecules that contain nucleotide 5'-[α-thio]triphosphates in one strand of a restriction site (Walker *et al.*,  
30 1992, incorporated herein by reference in its entirety), may also be useful in the amplification of nucleic acids in the present invention.

Strand Displacement Amplification (SDA) is another method of carrying out isothermal amplification of nucleic acids which involves multiple rounds of strand displacement and synthesis, *i.e.* nick translation. A similar method, called Repair Chain Reaction (RCR) is another method of amplification which may be useful in the present invention and is involves annealing several probes throughout a region targeted for amplification, followed by a repair reaction in which only two of the four bases are present. The other two bases can be added as biotinylated derivatives for easy detection. A similar approach is used in SDA.

Sequences can also be detected using a cyclic probe reaction (CPR). In CPR, a probe having a 3' and 5' sequences of non-target DNA and an internal or "middle" sequence of the target protein specific RNA is hybridized to DNA which is present in a sample. Upon hybridization, the reaction is treated with RNaseH, and the products of the probe are identified as distinctive products by generating a signal that is released after digestion. The original template is annealed to another cycling probe and the reaction is repeated. Thus, CPR involves amplifying a signal generated by hybridization of a probe to a target gene specific expressed nucleic acid.

Still other amplification methods described in Great Britain Pat. Appl. No. 2 202 328, and in PCT Intl. Pat. Appl. Publ. No. PCT/US89/01025, each of which is incorporated herein by reference in its entirety, may be used in accordance with the present invention. In the former application, "modified" primers are used in a PCR-like, template and enzyme dependent synthesis. The primers may be modified by labeling with a capture moiety (*e.g.*, biotin) and/or a detector moiety (*e.g.*, enzyme). In the latter application, an excess of labeled probes is added to a sample. In the presence of the target sequence, the probe binds and is cleaved catalytically. After cleavage, the target sequence is released intact to be bound by excess probe. Cleavage of the labeled probe signals the presence of the target sequence.

Other nucleic acid amplification procedures include transcription-based amplification systems (TAS) (Kwoh *et al.*, 1989; PCT Intl. Pat. Appl. Publ. No. WO 88/10315, incorporated herein by reference in its entirety), including nucleic acid sequence based amplification (NASBA) and 3SR. In NASBA, the nucleic acids can be prepared for amplification by standard phenol/chloroform extraction, heat denaturation



of a sample, treatment with lysis buffer and minispin columns for isolation of DNA and RNA or guanidinium chloride extraction of RNA. These amplification techniques involve annealing a primer that has sequences specific to the target sequence. Following polymerization, DNA/RNA hybrids are digested with RNase H while double stranded DNA molecules are heat-denatured again. In either case the single stranded DNA is made fully double stranded by addition of second target-specific primer, followed by polymerization. The double stranded DNA molecules are then multiply transcribed by a polymerase such as T7 or SP6. In an isothermal cyclic reaction, the RNAs are reverse transcribed into DNA, and transcribed once again with a polymerase such as T7 or SP6. The resulting products, whether truncated or complete, indicate target-specific sequences.

Eur. Pat. Appl. Publ. No. 329,822, incorporated herein by reference in its entirety, disclose a nucleic acid amplification process involving cyclically synthesizing single-stranded RNA ("ssRNA"), ssDNA, and double-stranded DNA (dsDNA), which may be used in accordance with the present invention. The ssRNA is a first template for a first primer oligonucleotide, which is elongated by reverse transcriptase (RNA-dependent DNA polymerase). The RNA is then removed from resulting DNA:RNA duplex by the action of ribonuclease H (RNase H, an RNase specific for RNA in a duplex with either DNA or RNA). The resultant ssDNA is a second template for a second primer, which also includes the sequences of an RNA polymerase promoter (exemplified by T7 RNA polymerase) 5' to its homology to its template. This primer is then extended by DNA polymerase (exemplified by the large "Klenow" fragment of *E. coli* DNA polymerase I), resulting as a double-stranded DNA ("dsDNA") molecule, having a sequence identical to that of the original RNA between the primers and having additionally, at one end, a promoter sequence. This promoter sequence can be used by the appropriate RNA polymerase to make many RNA copies of the DNA. These copies can then re-enter the cycle leading to very swift amplification. With proper choice of enzymes, this amplification can be done isothermally without addition of enzymes at each cycle. Because of the cyclical nature of this process, the starting sequence can be chosen to be in the form of either DNA or RNA.

PCT Intl. Pat. Appl. Publ. No. WO 89/06700, incorporated herein by reference in its entirety, disclose a nucleic acid sequence amplification scheme based on the hybridization of a promoter/primer sequence to a target single-stranded DNA ("ssDNA") followed by transcription of many RNA copies of the sequence. This  
5 scheme is not cyclic; i.e. new templates are not produced from the resultant RNA transcripts. Other amplification methods include "RACE" (Frohman, 1990), and "one-sided PCR" (Ohara, 1989) which are well-known to those of skill in the art.

Methods based on ligation of two (or more) oligonucleotides in the presence of nucleic acid having the sequence of the resulting "di-oligonucleotide",  
10 thereby amplifying the di-oligonucleotide (Wu and Dean, 1996, incorporated herein by reference in its entirety), may also be used in the amplification of DNA sequences of the present invention.

#### BIOLOGICAL FUNCTIONAL EQUIVALENTS

Modification and changes may be made in the structure of the  
15 polynucleotides and polypeptides of the present invention and still obtain a functional molecule that encodes a polypeptide with desirable characteristics. As mentioned above, it is often desirable to introduce one or more mutations into a specific polynucleotide sequence. In certain circumstances, the resulting encoded polypeptide sequence is altered by this mutation, or in other cases, the sequence of the polypeptide  
20 is unchanged by one or more mutations in the encoding polynucleotide.

When it is desirable to alter the amino acid sequence of a polypeptide to create an equivalent, or even an improved, second-generation molecule, the amino acid changes may be achieved by changing one or more of the codons of the encoding DNA sequence, according to Table 1.

25 For example, certain amino acids may be substituted for other amino acids in a protein structure without appreciable loss of interactive binding capacity with structures such as, for example, antigen-binding regions of antibodies or binding sites on substrate molecules. Since it is the interactive capacity and nature of a protein that defines that protein's biological functional activity, certain amino acid sequence  
30 substitutions can be made in a protein sequence, and, of course, its underlying DNA

coding sequence, and nevertheless obtain a protein with like properties. It is thus contemplated by the inventors that various changes may be made in the peptide sequences of the disclosed compositions, or corresponding DNA sequences which encode said peptides without appreciable loss of their biological utility or activity.

5

TABLE I

Amino Acids			Codons						
Alanine	Ala	A	GCA	GCC	GCG	GCU			
Cysteine	Cys	C	UGC	UGU					
Aspartic acid	Asp	D	GAC	GAU					
Glutamic acid	Glu	E	GAA	GAG					
Phenylalanine	Phe	F	UUC	UUU					
Glycine	Gly	G	GGA	GGC	GGG	GGU			
Histidine	His	H	CAC	CAU					
Isoleucine	Ile	I	AUA	AUC	AUU				
Lysine	Lys	K	AAA	AAG					
Leucine	Leu	L	UUA	UUG	CUA	CUC	CUG	CUU	
Methionine	Met	M	AUG						
Asparagine	Asn	N	AAC	AAU					
Proline	Pro	P	CCA	CCC	CCG	CCU			
Glutamine	Gln	Q	CAA	CAG					
Arginine	Arg	R	AGA	AGG	CGA	CGC	CGG	CGU	
Serine	Ser	S	AGC	AGU	UCA	UCC	UCG	UCU	
Threonine	Thr	T	ACA	ACC	ACG	ACU			
Valine	Val	V	GUA	GUC	GUG	GUU			
Tryptophan	Trp	W	UGG						
Tyrosine	Tyr	Y	UAC	UAU					

In making such changes, the hydropathic index of amino acids may be considered. The importance of the hydropathic amino acid index in conferring interactive biologic function on a protein is generally understood in the art (Kyte and  
 10 Doolittle, 1982, incorporated herein by reference). It is accepted that the relative

Doolittle, 1982, incorporated herein by reference). It is accepted that the relative hydrophobic character of the amino acid contributes to the secondary structure of the resultant protein, which in turn defines the interaction of the protein with other molecules, for example, enzymes, substrates, receptors, DNA, antibodies, antigens, and the like. Each amino acid has been assigned a hydrophobic index on the basis of its hydrophobicity and charge characteristics (Kyte and Doolittle, 1982). These values are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (−0.4); threonine (−0.7); serine (−0.8); tryptophan (−0.9); tyrosine (−1.3); proline (−1.6); histidine (−3.2); glutamate (−3.5); glutamine (−3.5); aspartate (−3.5); asparagine (−3.5); lysine (−3.9); and arginine (−4.5).

It is known in the art that certain amino acids may be substituted by other amino acids having a similar hydrophobic index or score and still result in a protein with similar biological activity, *i.e.* still obtain a biological functionally equivalent protein. In making such changes, the substitution of amino acids whose hydrophobic indices are within  $\pm 2$  is preferred, those within  $\pm 1$  are particularly preferred, and those within  $\pm 0.5$  are even more particularly preferred. It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity. U. S. Patent 4,554,101 (specifically incorporated herein by reference in its entirety), states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with a biological property of the protein.

As detailed in U. S. Patent 4,554,101, the following hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0  $\pm$  1); glutamate (+3.0  $\pm$  1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (−0.4); proline (−0.5  $\pm$  1); alanine (−0.5); histidine (−0.5); cysteine (−1.0); methionine (−1.3); valine (−1.5); leucine (−1.8); isoleucine (−1.8); tyrosine (−2.3); phenylalanine (−2.5); tryptophan (−3.4). It is understood that an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent, and in particular, an immunologically equivalent protein. In such changes, the substitution of amino acids whose hydrophilicity values are within  $\pm 2$

is preferred, those within  $\pm 1$  are particularly preferred, and those within  $\pm 0.5$  are even more particularly preferred.

As outlined above, amino acid substitutions are generally therefore based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. Exemplary substitutions that take various of the foregoing characteristics into consideration are well known to those of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine.

In addition, any polynucleotide may be further modified to increase stability *in vivo*. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends; the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages in the backbone; and/or the inclusion of nontraditional bases such as inosine, queosine and wybutosine, as well as acetyl-methyl-, thio- and other modified forms of adenine, cytidine, guanine, thymine and uridine.

#### IN VIVO POLYNUCLEOTIDE DELIVERY TECHNIQUES

In additional embodiments, genetic constructs comprising one or more of the polynucleotides of the invention are introduced into cells *in vivo*. This may be achieved using any of a variety of well known approaches, several of which are outlined below for the purpose of illustration.

##### 1. ADENOVIRUS

One of the preferred methods for *in vivo* delivery of one or more nucleic acid sequences involves the use of an adenovirus expression vector. "Adenovirus expression vector" is meant to include those constructs containing adenovirus sequences sufficient to (a) support packaging of the construct and (b) to express a polynucleotide that has been cloned therein in a sense or antisense orientation. Of course, in the context of an antisense construct, expression does not require that the gene product be synthesized.

The expression vector comprises a genetically engineered form of an adenovirus. Knowledge of the genetic organization of adenovirus, a 36 kb, linear, double-stranded DNA virus, allows substitution of large pieces of adenoviral DNA with foreign sequences up to 7 kb (Grunhaus and Horwitz, 1992). In contrast to retrovirus, the adenoviral infection of host cells does not result in chromosomal integration because adenoviral DNA can replicate in an episomal manner without potential genotoxicity. Also, adenoviruses are structurally stable, and no genome rearrangement has been detected after extensive amplification. Adenovirus can infect virtually all epithelial cells regardless of their cell cycle stage. So far, adenoviral infection appears to be linked only to mild disease such as acute respiratory disease in humans.

Adenovirus is particularly suitable for use as a gene transfer vector because of its mid-sized genome, ease of manipulation, high titer, wide target-cell range and high infectivity. Both ends of the viral genome contain 100-200 base pair inverted repeats (ITRs), which are *cis* elements necessary for viral DNA replication and packaging. The early (E) and late (L) regions of the genome contain different transcription units that are divided by the onset of viral DNA replication. The E1 region (E1A and E1B) encodes proteins responsible for the regulation of transcription of the viral genome and a few cellular genes. The expression of the E2 region (E2A and E2B) results in the synthesis of the proteins for viral DNA replication. These proteins are involved in DNA replication, late gene expression and host cell shut-off (Renan, 1990). The products of the late genes, including the majority of the viral capsid proteins, are expressed only after significant processing of a single primary transcript issued by the major late promoter (MLP). The MLP, (located at 16.8 m.u.) is particularly efficient during the late phase of infection, and all the mRNA's issued from this promoter possess a 5'-tripartite leader (TPL) sequence which makes them preferred mRNA's for translation.

In a current system, recombinant adenovirus is generated from homologous recombination between shuttle vector and provirus vector. Due to the possible recombination between two proviral vectors, wild-type adenovirus may be generated from this process. Therefore, it is critical to isolate a single clone of virus from an individual plaque and examine its genomic structure.

Generation and propagation of the current adenovirus vectors, which are replication deficient, depend on a unique helper cell line, designated 293, which was transformed from human embryonic kidney cells by Ad5 DNA fragments and constitutively expresses E1 proteins (Graham *et al.*, 1977). Since the E3 region is dispensable from the adenovirus genome (Jones and Shenk, 1978), the current adenovirus vectors, with the help of 293 cells, carry foreign DNA in either the E1, the D3 or both regions (Graham and Prevec, 1991). In nature, adenovirus can package approximately 105% of the wild-type genome (Ghosh-Choudhury *et al.*, 1987), providing capacity for about 2 extra kB of DNA. Combined with the approximately 5.5 kB of DNA that is replaceable in the E1 and E3 regions, the maximum capacity of the current adenovirus vector is under 7.5 kB, or about 15% of the total length of the vector. More than 80% of the adenovirus viral genome remains in the vector backbone and is the source of vector-borne cytotoxicity. Also, the replication deficiency of the E1-deleted virus is incomplete. For example, leakage of viral gene expression has been observed with the currently available vectors at high multiplicities of infection (MOI) (Mulligan, 1993).

Helper cell lines may be derived from human cells such as human embryonic kidney cells, muscle cells, hematopoietic cells or other human embryonic mesenchymal or epithelial cells. Alternatively, the helper cells may be derived from the cells of other mammalian species that are permissive for human adenovirus. Such cells include, *e.g.*, Vero cells or other monkey embryonic mesenchymal or epithelial cells. As stated above, the currently preferred helper cell line is 293.

Recently, Racher *et al.* (1995) disclosed improved methods for culturing 293 cells and propagating adenovirus. In one format, natural cell aggregates are grown by inoculating individual cells into 1 liter siliconized spinner flasks (Techne, Cambridge, UK) containing 100-200 ml of medium. Following stirring at 40 rpm, the cell viability is estimated with trypan blue. In another format, Fibra-Cel microcarriers (Bibby Sterlin, Stone, UK) (5 g/l) is employed as follows. A cell inoculum, resuspended in 5 ml of medium, is added to the carrier (50 ml) in a 250 ml Erlenmeyer flask and left stationary, with occasional agitation, for 1 to 4 h. The medium is then replaced with 50 ml of fresh medium and shaking initiated. For virus production, cells

are allowed to grow to about 80% confluence, after which time the medium is replaced (to 25% of the final volume) and adenovirus added at an MOI of 0.05. Cultures are left stationary overnight, following which the volume is increased to 100% and shaking commenced for another 72 h.

5           Other than the requirement that the adenovirus vector be replication defective, or at least conditionally defective, the nature of the adenovirus vector is not believed to be crucial to the successful practice of the invention. The adenovirus may be of any of the 42 different known serotypes or subgroups A-F. Adenovirus type 5 of subgroup C is the preferred starting material in order to obtain a conditional replication-  
10   defective adenovirus vector for use in the present invention, since Adenovirus type 5 is a human adenovirus about which a great deal of biochemical and genetic information is known, and it has historically been used for most constructions employing adenovirus as a vector.

          As stated above, the typical vector according to the present invention is  
15   replication defective and will not have an adenovirus E1 region. Thus, it will be most convenient to introduce the polynucleotide encoding the gene of interest at the position from which the E1-coding sequences have been removed. However, the position of insertion of the construct within the adenovirus sequences is not critical to the invention. The polynucleotide encoding the gene of interest may also be inserted in lieu  
20   of the deleted E3 region in E3 replacement vectors as described by Karlsson *et al.* (1986) or in the E4 region where a helper cell line or helper virus complements the E4 defect.

          Adenovirus is easy to grow and manipulate and exhibits broad host range *in vitro* and *in vivo*. This group of viruses can be obtained in high titers, *e.g.*,  $10^9$ - $10^{11}$   
25   plaque-forming units per ml, and they are highly infective. The life cycle of adenovirus does not require integration into the host cell genome. The foreign genes delivered by adenovirus vectors are episomal and, therefore, have low genotoxicity to host cells. No side effects have been reported in studies of vaccination with wild-type adenovirus (Couch *et al.*, 1963; Top *et al.*, 1971), demonstrating their safety and therapeutic  
30   potential as *in vivo* gene transfer vectors.



Adenovirus vectors have been used in eukaryotic gene expression (Levrero *et al.*, 1991; Gomez-Foix *et al.*, 1992) and vaccine development (Grunhaus and Horwitz, 1992; Graham and Prevec, 1992). Recently, animal studies suggested that recombinant adenovirus could be used for gene therapy (Stratford-Perricaudet and Perricaudet, 1991; Stratford-Perricaudet *et al.*, 1990; Rich *et al.*, 1993). Studies in administering recombinant adenovirus to different tissues include trachea instillation (Rosenfeld *et al.*, 1991; Rosenfeld *et al.*, 1992), muscle injection (Ragot *et al.*, 1993), peripheral intravenous injections (Herz and Gerard, 1993) and stereotactic inoculation into the brain (Le Gal La Salle *et al.*, 1993).

## 10 2. RETROVIRUSES

The retroviruses are a group of single-stranded RNA viruses characterized by an ability to convert their RNA to double-stranded DNA in infected cells by a process of reverse-transcription (Coffin, 1990). The resulting DNA then stably integrates into cellular chromosomes as a provirus and directs synthesis of viral proteins. The integration results in the retention of the viral gene sequences in the recipient cell and its descendants. The retroviral genome contains three genes, gag, pol, and env that code for capsid proteins, polymerase enzyme, and envelope components, respectively. A sequence found upstream from the gag gene contains a signal for packaging of the genome into virions. Two long terminal repeat (LTR) sequences are present at the 5' and 3' ends of the viral genome. These contain strong promoter and enhancer sequences and are also required for integration in the host cell genome (Coffin, 1990).

In order to construct a retroviral vector, a nucleic acid encoding one or more oligonucleotide or polynucleotide sequences of interest is inserted into the viral genome in the place of certain viral sequences to produce a virus that is replication-defective. In order to produce virions, a packaging cell line containing the gag, pol, and env genes but without the LTR and packaging components is constructed (Mann *et al.*, 1983). When a recombinant plasmid containing a cDNA, together with the retroviral LTR and packaging sequences is introduced into this cell line (by calcium phosphate precipitation for example), the packaging sequence allows the RNA transcript of the

recombinant plasmid to be packaged into viral particles, which are then secreted into the culture media (Nicolas and Rubenstein, 1988; Temin, 1986; Mann *et al.*, 1983). The media containing the recombinant retroviruses is then collected, optionally concentrated, and used for gene transfer. Retroviral vectors are able to infect a broad  
5 variety of cell types. However, integration and stable expression require the division of host cells (Paskind *et al.*, 1975).

A novel approach designed to allow specific targeting of retrovirus vectors was recently developed based on the chemical modification of a retrovirus by the chemical addition of lactose residues to the viral envelope. This modification could  
10 permit the specific infection of hepatocytes *via* sialoglycoprotein receptors.

A different approach to targeting of recombinant retroviruses was designed in which biotinylated antibodies against a retroviral envelope protein and against a specific cell receptor were used. The antibodies were coupled *via* the biotin components by using streptavidin (Roux *et al.*, 1989). Using antibodies against major  
15 histocompatibility complex class I and class II antigens, they demonstrated the infection of a variety of human cells that bore those surface antigens with an ecotropic virus *in vitro* (Roux *et al.*, 1989).

### 3. ADENO-ASSOCIATED VIRUSES

AAV (Ridgeway, 1988; Hermonat and Muzyczka, 1984) is a parovirus,  
20 discovered as a contamination of adenoviral stocks. It is a ubiquitous virus (antibodies are present in 85% of the US human population) that has not been linked to any disease. It is also classified as a dependovirus, because its replications is dependent on the presence of a helper virus, such as adenovirus. Five serotypes have been isolated, of which AAV-2 is the best characterized. AAV has a single-stranded linear DNA that is  
25 encapsidated into capsid proteins VP1, VP2 and VP3 to form an icosahedral virion of 20 to 24 nm in diameter. (Muzyczka and McLaughlin, 1988).

The AAV DNA is approximately 4.7 kilobases long. It contains two open reading frames and is flanked by two ITRs. There are two major genes in the AAV genome: *rep* and *cap*. The *rep* gene codes for proteins responsible for viral  
30 replications, whereas *cap* codes for capsid protein VP1-3. Each ITR forms a T-shaped

hairpin structure. These terminal repeats are the only essential *cis* components of the AAV for chromosomal integration. Therefore, the AAV can be used as a vector with all viral coding sequences removed and replaced by the cassette of genes for delivery. Three viral promoters have been identified and named p5, p19, and p40, according to  
5 their map position. Transcription from p5 and p19 results in production of rep proteins, and transcription from p40 produces the capsid proteins (Hermonat and Muzyczka, 1984).

There are several factors that prompted researchers to study the possibility of using rAAV as an expression vector. One is that the requirements for  
10 delivering a gene to integrate into the host chromosome are surprisingly few. It is necessary to have the 145-bp ITRs, which are only 6% of the AAV genome. This leaves room in the vector to assemble a 4.5-kb DNA insertion. While this carrying capacity may prevent the AAV from delivering large genes, it is amply suited for delivering the antisense constructs of the present invention.

15 AAV is also a good choice of delivery vehicles due to its safety. There is a relatively complicated rescue mechanism: not only wild type adenovirus but also AAV genes are required to mobilize rAAV. Likewise, AAV is not pathogenic and not associated with any disease. The removal of viral coding sequences minimizes immune reactions to viral gene expression, and therefore, rAAV does not evoke an inflammatory  
20 response.

#### 4. OTHER VIRAL VECTORS AS EXPRESSION CONSTRUCTS

Other viral vectors may be employed as expression constructs in the present invention for the delivery of oligonucleotide or polynucleotide sequences to a host cell. Vectors derived from viruses such as vaccinia virus (Ridgeway, 1988; Coupar  
25 *et al.*, 1988), lentiviruses, polio viruses and herpes viruses may be employed. They offer several attractive features for various mammalian cells (Friedmann, 1989; Ridgeway, 1988; Coupar *et al.*, 1988; Horwich *et al.*, 1990).

With the recent recognition of defective hepatitis B viruses, new insight was gained into the structure-function relationship of different viral sequences. *In vitro*  
30 studies showed that the virus could retain the ability for helper-dependent packaging

and reverse transcription despite the deletion of up to 80% of its genome (Horwich *et al.*, 1990). This suggested that large portions of the genome could be replaced with foreign genetic material. The hepatotropism and persistence (integration) were particularly attractive properties for liver-directed gene transfer. Chang *et al.* (1991) introduced the chloramphenicol acetyltransferase (CAT) gene into duck hepatitis B virus genome in the place of the polymerase, surface, and pre-surface coding sequences. It was cotransfected with wild-type virus into an avian hepatoma cell line. Culture media containing high titers of the recombinant virus were used to infect primary duckling hepatocytes. Stable CAT gene expression was detected for at least 24 days after transfection (Chang *et al.*, 1991).

#### 5. NON-VIRAL VECTORS

In order to effect expression of the oligonucleotide or polynucleotide sequences of the present invention, the expression construct must be delivered into a cell. This delivery may be accomplished *in vitro*, as in laboratory procedures for transforming cells lines, or *in vivo* or *ex vivo*, as in the treatment of certain disease states. As described above, one preferred mechanism for delivery is *via* viral infection where the expression construct is encapsulated in an infectious viral particle.

Once the expression construct has been delivered into the cell the nucleic acid encoding the desired oligonucleotide or polynucleotide sequences may be positioned and expressed at different sites. In certain embodiments, the nucleic acid encoding the construct may be stably integrated into the genome of the cell. This integration may be in the specific location and orientation *via* homologous recombination (gene replacement) or it may be integrated in a random, non-specific location (gene augmentation). In yet further embodiments, the nucleic acid may be stably maintained in the cell as a separate, episomal segment of DNA. Such nucleic acid segments or "episomes" encode sequences sufficient to permit maintenance and replication independent of or in synchronization with the host cell cycle. How the expression construct is delivered to a cell and where in the cell the nucleic acid remains is dependent on the type of expression construct employed.

In certain embodiments of the invention, the expression construct comprising one or more oligonucleotide or polynucleotide sequences may simply consist of naked recombinant DNA or plasmids. Transfer of the construct may be performed by any of the methods mentioned above which physically or chemically permeabilize the cell membrane. This is particularly applicable for transfer *in vitro* but it may be applied to *in vivo* use as well. Dubensky *et al.* (1984) successfully injected polyomavirus DNA in the form of calcium phosphate precipitates into liver and spleen of adult and newborn mice demonstrating active viral replication and acute infection. Benvenisty and Reshef (1986) also demonstrated that direct intraperitoneal injection of calcium phosphate-precipitated plasmids results in expression of the transfected genes. It is envisioned that DNA encoding a gene of interest may also be transferred in a similar manner *in vivo* and express the gene product.

Another embodiment of the invention for transferring a naked DNA expression construct into cells may involve particle bombardment. This method depends on the ability to accelerate DNA-coated microprojectiles to a high velocity allowing them to pierce cell membranes and enter cells without killing them (Klein *et al.*, 1987). Several devices for accelerating small particles have been developed. One such device relies on a high voltage discharge to generate an electrical current, which in turn provides the motive force (Yang *et al.*, 1990). The microprojectiles used have consisted of biologically inert substances such as tungsten or gold beads.

Selected organs including the liver, skin, and muscle tissue of rats and mice have been bombarded *in vivo* (Yang *et al.*, 1990; Zelenin *et al.*, 1991). This may require surgical exposure of the tissue or cells, to eliminate any intervening tissue between the gun and the target organ, *i.e. ex vivo* treatment. Again, DNA encoding a particular gene may be delivered *via* this method and still be incorporated by the present invention.

#### ANTISENSE OLIGONUCLEOTIDES

The end result of the flow of genetic information is the synthesis of protein. DNA is transcribed by polymerases into messenger RNA and translated on the ribosome to yield a folded, functional protein. Thus there are several steps along the

route where protein synthesis can be inhibited. The native DNA segment coding for a polypeptide described herein, as all such mammalian DNA strands, has two strands: a sense strand and an antisense strand held together by hydrogen bonding. The messenger RNA coding for polypeptide has the same nucleotide sequence as the sense  
5 DNA strand except that the DNA thymidine is replaced by uridine. Thus, synthetic antisense nucleotide sequences will bind to a mRNA and inhibit expression of the protein encoded by that mRNA.

The targeting of antisense oligonucleotides to mRNA is thus one mechanism to shut down protein synthesis, and, consequently, represents a powerful  
10 and targeted therapeutic approach. For example, the synthesis of polygalacturonase and the muscarine type 2 acetylcholine receptor are inhibited by antisense oligonucleotides directed to their respective mRNA sequences (U. S. Patent 5,739,119 and U. S. Patent 5,759,829, each specifically incorporated herein by reference in its entirety). Further, examples of antisense inhibition have been demonstrated with the  
15 nuclear protein cyclin, the multiple drug resistance gene (MDG1), ICAM-1, E-selectin, STK-1, striatal GABA<sub>A</sub> receptor and human EGF (Jaskulski *et al.*, 1988; Vasanthakumar and Ahmed, 1989; Peris *et al.*, 1998; U. S. Patent 5,801,154; U. S. Patent 5,789,573; U. S. Patent 5,718,709 and U. S. Patent 5,610,288, each specifically incorporated herein by reference in its entirety). Antisense constructs have also been  
20 described that inhibit and can be used to treat a variety of abnormal cellular proliferations, *e.g.* cancer (U. S. Patent 5,747,470; U. S. Patent 5,591,317 and U. S. Patent 5,783,683, each specifically incorporated herein by reference in its entirety).

Therefore, in exemplary embodiments, the invention provides oligonucleotide sequences that comprise all, or a portion of, any sequence that is  
25 capable of specifically binding to polynucleotide sequence described herein, or a complement thereof. In one embodiment, the antisense oligonucleotides comprise DNA or derivatives thereof. In another embodiment, the oligonucleotides comprise RNA or derivatives thereof. In a third embodiment, the oligonucleotides are modified DNAs comprising a phosphorothioated modified backbone. In a fourth embodiment, the  
30 oligonucleotide sequences comprise peptide nucleic acids or derivatives thereof. In each case, preferred compositions comprise a sequence region that is complementary,

and more preferably substantially-complementary, and even more preferably, completely complementary to one or more portions of polynucleotides disclosed herein.

Selection of antisense compositions specific for a given gene sequence is based upon analysis of the chosen target sequence (*i.e.* in these illustrative examples the  
5 rat and human sequences) and determination of secondary structure,  $T_m$ , binding energy, relative stability, and antisense compositions were selected based upon their relative inability to form dimers, hairpins, or other secondary structures that would reduce or prohibit specific binding to the target mRNA in a host cell.

Highly preferred target regions of the mRNA, are those which are at or  
10 near the AUG translation initiation codon, and those sequences which were substantially complementary to 5' regions of the mRNA. These secondary structure analyses and target site selection considerations were performed using v.4 of the OLIGO primer analysis software (Rychlik, 1997) and the BLASTN 2.0.5 algorithm software (Altschul *et al.*, 1997).

15 The use of an antisense delivery method employing a short peptide vector, termed MPG (27 residues), is also contemplated. The MPG peptide contains a hydrophobic domain derived from the fusion sequence of HIV gp41 and a hydrophilic domain from the nuclear localization sequence of SV40 T-antigen (Morris *et al.*, 1997). It has been demonstrated that several molecules of the MPG peptide coat the antisense  
20 oligonucleotides and can be delivered into cultured mammalian cells in less than 1 hour with relatively high efficiency (90%). Further, the interaction with MPG strongly increases both the stability of the oligonucleotide to nuclease and the ability to cross the plasma membrane (Morris *et al.*, 1997).

## RIBOZYMES

25 Although proteins traditionally have been used for catalysis of nucleic acids, another class of macromolecules has emerged as useful in this endeavor. Ribozymes are RNA-protein complexes that cleave nucleic acids in a site-specific fashion. Ribozymes have specific catalytic domains that possess endonuclease activity (Kim and Cech, 1987; Gerlach *et al.*, 1987; Forster and Symons, 1987). For example, a  
30 large number of ribozymes accelerate phosphoester transfer reactions with a high degree

of specificity, often cleaving only one of several phosphoesters in an oligonucleotide substrate (Cech *et al.*, 1981; Michel and Westhof, 1990; Reinhold-Hurek and Shub, 1992). This specificity has been attributed to the requirement that the substrate bind via specific base-pairing interactions to the internal guide sequence ("IGS") of the ribozyme  
5 prior to chemical reaction.

Ribozyme catalysis has primarily been observed as part of sequence-specific cleavage/ligation reactions involving nucleic acids (Joyce, 1989; Cech *et al.*, 1981). For example, U. S. Patent No. 5,354,855 (specifically incorporated herein by reference) reports that certain ribozymes can act as endonucleases with a sequence  
10 specificity greater than that of known ribonucleases and approaching that of the DNA restriction enzymes. Thus, sequence-specific ribozyme-mediated inhibition of gene expression may be particularly suited to therapeutic applications (Scanlon *et al.*, 1991; Sarver *et al.*, 1990). Recently, it was reported that ribozymes elicited genetic changes in some cells lines to which they were applied; the altered genes included the oncogenes  
15 H-ras, c-fos and genes of HIV. Most of this work involved the modification of a target mRNA, based on a specific mutant codon that is cleaved by a specific ribozyme.

Six basic varieties of naturally-occurring enzymatic RNAs are known presently. Each can catalyze the hydrolysis of RNA phosphodiester bonds *in trans* (and thus can cleave other RNA molecules) under physiological conditions. In general,  
20 enzymatic nucleic acids act by first binding to a target RNA. Such binding occurs through the target binding portion of a enzymatic nucleic acid which is held in close proximity to an enzymatic portion of the molecule that acts to cleave the target RNA. Thus, the enzymatic nucleic acid first recognizes and then binds a target RNA through complementary base-pairing, and once bound to the correct site, acts enzymatically to  
25 cut the target RNA. Strategic cleavage of such a target RNA will destroy its ability to direct synthesis of an encoded protein. After an enzymatic nucleic acid has bound and cleaved its RNA target, it is released from that RNA to search for another target and can repeatedly bind and cleave new targets.

The enzymatic nature of a ribozyme is advantageous over many  
30 technologies, such as antisense technology (where a nucleic acid molecule simply binds to a nucleic acid target to block its translation) since the concentration of ribozyme



necessary to affect a therapeutic treatment is lower than that of an antisense oligonucleotide. This advantage reflects the ability of the ribozyme to act enzymatically. Thus, a single ribozyme molecule is able to cleave many molecules of target RNA. In addition, the ribozyme is a highly specific inhibitor, with the specificity  
5 of inhibition depending not only on the base pairing mechanism of binding to the target RNA, but also on the mechanism of target RNA cleavage. Single mismatches, or base-substitutions, near the site of cleavage can completely eliminate catalytic activity of a ribozyme. Similar mismatches in antisense molecules do not prevent their action (Woolf *et al.*, 1992). Thus, the specificity of action of a ribozyme is greater than that of  
10 an antisense oligonucleotide binding the same RNA site.

The enzymatic nucleic acid molecule may be formed in a hammerhead, hairpin, a hepatitis  $\delta$  virus, group I intron or RNaseP RNA (in association with an RNA guide sequence) or Neurospora VS RNA motif. Examples of hammerhead motifs are described by Rossi *et al.* (1992). Examples of hairpin motifs are described by Hampel  
15 *et al.* (Eur. Pat. Appl. Publ. No. EP 0360257), Hampel and Tritz (1989), Hampel *et al.* (1990) and U. S. Patent 5,631,359 (specifically incorporated herein by reference). An example of the hepatitis  $\delta$  virus motif is described by Perrotta and Been (1992); an example of the RNaseP motif is described by Guerrier-Takada *et al.* (1983); Neurospora VS RNA ribozyme motif is described by Collins (Saville and Collins, 1990; Saville and  
20 Collins, 1991; Collins and Olive, 1993); and an example of the Group I intron is described in (U. S. Patent 4,987,071, specifically incorporated herein by reference). All that is important in an enzymatic nucleic acid molecule of this invention is that it has a specific substrate binding site which is complementary to one or more of the target gene RNA regions, and that it have nucleotide sequences within or surrounding that substrate  
25 binding site which impart an RNA cleaving activity to the molecule. Thus the ribozyme constructs need not be limited to specific motifs mentioned herein.

In certain embodiments, it may be important to produce enzymatic cleaving agents which exhibit a high degree of specificity for the RNA of a desired target, such as one of the sequences disclosed herein. The enzymatic nucleic acid  
30 molecule is preferably targeted to a highly conserved sequence region of a target mRNA. Such enzymatic nucleic acid molecules can be delivered exogenously to

specific cells as required. Alternatively, the ribozymes can be expressed from DNA or RNA vectors that are delivered to specific cells.

Small enzymatic nucleic acid motifs (*e.g.*, of the hammerhead or the hairpin structure) may also be used for exogenous delivery. The simple structure of these molecules increases the ability of the enzymatic nucleic acid to invade targeted regions of the mRNA structure. Alternatively, catalytic RNA molecules can be expressed within cells from eukaryotic promoters (*e.g.*, Scanlon *et al.*, 1991; Kashani-Sabet *et al.*, 1992; Dropulic *et al.*, 1992; Weerasinghe *et al.*, 1991; Ojwang *et al.*, 1992; Chen *et al.*, 1992; Sarver *et al.*, 1990). Those skilled in the art realize that any ribozyme can be expressed in eukaryotic cells from the appropriate DNA vector. The activity of such ribozymes can be augmented by their release from the primary transcript by a second ribozyme (Int. Pat. Appl. Publ. No. WO 93/23569, and Int. Pat. Appl. Publ. No. WO 94/02595, both hereby incorporated by reference; Ohkawa *et al.*, 1992; Taira *et al.*, 1991; and Ventura *et al.*, 1993).

Ribozymes may be added directly, or can be complexed with cationic lipids, lipid complexes, packaged within liposomes, or otherwise delivered to target cells. The RNA or RNA complexes can be locally administered to relevant tissues *ex vivo*, or *in vivo* through injection, aerosol inhalation, infusion pump or stent, with or without their incorporation in biopolymers.

Ribozymes may be designed as described in Int. Pat. Appl. Publ. No. WO 93/23569 and Int. Pat. Appl. Publ. No. WO 94/02595, each specifically incorporated herein by reference) and synthesized to be tested *in vitro* and *in vivo*, as described. Such ribozymes can also be optimized for delivery. While specific examples are provided, those in the art will recognize that equivalent RNA targets in other species can be utilized when necessary.

Hammerhead or hairpin ribozymes may be individually analyzed by computer folding (Jaeger *et al.*, 1989) to assess whether the ribozyme sequences fold into the appropriate secondary structure. Those ribozymes with unfavorable intramolecular interactions between the binding arms and the catalytic core are eliminated from consideration. Varying binding arm lengths can be chosen to optimize

activity. Generally, at least 5 or so bases on each arm are able to bind to, or otherwise interact with, the target RNA.

Ribozymes of the hammerhead or hairpin motif may be designed to anneal to various sites in the mRNA message, and can be chemically synthesized. The method of synthesis used follows the procedure for normal RNA synthesis as described in Usman *et al.* (1987) and in Scaringe *et al.* (1990) and makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5'-end, and phosphoramidites at the 3'-end. Average stepwise coupling yields are typically >98%. Hairpin ribozymes may be synthesized in two parts and annealed to reconstruct an active ribozyme (Chowrira and Burke, 1992). Ribozymes may be modified extensively to enhance stability by modification with nuclease resistant groups, for example, 2'-amino, 2'-C-allyl, 2'-fluoro, 2'-o-methyl, 2'-H (for a review see *e.g.*, Usman and Cedergren, 1992). Ribozymes may be purified by gel electrophoresis using general methods or by high pressure liquid chromatography and resuspended in water.

Ribozyme activity can be optimized by altering the length of the ribozyme binding arms, or chemically synthesizing ribozymes with modifications that prevent their degradation by serum ribonucleases (see *e.g.*, Int. Pat. Appl. Publ. No. WO 92/07065; Perrault *et al.*, 1990; Pieken *et al.*, 1991; Usman and Cedergren, 1992; Int. Pat. Appl. Publ. No. WO 93/15187; Int. Pat. Appl. Publ. No. WO 91/03162; Eur. Pat. Appl. Publ. No. 92110298.4; U. S. Patent 5,334,711; and Int. Pat. Appl. Publ. No. WO 94/13688, which describe various chemical modifications that can be made to the sugar moieties of enzymatic RNA molecules), modifications which enhance their efficacy in cells, and removal of stem II bases to shorten RNA synthesis times and reduce chemical requirements.

Sullivan *et al.* (Int. Pat. Appl. Publ. No. WO 94/02595) describes the general methods for delivery of enzymatic RNA molecules. Ribozymes may be administered to cells by a variety of methods known to those familiar to the art, including, but not restricted to, encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres. For some indications, ribozymes may be directly delivered *ex vivo* to cells or tissues with or without the aforementioned vehicles.

Alternatively, the RNA/vehicle combination may be locally delivered by direct inhalation, by direct injection or by use of a catheter, infusion pump or stent. Other routes of delivery include, but are not limited to, intravascular, intramuscular, subcutaneous or joint injection, aerosol inhalation, oral (tablet or pill form), topical, systemic, ocular, intraperitoneal and/or intrathecal delivery. More detailed descriptions of ribozyme delivery and administration are provided in Int. Pat. Appl. Publ. No. WO 94/02595 and Int. Pat. Appl. Publ. No. WO 93/23569, each specifically incorporated herein by reference.

Another means of accumulating high concentrations of a ribozyme(s) within cells is to incorporate the ribozyme-encoding sequences into a DNA expression vector. Transcription of the ribozyme sequences are driven from a promoter for eukaryotic RNA polymerase I (pol I), RNA polymerase II (pol II), or RNA polymerase III (pol III). Transcripts from pol II or pol III promoters will be expressed at high levels in all cells; the levels of a given pol II promoter in a given cell type will depend on the nature of the gene regulatory sequences (enhancers, silencers, *etc.*) present nearby. Prokaryotic RNA polymerase promoters may also be used, providing that the prokaryotic RNA polymerase enzyme is expressed in the appropriate cells (Elroy-Stein and Moss, 1990; Gao and Huang, 1993; Lieber *et al.*, 1993; Zhou *et al.*, 1990). Ribozymes expressed from such promoters can function in mammalian cells (*e.g.* Kashani-Saber *et al.*, 1992; Ojwang *et al.*, 1992; Chen *et al.*, 1992; Yu *et al.*, 1993; L'Huillier *et al.*, 1992; Lisiewicz *et al.*, 1993). Such transcription units can be incorporated into a variety of vectors for introduction into mammalian cells, including but not restricted to, plasmid DNA vectors, viral DNA vectors (such as adenovirus or adeno-associated vectors), or viral RNA vectors (such as retroviral, semliki forest virus, sindbis virus vectors).

Ribozymes may be used as diagnostic tools to examine genetic drift and mutations within diseased cells. They can also be used to assess levels of the target RNA molecule. The close relationship between ribozyme activity and the structure of the target RNA allows the detection of mutations in any region of the molecule which alters the base-pairing and three-dimensional structure of the target RNA. By using multiple ribozymes, one may map nucleotide changes which are important to RNA

structure and function *in vitro*, as well as in cells and tissues. Cleavage of target RNAs with ribozymes may be used to inhibit gene expression and define the role (essentially) of specified gene products in the progression of disease. In this manner, other genetic targets may be defined as important mediators of the disease. These studies will lead to better treatment of the disease progression by affording the possibility of combinational therapies (*e.g.*, multiple ribozymes targeted to different genes, ribozymes coupled with known small molecule inhibitors, or intermittent treatment with combinations of ribozymes and/or other chemical or biological molecules). Other *in vitro* uses of ribozymes are well known in the art, and include detection of the presence of mRNA associated with an IL-5 related condition. Such RNA is detected by determining the presence of a cleavage product after treatment with a ribozyme using standard methodology.

#### PEPTIDE NUCLEIC ACIDS

In certain embodiments, the inventors contemplate the use of peptide nucleic acids (PNAs) in the practice of the methods of the invention. PNA is a DNA mimic in which the nucleobases are attached to a pseudopeptide backbone (Good and Nielsen, 1997). PNA is able to be utilized in a number methods that traditionally have used RNA or DNA. Often PNA sequences perform better in techniques than the corresponding RNA or DNA sequences and have utilities that are not inherent to RNA or DNA. A review of PNA including methods of making, characteristics of, and methods of using, is provided by Corey (1997) and is incorporated herein by reference. As such, in certain embodiments, one may prepare PNA sequences that are complementary to one or more portions of the ACE mRNA sequence, and such PNA compositions may be used to regulate, alter, decrease, or reduce the translation of ACE-specific mRNA, and thereby alter the level of ACE activity in a host cell to which such PNA compositions have been administered.

PNAs have 2-aminoethyl-glycine linkages replacing the normal phosphodiester backbone of DNA (Nielsen *et al.*, 1991; Hanvey *et al.*, 1992; Hyrup and Nielsen, 1996; Neilsen, 1996). This chemistry has three important consequences: firstly, in contrast to DNA or phosphorothioate oligonucleotides, PNAs are neutral

molecules; secondly, PNAs are achiral, which avoids the need to develop a stereoselective synthesis; and thirdly, PNA synthesis uses standard Boc (Dueholm *et al.*, 1994) or Fmoc (Thomson *et al.*, 1995) protocols for solid-phase peptide synthesis, although other methods, including a modified Merrifield method, have been used  
5 (Christensen *et al.*, 1995).

PNA monomers or ready-made oligomers are commercially available from PerSeptive Biosystems (Framingham, MA). PNA syntheses by either Boc or Fmoc protocols are straightforward using manual or automated protocols (Norton *et al.*, 1995). The manual protocol lends itself to the production of chemically modified PNAs  
10 or the simultaneous synthesis of families of closely related PNAs.

As with peptide synthesis, the success of a particular PNA synthesis will depend on the properties of the chosen sequence. For example, while in theory PNAs can incorporate any combination of nucleotide bases, the presence of adjacent purines can lead to deletions of one or more residues in the product. In expectation of this  
15 difficulty, it is suggested that, in producing PNAs with adjacent purines, one should repeat the coupling of residues likely to be added inefficiently. This should be followed by the purification of PNAs by reverse-phase high-pressure liquid chromatography (Norton *et al.*, 1995) providing yields and purity of product similar to those observed during the synthesis of peptides.

20 Modifications of PNAs for a given application may be accomplished by coupling amino acids during solid-phase synthesis or by attaching compounds that contain a carboxylic acid group to the exposed N-terminal amine. Alternatively, PNAs can be modified after synthesis by coupling to an introduced lysine or cysteine. The ease with which PNAs can be modified facilitates optimization for better solubility or  
25 for specific functional requirements. Once synthesized, the identity of PNAs and their derivatives can be confirmed by mass spectrometry. Several studies have made and utilized modifications of PNAs (Norton *et al.*, 1995; Haaima *et al.*, 1996; Stetsenko *et al.*, 1996; Petersen *et al.*, 1995; Ulmann *et al.*, 1996; Koch *et al.*, 1995; Orum *et al.*, 1995; Footer *et al.*, 1996; Griffith *et al.*, 1995; Kremsky *et al.*, 1996; Pardridge *et al.*,  
30 1995; Boffa *et al.*, 1995; Landsdorp *et al.*, 1996; Gambacorti-Passerini *et al.*, 1996; Armitage *et al.*, 1997; Seeger *et al.*, 1997; Ruskowski *et al.*, 1997). U.S. Patent No.

5,700,922 discusses PNA-DNA-PNA chimeric molecules and their uses in diagnostics, modulating protein in organisms, and treatment of conditions susceptible to therapeutics.

In contrast to DNA and RNA, which contain negatively charged linkages, the PNA backbone is neutral. In spite of this dramatic alteration, PNAs recognize complementary DNA and RNA by Watson-Crick pairing (Egholm *et al.*, 1993), validating the initial modeling by Nielsen *et al.* (1991). PNAs lack 3' to 5' polarity and can bind in either parallel or antiparallel fashion, with the antiparallel mode being preferred (Egholm *et al.*, 1993).

Hybridization of DNA oligonucleotides to DNA and RNA is destabilized by electrostatic repulsion between the negatively charged phosphate backbones of the complementary strands. By contrast, the absence of charge repulsion in PNA-DNA or PNA-RNA duplexes increases the melting temperature ( $T_m$ ) and reduces the dependence of  $T_m$  on the concentration of mono- or divalent cations (Nielsen *et al.*, 1991). The enhanced rate and affinity of hybridization are significant because they are responsible for the surprising ability of PNAs to perform strand invasion of complementary sequences within relaxed double-stranded DNA. In addition, the efficient hybridization at inverted repeats suggests that PNAs can recognize secondary structure effectively within double-stranded DNA. Enhanced recognition also occurs with PNAs immobilized on surfaces, and Wang *et al.* have shown that support-bound PNAs can be used to detect hybridization events (Wang *et al.*, 1996).

One might expect that tight binding of PNAs to complementary sequences would also increase binding to similar (but not identical) sequences, reducing the sequence specificity of PNA recognition. As with DNA hybridization, however, selective recognition can be achieved by balancing oligomer length and incubation temperature. Moreover, selective hybridization of PNAs is encouraged by PNA-DNA hybridization being less tolerant of base mismatches than DNA-DNA hybridization. For example, a single mismatch within a 16 bp PNA-DNA duplex can reduce the  $T_m$  by up to 15°C (Egholm *et al.*, 1993). This high level of discrimination has allowed the development of several PNA-based strategies for the analysis of point mutations (Wang

*et al.*, 1996; Carlsson *et al.*, 1996; Thiede *et al.*, 1996; Webb and Hurskainen, 1996; Perry-O'Keefe *et al.*, 1996).

High-affinity binding provides clear advantages for molecular recognition and the development of new applications for PNAs. For example, 11-13  
5 nucleotide PNAs inhibit the activity of telomerase, a ribonucleo-protein that extends telomere ends using an essential RNA template, while the analogous DNA oligomers do not (Norton *et al.*, 1996).

Neutral PNAs are more hydrophobic than analogous DNA oligomers, and this can lead to difficulty solubilizing them at neutral pH, especially if the PNAs  
10 have a high purine content or if they have the potential to form secondary structures. Their solubility can be enhanced by attaching one or more positive charges to the PNA termini (Nielsen *et al.*, 1991).

Findings by Allfrey and colleagues suggest that strand invasion will occur spontaneously at sequences within chromosomal DNA (Boffa *et al.*, 1995; Boffa  
15 *et al.*, 1996). These studies targeted PNAs to triplet repeats of the nucleotides CAG and used this recognition to purify transcriptionally active DNA (Boffa *et al.*, 1995) and to inhibit transcription (Boffa *et al.*, 1996). This result suggests that if PNAs can be delivered within cells then they will have the potential to be general sequence-specific regulators of gene expression. Studies and reviews concerning the use of PNAs as  
20 antisense and anti-gene agents include Nielsen *et al.* (1993b), Hanvey *et al.* (1992), and Good and Nielsen (1997). Koppelhus *et al.* (1997) have used PNAs to inhibit HIV-1 inverse transcription, showing that PNAs may be used for antiviral therapies.

Methods of characterizing the antisense binding properties of PNAs are discussed in Rose (1993) and Jensen *et al.* (1997). Rose uses capillary gel  
25 electrophoresis to determine binding of PNAs to their complementary oligonucleotide, measuring the relative binding kinetics and stoichiometry. Similar types of measurements were made by Jensen *et al.* using BIAcore™ technology.

Other applications of PNAs include use in DNA strand invasion (Nielsen *et al.*, 1991), antisense inhibition (Hanvey *et al.*, 1992), mutational analysis (Orum *et al.*, 1993), enhancers of transcription (Mollegaard *et al.*, 1994), nucleic acid purification  
30 (Orum *et al.*, 1995), isolation of transcriptionally active genes (Boffa *et al.*, 1995),



blocking of transcription factor binding (Vickers *et al.*, 1995), genome cleavage (Veselkov *et al.*, 1996), biosensors (Wang *et al.*, 1996), *in situ* hybridization (Thisted *et al.*, 1996), and in an alternative to Southern blotting (Perry-O'Keefe, 1996).

#### POLYPEPTIDE COMPOSITIONS

5                   The present invention, in other aspects, provides polypeptide compositions. Generally, a polypeptide of the invention will be an isolated polypeptide (or an epitope, variant, or active fragment thereof) derived from a mammalian species. Preferably, the polypeptide is encoded by a polynucleotide sequence disclosed herein or a sequence which hybridizes under moderately stringent conditions to a polynucleotide  
10                   sequence disclosed herein. Alternatively, the polypeptide may be defined as a polypeptide which comprises a contiguous amino acid sequence from an amino acid sequence disclosed herein, or which polypeptide comprises an entire amino acid sequence disclosed herein.

                  In the present invention, a polypeptide composition is also understood to  
15                   comprise one or more polypeptides that are immunologically reactive with antibodies generated against a polypeptide of the invention, or to active fragments, or to variants or biological functional equivalents thereof.

                  Likewise, a polypeptide composition of the present invention is understood to comprise one or more polypeptides that are capable of eliciting antibodies  
20                   that are immunologically reactive with one or more polypeptides encoded by one or more contiguous nucleic acid sequences contained in SEQ ID NO: 1-38, 42-204, 205, 207 and 210-290, or to active fragments, or to variants thereof, or to one or more nucleic acid sequences which hybridize to one or more of these sequences under conditions of moderate to high stringency.

25                   As used herein, an active fragment of a polypeptide includes a whole or a portion of a polypeptide which is modified by conventional techniques, *e.g.*, mutagenesis, or by addition, deletion, or substitution, but which active fragment exhibits substantially the same structure function, antigenicity, etc., as a polypeptide as described herein.

In certain illustrative embodiments, the polypeptides of the invention will comprise at least an immunogenic portion of a breast tumor protein or a variant thereof, as described herein. As noted above, a "breast tumor protein" is a protein that is expressed by breast tumor cells. Proteins that are breast tumor proteins react  
5 detectably within an immunoassay (such as an ELISA) with antisera from a patient with breast cancer. Polypeptides as described herein may be of any length. Additional sequences derived from the native protein and/or heterologous sequences may be present, and such sequences may (but need not) possess further immunogenic or antigenic properties.

10 An "immunogenic portion," as used herein is a portion of a protein that is recognized (*i.e.*, specifically bound) by a B-cell and/or T-cell surface antigen receptor. Such immunogenic portions generally comprise at least 5 amino acid residues, more preferably at least 10, and still more preferably at least 20 amino acid residues of a breast tumor protein or a variant thereof. Certain preferred immunogenic  
15 portions include peptides in which an N-terminal leader sequence and/or transmembrane domain have been deleted. Other preferred immunogenic portions may contain a small N- and/or C-terminal deletion (*e.g.*, 1-30 amino acids, preferably 5-15 amino acids), relative to the mature protein.

Immunogenic portions may generally be identified using well known  
20 techniques, such as those summarized in Paul, *Fundamental Immunology*, 3rd ed., 243-247 (Raven Press, 1993) and references cited therein. Such techniques include screening polypeptides for the ability to react with antigen-specific antibodies, antisera and/or T-cell lines or clones. As used herein, antisera and antibodies are "antigen-specific" if they specifically bind to an antigen (*i.e.*, they react with the protein in an  
25 ELISA or other immunoassay, and do not react detectably with unrelated proteins). Such antisera and antibodies may be prepared as described herein, and using well known techniques. An immunogenic portion of a native breast tumor protein is a portion that reacts with such antisera and/or T-cells at a level that is not substantially less than the reactivity of the full length polypeptide (*e.g.*, in an ELISA and/or T-cell  
30 reactivity assay). Such immunogenic portions may react within such assays at a level that is similar to or greater than the reactivity of the full length polypeptide. Such

5 screens may generally be performed using methods well known to those of ordinary skill in the art, such as those described in Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1980. For example, a polypeptide may be immobilized on a solid support and contacted with patient sera to allow binding of antibodies within the sera to the immobilized polypeptide. Unbound sera may then be removed and bound antibodies detected using, for example, <sup>125</sup>I-labeled Protein A.

As noted above, a composition may comprise a variant of a native breast tumor protein. A polypeptide "variant," as used herein, is a polypeptide that differs from a native breast tumor protein in one or more substitutions, deletions, additions  
10 and/or insertions, such that the immunogenicity of the polypeptide is not substantially diminished. In other words, the ability of a variant to react with antigen-specific antisera may be enhanced or unchanged, relative to the native protein, or may be diminished by less than 50%, and preferably less than 20%, relative to the native protein. Such variants may generally be identified by modifying one of the above  
15 polypeptide sequences and evaluating the reactivity of the modified polypeptide with antigen-specific antibodies or antisera as described herein. Preferred variants include those in which one or more portions, such as an N-terminal leader sequence or transmembrane domain, have been removed. Other preferred variants include variants in which a small portion (*e.g.*, 1-30 amino acids, preferably 5-15 amino acids) has been  
20 removed from the N- and/or C-terminal of the mature protein.

Polypeptide variants encompassed by the present invention include those exhibiting at least about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more identity (determined as described above) to the polypeptides disclosed herein.

25 Preferably, a variant contains conservative substitutions. A "conservative substitution" is one in which an amino acid is substituted for another amino acid that has similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydrophobic nature of the polypeptide to be substantially unchanged. Amino acid substitutions may generally be  
30 made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity and/or the amphipathic nature of the residues. For example, negatively

charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine and valine; glycine and alanine; asparagine and glutamine; and serine, threonine, phenylalanine and tyrosine.

- 5 Other groups of amino acids that may represent conservative changes include: (1) ala, pro, gly, glu, asp, gln, asn, ser, thr; (2) cys, ser, tyr, thr; (3) val, ile, leu, met, ala, phe; (4) lys, arg, his; and (5) phe, tyr, trp, his. A variant may also, or alternatively, contain nonconservative changes. In a preferred embodiment, variant polypeptides differ from a native sequence by substitution, deletion or addition of five amino acids or fewer.
- 10 Variants may also (or alternatively) be modified by, for example, the deletion or addition of amino acids that have minimal influence on the immunogenicity, secondary structure and hydrophobic nature of the polypeptide.

As noted above, polypeptides may comprise a signal (or leader) sequence at the N-terminal end of the protein, which co-translationally or post-translationally directs transfer of the protein. The polypeptide may also be conjugated to a linker or other sequence for ease of synthesis, purification or identification of the polypeptide (e.g., poly-His), or to enhance binding of the polypeptide to a solid support. For example, a polypeptide may be conjugated to an immunoglobulin Fc region.

15

Polypeptides may be prepared using any of a variety of well known techniques. Recombinant polypeptides encoded by DNA sequences as described above may be readily prepared from the DNA sequences using any of a variety of expression vectors known to those of ordinary skill in the art. Expression may be achieved in any appropriate host cell that has been transformed or transfected with an expression vector containing a DNA molecule that encodes a recombinant polypeptide. Suitable host cells include prokaryotes, yeast, and higher eukaryotic cells, such as mammalian cells and plant cells. Preferably, the host cells employed are *E. coli*, yeast or a mammalian cell line such as COS or CHO. Supernatants from suitable host/vector systems which secrete recombinant protein or polypeptide into culture media may be first concentrated using a commercially available filter. Following concentration, the concentrate may be applied to a suitable purification matrix such as an affinity matrix or an ion exchange

20

25

30

resin. Finally, one or more reverse phase HPLC steps can be employed to further purify a recombinant polypeptide.

Portions and other variants having less than about 100 amino acids, and generally less than about 50 amino acids, may also be generated by synthetic means, using techniques well known to those of ordinary skill in the art. For example, such polypeptides may be synthesized using any of the commercially available solid-phase techniques, such as the Merrifield solid-phase synthesis method, where amino acids are sequentially added to a growing amino acid chain. See Merrifield, *J. Am. Chem. Soc.* 85:2149-2146, 1963. Equipment for automated synthesis of polypeptides is commercially available from suppliers such as Perkin Elmer/Applied BioSystems Division (Foster City, CA), and may be operated according to the manufacturer's instructions.

Within certain specific embodiments, a polypeptide may be a fusion protein that comprises multiple polypeptides as described herein, or that comprises at least one polypeptide as described herein and an unrelated sequence, such as a known tumor protein. A fusion partner may, for example, assist in providing T helper epitopes (an immunological fusion partner), preferably T helper epitopes recognized by humans, or may assist in expressing the protein (an expression enhancer) at higher yields than the native recombinant protein. Certain preferred fusion partners are both immunological and expression enhancing fusion partners. Other fusion partners may be selected so as to increase the solubility of the protein or to enable the protein to be targeted to desired intracellular compartments. Still further fusion partners include affinity tags, which facilitate purification of the protein.

Fusion proteins may generally be prepared using standard techniques, including chemical conjugation. Preferably, a fusion protein is expressed as a recombinant protein, allowing the production of increased levels, relative to a non-fused protein, in an expression system. Briefly, DNA sequences encoding the polypeptide components may be assembled separately, and ligated into an appropriate expression vector. The 3' end of the DNA sequence encoding one polypeptide component is ligated, with or without a peptide linker, to the 5' end of a DNA sequence encoding the second polypeptide component so that the reading frames of the sequences are in phase.

This permits translation into a single fusion protein that retains the biological activity of both component polypeptides.

A peptide linker sequence may be employed to separate the first and second polypeptide components by a distance sufficient to ensure that each polypeptide folds into its secondary and tertiary structures. Such a peptide linker sequence is incorporated into the fusion protein using standard techniques well known in the art. Suitable peptide linker sequences may be chosen based on the following factors: (1) their ability to adopt a flexible extended conformation; (2) their inability to adopt a secondary structure that could interact with functional epitopes on the first and second polypeptides; and (3) the lack of hydrophobic or charged residues that might react with the polypeptide functional epitopes. Preferred peptide linker sequences contain Gly, Asn and Ser residues. Other near neutral amino acids, such as Thr and Ala may also be used in the linker sequence. Amino acid sequences which may be usefully employed as linkers include those disclosed in Maratea et al., *Gene* 40:39-46, 1985; Murphy et al., *Proc. Natl. Acad. Sci. USA* 83:8258-8262, 1986; U.S. Patent No. 4,935,233 and U.S. Patent No. 4,751,180. The linker sequence may generally be from 1 to about 50 amino acids in length. Linker sequences are not required when the first and second polypeptides have non-essential N-terminal amino acid regions that can be used to separate the functional domains and prevent steric interference.

The ligated DNA sequences are operably linked to suitable transcriptional or translational regulatory elements. The regulatory elements responsible for expression of DNA are located only 5' to the DNA sequence encoding the first polypeptides. Similarly, stop codons required to end translation and transcription termination signals are only present 3' to the DNA sequence encoding the second polypeptide.

Fusion proteins are also provided. Such proteins comprise a polypeptide as described herein together with an unrelated immunogenic protein. Preferably the immunogenic protein is capable of eliciting a recall response. Examples of such proteins include tetanus, tuberculosis and hepatitis proteins (*see, for example, Stoute et al. New Engl. J. Med.*, 336:86-91, 1997).

Within preferred embodiments, an immunological fusion partner is derived from protein D, a surface protein of the gram-negative bacterium *Haemophilus influenza B* (WO 91/18926). Preferably, a protein D derivative comprises approximately the first third of the protein (e.g., the first N-terminal 100-110 amino acids), and a protein D derivative may be lipidated. Within certain preferred  
5       embodiments, the first 109 residues of a Lipoprotein D fusion partner is included on the N-terminus to provide the polypeptide with additional exogenous T-cell epitopes and to increase the expression level in *E. coli* (thus functioning as an expression enhancer). The lipid tail ensures optimal presentation of the antigen to antigen presenting cells.

10       Other fusion partners include the non-structural protein from influenzae virus, NS1 (hemagglutinin). Typically, the N-terminal 81 amino acids are used, although different fragments that include T-helper epitopes may be used.

In another embodiment, the immunological fusion partner is the protein known as LYTA, or a portion thereof (preferably a C-terminal portion). LYTA is  
15       derived from *Streptococcus pneumoniae*, which synthesizes an N-acetyl-L-alanine amidase known as amidase LYTA (encoded by the *LytA* gene; *Gene* 43:265-292, 1986). LYTA is an autolysin that specifically degrades certain bonds in the peptidoglycan backbone. The C-terminal domain of the LYTA protein is responsible for the affinity to the choline or to some choline analogues such as DEAE. This  
20       property has been exploited for the development of *E. coli* C-LYTA expressing plasmids useful for expression of fusion proteins. Purification of hybrid proteins containing the C-LYTA fragment at the amino terminus has been described (see *Biotechnology* 10:795-798, 1992). Within a preferred embodiment, a repeat portion of LYTA may be incorporated into a fusion protein. A repeat portion is found in the C-  
25       terminal region starting at residue 178. A particularly preferred repeat portion incorporates residues 188-305.

In general, polypeptides (including fusion proteins) and polynucleotides as described herein are isolated. An "isolated" polypeptide or polynucleotide is one that is removed from its original environment. For example, a naturally-occurring protein is  
30       isolated if it is separated from some or all of the coexisting materials in the natural system. Preferably, such polypeptides are at least about 90% pure, more preferably at

least about 95% pure and most preferably at least about 99% pure. A polynucleotide is considered to be isolated if, for example, it is cloned into a vector that is not a part of the natural environment.

#### BINDING AGENTS

5           The present invention further provides agents, such as antibodies and antigen-binding fragments thereof, that specifically bind to a breast tumor protein. As used herein, an antibody, or antigen-binding fragment thereof, is said to "specifically bind" to a breast tumor protein if it reacts at a detectable level (within, for example, an ELISA) with a breast tumor protein, and does not react detectably with unrelated  
10 proteins under similar conditions. As used herein, "binding" refers to a noncovalent association between two separate molecules such that a complex is formed. The ability to bind may be evaluated by, for example, determining a binding constant for the formation of the complex. The binding constant is the value obtained when the concentration of the complex is divided by the product of the component  
15 concentrations. In general, two compounds are said to "bind," in the context of the present invention, when the binding constant for complex formation exceeds about  $10^3$  L/mol. The binding constant may be determined using methods well known in the art.

Binding agents may be further capable of differentiating between patients with and without a cancer, such as breast cancer, using the representative assays  
20 provided herein. In other words, antibodies or other binding agents that bind to a breast tumor protein will generate a signal indicating the presence of a cancer in at least about 20% of patients with the disease, and will generate a negative signal indicating the absence of the disease in at least about 90% of individuals without the cancer. To determine whether a binding agent satisfies this requirement, biological samples (*e.g.*,  
25 blood, sera, sputum, urine and/or tumor biopsies) from patients with and without a cancer (as determined using standard clinical tests) may be assayed as described herein for the presence of polypeptides that bind to the binding agent. It will be apparent that a statistically significant number of samples with and without the disease should be assayed. Each binding agent should satisfy the above criteria; however, those of



ordinary skill in the art will recognize that binding agents may be used in combination to improve sensitivity.

Any agent that satisfies the above requirements may be a binding agent. For example, a binding agent may be a ribosome, with or without a peptide component, an RNA molecule or a polypeptide. In a preferred embodiment, a binding agent is an antibody or an antigen-binding fragment thereof. Antibodies may be prepared by any of a variety of techniques known to those of ordinary skill in the art. *See, e.g.,* Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988. In general, antibodies can be produced by cell culture techniques, including the generation of monoclonal antibodies as described herein, or via transfection of antibody genes into suitable bacterial or mammalian cell hosts, in order to allow for the production of recombinant antibodies. In one technique, an immunogen comprising the polypeptide is initially injected into any of a wide variety of mammals (*e.g.,* mice, rats, rabbits, sheep or goats). In this step, the polypeptides of this invention may serve as the immunogen without modification. Alternatively, particularly for relatively short polypeptides, a superior immune response may be elicited if the polypeptide is joined to a carrier protein, such as bovine serum albumin or keyhole limpet hemocyanin. The immunogen is injected into the animal host, preferably according to a predetermined schedule incorporating one or more booster immunizations, and the animals are bled periodically. Polyclonal antibodies specific for the polypeptide may then be purified from such antisera by, for example, affinity chromatography using the polypeptide coupled to a suitable solid support.

Monoclonal antibodies specific for an antigenic polypeptide of interest may be prepared, for example, using the technique of Kohler and Milstein, *Eur. J. Immunol.* 6:511-519, 1976, and improvements thereto. Briefly, these methods involve the preparation of immortal cell lines capable of producing antibodies having the desired specificity (*i.e.,* reactivity with the polypeptide of interest). Such cell lines may be produced, for example, from spleen cells obtained from an animal immunized as described above. The spleen cells are then immortalized by, for example, fusion with a myeloma cell fusion partner, preferably one that is syngeneic with the immunized animal. A variety of fusion techniques may be employed. For example, the spleen cells

and myeloma cells may be combined with a nonionic detergent for a few minutes and then plated at low density on a selective medium that supports the growth of hybrid cells, but not myeloma cells. A preferred selection technique uses HAT (hypoxanthine, aminopterin, thymidine) selection. After a sufficient time, usually about 1 to 2 weeks, colonies of hybrids are observed. Single colonies are selected and their culture supernatants tested for binding activity against the polypeptide. Hybridomas having high reactivity and specificity are preferred.

Monoclonal antibodies may be isolated from the supernatants of growing hybridoma colonies. In addition, various techniques may be employed to enhance the yield, such as injection of the hybridoma cell line into the peritoneal cavity of a suitable vertebrate host, such as a mouse. Monoclonal antibodies may then be harvested from the ascites fluid or the blood. Contaminants may be removed from the antibodies by conventional techniques, such as chromatography, gel filtration, precipitation, and extraction. The polypeptides of this invention may be used in the purification process in, for example, an affinity chromatography step.

Within certain embodiments, the use of antigen-binding fragments of antibodies may be preferred. Such fragments include Fab fragments, which may be prepared using standard techniques. Briefly, immunoglobulins may be purified from rabbit serum by affinity chromatography on Protein A bead columns (Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988) and digested by papain to yield Fab and Fc fragments. The Fab and Fc fragments may be separated by affinity chromatography on protein A bead columns.

Monoclonal antibodies of the present invention may be coupled to one or more therapeutic agents. Suitable agents in this regard include radionuclides, differentiation inducers, drugs, toxins, and derivatives thereof. Preferred radionuclides include  $^{90}\text{Y}$ ,  $^{123}\text{I}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{186}\text{Re}$ ,  $^{188}\text{Re}$ ,  $^{211}\text{At}$ , and  $^{212}\text{Bi}$ . Preferred drugs include methotrexate, and pyrimidine and purine analogs. Preferred differentiation inducers include phorbol esters and butyric acid. Preferred toxins include ricin, abrin, diphtheria toxin, cholera toxin, gelonin, *Pseudomonas* exotoxin, *Shigella* toxin, and pokeweed antiviral protein.

A therapeutic agent may be coupled (*e.g.*, covalently bonded) to a suitable monoclonal antibody either directly or indirectly (*e.g.*, via a linker group). A direct reaction between an agent and an antibody is possible when each possesses a substituent capable of reacting with the other. For example, a nucleophilic group, such as an amino or sulfhydryl group, on one may be capable of reacting with a carbonyl-containing group, such as an anhydride or an acid halide, or with an alkyl group containing a good leaving group (*e.g.*, a halide) on the other.

Alternatively, it may be desirable to couple a therapeutic agent and an antibody via a linker group. A linker group can function as a spacer to distance an antibody from an agent in order to avoid interference with binding capabilities. A linker group can also serve to increase the chemical reactivity of a substituent on an agent or an antibody, and thus increase the coupling efficiency. An increase in chemical reactivity may also facilitate the use of agents, or functional groups on agents, which otherwise would not be possible.

It will be evident to those skilled in the art that a variety of bifunctional or polyfunctional reagents, both homo- and hetero-functional (such as those described in the catalog of the Pierce Chemical Co., Rockford, IL), may be employed as the linker group. Coupling may be effected, for example, through amino groups, carboxyl groups, sulfhydryl groups or oxidized carbohydrate residues. There are numerous references describing such methodology, *e.g.*, U.S. Patent No. 4,671,958, to Rodwell et al.

Where a therapeutic agent is more potent when free from the antibody portion of the immunoconjugates of the present invention, it may be desirable to use a linker group which is cleavable during or upon internalization into a cell. A number of different cleavable linker groups have been described. The mechanisms for the intracellular release of an agent from these linker groups include cleavage by reduction of a disulfide bond (*e.g.*, U.S. Patent No. 4,489,710, to Spitler), by irradiation of a photolabile bond (*e.g.*, U.S. Patent No. 4,625,014, to Senter et al.), by hydrolysis of derivatized amino acid side chains (*e.g.*, U.S. Patent No. 4,638,045, to Kohn et al.), by serum complement-mediated hydrolysis (*e.g.*, U.S. Patent No. 4,671,958, to Rodwell et al.), and acid-catalyzed hydrolysis (*e.g.*, U.S. Patent No. 4,569,789, to Blattler et al.).

It may be desirable to couple more than one agent to an antibody. In one embodiment, multiple molecules of an agent are coupled to one antibody molecule. In another embodiment, more than one type of agent may be coupled to one antibody. Regardless of the particular embodiment, immunoconjugates with more than one agent  
5 may be prepared in a variety of ways. For example, more than one agent may be coupled directly to an antibody molecule, or linkers that provide multiple sites for attachment can be used. Alternatively, a carrier can be used.

A carrier may bear the agents in a variety of ways, including covalent bonding either directly or via a linker group. Suitable carriers include proteins such as  
10 albumins (*e.g.*, U.S. Patent No. 4,507,234, to Kato et al.), peptides and polysaccharides such as aminodextran (*e.g.*, U.S. Patent No. 4,699,784, to Shih et al.). A carrier may also bear an agent by noncovalent bonding or by encapsulation, such as within a liposome vesicle (*e.g.*, U.S. Patent Nos. 4,429,008 and 4,873,088). Carriers specific for radionuclide agents include radiohalogenated small molecules and chelating  
15 compounds. For example, U.S. Patent No. 4,735,792 discloses representative radiohalogenated small molecules and their synthesis. A radionuclide chelate may be formed from chelating compounds that include those containing nitrogen and sulfur atoms as the donor atoms for binding the metal, or metal oxide, radionuclide. For example, U.S. Patent No. 4,673,562, to Davison et al. discloses representative chelating  
20 compounds and their synthesis.

A variety of routes of administration for the antibodies and immunoconjugates may be used. Typically, administration will be intravenous, intramuscular, subcutaneous or in the bed of a resected tumor. It will be evident that the precise dose of the antibody/immunoconjugate will vary depending upon the antibody  
25 used, the antigen density on the tumor, and the rate of clearance of the antibody.

## T CELLS

Immunotherapeutic compositions may also, or alternatively, comprise T cells specific for a breast tumor protein. Such cells may generally be prepared *in vitro* or *ex vivo*, using standard procedures. For example, T cells may be isolated from bone  
30 marrow, peripheral blood, or a fraction of bone marrow or peripheral blood of a patient,

using a commercially available cell separation system, such as the Isolex™ System, available from Nexell Therapeutics, Inc. (Irvine, CA; see also U.S. Patent No. 5,240,856; U.S. Patent No. 5,215,926; WO 89/06280; WO 91/16116 and WO 92/07243). Alternatively, T cells may be derived from related or unrelated humans,  
5 non-human mammals, cell lines or cultures.

T cells may be stimulated with a breast tumor polypeptide, polynucleotide encoding a breast tumor polypeptide and/or an antigen presenting cell (APC) that expresses such a polypeptide. Such stimulation is performed under conditions and for a time sufficient to permit the generation of T cells that are specific  
10 for the polypeptide. Preferably, a breast tumor polypeptide or polynucleotide is present within a delivery vehicle, such as a microsphere, to facilitate the generation of specific T cells.

T cells are considered to be specific for a breast tumor polypeptide if the T cells specifically proliferate, secrete cytokines or kill target cells coated with the polypeptide or expressing a gene encoding the polypeptide. T cell specificity may be  
15 evaluated using any of a variety of standard techniques. For example, within a chromium release assay or proliferation assay, a stimulation index of more than two fold increase in lysis and/or proliferation, compared to negative controls, indicates T cell specificity. Such assays may be performed, for example, as described in Chen et al., *Cancer Res.* 54:1065-1070, 1994. Alternatively, detection of the proliferation of  
20 T cells may be accomplished by a variety of known techniques. For example, T cell proliferation can be detected by measuring an increased rate of DNA synthesis (*e.g.*, by pulse-labeling cultures of T cells with tritiated thymidine and measuring the amount of tritiated thymidine incorporated into DNA). Contact with a breast tumor polypeptide  
25 (100 ng/ml - 100 µg/ml, preferably 200 ng/ml - 25 µg/ml) for 3 - 7 days should result in at least a two fold increase in proliferation of the T cells. Contact as described above for 2-3 hours should result in activation of the T cells, as measured using standard cytokine assays in which a two fold increase in the level of cytokine release (*e.g.*, TNF or IFN-γ) is indicative of T cell activation (*see* Coligan et al., *Current Protocols in*  
30 *Immunology*, vol. 1, Wiley Interscience (Greene 1998)). T cells that have been activated in response to a breast tumor polypeptide, polynucleotide or polypeptide-

expressing APC may be CD4<sup>+</sup> and/or CD8<sup>+</sup>. Breast tumor protein-specific T cells may be expanded using standard techniques. Within preferred embodiments, the T cells are derived from a patient, a related donor or an unrelated donor, and are administered to the patient following stimulation and expansion.

5                   For therapeutic purposes, CD4<sup>+</sup> or CD8<sup>+</sup> T cells that proliferate in response to a breast tumor polypeptide, polynucleotide or APC can be expanded in number either *in vitro* or *in vivo*. Proliferation of such T cells *in vitro* may be accomplished in a variety of ways. For example, the T cells can be re-exposed to a breast tumor polypeptide, or a short peptide corresponding to an immunogenic portion  
10 of such a polypeptide, with or without the addition of T cell growth factors, such as interleukin-2, and/or stimulator cells that synthesize a breast tumor polypeptide. Alternatively, one or more T cells that proliferate in the presence of a breast tumor protein can be expanded in number by cloning. Methods for cloning cells are well known in the art, and include limiting dilution.

## 15   PHARMACEUTICAL COMPOSITIONS

In additional embodiments, the present invention concerns formulation of one or more of the polynucleotide, polypeptide, T-cell and/or antibody compositions disclosed herein in pharmaceutically-acceptable solutions for administration to a cell or an animal, either alone, or in combination with one or more other modalities of therapy.

20                   It will also be understood that, if desired, the nucleic acid segment, RNA, DNA or PNA compositions that express a polypeptide as disclosed herein may be administered in combination with other agents as well, such as, *e.g.*, other proteins or polypeptides or various pharmaceutically-active agents. In fact, there is virtually no limit to other components that may also be included, given that the additional agents do  
25 not cause a significant adverse effect upon contact with the target cells or host tissues. The compositions may thus be delivered along with various other agents as required in the particular instance. Such compositions may be purified from host cells or other biological sources, or alternatively may be chemically synthesized as described herein. Likewise, such compositions may further comprise substituted or derivatized RNA or  
30 DNA compositions.

Formulation of pharmaceutically-acceptable excipients and carrier solutions is well-known to those of skill in the art, as is the development of suitable dosing and treatment regimens for using the particular compositions described herein in a variety of treatment regimens, including *e.g.*, oral, parenteral, intravenous, intranasal, and intramuscular administration and formulation.

#### 1. ORAL DELIVERY

In certain applications, the pharmaceutical compositions disclosed herein may be delivered *via* oral administration to an animal. As such, these compositions may be formulated with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard- or soft-shell gelatin capsule, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet.

The active compounds may even be incorporated with excipients and used in the form of ingestible tablets, buccal tables, troches, capsules, elixirs, suspensions, syrups, wafers, and the like (Mathiowitz *et al.*, 1997; Hwang *et al.*, 1998; U. S. Patent 5,641,515; U. S. Patent 5,580,579 and U. S. Patent 5,792,451, each specifically incorporated herein by reference in its entirety). The tablets, troches, pills, capsules and the like may also contain the following: a binder, as gum tragacanth, acacia, cornstarch, or gelatin; excipients, such as dicalcium phosphate; a disintegrating agent, such as corn starch, potato starch, alginic acid and the like; a lubricant, such as magnesium stearate; and a sweetening agent, such as sucrose, lactose or saccharin may be added or a flavoring agent, such as peppermint, oil of wintergreen, or cherry flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar, or both. A syrup or elixir may contain the active compound sucrose as a sweetening agent methyl and propylparabens as preservatives, a dye and flavoring, such as cherry or orange flavor. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In

addition, the active compounds may be incorporated into sustained-release preparation and formulations.

Typically, these formulations may contain at least about 0.1% of the active compound or more, although the percentage of the active ingredient(s) may, of course, be varied and may conveniently be between about 1 or 2% and about 60% or 70% or more of the weight or volume of the total formulation. Naturally, the amount of active compound(s) in each therapeutically useful composition may be prepared in such a way that a suitable dosage will be obtained in any given unit dose of the compound. Factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life, as well as other pharmacological considerations will be contemplated by one skilled in the art of preparing such pharmaceutical formulations, and as such, a variety of dosages and treatment regimens may be desirable.

For oral administration the compositions of the present invention may alternatively be incorporated with one or more excipients in the form of a mouthwash, dentifrice, buccal tablet, oral spray, or sublingual orally-administered formulation. For example, a mouthwash may be prepared incorporating the active ingredient in the required amount in an appropriate solvent, such as a sodium borate solution (Dobell's Solution). Alternatively, the active ingredient may be incorporated into an oral solution such as one containing sodium borate, glycerin and potassium bicarbonate, or dispersed in a dentifrice, or added in a therapeutically-effective amount to a composition that may include water, binders, abrasives, flavoring agents, foaming agents, and humectants. Alternatively the compositions may be fashioned into a tablet or solution form that may be placed under the tongue or otherwise dissolved in the mouth.

## 2. INJECTABLE DELIVERY

In certain circumstances it will be desirable to deliver the pharmaceutical compositions disclosed herein parenterally, intravenously, intramuscularly, or even intraperitoneally as described in U. S. Patent 5,543,158; U. S. Patent 5,641,515 and U. S. Patent 5,399,363 (each specifically incorporated herein by reference in its entirety). Solutions of the active compounds as free base or pharmacologically acceptable salts may be prepared in water suitably mixed with a surfactant, such as



hydroxypropylcellulose. Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

5                   The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions (U. S. Patent 5,466,468, specifically incorporated herein by reference in its entirety). In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable  
10 under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (*e.g.*, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils. Proper fluidity may be maintained, for  
15 example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be facilitated by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars  
20 or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered  
25 isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, a sterile aqueous medium that can be employed will be known to those of skill in the art in light of the present disclosure. For example, one dosage may be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml  
30 of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 1035-1038 and 1570-

1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject. Moreover, for human administration, preparations should meet sterility, pyrogenicity, and the general safety  
5 and purity standards as required by FDA Office of Biologics standards.

Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a  
10 sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered  
15 solution thereof.

The compositions disclosed herein may be formulated in a neutral or salt form. Pharmaceutically-acceptable salts, include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic,  
20 oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like. Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount  
25 as is therapeutically effective. The formulations are easily administered in a variety of dosage forms such as injectable solutions, drug-release capsules, and the like.

As used herein, "carrier" includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like. The use  
30 of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active

ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

The phrase "pharmaceutically-acceptable" refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a human. The preparation of an aqueous composition that contains a protein as an active ingredient is well understood in the art. Typically, such compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection can also be prepared. The preparation can also be emulsified.

### 10 3. NASAL DELIVERY

In certain embodiments, the pharmaceutical compositions may be delivered by intranasal sprays, inhalation, and/or other aerosol delivery vehicles. Methods for delivering genes, nucleic acids, and peptide compositions directly to the lungs *via* nasal aerosol sprays has been described *e.g.*, in U. S. Patent 5,756,353 and U. S. Patent 5,804,212 (each specifically incorporated herein by reference in its entirety). Likewise, the delivery of drugs using intranasal microparticle resins (Takenaga *et al.*, 1998) and lysophosphatidyl-glycerol compounds (U. S. Patent 5,725,871, specifically incorporated herein by reference in its entirety) are also well-known in the pharmaceutical arts. Likewise, transmucosal drug delivery in the form of a polytetrafluoroethylene support matrix is described in U. S. Patent 5,780,045 (specifically incorporated herein by reference in its entirety).

### 4. LIPOSOME-, NANOCAPSULE-, AND MICROPARTICLE-MEDIATED DELIVERY

In certain embodiments, the inventors contemplate the use of liposomes, nanocapsules, microparticles, microspheres, lipid particles, vesicles, and the like, for the introduction of the compositions of the present invention into suitable host cells. In particular, the compositions of the present invention may be formulated for delivery either encapsulated in a lipid particle, a liposome, a vesicle, a nanosphere, or a nanoparticle or the like.

Such formulations may be preferred for the introduction of pharmaceutically-acceptable formulations of the nucleic acids or constructs disclosed herein. The formation and use of liposomes is generally known to those of skill in the art (see for example, Couvreur *et al.*, 1977; Couvreur, 1988; Lasic, 1998; which  
5 describes the use of liposomes and nanocapsules in the targeted antibiotic therapy for intracellular bacterial infections and diseases). Recently, liposomes were developed with improved serum stability and circulation half-times (Gabizon and Papahadjopoulos, 1988; Allen and Choun, 1987; U. S. Patent 5,741,516, specifically incorporated herein by reference in its entirety). Further, various methods of liposome  
10 and liposome like preparations as potential drug carriers have been reviewed (Takakura, 1998; Chandran *et al.*, 1997; Margalit, 1995; U. S. Patent 5,567,434; U. S. Patent 5,552,157; U. S. Patent 5,565,213; U. S. Patent 5,738,868 and U. S. Patent 5,795,587, each specifically incorporated herein by reference in its entirety).

Liposomes have been used successfully with a number of cell types that  
15 are normally resistant to transfection by other procedures including T cell suspensions, primary hepatocyte cultures and PC 12 cells (Renneisen *et al.*, 1990; Muller *et al.*, 1990). In addition, liposomes are free of the DNA length constraints that are typical of viral-based delivery systems. Liposomes have been used effectively to introduce genes, drugs (Heath and Martin, 1986; Heath *et al.*, 1986; Balazsovits *et al.*, 1989; Fresta and  
20 Puglisi, 1996), radiotherapeutic agents (Pikul *et al.*, 1987), enzymes (Imaizumi *et al.*, 1990a; Imaizumi *et al.*, 1990b), viruses (Faller and Baltimore, 1984), transcription factors and allosteric effectors (Nicolau and Gersonde, 1979) into a variety of cultured cell lines and animals. In addition, several successful clinical trials examining the effectiveness of liposome-mediated drug delivery have been completed (Lopez-  
25 Berestein *et al.*, 1985a; 1985b; Coune, 1988; Sculier *et al.*, 1988). Furthermore, several studies suggest that the use of liposomes is not associated with autoimmune responses, toxicity or gonadal localization after systemic delivery (Mori and Fukatsu, 1992).

Liposomes are formed from phospholipids that are dispersed in an aqueous medium and spontaneously form multilamellar concentric bilayer vesicles (also  
30 termed multilamellar vesicles (MLVs). MLVs generally have diameters of from 25 nm to 4  $\mu$ m. Sonication of MLVs results in the formation of small unilamellar vesicles

(SUVs) with diameters in the range of 200 to 500 Å, containing an aqueous solution in the core.

Liposomes bear resemblance to cellular membranes and are contemplated for use in connection with the present invention as carriers for the peptide compositions. They are widely suitable as both water- and lipid-soluble substances can be entrapped, *i.e.* in the aqueous spaces and within the bilayer itself, respectively. It is possible that the drug-bearing liposomes may even be employed for site-specific delivery of active agents by selectively modifying the liposomal formulation.

In addition to the teachings of Couvreur *et al.* (1977; 1988), the following information may be utilized in generating liposomal formulations. Phospholipids can form a variety of structures other than liposomes when dispersed in water, depending on the molar ratio of lipid to water. At low ratios the liposome is the preferred structure. The physical characteristics of liposomes depend on pH, ionic strength and the presence of divalent cations. Liposomes can show low permeability to ionic and polar substances, but at elevated temperatures undergo a phase transition which markedly alters their permeability. The phase transition involves a change from a closely packed, ordered structure, known as the gel state, to a loosely packed, less-ordered structure, known as the fluid state. This occurs at a characteristic phase-transition temperature and results in an increase in permeability to ions, sugars and drugs.

In addition to temperature, exposure to proteins can alter the permeability of liposomes. Certain soluble proteins, such as cytochrome c, bind, deform and penetrate the bilayer, thereby causing changes in permeability. Cholesterol inhibits this penetration of proteins, apparently by packing the phospholipids more tightly. It is contemplated that the most useful liposome formations for antibiotic and inhibitor delivery will contain cholesterol.

The ability to trap solutes varies between different types of liposomes. For example, MLVs are moderately efficient at trapping solutes, but SUVs are extremely inefficient. SUVs offer the advantage of homogeneity and reproducibility in size distribution, however, and a compromise between size and trapping efficiency is

offered by large unilamellar vesicles (LUVs). These are prepared by ether evaporation and are three to four times more efficient at solute entrapment than MLVs.

In addition to liposome characteristics, an important determinant in entrapping compounds is the physicochemical properties of the compound itself. Polar compounds are trapped in the aqueous spaces and nonpolar compounds bind to the lipid bilayer of the vesicle. Polar compounds are released through permeation or when the bilayer is broken, but nonpolar compounds remain affiliated with the bilayer unless it is disrupted by temperature or exposure to lipoproteins. Both types show maximum efflux rates at the phase transition temperature.

Liposomes interact with cells via four different mechanisms: endocytosis by phagocytic cells of the reticuloendothelial system such as macrophages and neutrophils; adsorption to the cell surface, either by nonspecific weak hydrophobic or electrostatic forces, or by specific interactions with cell-surface components; fusion with the plasma cell membrane by insertion of the lipid bilayer of the liposome into the plasma membrane, with simultaneous release of liposomal contents into the cytoplasm; and by transfer of liposomal lipids to cellular or subcellular membranes, or vice versa, without any association of the liposome contents. It often is difficult to determine which mechanism is operative and more than one may operate at the same time.

The fate and disposition of intravenously injected liposomes depend on their physical properties, such as size, fluidity, and surface charge. They may persist in tissues for h or days, depending on their composition, and half lives in the blood range from min to several h. Larger liposomes, such as MLVs and LUVs, are taken up rapidly by phagocytic cells of the reticuloendothelial system, but physiology of the circulatory system restrains the exit of such large species at most sites. They can exit only in places where large openings or pores exist in the capillary endothelium, such as the sinusoids of the liver or spleen. Thus, these organs are the predominate site of uptake. On the other hand, SUVs show a broader tissue distribution but still are sequestered highly in the liver and spleen. In general, this *in vivo* behavior limits the potential targeting of liposomes to only those organs and tissues accessible to their large size. These include the blood, liver, spleen, bone marrow, and lymphoid organs.

Targeting is generally not a limitation in terms of the present invention. However, should specific targeting be desired, methods are available for this to be accomplished. Antibodies may be used to bind to the liposome surface and to direct the antibody and its drug contents to specific antigenic receptors located on a particular cell-type surface. Carbohydrate determinants (glycoprotein or glycolipid cell-surface components that play a role in cell-cell recognition, interaction and adhesion) may also be used as recognition sites as they have potential in directing liposomes to particular cell types. Mostly, it is contemplated that intravenous injection of liposomal preparations would be used, but other routes of administration are also conceivable.

Alternatively, the invention provides for pharmaceutically-acceptable nanocapsule formulations of the compositions of the present invention. Nanocapsules can generally entrap compounds in a stable and reproducible way (Henry-Michelland *et al.*, 1987; Quintanar-Guerrero *et al.*, 1998; Douglas *et al.*, 1987). To avoid side effects due to intracellular polymeric overloading, such ultrafine particles (sized around 0.1  $\mu\text{m}$ ) should be designed using polymers able to be degraded *in vivo*. Biodegradable polyalkyl-cyanoacrylate nanoparticles that meet these requirements are contemplated for use in the present invention. Such particles may be easily made, as described (Couvreur *et al.*, 1980; 1988; zur Muhlen *et al.*, 1998; Zambaux *et al.* 1998; Pinto-Alphandry *et al.*, 1995 and U. S. Patent 5,145,684, specifically incorporated herein by reference in its entirety).

## VACCINES

In certain preferred embodiments of the present invention, vaccines are provided. The vaccines will generally comprise one or more pharmaceutical compositions, such as those discussed above, in combination with an immunostimulant. An immunostimulant may be any substance that enhances or potentiates an immune response (antibody and/or cell-mediated) to an exogenous antigen. Examples of immunostimulants include adjuvants, biodegradable microspheres (*e.g.*, polylactic galactide) and liposomes (into which the compound is incorporated; *see e.g.*, Fullerton, U.S. Patent No. 4,235,877). Vaccine preparation is generally described in, for example, M.F. Powell and M.J. Newman, eds., "Vaccine Design (the subunit and adjuvant

approach)," Plenum Press (NY, 1995). Pharmaceutical compositions and vaccines within the scope of the present invention may also contain other compounds, which may be biologically active or inactive. For example, one or more immunogenic portions of other tumor antigens may be present, either incorporated into a fusion polypeptide or as a separate compound, within the composition or vaccine.

Illustrative vaccines may contain DNA encoding one or more of the polypeptides as described above, such that the polypeptide is generated *in situ*. As noted above, the DNA may be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid expression systems, bacteria and viral expression systems. Numerous gene delivery techniques are well known in the art, such as those described by Rolland, *Crit. Rev. Therap. Drug Carrier Systems* 15:143-198, 1998, and references cited therein. Appropriate nucleic acid expression systems contain the necessary DNA sequences for expression in the patient (such as a suitable promoter and terminating signal). Bacterial delivery systems involve the administration of a bacterium (such as *Bacillus-Calmette-Guerrin*) that expresses an immunogenic portion of the polypeptide on its cell surface or secretes such an epitope. In a preferred embodiment, the DNA may be introduced using a viral expression system (e.g., vaccinia or other pox virus, retrovirus, or adenovirus), which may involve the use of a non-pathogenic (defective), replication competent virus. Suitable systems are disclosed, for example, in Fisher-Hoch et al., *Proc. Natl. Acad. Sci. USA* 86:317-321, 1989; Flexner et al., *Ann. N.Y. Acad. Sci.* 569:86-103, 1989; Flexner et al., *Vaccine* 8:17-21, 1990; U.S. Patent Nos. 4,603,112, 4,769,330, and 5,017,487; WO 89/01973; U.S. Patent No. 4,777,127; GB 2,200,651; EP 0,345,242; WO 91/02805; Berkner, *Biotechniques* 6:616-627, 1988; Rosenfeld et al., *Science* 252:431-434, 1991; Kolls et al., *Proc. Natl. Acad. Sci. USA* 91:215-219, 1994; Kass-Eisler et al., *Proc. Natl. Acad. Sci. USA* 90:11498-11502, 1993; Guzman et al., *Circulation* 88:2838-2848, 1993; and Guzman et al., *Cir. Res.* 73:1202-1207, 1993. Techniques for incorporating DNA into such expression systems are well known to those of ordinary skill in the art. The DNA may also be "naked," as described, for example, in Ulmer et al., *Science* 259:1745-1749, 1993 and reviewed by Cohen, *Science* 259:1691-1692, 1993. The uptake of naked DNA may be increased by coating the DNA onto biodegradable beads, which are



efficiently transported into the cells. It will be apparent that a vaccine may comprise both a polynucleotide and a polypeptide component. Such vaccines may provide for an enhanced immune response.

It will be apparent that a vaccine may contain pharmaceutically acceptable salts of the polynucleotides and polypeptides provided herein. Such salts may be prepared from pharmaceutically acceptable non-toxic bases, including organic bases (*e.g.*, salts of primary, secondary and tertiary amines and basic amino acids) and inorganic bases (*e.g.*, sodium, potassium, lithium, ammonium, calcium and magnesium salts).

While any suitable carrier known to those of ordinary skill in the art may be employed in the vaccine compositions of this invention, the type of carrier will vary depending on the mode of administration. Compositions of the present invention may be formulated for any appropriate manner of administration, including for example, topical, oral, nasal, intravenous, intracranial, intraperitoneal, subcutaneous or intramuscular administration. For parenteral administration, such as subcutaneous injection, the carrier preferably comprises water, saline, alcohol, a fat, a wax or a buffer. For oral administration, any of the above carriers or a solid carrier, such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, and magnesium carbonate, may be employed. Biodegradable microspheres (*e.g.*, polylactate polyglycolate) may also be employed as carriers for the pharmaceutical compositions of this invention. Suitable biodegradable microspheres are disclosed, for example, in U.S. Patent Nos. 4,897,268; 5,075,109; 5,928,647; 5,811,128; 5,820,883; 5,853,763; 5,814,344 and 5,942,252. One may also employ a carrier comprising the particulate-protein complexes described in U.S. Patent No. 5,928,647, which are capable of inducing a class I-restricted cytotoxic T lymphocyte responses in a host.

Such compositions may also comprise buffers (*e.g.*, neutral buffered saline or phosphate buffered saline), carbohydrates (*e.g.*, glucose, mannose, sucrose or dextrans), mannitol, proteins, polypeptides or amino acids such as glycine, antioxidants, bacteriostats, chelating agents such as EDTA or glutathione, adjuvants (*e.g.*, aluminum hydroxide), solutes that render the formulation isotonic, hypotonic or weakly hypertonic

with the blood of a recipient, suspending agents, thickening agents and/or preservatives. Alternatively, compositions of the present invention may be formulated as a lyophilizate. Compounds may also be encapsulated within liposomes using well known technology.

5                   Any of a variety of immunostimulants may be employed in the vaccines of this invention. For example, an adjuvant may be included. Most adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A, *Bordetella pertussis* or *Mycobacterium tuberculosis* derived proteins. Suitable  
10                   adjuvants are commercially available as, for example, Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, MI); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ); AS-2 (SmithKline Beecham, Philadelphia, PA); aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars;  
15                   cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quil A. Cytokines, such as GM-CSF or interleukin-2, -7, or -12, may also be used as adjuvants.

                  Within the vaccines provided herein, the adjuvant composition is preferably designed to induce an immune response predominantly of the Th1 type.  
20                   High levels of Th1-type cytokines (e.g., IFN- $\gamma$ , TNF $\alpha$ , IL-2 and IL-12) tend to favor the induction of cell mediated immune responses to an administered antigen. In contrast, high levels of Th2-type cytokines (e.g., IL-4, IL-5, IL-6 and IL-10) tend to favor the induction of humoral immune responses. Following application of a vaccine as provided herein, a patient will support an immune response that includes Th1- and Th2-  
25                   type responses. Within a preferred embodiment, in which a response is predominantly Th1-type, the level of Th1-type cytokines will increase to a greater extent than the level of Th2-type cytokines. The levels of these cytokines may be readily assessed using standard assays. For a review of the families of cytokines, see Mosmann and Coffman, *Ann. Rev. Immunol.* 7:145-173, 1989.

30                   Preferred adjuvants for use in eliciting a predominantly Th1-type response include, for example, a combination of monophosphoryl lipid A, preferably 3-

de-O-acylated monophosphoryl lipid A (3D-MPL), together with an aluminum salt. MPL adjuvants are available from Corixa Corporation (Seattle, WA; *see* US Patent Nos. 4,436,727; 4,877,611; 4,866,034 and 4,912,094). CpG-containing oligonucleotides (in which the CpG dinucleotide is unmethylated) also induce a predominantly Th1  
5 response. Such oligonucleotides are well known and are described, for example, in WO 96/02555, WO 99/33488 and U.S. Patent Nos. 6,008,200 and 5,856,462. Immunostimulatory DNA sequences are also described, for example, by Sato et al., *Science* 273:352, 1996. Another preferred adjuvant is a saponin, preferably QS21 (Aquila Biopharmaceuticals Inc., Framingham, MA), which may be used alone or in  
10 combination with other adjuvants. For example, an enhanced system involves the combination of a monophosphoryl lipid A and saponin derivative, such as the combination of QS21 and 3D-MPL as described in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol, as described in WO 96/33739. Other preferred formulations comprise an oil-in-water emulsion and  
15 tocopherol. A particularly potent adjuvant formulation involving QS21, 3D-MPL and tocopherol in an oil-in-water emulsion is described in WO 95/17210.

Other preferred adjuvants include Montanide ISA 720 (Seppic, France), SAF (Chiron, California, United States), ISCOMS (CSL), MF-59 (Chiron), the SBAS series of adjuvants (*e.g.*, SBAS-2 or SBAS-4, available from SmithKline Beecham,  
20 Rixensart, Belgium), Detox (Corixa, Hamilton, MT), RC-529 (Corixa, Hamilton, MT) and other aminoalkyl glucosaminide 4-phosphates (AGPs), such as those described in pending U.S. Patent Application Serial Nos. 08/853,826 and 09/074,720, the disclosures of which are incorporated herein by reference in their entireties.

Any vaccine provided herein may be prepared using well known  
25 methods that result in a combination of antigen, immune response enhancer and a suitable carrier or excipient. The compositions described herein may be administered as part of a sustained release formulation (*i.e.*, a formulation such as a capsule, sponge or gel (composed of polysaccharides, for example) that effects a slow release of compound following administration). Such formulations may generally be prepared using well  
30 known technology (*see, e.g.*, Coombes et al., *Vaccine* 14:1429-1438, 1996) and administered by, for example, oral, rectal or subcutaneous implantation, or by

implantation at the desired target site. Sustained-release formulations may contain a polypeptide, polynucleotide or antibody dispersed in a carrier matrix and/or contained within a reservoir surrounded by a rate controlling membrane.

Carriers for use within such formulations are biocompatible, and may also be biodegradable; preferably the formulation provides a relatively constant level of active component release. Such carriers include microparticles of poly(lactide-co-glycolide), polyacrylate, latex, starch, cellulose, dextran and the like. Other delayed-release carriers include supramolecular biovectors, which comprise a non-liquid hydrophilic core (e.g., a cross-linked polysaccharide or oligosaccharide) and, optionally, an external layer comprising an amphiphilic compound, such as a phospholipid (see e.g., U.S. Patent No. 5,151,254 and PCT applications WO 94/20078, WO/94/23701 and WO 96/06638). The amount of active compound contained within a sustained release formulation depends upon the site of implantation, the rate and expected duration of release and the nature of the condition to be treated or prevented.

Any of a variety of delivery vehicles may be employed within pharmaceutical compositions and vaccines to facilitate production of an antigen-specific immune response that targets tumor cells. Delivery vehicles include antigen presenting cells (APCs), such as dendritic cells, macrophages, B cells, monocytes and other cells that may be engineered to be efficient APCs. Such cells may, but need not, be genetically modified to increase the capacity for presenting the antigen, to improve activation and/or maintenance of the T cell response, to have anti-tumor effects *per se* and/or to be immunologically compatible with the receiver (i.e., matched HLA haplotype). APCs may generally be isolated from any of a variety of biological fluids and organs, including tumor and peritumoral tissues, and may be autologous, allogeneic, syngeneic or xenogeneic cells.

Certain preferred embodiments of the present invention use dendritic cells or progenitors thereof as antigen-presenting cells. Dendritic cells are highly potent APCs (Banchereau and Steinman, *Nature* 392:245-251, 1998) and have been shown to be effective as a physiological adjuvant for eliciting prophylactic or therapeutic antitumor immunity (see Timmerman and Levy, *Ann. Rev. Med.* 50:507-529, 1999). In general, dendritic cells may be identified based on their typical shape (stellate *in situ*,

with marked cytoplasmic processes (dendrites) visible *in vitro*), their ability to take up, process and present antigens with high efficiency and their ability to activate naïve T cell responses. Dendritic cells may, of course, be engineered to express specific cell-surface receptors or ligands that are not commonly found on dendritic cells *in vivo* or *ex vivo*, and such modified dendritic cells are contemplated by the present invention. As an alternative to dendritic cells, secreted vesicles antigen-loaded dendritic cells (called exosomes) may be used within a vaccine (see Zitvogel et al., *Nature Med.* 4:594-600, 1998).

Dendritic cells and progenitors may be obtained from peripheral blood, bone marrow, tumor-infiltrating cells, peritumoral tissues-infiltrating cells, lymph nodes, spleen, skin, umbilical cord blood or any other suitable tissue or fluid. For example, dendritic cells may be differentiated *ex vivo* by adding a combination of cytokines such as GM-CSF, IL-4, IL-13 and/or TNF $\alpha$  to cultures of monocytes harvested from peripheral blood. Alternatively, CD34 positive cells harvested from peripheral blood, umbilical cord blood or bone marrow may be differentiated into dendritic cells by adding to the culture medium combinations of GM-CSF, IL-3, TNF $\alpha$ , CD40 ligand, LPS, flt3 ligand and/or other compound(s) that induce differentiation, maturation and proliferation of dendritic cells.

Dendritic cells are conveniently categorized as "immature" and "mature" cells, which allows a simple way to discriminate between two well characterized phenotypes. However, this nomenclature should not be construed to exclude all possible intermediate stages of differentiation. Immature dendritic cells are characterized as APC with a high capacity for antigen uptake and processing, which correlates with the high expression of Fc $\gamma$  receptor and mannose receptor. The mature phenotype is typically characterized by a lower expression of these markers, but a high expression of cell surface molecules responsible for T cell activation such as class I and class II MHC, adhesion molecules (*e.g.*, CD54 and CD11) and costimulatory molecules (*e.g.*, CD40, CD80, CD86 and 4-1BB).

APCs may generally be transfected with a polynucleotide encoding a breast tumor protein (or portion or other variant thereof) such that the breast tumor polypeptide, or an immunogenic portion thereof, is expressed on the cell surface. Such

transfection may take place *ex vivo*, and a composition or vaccine comprising such transfected cells may then be used for therapeutic purposes, as described herein. Alternatively, a gene delivery vehicle that targets a dendritic or other antigen presenting cell may be administered to a patient, resulting in transfection that occurs *in vivo*. *In vivo* and *ex vivo* transfection of dendritic cells, for example, may generally be performed using any methods known in the art, such as those described in WO 97/24447, or the gene gun approach described by Mahvi et al., *Immunology and cell Biology* 75:456-460, 1997. Antigen loading of dendritic cells may be achieved by incubating dendritic cells or progenitor cells with the breast tumor polypeptide, DNA (naked or within a plasmid vector) or RNA; or with antigen-expressing recombinant bacterium or viruses (*e.g.*, vaccinia, fowlpox, adenovirus or lentivirus vectors). Prior to loading, the polypeptide may be covalently conjugated to an immunological partner that provides T cell help (*e.g.*, a carrier molecule). Alternatively, a dendritic cell may be pulsed with a non-conjugated immunological partner, separately or in the presence of the polypeptide.

Vaccines and pharmaceutical compositions may be presented in unit-dose or multi-dose containers, such as sealed ampoules or vials. Such containers are preferably hermetically sealed to preserve sterility of the formulation until use. In general, formulations may be stored as suspensions, solutions or emulsions in oily or aqueous vehicles. Alternatively, a vaccine or pharmaceutical composition may be stored in a freeze-dried condition requiring only the addition of a sterile liquid carrier immediately prior to use.

#### CANCER THERAPY

In further aspects of the present invention, the compositions described herein may be used for immunotherapy of cancer, such as breast cancer. Within such methods, pharmaceutical compositions and vaccines are typically administered to a patient. As used herein, a "patient" refers to any warm-blooded animal, preferably a human. A patient may or may not be afflicted with cancer. Accordingly, the above pharmaceutical compositions and vaccines may be used to prevent the development of a cancer or to treat a patient afflicted with a cancer. A cancer may be diagnosed using

criteria generally accepted in the art, including the presence of a malignant tumor. Pharmaceutical compositions and vaccines may be administered either prior to or following surgical removal of primary tumors and/or treatment such as administration of radiotherapy or conventional chemotherapeutic drugs. Administration may be by any  
5 suitable method, including administration by intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal, intradermal, anal, vaginal, topical and oral routes.

Within certain embodiments, immunotherapy may be active immunotherapy, in which treatment relies on the *in vivo* stimulation of the endogenous  
10 host immune system to react against tumors with the administration of immune response-modifying agents (such as polypeptides and polynucleotides as provided herein).

Within other embodiments, immunotherapy may be passive immunotherapy, in which treatment involves the delivery of agents with established  
15 tumor-immune reactivity (such as effector cells or antibodies) that can directly or indirectly mediate antitumor effects and does not necessarily depend on an intact host immune system. Examples of effector cells include T cells as discussed above, T lymphocytes (such as CD8<sup>+</sup> cytotoxic T lymphocytes and CD4<sup>+</sup> T-helper tumor-infiltrating lymphocytes), killer cells (such as Natural Killer cells and lymphokine-  
20 activated killer cells), B cells and antigen-presenting cells (such as dendritic cells and macrophages) expressing a polypeptide provided herein. T cell receptors and antibody receptors specific for the polypeptides recited herein may be cloned, expressed and transferred into other vectors or effector cells for adoptive immunotherapy. The polypeptides provided herein may also be used to generate antibodies or anti-idiotypic  
25 antibodies (as described above and in U.S. Patent No. 4,918,164) for passive immunotherapy.

Effector cells may generally be obtained in sufficient quantities for adoptive immunotherapy by growth *in vitro*, as described herein. Culture conditions for expanding single antigen-specific effector cells to several billion in number with  
30 retention of antigen recognition *in vivo* are well known in the art. Such *in vitro* culture conditions typically use intermittent stimulation with antigen, often in the presence of

cytokines (such as IL-2) and non-dividing feeder cells. As noted above, immunoreactive polypeptides as provided herein may be used to rapidly expand antigen-specific T cell cultures in order to generate a sufficient number of cells for immunotherapy. In particular, antigen-presenting cells, such as dendritic, macrophage, 5 monocyte, fibroblast and/or B cells, may be pulsed with immunoreactive polypeptides or transfected with one or more polynucleotides using standard techniques well known in the art. For example, antigen-presenting cells can be transfected with a polynucleotide having a promoter appropriate for increasing expression in a recombinant virus or other expression system. Cultured effector cells for use in therapy 10 must be able to grow and distribute widely, and to survive long term *in vivo*. Studies have shown that cultured effector cells can be induced to grow *in vivo* and to survive long term in substantial numbers by repeated stimulation with antigen supplemented with IL-2 (*see, for example, Cheever et al., Immunological Reviews 157:177, 1997*).

Alternatively, a vector expressing a polypeptide recited herein may be 15 introduced into antigen presenting cells taken from a patient and clonally propagated *ex vivo* for transplant back into the same patient. Transfected cells may be reintroduced into the patient using any means known in the art, preferably in sterile form by intravenous, intracavitary, intraperitoneal or intratumor administration.

Routes and frequency of administration of the therapeutic compositions 20 described herein, as well as dosage, will vary from individual to individual, and may be readily established using standard techniques. In general, the pharmaceutical compositions and vaccines may be administered by injection (*e.g.*, intracutaneous, intramuscular, intravenous or subcutaneous), intranasally (*e.g.*, by aspiration) or orally. Preferably, between 1 and 10 doses may be administered over a 52 week period. 25 Preferably, 6 doses are administered, at intervals of 1 month, and booster vaccinations may be given periodically thereafter. Alternate protocols may be appropriate for individual patients. A suitable dose is an amount of a compound that, when administered as described above, is capable of promoting an anti-tumor immune response, and is at least 10-50% above the basal (*i.e.*, untreated) level. Such response 30 can be monitored by measuring the anti-tumor antibodies in a patient or by vaccine-dependent generation of cytolytic effector cells capable of killing the patient's tumor



cells *in vitro*. Such vaccines should also be capable of causing an immune response that leads to an improved clinical outcome (e.g., more frequent remissions, complete or partial or longer disease-free survival) in vaccinated patients as compared to non-vaccinated patients. In general, for pharmaceutical compositions and vaccines  
5 comprising one or more polypeptides, the amount of each polypeptide present in a dose ranges from about 25 µg to 5 mg per kg of host. Suitable dose sizes will vary with the size of the patient, but will typically range from about 0.1 mL to about 5 mL.

In general, an appropriate dosage and treatment regimen provides the active compound(s) in an amount sufficient to provide therapeutic and/or prophylactic  
10 benefit. Such a response can be monitored by establishing an improved clinical outcome (e.g., more frequent remissions, complete or partial, or longer disease-free survival) in treated patients as compared to non-treated patients. Increases in preexisting immune responses to a breast tumor protein generally correlate with an improved clinical outcome. Such immune responses may generally be evaluated using  
15 standard proliferation, cytotoxicity or cytokine assays, which may be performed using samples obtained from a patient before and after treatment.

#### CANCER DETECTION AND DIAGNOSIS

In general, a cancer may be detected in a patient based on the presence of one or more breast tumor proteins and/or polynucleotides encoding such proteins in a  
20 biological sample (for example, blood, sera, sputum urine and/or tumor biopsies) obtained from the patient. In other words, such proteins may be used as markers to indicate the presence or absence of a cancer such as breast cancer. In addition, such proteins may be useful for the detection of other cancers. The binding agents provided herein generally permit detection of the level of antigen that binds to the agent in the  
25 biological sample. Polynucleotide primers and probes may be used to detect the level of mRNA encoding a tumor protein, which is also indicative of the presence or absence of a cancer. In general, a breast tumor sequence should be present at a level that is at least three fold higher in tumor tissue than in normal tissue

There are a variety of assay formats known to those of ordinary skill in  
30 the art for using a binding agent to detect polypeptide markers in a sample. *See, e.g.,*

Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988. In general, the presence or absence of a cancer in a patient may be determined by (a) contacting a biological sample obtained from a patient with a binding agent; (b) detecting in the sample a level of polypeptide that binds to the binding agent; and (c) 5 comparing the level of polypeptide with a predetermined cut-off value.

In a preferred embodiment, the assay involves the use of binding agent immobilized on a solid support to bind to and remove the polypeptide from the remainder of the sample. The bound polypeptide may then be detected using a detection reagent that contains a reporter group and specifically binds to the binding 10 agent/polypeptide complex. Such detection reagents may comprise, for example, a binding agent that specifically binds to the polypeptide or an antibody or other agent that specifically binds to the binding agent, such as an anti-immunoglobulin, protein G, protein A or a lectin. Alternatively, a competitive assay may be utilized, in which a polypeptide is labeled with a reporter group and allowed to bind to the immobilized 15 binding agent after incubation of the binding agent with the sample. The extent to which components of the sample inhibit the binding of the labeled polypeptide to the binding agent is indicative of the reactivity of the sample with the immobilized binding agent. Suitable polypeptides for use within such assays include full length breast tumor proteins and portions thereof to which the binding agent binds, as described above.

20 The solid support may be any material known to those of ordinary skill in the art to which the tumor protein may be attached. For example, the solid support may be a test well in a microtiter plate or a nitrocellulose or other suitable membrane. Alternatively, the support may be a bead or disc, such as glass, fiberglass, latex or a plastic material such as polystyrene or polyvinylchloride. The support may also be a 25 magnetic particle or a fiber optic sensor, such as those disclosed, for example, in U.S. Patent No. 5,359,681. The binding agent may be immobilized on the solid support using a variety of techniques known to those of skill in the art, which are amply described in the patent and scientific literature. In the context of the present invention, the term "immobilization" refers to both noncovalent association, such as adsorption, 30 and covalent attachment (which may be a direct linkage between the agent and functional groups on the support or may be a linkage by way of a cross-linking agent).

Immobilization by adsorption to a well in a microtiter plate or to a membrane is preferred. In such cases, adsorption may be achieved by contacting the binding agent, in a suitable buffer, with the solid support for a suitable amount of time. The contact time varies with temperature, but is typically between about 1 hour and about 1 day. In  
5 general, contacting a well of a plastic microtiter plate (such as polystyrene or polyvinylchloride) with an amount of binding agent ranging from about 10 ng to about 10  $\mu$ g, and preferably about 100 ng to about 1  $\mu$ g, is sufficient to immobilize an adequate amount of binding agent.

Covalent attachment of binding agent to a solid support may generally be  
10 achieved by first reacting the support with a bifunctional reagent that will react with both the support and a functional group, such as a hydroxyl or amino group, on the binding agent. For example, the binding agent may be covalently attached to supports having an appropriate polymer coating using benzoquinone or by condensation of an aldehyde group on the support with an amine and an active hydrogen on the binding  
15 partner (*see, e.g.,* Pierce Immunotechnology Catalog and Handbook, 1991, at A12-A13).

In certain embodiments, the assay is a two-antibody sandwich assay. This assay may be performed by first contacting an antibody that has been immobilized on a solid support, commonly the well of a microtiter plate, with the sample, such that  
20 polypeptides within the sample are allowed to bind to the immobilized antibody. Unbound sample is then removed from the immobilized polypeptide-antibody complexes and a detection reagent (preferably a second antibody capable of binding to a different site on the polypeptide) containing a reporter group is added. The amount of detection reagent that remains bound to the solid support is then determined using a  
25 method appropriate for the specific reporter group.

More specifically, once the antibody is immobilized on the support as described above, the remaining protein binding sites on the support are typically blocked. Any suitable blocking agent known to those of ordinary skill in the art, such as bovine serum albumin or Tween 20™ (Sigma Chemical Co., St. Louis, MO). The  
30 immobilized antibody is then incubated with the sample, and polypeptide is allowed to bind to the antibody. The sample may be diluted with a suitable diluent, such as

phosphate-buffered saline (PBS) prior to incubation. In general, an appropriate contact time (*i.e.*, incubation time) is a period of time that is sufficient to detect the presence of polypeptide within a sample obtained from an individual with breast cancer. Preferably, the contact time is sufficient to achieve a level of binding that is at least about 95% of that achieved at equilibrium between bound and unbound polypeptide. Those of ordinary skill in the art will recognize that the time necessary to achieve equilibrium may be readily determined by assaying the level of binding that occurs over a period of time. At room temperature, an incubation time of about 30 minutes is generally sufficient.

10                Unbound sample may then be removed by washing the solid support with an appropriate buffer, such as PBS containing 0.1% Tween 20™. The second antibody, which contains a reporter group, may then be added to the solid support. Preferred reporter groups include those groups recited above.

                  The detection reagent is then incubated with the immobilized antibody-polypeptide complex for an amount of time sufficient to detect the bound polypeptide. An appropriate amount of time may generally be determined by assaying the level of binding that occurs over a period of time. Unbound detection reagent is then removed and bound detection reagent is detected using the reporter group. The method employed for detecting the reporter group depends upon the nature of the reporter group. For radioactive groups, scintillation counting or autoradiographic methods are generally appropriate. Spectroscopic methods may be used to detect dyes, luminescent groups and fluorescent groups. Biotin may be detected using avidin, coupled to a different reporter group (commonly a radioactive or fluorescent group or an enzyme). Enzyme reporter groups may generally be detected by the addition of substrate (generally for a specific period of time), followed by spectroscopic or other analysis of the reaction products.

                  To determine the presence or absence of a cancer, such as breast cancer, the signal detected from the reporter group that remains bound to the solid support is generally compared to a signal that corresponds to a predetermined cut-off value. In one preferred embodiment, the cut-off value for the detection of a cancer is the average mean signal obtained when the immobilized antibody is incubated with samples from

patients without the cancer. In general, a sample generating a signal that is three standard deviations above the predetermined cut-off value is considered positive for the cancer. In an alternate preferred embodiment, the cut-off value is determined using a Receiver Operator Curve, according to the method of Sackett et al., *Clinical*  
5 *Epidemiology: A Basic Science for Clinical Medicine*, Little Brown and Co., 1985, p. 106-7. Briefly, in this embodiment, the cut-off value may be determined from a plot of pairs of true positive rates (*i.e.*, sensitivity) and false positive rates (100%-specificity) that correspond to each possible cut-off value for the diagnostic test result. The cut-off value on the plot that is the closest to the upper left-hand corner (*i.e.*, the value that  
10 encloses the largest area) is the most accurate cut-off value, and a sample generating a signal that is higher than the cut-off value determined by this method may be considered positive. Alternatively, the cut-off value may be shifted to the left along the plot, to minimize the false positive rate, or to the right, to minimize the false negative rate. In general, a sample generating a signal that is higher than the cut-off value determined by  
15 this method is considered positive for a cancer.

In a related embodiment, the assay is performed in a flow-through or strip test format, wherein the binding agent is immobilized on a membrane, such as nitrocellulose. In the flow-through test, polypeptides within the sample bind to the immobilized binding agent as the sample passes through the membrane. A second,  
20 labeled binding agent then binds to the binding agent-polypeptide complex as a solution containing the second binding agent flows through the membrane. The detection of bound second binding agent may then be performed as described above. In the strip test format, one end of the membrane to which binding agent is bound is immersed in a solution containing the sample. The sample migrates along the membrane through a  
25 region containing second binding agent and to the area of immobilized binding agent. Concentration of second binding agent at the area of immobilized antibody indicates the presence of a cancer. Typically, the concentration of second binding agent at that site generates a pattern, such as a line, that can be read visually. The absence of such a pattern indicates a negative result. In general, the amount of binding agent immobilized  
30 on the membrane is selected to generate a visually discernible pattern when the biological sample contains a level of polypeptide that would be sufficient to generate a

positive signal in the two-antibody sandwich assay, in the format discussed above. Preferred binding agents for use in such assays are antibodies and antigen-binding fragments thereof. Preferably, the amount of antibody immobilized on the membrane ranges from about 25 ng to about 1 $\mu$ g, and more preferably from about 50 ng to about 500 ng. Such tests can typically be performed with a very small amount of biological sample.

Of course, numerous other assay protocols exist that are suitable for use with the tumor proteins or binding agents of the present invention. The above descriptions are intended to be exemplary only. For example, it will be apparent to those of ordinary skill in the art that the above protocols may be readily modified to use breast tumor polypeptides to detect antibodies that bind to such polypeptides in a biological sample. The detection of such breast tumor protein specific antibodies may correlate with the presence of a cancer.

A cancer may also, or alternatively, be detected based on the presence of T cells that specifically react with a breast tumor protein in a biological sample. Within certain methods, a biological sample comprising CD4<sup>+</sup> and/or CD8<sup>+</sup> T cells isolated from a patient is incubated with a breast tumor polypeptide, a polynucleotide encoding such a polypeptide and/or an APC that expresses at least an immunogenic portion of such a polypeptide, and the presence or absence of specific activation of the T cells is detected. Suitable biological samples include, but are not limited to, isolated T cells. For example, T cells may be isolated from a patient by routine techniques (such as by Ficoll/Hypaque density gradient centrifugation of peripheral blood lymphocytes). T cells may be incubated *in vitro* for 2-9 days (typically 4 days) at 37°C with polypeptide (e.g., 5 - 25  $\mu$ g/ml). It may be desirable to incubate another aliquot of a T cell sample in the absence of breast tumor polypeptide to serve as a control. For CD4<sup>+</sup> T cells, activation is preferably detected by evaluating proliferation of the T cells. For CD8<sup>+</sup> T cells, activation is preferably detected by evaluating cytolytic activity. A level of proliferation that is at least two fold greater and/or a level of cytolytic activity that is at least 20% greater than in disease-free patients indicates the presence of a cancer in the patient.

As noted above, a cancer may also, or alternatively, be detected based on the level of mRNA encoding a breast tumor protein in a biological sample. For example, at least two oligonucleotide primers may be employed in a polymerase chain reaction (PCR) based assay to amplify a portion of a breast tumor cDNA derived from a biological sample, wherein at least one of the oligonucleotide primers is specific for (i.e., hybridizes to) a polynucleotide encoding the breast tumor protein. The amplified cDNA is then separated and detected using techniques well known in the art, such as gel electrophoresis. Similarly, oligonucleotide probes that specifically hybridize to a polynucleotide encoding a breast tumor protein may be used in a hybridization assay to detect the presence of polynucleotide encoding the tumor protein in a biological sample.

To permit hybridization under assay conditions, oligonucleotide primers and probes should comprise an oligonucleotide sequence that has at least about 60%, preferably at least about 75% and more preferably at least about 90%, identity to a portion of a polynucleotide encoding a breast tumor protein that is at least 10 nucleotides, and preferably at least 20 nucleotides, in length. Preferably, oligonucleotide primers and/or probes hybridize to a polynucleotide encoding a polypeptide described herein under moderately stringent conditions, as defined above. Oligonucleotide primers and/or probes which may be usefully employed in the diagnostic methods described herein preferably are at least 10-40 nucleotides in length. In a preferred embodiment, the oligonucleotide primers comprise at least 10 contiguous nucleotides, more preferably at least 15 contiguous nucleotides, of a DNA molecule having a sequence recited in SEQ ID NO: 1-38, 42-204, 205, 207 and 210-290. Techniques for both PCR based assays and hybridization assays are well known in the art (see, for example, Mullis et al., *Cold Spring Harbor Symp. Quant. Biol.*, 51:263, 1987; Erlich ed., *PCR Technology*, Stockton Press, NY, 1989).

One preferred assay employs RT-PCR, in which PCR is applied in conjunction with reverse transcription. Typically, RNA is extracted from a biological sample, such as biopsy tissue, and is reverse transcribed to produce cDNA molecules. PCR amplification using at least one specific primer generates a cDNA molecule, which may be separated and visualized using, for example, gel electrophoresis. Amplification may be performed on biological samples taken from a test patient and from an

individual who is not afflicted with a cancer. The amplification reaction may be performed on several dilutions of cDNA spanning two orders of magnitude. A two-fold or greater increase in expression in several dilutions of the test patient sample as compared to the same dilutions of the non-cancerous sample is typically considered  
5 positive.

In another embodiment, the compositions described herein may be used as markers for the progression of cancer. In this embodiment, assays as described above for the diagnosis of a cancer may be performed over time, and the change in the level of reactive polypeptide(s) or polynucleotide(s) evaluated. For example, the assays  
10 may be performed every 24-72 hours for a period of 6 months to 1 year, and thereafter performed as needed. In general, a cancer is progressing in those patients in whom the level of polypeptide or polynucleotide detected increases over time. In contrast, the cancer is not progressing when the level of reactive polypeptide or polynucleotide either remains constant or decreases with time.

15 Certain *in vivo* diagnostic assays may be performed directly on a tumor. One such assay involves contacting tumor cells with a binding agent. The bound binding agent may then be detected directly or indirectly via a reporter group. Such binding agents may also be used in histological applications. Alternatively, polynucleotide probes may be used within such applications.

20 As noted above, to improve sensitivity, multiple breast tumor protein markers may be assayed within a given sample. It will be apparent that binding agents specific for different proteins provided herein may be combined within a single assay. Further, multiple primers or probes may be used concurrently. The selection of tumor protein markers may be based on routine experiments to determine combinations that  
25 results in optimal sensitivity. In addition, or alternatively, assays for tumor proteins provided herein may be combined with assays for other known tumor antigens.

#### **DIAGNOSTIC KITS**

The present invention further provides kits for use within any of the above diagnostic methods. Such kits typically comprise two or more components  
30 necessary for performing a diagnostic assay. Components may be compounds,



reagents, containers and/or equipment. For example, one container within a kit may contain a monoclonal antibody or fragment thereof that specifically binds to a breast tumor protein. Such antibodies or fragments may be provided attached to a support material, as described above. One or more additional containers may enclose elements, such as reagents or buffers, to be used in the assay. Such kits may also, or alternatively, contain a detection reagent as described above that contains a reporter group suitable for direct or indirect detection of antibody binding.

Alternatively, a kit may be designed to detect the level of mRNA encoding a breast tumor protein in a biological sample. Such kits generally comprise at least one oligonucleotide probe or primer, as described above, that hybridizes to a polynucleotide encoding a breast tumor protein. Such an oligonucleotide may be used, for example, within a PCR or hybridization assay. Additional components that may be present within such kits include a second oligonucleotide and/or a diagnostic reagent or container to facilitate the detection of a polynucleotide encoding a breast tumor protein.

The following Examples are offered by way of illustration and not by way of limitation.

## EXAMPLE 1

IDENTIFICATION OF BREAST TUMOR PROTEIN cDNAS USING  
SUBTRACTION METHODOLOGY

This Example illustrates the identification of cDNA molecules encoding  
5 breast tumor proteins.

A human metastatic breast tumor cDNA expression library was constructed from metastatic breast tumor poly A<sup>+</sup> RNA using a Superscript Plasmid System for cDNA Synthesis and Plasmid Cloning kit (BRL Life Technologies, Gaithersburg, MD 20897) following the manufacturer's protocol. Specifically, breast  
10 tumor tissues were homogenized with polytron (Kinematica, Switzerland) and total RNA was extracted using Trizol reagent (BRL Life Technologies) as directed by the manufacturer. The poly A<sup>+</sup> RNA was then purified using a Qiagen oligotex spin column mRNA purification kit (Qiagen, Santa Clarita, CA 91355) according to the manufacturer's protocol. First-strand cDNA was synthesized using the NotI/Oligo-  
15 dT18 primer. Double-stranded cDNA was synthesized, ligated with EcoRI/BstX I adaptors (Invitrogen, Carlsbad, CA) and digested with NotI. Following size fractionation with Chroma Spin-1000 columns (Clontech, Palo Alto, CA 94303), the cDNA was ligated into the EcoRI/NotI site of pCDNA3.1 (Invitrogen, Carlsbad, CA) and transformed into ElectroMax *E. coli* DH10B cells (BRL Life Technologies) by  
20 electroporation.

Using the same procedure, a normal human breast cDNA expression library was prepared from a pool of four normal breast tissue specimens. The cDNA libraries were characterized by determining the number of independent colonies, the percentage of clones that carried insert, the average insert size and by sequence analysis.  
25 Sequencing analysis showed both libraries to contain good complex cDNA clones that were synthesized from mRNA, with minimal rRNA and mitochondrial DNA contamination sequencing.

A cDNA subtracted library (referred to as BS3) was prepared using the above metastatic breast tumor and normal breast cDNA libraries, as described by Hara  
30 *et al.* (*Blood*, 84:189-199, 1994) with some modifications. Specifically, a breast tumor-

specific subtracted cDNA library was generated as follows. Normal breast cDNA library (70 µg) was digested with EcoRI, NotI, and SfuI, followed by a filling-in reaction with DNA polymerase Klenow fragment. After phenol-chloroform extraction and ethanol precipitation, the DNA was dissolved in 100 µl of H<sub>2</sub>O, heat-denatured and  
5 mixed with 100 µl (100 µg) of Photoprobe biotin (Vector Laboratories, Burlingame, CA), the resulting mixture was irradiated with a 270 W sunlamp on ice for 20 minutes. Additional Photoprobe biotin (50 µl) was added and the biotinylation reaction was repeated. After extraction with butanol five times, the DNA was ethanol-precipitated and dissolved in 23 µl H<sub>2</sub>O to form the driver DNA.

10 To form the tracer DNA, 10 µg breast tumor cDNA library was digested with BamHI and XhoI, phenol chloroform extracted and passed through Chroma spin-400 columns (Clontech). Following ethanol precipitation, the tracer DNA was dissolved in 5 µl H<sub>2</sub>O. Tracer DNA was mixed with 15 µl driver DNA and 20 µl of 2 x hybridization buffer (1.5 M NaCl/10 mM EDTA/50 mM HEPES pH 7.5/0.2% sodium  
15 dodecyl sulfate), overlaid with mineral oil, and heat-denatured completely. The sample was immediately transferred into a 68 °C water bath and incubated for 20 hours (long hybridization [LH]). The reaction mixture was then subjected to a streptavidin treatment followed by phenol/chloroform extraction. This process was repeated three more times. Subtracted DNA was precipitated, dissolved in 12 µl H<sub>2</sub>O, mixed with 8 µl  
20 driver DNA and 20 µl of 2 x hybridization buffer, and subjected to a hybridization at 68 °C for 2 hours (short hybridization [SH]). After removal of biotinylated double-stranded DNA, subtracted cDNA was ligated into BamHI/XhoI site of chloramphenicol resistant pBCSK<sup>+</sup> (Stratagene, La Jolla, CA 92037) and transformed into ElectroMax *E. coli* DH10B cells by electroporation to generate a breast tumor specific subtracted  
25 cDNA library.

To analyze the subtracted cDNA library, plasmid DNA was prepared from independent clones, randomly picked from the subtracted breast tumor specific library and characterized by DNA sequencing with a Perkin Elmer/Applied Biosystems Division Automated Sequencer Model 373A (Foster City, CA).

30 A second cDNA subtraction library containing cDNA from breast tumor subtracted with normal breast cDNA, and known as BT, was constructed as follows.

Total RNA was extracted from primary breast tumor tissues using Trizol reagent (Gibco BRL Life Technologies, Gaithersburg, MD) as described by the manufacturer. The polyA+ RNA was purified using an oligo(dT) cellulose column according to standard protocols. First strand cDNA was synthesized using the primer supplied in a Clontech  
5 PCR-Select cDNA Subtraction Kit (Clontech, Palo Alto, CA). The driver DNA consisted of cDNAs from two normal breast tissues with the tester cDNA being from three primary breast tumors. Double-stranded cDNA was synthesized for both tester and driver, and digested with a combination of endonucleases (MluI, MscI, PvuII, SalI and StuI) which recognize six base pairs DNA. This modification increased the average  
10 cDNA size dramatically compared with cDNAs generated according to the protocol of Clontech. The digested tester cDNAs were ligated to two different adaptors and the subtraction was performed according to Clontech's protocol. The subtracted cDNAs were subjected to two rounds of PCR amplification, following the manufacturer's protocol. The resulting PCR products were subcloned into the TA cloning vector,  
15 pCRII (Invitrogen, San Diego, CA) and transformed into ElectroMax *E. coli* DH10B cells (Gibco BRL Life, Technologies) by electroporation. DNA was isolated from independent clones and sequenced using a Perkin Elmer/Applied Biosystems Division (Foster City, CA) Automated Sequencer Model 373A.

Two additional subtracted cDNA libraries were prepared from cDNA  
20 from breast tumors subtracted with a pool of cDNA from six normal tissues (liver, brain, stomach, small intestine, kidney and heart; referred to as 2BT and BC6) using the PCR-subtraction protocol of Clontech, described above. A fourth subtracted library (referred to as Bt-Met) was prepared using the protocol of Clontech from cDNA from metastatic breast tumors subtracted with cDNA from five normal tissues (brain, lung,  
25 PBMC, pancreas and normal breast).

cDNA clones isolated in the breast subtractions BS3, BT, 2BT, BC6 and BT-Met, described above, were colony PCR amplified and their mRNA expression levels in breast tumor, normal breast and various other normal tissues were determined using microarray technology. Briefly, the PCR amplification products were dotted onto  
30 slides in an array format, with each product occupying a unique location in the array. mRNA was extracted from the tissue sample to be tested, reverse transcribed, and

fluorescent-labeled cDNA probes were generated. The microarrays were probed with the labeled cDNA probes, the slides scanned and fluorescence intensity was measured. This intensity correlates with the hybridization intensity.

The determined cDNA sequences of 131 clones determined to be over-expressed in breast tumor tissue compared to other tissues tested by a visual analysis of the microarray data are provided in SEQ ID NO: 1-35 and 42-137. Comparison of these cDNA sequences with known sequences in the gene bank using the EMBL and GenBank databases revealed no significant homologies to the sequences provided in SEQ ID NO: 7, 10, 21, 26, 30, 63, 81 and 104. The sequences of SEQ ID NO: 2-5, 8, 9, 13, 15, 16, 22, 25, 27, 28, 33, 35, 72, 73, 103, 107, 109, 118, 128, 129 134 and 136 showed some homology to previously isolated expressed sequences tags (ESTs), while the sequences of SEQ ID NO: 1, 6, 11, 12, 14, 17-20, 23, 24, 29, 31, 32, 34, 42-62, 64-71, 74-80, 82-102, 105, 106, 108, 110-117, 119-127, 130-133, 135 and 137 showed some homology to previously identified genes.

The determined cDNA sequences of an additional 45 clones isolated from the BT-Met library as described above and found to be over-expressed in breast tumors and metastatic breast tumors compared to other tissues tested, are provided in SEQ ID NO: 138-182. Comparison of the sequences of SEQ ID NO: 159-161, 164 and 181 revealed no significant homologies to previously identified sequences. The sequences of SEQ ID NO: 138-158, 162, 163, 165-180 and 182 showed some homology to previously identified genes.

In further studies, suppression subtractive hybridization (Clontech) was performed using a pool of cDNA from 3 unique human breast tumors as the tester and a pool of cDNA from 6 other normal human tissues (liver, brain, stomach, small intestine, heart and kidney) as the driver. The isolated cDNA fragments were subcloned and characterized by DNA sequencing. The determined cDNA sequences of 22 isolated clones are provided in SEQ ID NO: 183-204. Comparison of these sequences with those in the public databases revealed no significant homologies to previously identified sequences.

The determined cDNA sequences of 71 additional breast-specific genes isolated during characterization of breast tumor cDNA libraries are provided in SEQ ID

NO: 210-290. Comparison of these sequences with those in the GenBank and Geneseq databases revealed no significant homologies.

## EXAMPLE 2

### 5     IDENTIFICATION OF BREAST TUMOR PROTEIN cDNAS BY RT-PCR

GABA<sub>A</sub> receptor clones were isolated from human breast cancer cDNA libraries by first preparing cDNA libraries from breast tumor samples from different patients as described above. PCR primers were designed based on the GABA<sub>A</sub> receptor subunit sequences described by Hedblom and Kirkness (*Jnl. Biol. Chem.* 272:15346-10 15350, 1997) and used to amplify sequences from the breast tumor cDNA libraries by RT-PCR. The determined cDNA sequences of three GABA<sub>A</sub> receptor clones are provided in SEQ ID NO: 36-38, with the corresponding amino acid sequences being provided in SEQ ID NO: 39-41.

The clone with the longest open reading frame (ORF; SEQ ID NO: 36) 15 showed homology to the GABA<sub>A</sub> receptor of Hedblom and Kirkness, with four potential transmembrane regions at the C-terminal part of the protein, while the clones of SEQ ID NO: 37 and 38 retained either no transmembrane region or only the first transmembrane region. Some patients were found to have only the clones with the shorter ORFs while others had both the clones with longer and shorter ORFs.

20

## EXAMPLE 3

### EXPRESSION OF OVARIAN TUMOR-DERIVED ANTIGENS IN BREAST

Isolation of the antigens O772P and O8E from ovarian tumor tissue is 25 described in US Patent Application No. 09/338,933, filed June 23, 1999. The determined cDNA sequence for O772P is provided in SEQ ID NO: 205, with the corresponding amino acid sequence being provided in SEQ ID NO: 206. The full-length cDNA sequence for O8E is provided in SEQ ID NO: 207. Two protein sequences may be translated from the full length O8E. Form "A" (SEQ ID NO: 208)

begins with a putative start methionine. A second form "B" (SEQ ID NO: 209) includes 27 additional upstream residues to the 5' end of the nucleotide sequence.

The expression levels of O772P and O8E in a variety of tumor and normal tissues, including metastatic breast tumors, were analyzed by real time PCR. Both genes were found to have increased mRNA expression in 30-50% of breast tumors. For O772P, elevated expression was also observed in normal trachea, ureter, uterus and ovary. For O8E, elevated expression was also observed in normal trachea, kidney and ovary. Additional analysis employing a panel of tumor cell lines demonstrated increased expression of O8E in the breast tumor cell lines SKBR3, MDA-MB-415 and BT474, and increased expression of O772P in SKBR3. Collectively, the data indicate that O772P and O8E may be useful in the diagnosis and therapy of breast cancer.

#### EXAMPLE 4

15

#### SYNTHESIS OF POLYPEPTIDES

Polypeptides may be synthesized on a Perkin Elmer/Applied Biosystems Division 430A peptide synthesizer using Fmoc chemistry with HPTU (O-Benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate) activation. A Gly-Cys-Gly sequence may be attached to the amino terminus of the peptide to provide a method of conjugation, binding to an immobilized surface, or labeling of the peptide. Cleavage of the peptides from the solid support may be carried out using the following cleavage mixture: trifluoroacetic acid:ethanedithiol:thioanisole:water:phenol (40:1:2:2:3). After cleaving for 2 hours, the peptides may be precipitated in cold methyl-t-butyl-ether. The peptide pellets may then be dissolved in water containing 0.1% trifluoroacetic acid (TFA) and lyophilized prior to purification by C18 reverse phase HPLC. A gradient of 0%-60% acetonitrile (containing 0.1% TFA) in water (containing 0.1% TFA) may be used to elute the peptides. Following lyophilization of the pure fractions, the peptides may be characterized using electrospray or other types of mass spectrometry and by amino acid analysis.

30

From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.



## CLAIMS

1. An isolated polypeptide, comprising at least an immunogenic portion of a breast tumor protein, or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antisera is not substantially diminished, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

(a) sequences recited in SEQ ID NOs: 2-5, 7, 10, 13, 15, 16, 21, 22, 25, 28, 30, 33, 35, 63, 72, 73, 81, 103, 104, 107, 109, 118, 128, 129, 134, 136, 159-161, 164, 181, 183-204 and 210-290;

(b) sequences that hybridize to a sequence recited in any one of SEQ ID NOs: 2-5, 7, 10, 13, 15, 16, 21, 22, 25, 28, 30, 33, 35, 63, 72, 73, 81, 103, 104, 107, 109, 118, 128, 129, 134, 136, 159-161, 164, 181, 183-204 and 210-290 under moderately stringent conditions; and

(c) complements of sequences of (a) or (b).

2. An isolated polypeptide according to claim 1, wherein the polypeptide comprises an amino acid sequence that is encoded by a polynucleotide sequence recited in any one of SEQ ID NOs: 2-5, 7, 10, 13, 15, 16, 21, 22, 25, 28, 30, 33, 35, 63, 72, 73, 81, 103, 104, 107, 109, 118, 128, 129, 134, 136, 159-161, 164, 181, 183-204 and 210-290 or a complement of any of the foregoing polynucleotide sequences.

3. An isolated polynucleotide encoding at least 15 amino acid residues of a breast tumor protein, or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antisera is not substantially diminished, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide comprising a sequence recited in any one of SEQ ID NOs: 2-5, 7, 10, 13, 15, 16, 21, 22,

25, 28, 30, 33, 35, 63, 72, 73, 81, 103, 104, 107, 109, 118, 128, 129, 134, 136, 159-161, 164, 181, 183-204 and 210-290 or a complement of any of the foregoing sequences.

4. An isolated polynucleotide encoding a breast tumor protein, or a variant thereof, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide comprising a sequence recited in any one of SEQ ID NOs: 2-5, 7, 10, 13, 15, 16, 21, 22, 25, 28, 30, 33, 35, 63, 72, 73, 81, 103, 104, 107, 109, 118, 128, 129, 134, 136, 159-161, 164, 181, 183-204 and 210-290 or a complement of any of the foregoing sequences.

5. An isolated polynucleotide, comprising a sequence recited in any one of SEQ ID NOs: 2-5, 7, 10, 13, 15, 16, 21, 22, 25, 28, 30, 33, 35, 63, 72, 73, 81, 103, 104, 107, 109, 118, 128, 129, 134, 136, 159-161, 164, 181, 183-204 and 210-290.

6. An isolated polynucleotide, comprising a sequence that hybridizes to a sequence recited in any one of SEQ ID NOs: 2-5, 7, 10, 13, 15, 16, 21, 22, 25, 28, 30, 33, 35, 63, 72, 73, 81, 103, 104, 107, 109, 118, 128, 129, 134, 136, 159-161, 164, 181, 183-204 and 210-290 under moderately stringent conditions.

7. An isolated polynucleotide complementary to a polynucleotide according to any one of claims 3-6.

8. An expression vector, comprising a polynucleotide according to any one of claims 3-7.

9. A host cell transformed or transfected with an expression vector according to claim 8.

10. An isolated antibody, or antigen-binding fragment thereof, that specifically binds to a breast tumor protein that comprises an amino acid sequence that is encoded by a polynucleotide sequence recited in any one of SEQ ID NOs: 2-5, 7, 10, 13, 15, 16, 21, 22, 25, 28, 30, 33, 35, 63, 72, 73, 81, 103, 104, 107, 109, 118, 128, 129,

134, 136, 159-161, 164, 181, 183-204 and 210-290 or a complement of any of the foregoing polynucleotide sequences.

11. A fusion protein, comprising at least one polypeptide according to claim 1.

12. A fusion protein according to claim 11, wherein the fusion protein comprises an expression enhancer that increases expression of the fusion protein in a host cell transfected with a polynucleotide encoding the fusion protein.

13. A fusion protein according to claim 11, wherein the fusion protein comprises a T helper epitope that is not present within the polypeptide of claim 1.

14. A fusion protein according to claim 11, wherein the fusion protein comprises an affinity tag.

15. An isolated polynucleotide encoding a fusion protein according to claim 11.

16. A pharmaceutical composition, comprising a physiologically acceptable carrier and at least one component selected from the group consisting of:

- (a) a polypeptide according to claim 1;
- (b) a polynucleotide according to claim 3;
- (c) an antibody according to claim 10;
- (d) a fusion protein according to claim 11; and
- (e) a polynucleotide according to claim 15.

17. A vaccine comprising an immunostimulant and at least one component selected from the group consisting of:

- (a) a polypeptide according to claim 1;

- (b) a polynucleotide according to claim 3;
- (c) an antibody according to claim 10;
- (d) a fusion protein according to claim 11; and
- (e) a polynucleotide according to claim 15.

18. A vaccine according to claim 17, wherein the immunostimulant is an adjuvant.

19. A vaccine according to any claim 17, wherein the immunostimulant induces a predominantly Type I response.

20. A method for inhibiting the development of a cancer in a patient, comprising administering to a patient an effective amount of a pharmaceutical composition according to claim 16.

21. A method for inhibiting the development of a cancer in a patient, comprising administering to a patient an effective amount of a vaccine according to claim 17.

22. A pharmaceutical composition comprising an antigen-presenting cell that expresses a polypeptide according to claim 1, in combination with a pharmaceutically acceptable carrier or excipient.

23. A pharmaceutical composition according to claim 22, wherein the antigen presenting cell is a dendritic cell or a macrophage.

24. A vaccine comprising an antigen-presenting cell that expresses a polypeptide comprising at least an immunogenic portion of a breast tumor protein, or a variant thereof, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

- (a) sequences recited in SEQ ID NOs: 1-38, 42-204, 205, 207 and 210-290;
- (b) sequences that hybridize to a sequence recited in any one of SEQ ID NOs: 1-38, 42-204, 205, 207 and 210-290 under moderately stringent conditions; and
- (c) complements of sequences of (i) or (ii);  
in combination with an immunostimulant.

25. A vaccine according to claim 24, wherein the immunostimulant is an adjuvant.

26. A vaccine according to claim 24, wherein the immunostimulant induces a predominantly Type I response.

27. A vaccine according to claim 24, wherein the antigen-presenting cell is a dendritic cell.

28. A method for inhibiting the development of a cancer in a patient, comprising administering to a patient an effective amount of an antigen-presenting cell that expresses a polypeptide comprising at least an immunogenic portion of a breast tumor protein, or a variant thereof, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

- (a) sequences recited in SEQ ID NOs: 1-38, 42-204, 205, 207 and 210-290;
- (b) sequences that hybridize to a sequence recited in any one of SEQ ID NOs: 1-38, 42-204, 205, 207 and 210-290 under moderately stringent conditions; and
- (c) complements of sequences of (i) or (ii) encoded by a polynucleotide recited in any one of SEQ ID NOs: 1-38, 42-204, 205, 207 and 210-290; and thereby inhibiting the development of a cancer in the patient.

29. A method according to claim 28, wherein the antigen-presenting cell is a dendritic cell.

30. A method according to any one of claims 20, 21 and 28, wherein the cancer is breast cancer.

31. A method for removing tumor cells from a biological sample, comprising contacting a biological sample with T cells that specifically react with a breast tumor protein, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

(i) polynucleotides recited in any one of SEQ ID NOs: 1-38, 42-204, 205, 207 and 210-290; and

(ii) complements of the foregoing polynucleotides;

wherein the step of contacting is performed under conditions and for a time sufficient to permit the removal of cells expressing the antigen from the sample.

32. A method according to claim 31, wherein the biological sample is blood or a fraction thereof.

33. A method for inhibiting the development of a cancer in a patient, comprising administering to a patient a biological sample treated according to the method of claim 31.

34. A method for stimulating and/or expanding T cells specific for a breast tumor protein, comprising contacting T cells with at least one component selected from the group consisting of:

(a) polypeptides comprising at least an immunogenic portion of a breast tumor protein, or a variant thereof, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

- (i) sequences recited in SEQ ID NOs: 1-38, 42-204, 205, 207 and 210-290;
  - (ii) sequences that hybridize to a sequence recited in any one of SEQ ID NOs: 1-38, 42-204, 205, 207 and 210-290 under moderately stringent conditions; and
  - (iii) complements of sequences of (i) or (ii);
- (b) polynucleotides encoding a polypeptide of (a); and
  - (c) antigen presenting cells that express a polypeptide of (a);
- under conditions and for a time sufficient to permit the stimulation and/or expansion of T cells.

35. An isolated T cell population, comprising T cells prepared according to the method of claim 34.

36. A method for inhibiting the development of a cancer in a patient, comprising administering to a patient an effective amount of a T cell population according to claim 35.

37. A method for inhibiting the development of a cancer in a patient, comprising the steps of:

(a) incubating CD4<sup>+</sup> and/or CD8<sup>+</sup> T cells isolated from a patient with at least one component selected from the group consisting of:

(i) polypeptides comprising at least an immunogenic portion of a breast tumor protein, or a variant thereof, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

(1) sequences recited in SEQ ID NOs: 1-38, 42-204, 205, 207 and 210-290;

(2) sequences that hybridize to a sequence recited in any one of SEQ ID NOs: 1-38, 42-204, 205, 207 and 210-290 under moderately stringent conditions; and

- (3) complements of sequences of (1) or (2);
- (ii) polynucleotides encoding a polypeptide of (i); and
- (iii) antigen presenting cells that expresses a polypeptide of (i);

such that T cells proliferate; and

- (b) administering to the patient an effective amount of the proliferated T cells, and thereby inhibiting the development of a cancer in the patient.

38. A method for inhibiting the development of a cancer in a patient, comprising the steps of:

- (a) incubating CD4<sup>+</sup> and/or CD8<sup>+</sup> T cells isolated from a patient with at least one component selected from the group consisting of:

- (i) polypeptides comprising at least an immunogenic portion of a breast tumor protein, or a variant thereof, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

- (1) sequences recited in SEQ ID NOs: 1-38, 42-204, 205, 207 and 210-290;

- (2) sequences that hybridize to a sequence recited in any one of SEQ ID NOs: 1-38, 42-204, 205, 207 and 210-290 under moderately stringent conditions; and

- (3) complements of sequences of (1) or (2);

- (ii) polynucleotides encoding a polypeptide of (i); and

- (iii) antigen presenting cells that express a polypeptide of (i);

such that T cells proliferate;

- (b) cloning at least one proliferated cell to provide cloned T cells;

and

- (c) administering to the patient an effective amount of the cloned T cells, and thereby inhibiting the development of a cancer in the patient.



39. A method for determining the presence or absence of a cancer in a patient, comprising the steps of:

(a) contacting a biological sample obtained from a patient with a binding agent that binds to a breast tumor protein, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide sequence recited in any one of SEQ ID NOs: 1-38, 42-204, 205, 207 and 210-290 or a complement of any of the foregoing polynucleotide sequences;

(b) detecting in the sample an amount of polypeptide that binds to the binding agent; and

(c) comparing the amount of polypeptide to a predetermined cut-off value, and therefrom determining the presence or absence of a cancer in the patient.

40. A method according to claim 39, wherein the binding agent is an antibody.

41. A method according to claim 40, wherein the antibody is a monoclonal antibody.

42. A method according to claim 40, wherein the cancer is breast cancer.

43. A method for monitoring the progression of a cancer in a patient, comprising the steps of:

(a) contacting a biological sample obtained from a patient at a first point in time with a binding agent that binds to a breast tumor protein, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide sequence recited in any one of SEQ ID NOs: 1-38, 42-204, 205, 207 and 210-290 or a complement of any of the foregoing polynucleotide sequences;

(b) detecting in the sample an amount of polypeptide that binds to the binding agent;

(c) repeating steps (a) and (b) using a biological sample obtained from the patient at a subsequent point in time; and

(d) comparing the amount of polypeptide detected in step (c) to the amount detected in step (b) and therefrom monitoring the progression of the cancer in the patient.

44. A method according to claim 43, wherein the binding agent is an antibody.

45. A method according to claim 44, wherein the antibody is a monoclonal antibody.

46. A method according to claim 43, wherein the cancer is a breast cancer.

47. A method for determining the presence or absence of a cancer in a patient, comprising the steps of:

(a) contacting a biological sample obtained from a patient with an oligonucleotide that hybridizes to a polynucleotide that encodes a breast tumor protein, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide sequence recited in any one of SEQ ID NO: 1-38, 42-204, 205, 207 and 210-290 or a complement of any of the foregoing polynucleotide sequences;

(b) detecting in the sample an amount of a polynucleotide that hybridizes to the oligonucleotide; and

(c) comparing the amount of polynucleotide that hybridizes to the oligonucleotide to a predetermined cut-off value, and therefrom determining the presence or absence of a cancer in the patient.

48. A method according to claim 47, wherein the amount of polynucleotide that hybridizes to the oligonucleotide is determined using a polymerase chain reaction.

49. A method according to claim 47, wherein the amount of polynucleotide that hybridizes to the oligonucleotide is determined using a hybridization assay.

50. A method for monitoring the progression of a cancer in a patient, comprising the steps of:

(a) contacting a biological sample obtained from a patient with an oligonucleotide that hybridizes to a polynucleotide that encodes a breast tumor protein, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide sequence recited in any one of SEQ ID NO: 1-38, 42-204, 205, 207 and 210-290 or a complement of any of the foregoing polynucleotide sequences;

(b) detecting in the sample an amount of a polynucleotide that hybridizes to the oligonucleotide;

(c) repeating steps (a) and (b) using a biological sample obtained from the patient at a subsequent point in time; and

(d) comparing the amount of polynucleotide detected in step (c) to the amount detected in step (b) and therefrom monitoring the progression of the cancer in the patient.

51. A method according to claim 50, wherein the amount of polynucleotide that hybridizes to the oligonucleotide is determined using a polymerase chain reaction.

52. A method according to claim 50, wherein the amount of polynucleotide that hybridizes to the oligonucleotide is determined using a hybridization assay.

53. A diagnostic kit, comprising:

(a) one or more antibodies according to claim 10; and

(b) a detection reagent comprising a reporter group.

54. A kit according to claim 53, wherein the antibodies are immobilized on a solid support.

55. A kit according to claim 53, wherein the detection reagent comprises an anti-immunoglobulin, protein G, protein A or lectin.

56. A kit according to claim 53, wherein the reporter group is selected from the group consisting of radioisotopes, fluorescent groups, luminescent groups, enzymes, biotin and dye particles.

57. An oligonucleotide comprising 10 to 40 contiguous nucleotides that hybridize under moderately stringent conditions to a polynucleotide that encodes a breast tumor protein, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide sequence recited in any one of SEQ ID NOs: 2-5, 7, 10, 13, 15, 16, 21, 22, 25, 28, 30, 33, 35, 63, 72, 73, 81, 103, 104, 107, 109, 118, 128, 129, 134, 136, 159-161, 164, 181, 183-204 and 210-290 or a complement of any of the foregoing polynucleotides.

58. A oligonucleotide according to claim 57, wherein the oligonucleotide comprises 10-40 contiguous nucleotides recited in any one of SEQ ID NOs: 2-5, 7, 10, 13, 15, 16, 21, 22, 25, 28, 30, 33, 35, 63, 72, 73, 81, 103, 104, 107, 109, 118, 128, 129, 134, 136, 159-161, 164, 181, 183-204 and 210-290.

59. A diagnostic kit, comprising:

- (a) an oligonucleotide according to claim 58; and
- (b) a diagnostic reagent for use in a polymerase chain reaction or hybridization assay.

## SEQUENCE LISTING

<110> Corixa Corporation  
 Dillon, Davin C.  
 Day, Craig H.  
 Jiang, Yuqiu  
 Wang, Aijun  
 Houghton, Raymond L.  
 Mitcham, Jennifer L.

<120> COMPOSITIONS AND METHODS FOR THERAPY AND  
 DIAGNOSIS OF BREAST CANCER

<130> 210121.491PC

<140> PCT

<141> 2000-11-29

<160> 290

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 298

<212> DNA

<213> Homo sapien

<400> 1

ctgaacagtg tcagctccgt gctggagaca gtccctgctga tcacctgaat gctgaacatg	60
cttcgtgggg ctatcttttg tttctctgt agtctcttg gtgatctcat ctgctttct	120
gctcgagtga tgacagcctt gaaccttgct cttccttgct tcagagggga aaaaggaatt	180
ggatttcttc agggctcggg gcctgggctg tggcttgagg ttccgagact gatgaatcca	240
agcatgcttg agggcctggt ccggggctcat gcgaagagaa gggtcccata ccaaacac	298

<210> 2

<211> 276

<212> DNA

<213> Homo sapien

<400> 2

tggaagggtg ggtgactaag ggccacggtt attgggtgaa atttgagatt gtaggccaac	60
tgtattttca agcttctgaa cttaggcaaa atattcatcg caaagtctct agcgtcatat	120
ttttctcacc taaattacgt ttccacgaga ttatttatat atagttggct tatctctgca	180
gtccttgaag gtgaagttgt gtgttactag gctgtgtttt gggatgtcag cagtggcctg	240
aagtgagttg tgcaataaat gttaagttga aacctc	276

<210> 3

<211> 405

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(405)

<223> n = A,T,C or G

<400> 3

tcacatggct	atttcattta	tttagtagtt	ttgaaatggt	agcaaata	aggtatttgt	60
aaagcatctt	tcattataaa	gagattagta	atattcacca	atcatgccaa	tgagattata	120
cactctgcc	aagactacta	naaaaatttg	atcattatta	aattcaatgt	tatttgacag	180
tgtgaactct	atgtaacagc	acaaattctg	gactttgaat	ctggctgctg	tcctcacctg	240
aaccattaaa	atgaccttgt	taacaaggaa	ggaatcaatg	gggaaatc	acaaccagag	300
attggctgtg	tgtccaaggg	tgctttgtct	tgttgccagg	atcagactgt	gaaatcacag	360
aggcaagctg	atgtcatcag	aggtgactct	gcccccaaca	caatg		405

<210> 4  
 <211> 696  
 <212> DNA  
 <213> Homo sapien

<400> 4						
cattgtgttg	ggcactgtta	cagtgaacg	gaaacgtgga	aatcacagc	caaactgtgc	60
tctgaaagaa	cactctatgt	ctaataatagc	cagcgtcaag	agtccttatg	aggcggagaa	120
ctccggggaa	gagctggatc	agaggtattc	caaggccaag	ccaatgtgta	acacatgtgg	180
gaaagtgttt	tcagaagcca	gcagtttgag	aaggcacatg	agaatacata	aaggagtcaa	240
accttacgtc	tgccacttat	gtggaaaggc	atttacccaa	tgtaaccagc	tgaaaacgca	300
tgtaagaact	catacaggtg	agaagccata	caaagtgtgaa	ttgtgtgata	aaggatttgc	360
tcagaaaatgt	cagctagtct	tccatagtcg	catgcatcat	ggtgaagaaa	aaccctataa	420
atgtgatgta	tgcaacttac	agtttgcaac	ttctagcaat	ctcaagattc	atgcaaggaa	480
gcatagtgga	gagaagccat	atgtctgtga	taggtgtgga	cagagatttg	ctcaagccag	540
cacactgacc	tatcatgtcc	gtaggcatac	tggagaaaag	ccttatgtat	gtgatacctg	600
tgggaaggca	tttgetgtct	ctagttctct	tatcactcat	tctcgaaaac	atacaggtaa	660
gtttgacagg	gagagactgc	ttaaaataaa	gttata			696

<210> 5  
 <211> 580  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1) ... (580)  
 <223> n = A,T,C or G

<400> 5						
acatcaaaaa	ggaaatattt	ttgacttgct	ttttctctgt	aaatcctccc	atctcactaa	60
tatttacaac	aatccagagt	agcgtttatg	agacactgaa	aaagacaggg	aggaaatcct	120
ttttcaagat	atgaagtcag	aacctgaatg	tagacatcgg	acagagaagt	cctcaaccac	180
aaacctgtcc	tccagctcta	gagagagtaa	ggctgtattt	ccaaccttga	gatttttcat	240
tacattttcc	cctttttggg	tgttaaattc	tttccaagaa	tgtgtactt	gtaaaaatga	300
ttttattcta	gctacaaaac	atttcattta	anaaaaccgc	attttatatc	cttgtgtgaa	360
atgtctccaa	aagccatcaa	gatatggaga	caacagattt	taaaaacata	aatctaataca	420
tatgggcttg	aaacagtatg	aacatttaac	agagtgcac	gatatcatta	ttatatattgt	480
ttgtcatgag	atgaaaggcc	tggaggcaga	tgggtgattaa	tcataattcc	tgagcttcta	540
cagaaatttt	aaaatgaaat	tactaactgc	ttaaaattat			580

<210> 6  
 <211> 557  
 <212> DNA  
 <213> Homo sapien

<400> 6						
attacattca	agataaaaga	tttattcaca	ccacaaaaag	ataatcacia	caaaatatac	60
actaaactta	aaaacaaaag	attatagtga	cataaaatgt	tatattctct	ttttaagtgg	120
gtaaaagtat	tttgtttgct	tctacataaa	tttctattca	tgagagaata	acaaatatta	180

aaatacagtg	atagtttgca	tttcttctat	agaatgaaca	tagacataac	cctgaagctt	240
ttagtttaca	gggagtttcc	atgaagccac	aaactaaact	aattatcaaa	cacattagtt	300
atttccagac	tcaaatagat	acacattcaa	ccaataaact	gagaaagaag	catttcatgt	360
tctctttcat	tttgctataa	agcatttttt	cttttgacta	aatgcaaagt	gagaaattgt	420
attttttctc	cttttaattg	acctcagaag	atgcactatc	taattcatga	gaaatacgaa	480
atttcaggtg	tttatcttct	tccttacttt	tggggtctac	aaccagcata	tcttcatggc	540
tgtgaaattc	atggctg					557

&lt;210&gt; 7

&lt;211&gt; 653

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 7

cattgtgttg	ggggaagtag	ggaatattat	tgaggcaggg	taagaaatgg	tttacaattc	60
tgaaaggatg	atcaaagaaa	aactcattgt	tgagaaagta	atatgagtag	agacctgaaa	120
taagtgaggg	agtgacgggt	tatgtccagg	gcaataatgt	ttctgacaga	ggggagagtc	180
atttcagaag	cctagaggca	tgtgtaaagc	tgtagaatg	ccagacagtc	accaggccaa	240
gatgtgcaga	tatccataag	tgaaggggaa	agaaatacaa	aatgaaggca	gagaaatcac	300
aaaattggat	aagtggtgcc	ttgtaggcca	tgatgatttt	agttcatact	aaaattgagt	360
taggctgcca	ttgtagggtt	tgtgagctca	gggataacat	ggtctgaatt	ttattttctaa	420
aaggatcact	ccaagtgtta	cattgcaaag	aataacgtaa	ggtggctggg	gtagtagact	480
aaagtggaat	atagtaacag	tgaaatacat	tttgtggtaa	agcttggtag	atttgaccac	540
acaaaattgt	gaaattacct	gtggcacaaa	aaatatcaaa	ggtacataca	gacagaagaa	600
ccttgcgatt	gtttattaat	gtccttaatt	tataatgtta	ataccagtag	aag	653

&lt;210&gt; 8

&lt;211&gt; 456

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 8

cattgtgttg	ggctaatect	tggctctctat	ccacctgcc	tagcaattta	tctcaaagct	60
tcaagttcct	gccatctaca	tgtgcccagg	tcaaccaatc	aatggctcag	acagataagc	120
caacatgcat	cccgccggag	ctgccgaaaa	tgctgaagga	gtttgccaaa	gccgccattc	180
ggggcgagcc	gcaggacctc	atccagtggg	ggggcgatta	ttttgaggcc	ctgtcccgtg	240
gagagacgcc	tccgggtgaga	gagcggctctg	agcgagtcgc	tttgtgtaac	tgggcagagc	300
taacacctga	gctgttaaag	atcctgcatt	ctcagggtgc	tggcagactg	atcatccgtg	360
cagaggagct	ggcccagatg	tggaaagtgg	tgaatctccc	aacagatctg	tttaatagtg	420
tgatgaatgt	gggtcgcttc	acggaggaga	tcgagt			456

&lt;210&gt; 9

&lt;211&gt; 512

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 9

gtttttgatt	cattttattt	taacaatggt	taacaatgta	agtccacata	taagataccc	60
aagctttaaa	tatctataca	tataaactga	tttcaacatc	tttggcttca	aaacagtaaa	120
attgtttttc	caatatcaaa	caagtcaa	ttggaaaagg	cataaatctg	tatgaacatc	180
ctgtatccat	ggagatgtca	tgactaaatt	cagaaatagc	ctcatctctc	tttgtttttg	240
ctttcttatg	tctgagttct	gcatccaatt	ctgtttatta	catagttttc	tataagattg	300
tacctctttt	aaacagtgtc	tattgatata	tattctaggt	gtctggaagt	ctttttctat	360
agtcggctct	tggttgtctc	tgggaatatg	aatggaagga	gcagagtga	aataaatctg	420
agggcaatat	tcataaataa	tccaagagct	acactgtagt	caactctccc	cagagcctga	480
ccacagtgtt	tccctctctc	ctcctcccaa	cc			512

&lt;210&gt; 10

<211> 308  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(308)  
 <223> n = A,T,C or G

<400> 10  
 atgtttatga agacctttta atatttatat agaaacaaaa tgtcattgca acctaacatc 60  
 atccattaaa aataaaaagga aaggaaaacg gcagggaataa gtgcagtaat aacaaatggg 120  
 gacatgcttg gtcttaagca tcatagcaaa ctcatatttt ccaatgaaac aaggattttt 180  
 agacccatct ttggaaatga ttcccaaatt aganaaccat caggtctcaa aaaaggaagg 240  
 gtcacaaag tccatccagc ccagccaccc tgaggngcct gtatctcttc aacaagccca 300  
 acacaatg 308

<210> 11  
 <211> 510  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(510)  
 <223> n = A,T,C or G

<400> 11  
 attatatgaa tattttaatg caaaatgctt aacacttaaa attagcaaag cgtcatttaa 60  
 attaaaattc catttaacta aagatgggta accccaanaa attgtacagt agttgatttc 120  
 tgctatataa tgccagtcct atgccataca ataagaactg caacattagc tgtcacttcc 180  
 tccattgctc ttctggaccc taagggatga gggaggggac tcagacacaa aacacaaccc 240  
 aaataaactg tgcagtgatt cctaatagtt ataaacccaa tctaagttgt ccaaacagct 300  
 gaagaataac tgcaggtatt gttccanagc tgatacgagg ttttgctttt acagcctggg 360  
 aaaagttctg cactaggtga gaagtcacag ttttaaggatg catgttctgt aaatagttac 420  
 tacatataca catttactgt ctgtaaacac tagaaatata cattagacag agtaccctca 480  
 caagttgggt acagtttaaa aaagaagatg 510

<210> 12  
 <211> 611  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(611)  
 <223> n = A,T,C or G

<400> 12  
 agttttataa aatattttat ttacagtaga gctttacaaa aatagtctta aattaatata 60  
 aatccctttt gcaatataac ttatatgact atcttctcaa aaacgtgaca ttcgattata 120  
 acacataaac tacatttata gttgttaagt caccttgtag tataaatatg ttttcatctt 180  
 ttttttgtaa taagggnacat accaataaca atgaacaaat gacaacaaat cttattttgt 240  
 tattcttcca atgtaaaatt catctctggc caaaacaaaa ttaaccaaag aaaagtaaaa 300  
 caattgtccc tctgttcaac aatacagtcc tttttaatta tttgagagtt tatctgacag 360  
 agacacagca ttaaactgaa agcaccatgg cataaagtct agtaacatta tcctcaaaaag 420  
 ctttttccaa tgtctttcct tcaactgttt attcagtatt tggccagtac aaataaagat 480  
 tgggtctcaac tctctctttc attagtctca agtggtccta ttatgcactg agttttcaga 540



ccttcccaac tggcatgtgt tttaagtgtg agtttctttc tttggcttca agtggagttt 600  
cacaacattt a 611

<210> 13  
<211> 394  
<212> DNA  
<213> Homo sapien  
  
<220>  
<221> misc\_feature  
<222> (1)... (394)  
<223> n = A,T,C or G

<400> 13  
caatgttttag attcatttta ttagtggcat atacaaagca ccatataata tatgaaacgt 60  
anaacaatca tgactatgta attaactgta naaataactg ctaanaaaat atagcaatat 120  
ttaacacagg atttctaaaa ccattatatt ttcattactt ttcccaaagc taatgtccca 180  
tgttttattt tatanacttt gtttatcaag atttatatgc atttggcacc tttttgggct 240  
gaaaatagtt gatgtactct gtacagtaat gttacagttt tatacaaaat tcanaaatat 300  
tgcatttgga atagtcttta tggctcctctt ccaagtattc agtttcacac aacagcaaac 360  
actctgaatg cctttcctcc tgcccaaac aatg 394

<210> 14  
<211> 361  
<212> DNA  
<213> Homo sapien  
  
<220>  
<221> misc\_feature  
<222> (1)... (361)  
<223> n = A,T,C or G

<400> 14  
agcaggnact ataattttat aattaatttt acaattcatg tagcaaatgg aaaatcatac 60  
agagaggcca atgtatataa ataagagttt atacagaaac tgccaattca caaaacagca 120  
ctgcatgggt tctatattgc aagcacaaga catggtcaca tggttccact gtacaggtag 180  
aaacaagccc acagacaata catagagtac cacctgaaac gaggcccttg gagctgctca 240  
gcttcttana aaataganaa ctttcaatgg tcataatata ttttgattca aaatgtcttc 300  
taaaatgttt tcattgtggg agaaaattaa gaaggggcaa aaatccatct atggaacttc 360  
t 361

<210> 15  
<211> 537  
<212> DNA  
<213> Homo sapien  
  
<220>  
<221> misc\_feature  
<222> (1)... (537)  
<223> n = A,T,C or G

<400> 15  
acttacaaaa ttaattttat tttgcaaaac tcaacaaata cacgttcaga tctggtttct 60  
cttcaaaaca tgtgtttggt tttttaacaa acatgcaagt taatttggca tgccaaacat 120  
ctttctctct agctgcctt ggaaaaattt ttttcataac acaaacaagg gtgcaaatat 180  
tgtccaaacc tatttacatt ttaccctct agaattacat acattaatat ttattgggag 240  
gaaagcaaaa ctgcaaaaca tagtctttgg cattcacatt tgcttcagca gtataattaa 300  
aaccttatat ttgttttaaa gataaacagt ttgaaggaaa ttaataaat cttgttttgg 360

ctctgcaaag gagccactat atcaaagcat ttaactggag ctgttgagtt cctgctggta	420
gaatattact tccagcctat ttattagctt gtcttccggn ggcccaatac atgctttttt	480
ccctctacac tgaatgaaag tacaaaaaga aaaccatttc ttttcccaa cacaatg	537

<210> 16  
 <211> 547  
 <212> DNA  
 <213> Homo sapien  
  
 <220>  
 <221> misc\_feature  
 <222> (1)...(547)  
 <223> n = A,T,C or G

<400> 16					
gggtgtggng atgtatttat tcataatata ttttcagaac acattaataa tggagaataa	60				
cacttattca tatactgaat ataacttttc ctggagcact ctagagcttg tttggagttg	120				
gagaatactg ccaggctttt cctaattctt ttggtctttg gaagtgggca gggtttctca	180				
aaccaagtgt cttccatggg ccattggcaa aggcttccct tcatcagctt ggaggggcag	240				
aaagaccatg gcttcagcac ttccattttg gaaagaagta acaaaaaagt gaattaatga	300				
gcaatcggaa agactcaaag cattttgtac tccacagttc atttcttcac acaaacgtcc	360				
attactgcag cgggcatgaa aaccggcagg gtgttaggct catggcctga agagaagtca	420				
catcaccagc cgatgttttc atgcaaaagg caatcgtgat gattcanaac ctggttctga	480				
atttctccag gtgtgctcgt gagctgaagg tcatgcccac tctgtgcac ctgtgcccac	540				
cacaatg	547				

<210> 17  
 <211> 342  
 <212> DNA  
 <213> Homo sapien

<400> 17					
acattaagaa gctcctcttc tagcatgtcc ttaagaagcc tgtcttgac cactttcata	60				
tcttctttca tcaaacacat ctcgatgta aaaacagttt cttcactatc agtattacag	120				
aagacacttt tagccaatga agttttcaaa agaagaaagc ctctgttgtt cgcttttttg	180				
atatgcactg aacttctgaa atatcttttc ccaaaagtc acaaatctct tttccaaatc	240				
ttttaagac tgtgaatctt tttcaaaatt ctccagctcc tctatgataa tgaattggaa	300				
tttatcaagt tttttaatcc tagagtctct actttggatg at	342				

<210> 18  
 <211> 279  
 <212> DNA  
 <213> Homo sapien

<400> 18					
catcataagg ttttattcat atatatacag ggtattaaga attaagagga tgctgggctc	60				
tggtcttggc ttggaagatt ctatttaatt gaaactctct gttcagaaag caataacttt	120				
gtctcgttcc tgttgggctg aaccctaagg tgagtgtgca gtacagtgtg tgtgggtgaa	180				
atggagattt ggaattgaac tctctgcttg taaatgttcc ccaaataatt gttgtgtgta	240				
tgatacgtgt ataataaaaag tattcttgtt agaactctga	279				

<210> 19  
 <211> 239  
 <212> DNA  
 <213> Homo sapien

<400> 19					
ctgccagcgt ttttgtgtgg ctgcagtgtg cctgggcccac gctcacgggc agtgggtgga	60				

cctaactgcc	caggcaggcg	agagctactt	ccagagcctt	ccagtgcattg	ggagggcagg	120
gctagggtgta	gcggtgtctc	ctctttgaaa	ttaagaacta	tctttcttgt	agcaaagctg	180
cacctgatga	tgctgcctct	cctctctgtg	ttgtctgggc	ccttgtttac	aagcacgcg	239

&lt;210&gt; 20

&lt;211&gt; 527

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 20

ctgaaccatt	atgggataaa	ctgggtgcaa	ttctttgcct	tctctacttc	tcaactgattg	60
aacataagct	tccagggctc	ccctgatgag	gaggagcctg	tccttttcag	atggatggtc	120
atccagccac	tgagagaagc	gtgtgtggga	ccactctgcc	ctctggaaag	gagatttcag	180
ttcagcgggt	gctctcgtga	acaaaaactg	aataatgatg	ctgaacggaa	tcacatcccc	240
caatgcagga	ctactggcta	catgttcaact	tgcttgggaag	agcagaggtc	tgaatgatct	300
cagcatccga	taggactttc	ctaaatcaga	tactcgtcta	cagaatgaac	ccacagccaa	360
ctccatctgt	gcaaaatcag	cagcaagtcg	cattttccca	ccttcaccaa	gaggtcttat	420
gagactggca	tggcggataa	aaagttcaac	agctctttgg	gcaataacct	cagtgttgtc	480
aaagacaaaa	tccaagcatt	caaagtgttt	aaaatagtca	ctcataa		527

&lt;210&gt; 21

&lt;211&gt; 399

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 21

ctgcaatggg	tgcaagtgtc	atttccacct	agctctgact	ctccacttct	aaccagacaa	60
acagccaacc	aaccaatcaa	catgtattta	ataaccacct	atgggggtgca	aagcacaaaa	120
gggcactcat	cttgaaaagg	aaagaccaag	aatgtgctag	agtaaagaga	cagagaccag	180
accctactct	caagatcaag	agacttcagt	ctcggagaca	tctgccattt	ctctcttctt	240
aataaacctc	atttgccttt	aaaaatacat	ttgctttggg	ggcccagaat	caagaaagga	300
aactttacaa	agtaaacaga	agttactccc	cacaggaggg	cagaagcaga	ttaaccccaa	360
cagcagacat	ctgcccggaa	gagcaaaactc	cacatctgg			399

&lt;210&gt; 22

&lt;211&gt; 532

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 22

ccagaagggtg	aagaaaagtt	atctgataat	gctcaaagtg	cagtagaaat	acttttaacc	60
attgatgata	caaagagagc	tggaatgaaa	gagctaaaac	gtcatcctct	cttcagtgat	120
gtggactggg	aaaatctgca	gcacagact	atgcctttca	tccccagcc	agatgatgaa	180
acagatacct	cctattttga	agccaggaat	actgctcagc	acctgaccgt	atctggattt	240
agtctgtagc	acaaaaattt	tccttttagt	ctagcctcgt	gttatagaat	gaacttgcac	300
aattatatac	tccttaatac	tagattgac	taagggggaa	agatcattat	ttaacctagt	360
tcaatgtgct	tttaatgtac	gttacagctt	tcacagagtt	aaaaggctga	aaggaatata	420
gtcagtaatt	tatcttaacc	tcaaaactgt	atataaatct	tcaaagcttt	tttcatctat	480
ttattttgtt	tattgcactt	tatgaaaact	gaagcatcaa	taaaattaga	gg	532

&lt;210&gt; 23

&lt;211&gt; 215

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 23

tgcaataaag	ggctgctgtt	tgcagcacac	cgttcgtggg	gtccccctgg	gcttctatcc	60
taataccatc	gacgtccctc	cagaagagga	gtgtgaattt	tagacacttc	tgcagggatc	120

tgccctgcac ctgacacggg gccgtcccca gcacgggtgat tagtcccaga gctcgggtgc 180  
 cacctccacc ggacacctca gacacgcttc tgcag 215

<210> 24  
 <211> 215  
 <212> DNA  
 <213> Homo sapien

<400> 24  
 cctgaggctc caggctaaga agtagccaag ttccacctgg agagaagagt agaggggactt 60  
 cccaaatttc ttctgaact cagctctgat actcagaagg tcagtctcac atcgagagat 120  
 aaggatgcga atcaggactt ggtaattggg ctcagtttcc tagtagggga agaaagagat 180  
 ggggggtagt tagtgagagt ctactgaga gtagg 215

<210> 25  
 <211> 530  
 <212> DNA  
 <213> Homo sapien

<400> 25  
 ttttttttct agtaagacta gatttattca ataccctagt aaaagttttg attataagta 60  
 tccaacagta taaaaagtac aaaacagatc tgtagatttc taatatatta atacaaagtg 120  
 catgactaca tacagtacat cctacaggca aagagagggtg gaaggggaaa aagaagactg 180  
 tgggtgagggt ctagtaataa ataaataaat acagaagtag agatgatcca tattatagta 240  
 tattctacca ccaatactgc agccaaaatg tacaaaaaaa atcattttcaa ataactcagg 300  
 aggatgataa tggctggact tttgtaattc acctcaaaga ctgtgggaga gccaaactcaa 360  
 ctactgtat agtctgtgca tatggtggct tgtagcatgt aggttttttc caaaagaagg 420  
 aaatataaaa tgtttagatt aagaactata aaactacagg gtgcctataa aagggtggctt 480  
 actccttatt gttattatac tatccaattt ttaaaatgca gtttaaaaaa 530

<210> 26  
 <211> 366  
 <212> DNA  
 <213> Homo sapien

<400> 26  
 ccagcagttc tgggacctcc tctgggggca gggagaggcc attgggtcag gggctggacc 60  
 caggaggagt tggaatgggt gaaagatggg gagcaagttt ttagggtaga ggggtggcct 120  
 aagatgggtc agtagacaga tgggagcaca gagcagggca gggggtgagg tcaagtgagg 180  
 gccacaggat gtgctgaggg ctcccaggga gccctaccca ggctcacgtc ctccctgtca 240  
 ccacctgtac tgtctggggg ccacagggtg tgggcgttgc caggggagcac tgggagggcc 300  
 tcggtagggt ccacctgtag ggagaggatg tcaggaccac tagcctctgg gcaagggcag 360  
 aggagg 366

<210> 27  
 <211> 331  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(331)  
 <223> n = A,T,C or G

<400> 27  
 ccaaactcag agatgggtacc agccaggggc aagcatgacc agagccaggg accctgtggc 60  
 tctgatcccc catttatcca ccccatgtgc ctcaggacta gaggtagcaa tcatacctta 120  
 taaatgactt ttgtgccttt ctgctccagt ctcaaaattt cctacacctg ccagttcttt 180

acattttttcc aaggaaagga aaacggaagc aggggttcttg cctggtagct ccaggaccca	240
nctctgcagg cacccaaaga ccctctgtgt ccagcctctt ccttgagttc tcggaacctc	300
ctccctaatt ctcccttctt tccccacaag g	331

<210> 28  
 <211> 530  
 <212> DNA  
 <213> Homo sapien

<400> 28	
ccatgaatgc ccaacaagat aatattctat accagactgt tacaggattg aagaaagatt	60
tgtcaggagt tcagaaggtc cctgcactcc tagaaaatca agtggaggaa aggacttggt	120
ctgattcaga agatattgga agctctgagt gctctgacac agattctgaa gagcaggag	180
accatgcccg ccccaagaaa cacaccacgg acctgacat tgataaaaaa gaaagaaaaa	240
agatggtcaa ggaagcccag agagagaaaa gaaaaaaca aattcctaaa catgtgaaaa	300
aaagaaagga gaagacagcc aagacgaaaa aaggcaaata gaatgagaac catattatgt	360
acagtcattt tctcagttc cttttctcgc ctgaactctt aagctgcac tggaagatgg	420
cttattggtt ttaaccagat tgtcatcgtg gcaactgtct tgaagacgga ttcaaattgt	480
ttcatgtaac tatgtaaaaa gctctaagct cttagagtcta gatccagtca	530

<210> 29  
 <211> 571  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1) ... (571)  
 <223> n = A,T,C or G

<400> 29	
ccataatatt ctgatgatca aggagcacac atatacaaaa gttattggat tactgcaatt	60
ctcagaggca caaaacctga catgggtgtga tatagtatat aatcagtcac gggggggaaa	120
agaacattaa gtcttttaaaa aggcttagga agacataaac agtaaatctt tgtttttcta	180
ccttcctttg gacagtgtta tatttcactt tcttctttgc aaaatgtttc caaattcatt	240
tgctcaggat ttattttaaga taataactta aaacaactaa cagttgttta tgctatatgc	300
atatcatgca tgttctactg gttcaaggac aaaattaaaa caagatcttc tctgtaaaagc	360
aaatatattt attatgcact ttcataata cagggatttt ttgagtacca angggataaa	420
ataaaacttt tacaatgtga aattcaatgt acatttttgg ctattttacat acctcaaacc	480
aagggaaaaa taaaaagaaa gcatttggtt gcaactacat ttgctgagaa gtgtaaatgg	540
aggacattaa gcaaaacaaa tatttgcata g	571

<210> 30  
 <211> 917  
 <212> DNA  
 <213> Homo sapien

<400> 30	
actgccagag agtatgattt gaaggagatg ggagcagatg taattcttgg ctggaatctc	60
tcattttcaaa atcacttcac ataatggtgt catcatttaa acacttaaca gtcagtgcac	120
ctgccactgt aacatctagt tggacaaaac cacaaggagg gggaggagaa aatgccatca	180
ctattatggt aacaaacatt taatttaaata aaattaatca ctagtaaaatt tctgcagaaa	240
acagttttac ccgccccctt tcacagttcc aaattaatca aggatgcttt tctataatct	300
gatgcttagc aaattagctc atgattcaaa ttttgccctc ttgaagcaca tatacctttt	360
atttttaaaag tccattatag agaatttgga atatataagg tatttgaatt gcagaacacc	420
cctctaattc tgttaatata gcaaagacaa aacagtatca tatacatcaa gatcatactt	480
ttaaagtaag tttaaagggtc tcaattgccc agatattaaa tttatatatt ccttctatta	540
aaaaatatta catttcaatt ttgtaatat gtaacatatt ttaagatgac cagcaagacc	600

```

tagtcaattt gaaaataccc ttgcattcca tacacaagct ataccataag taataaccca 660
agtatatgat gtgtaaaagt tggatgaagg cataatactg aatttttttg caaatgtaaa 720
ctgctttcca agtaatcagc accatttttt actagactac attttaatca ctcccttagc 780
tgcttacaac ctctacttag gcataaataa aagaatctga aattggtata ttcccccctc 840
ctgctgtgtt aacaaaaaat actatttgac ttaaagatca aagagtcttt ttccctgaagg 900
tttttgtttt taaatgt 917

```

```

<210> 31
<211> 367
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(367)
<223> n = A,T,C or G

```

```

<400> 31
tcttttcttt ctgtatttcc caaattacag ggagctatgc ccttgggtatt gcacacagta 60
cactgcaaaa gattcacaaag gttagtgtgaa agtcattttt gccctgggtga ttcaaagctc 120
aaanaatttt ctagcataaa gtcttatttaa aaattttaat caaaatatta tttgagttaa 180
agttaataaa aacaatacca ctatatatac tctcaacaac ttcatatat aatcagtcct 240
atgaggttgt acttgctttt catatcacac tgattaagga caaaaataat tttgatgtac 300
atgtaccata cactgatatg caatctacac actgatgcat ttacatacat acaaccccaa 360
cacaatg 367

```

```

<210> 32
<211> 847
<212> DNA
<213> Homo sapien

```

```

<400> 32
cattgtgttg ggctggcagg atagaagcag cggctcactt ggactttttc accagggaaa 60
tcagagacaa tgatggggct cttcccaga actacagggg ctctggccat ctctgtggta 120
agtcctggat ttctctaata atcacaaact tccctgcttc ctcccttggt aaagaatatt 180
atatttgatt gcacaatctt tattataaat tctaaaagga gtgcagtgga aatcaacact 240
ttgaaatgaa atcgtgaaga ttaccaattt ccttcttttg ttgtttttta tgttgatatt 300
tacatagaaa aataaaccag aaagaaatga gttttaaaaa ccatttagaa ttttttttag 360
ttaatgaatt aagtaatctt aatcacaggt tatattttcc acaacatttt cactttcttt 420
aaagttagtc ttttactagt ttttctaacc cacaacaag aacacaggag ccacttctat 480
tttccaagat tacatgtctc ttagcatata gctaagaact ctacacgcct gggcttgata 540
cctgacacgc ttttaaaagt aaaaaatcgc agaattaaaa tcaaagcagt gtttgactct 600
agagaagttg ggaggattat taagtaagta tttatgttta gctattatgt gccaaaagaa 660
aatgtcagcc tttggggatg gggggaaaga catacaacat ttttaaagcca tttttttcag 720
aaaagtaata cttctgttga ttgagaaagt cgtacatagt attatctaaa agagaaacgg 780
aatgttacag actgtttaaa acctggatgt tacagactaa cttactcctt aactgtgttc 840
ttatagc 847

```

```

<210> 33
<211> 863
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(863)
<223> n = A,T,C or G

```

&lt;400&gt; 33

cattgtgttg	ggcttttatt	tgagtttatg	aacagaaata	gaaagtatgg	tgcttggggt	60
ttgccctttc	ttactcctga	aagttaaatc	agaagacact	gatttcattt	tgtgaaattt	120
agctcagaga	ctattgatct	tttgtttcat	taatatgaac	aactattagt	aaaaaatagc	180
tttaacagca	tttctgctga	tatctagtaa	tctattcctt	taatgtgaaa	ataagataaa	240
atgtcctgga	gctaattcta	gcttaaaatt	gccagtattt	ctgtatgtca	ttaagttttt	300
ttcctctaag	gttggaataa	naattttgtt	aatccttgca	tacctgatgg	catctatgtc	360
aatgctgatt	gggtaattat	aaattctgtg	ctaatttaaa	acttaatttg	cctcttaagg	420
tgattgtcct	ctgagtaatg	attgtagtta	aatgaagtat	agcttgcaac	tatactatca	480
catgggtcgt	taagtaaaaa	taaataaaac	aaatttgtct	gagacaggct	aagatcaatc	540
ttctcatcaa	accaaTTTTT	ctntaagagc	aatttcactt	tcagtttttag	ggtggacatt	600
nttgaatgcc	tcaaattaaa	cgttatctat	ttaatcttcc	tggaatagtc	tgtgacccaa	660
aaggagggtg	tgatatattt	aggtgtaaat	atatcacata	tatgggtgtg	tatatttggg	720
atttatatat	tcagctcatt	ctctgtgaag	aagtcttcct	gactaaaatt	ggtttcaaga	780
taaactaatt	tctgttagta	tttctactct	gcctaccatg	tatgcctttt	tgttagaaac	840
taataaatgt	atcagtcnct	agc				863

&lt;210&gt; 34

&lt;211&gt; 432

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 34

agtgcatttc	ctcttgattt	gtctgggtta	aaaccattcc	ttttgtatga	aatgttttga	60
cttaggaatc	attttatgta	cttgttctac	ctggattgtc	aacaactgaa	agtacatatt	120
tcacccaaat	caagctaaaa	tgtatttaag	ttgattctga	gagtacaggt	cagtaagcct	180
cattatttgg	aatttgagag	aaggtatagg	tgatcggatc	tgtttcattt	ataaaaggtc	240
cagtttttag	gactagtaca	ttcctgttat	tttctgggtt	ttatcatttt	gcctaaaata	300
ggatataaaa	gggacaaaaa	ataagtagac	tgtttttatg	tgtgaattat	atttctacta	360
aatgtttttg	tatgactgtg	ttatacttga	taatatatat	atatatatat	atatatatca	420
acttggttaa	tt					432

&lt;210&gt; 35

&lt;211&gt; 350

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 35

ccagaggggt	gtttatctta	gggttggaat	gtttctgatt	atgctgacaa	tagccattag	60
gctgatgttt	tggggctgga	tttaggcagt	ttttaataaa	aagagaactt	aaaatgggtg	120
tgtttgtcca	agatgggtgat	gttccctgctg	tcaattagca	taaacaaaag	agaattctga	180
taccctgttg	gaatgtcctc	attcctctga	gcttctccac	tcacaggata	aatgcaggag	240
tggcttcccc	tcattggacac	ctgcaaatgc	agagtgtggg	ggctctcctg	gccttgcatc	300
actagcaaga	gcaaaagctg	ctccgagctc	tgtttttaga	acctggtcga		350

&lt;210&gt; 36

&lt;211&gt; 1082

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 36

atgaactaca	gctccactt	ggccttcgtg	tgtctgagtc	tcttcactga	gaggatgtgc	60
atccagggga	gtcagttcaa	cgctgaggtc	ggcagaagtg	acaagctttc	cctgcctggc	120
tttgagaacc	tcacagcagg	atataacaaa	tttctcaggc	ccaatttttg	tggagaaccc	180
gtacagatag	cgctgactct	ggacattgca	agtatctcta	gcatttcaga	gagtaacatg	240
gactacacag	ccaccatata	cctccgacag	cgctggatgg	accagcggct	ggtgtttgaa	300
ggcaacaaga	gcttcaactc	ggatgcccgc	ctcgtggagt	tcctctgggt	gccagatact	360
tacattgtgg	agtccaagaa	gtccttcctc	catgaagtca	ctgtgggaaa	caggctcatc	420

cgccctcttct	ccaatggcac	ggtcctgtat	gccctcagaa	tcacgacaac	tgttgcatgt	480
aacatggatc	tgtctaaata	ccccatggac	acacagacat	gcaagttgca	gctggaaagc	540
tggggctatg	atggaaatga	tgtggagttc	acctggctga	gagggaaacga	ctctgtgcgt	600
ggactggaac	acctgcggt	tgctcagtac	accatagagc	ggtatttcac	cttagtcacc	660
agatcgagc	aggagacagg	aaattacact	agattggtct	tacagtttga	gcttcggagg	720
aatgttctgt	atttcatttt	ggatctctct	cgattcagtc	cctgcaagaa	cctgcattgg	780
ggacaacaaa	ggaagtagaa	gaagtcagta	ttactaatat	catcaacagc	tccatctcca	840
gctttaaacg	gaagatcagc	tttgccagca	ttgaaatttc	cagcgacaac	gttgactaca	900
gtgacttgac	aatgaaaacc	agcgacaagt	taaagtttgt	cttcgagaa	aagatgggca	960
ggattgttga	ttatttcaca	attcaaaacc	ccagtaatgt	tgatcactat	tccaaactac	1020
tgtttccttt	gatttttatg	ctagccaatg	tattttactg	ggcatactac	atgtattttt	1080
ga						1082

&lt;210&gt; 37

&lt;211&gt; 1135

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 37

atgaactaca	gcctccactt	ggccttcgtg	tgtctgagtc	tcttcactga	gaggatgtgc	60
atccagggga	gtcagttcaa	cgtcgaggtc	ggcagaagtg	acaagctttc	cctgcctggc	120
tttgagaacc	tcacagcagg	atataacaaa	tttctcaggc	ccaatttttg	tggagaaccc	180
gtacagatag	cgctgactct	ggacattgca	agtatctcta	gcatttcaga	gagtaacatg	240
gactacacag	ccaccatata	cctccgacag	cgctggatgg	accagcggct	ggtgtttgaa	300
ggcaacaaga	gcttcactct	ggatgccgcg	ctcgtggagt	tcctctgggt	gccagatact	360
tacattgtgg	agtccaagaa	gtccttctct	catgaagtca	ctgtgggaaa	caggctcatc	420
cgcctcttct	ccaatggcac	ggtcctgtat	gccctcagaa	tcacgacaac	tgttgcatgt	480
aacatggatc	tgtctaaata	ccccatggac	acacagacat	gcaagttgca	gctggaaagc	540
tggggctatg	atggaaatga	tgtggagttc	acctggctga	gagggaaacga	ctctgtgcgt	600
ggactggaac	acctgcggt	tgctcagtac	accatagagc	ggtatttcac	cttagtcacc	660
agatcgagc	aggagacagg	aaattacact	agattggtct	tacagtttga	gcttcggagg	720
aatgttctgt	atttcatttt	ggaaacctac	gttccttcca	ctttcctggg	ggtgttgtcc	780
tgggtttcat	tttgatctct	tctcgattca	gtccctgcaa	gaacccgcat	tggggacaac	840
aaaggaagta	gaagaagtca	gtattactaa	tatcatcaac	agctccatct	ccagctttaa	900
acggaagatc	agctttgcca	gcattgaaat	ttccagcagc	aacgttgact	acagtgactt	960
gacaatgaaa	accagcgaca	agttaaagtt	tgtcttccga	gaaaagatgg	gcaggattgt	1020
tgattatttc	acaattcaaa	accccagtaa	tgttgatcac	tattccaaac	tactgtttcc	1080
tttgattttt	atgctagcca	atgtatttta	ctgggcatcc	tacatgtatt	tttga	1135

&lt;210&gt; 38

&lt;211&gt; 1323

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 38

atgaactaca	gcctccactt	ggccttcgtg	tgtctgagtc	tcttcactga	gaggatgtgc	60
atccagggga	gtcagttcaa	cgtcgaggtc	ggcagaagtg	acaagctttc	cctgcctggc	120
tttgagaacc	tcacagcagg	atataacaaa	tttctcaggc	ccaatttttg	tggagaaccc	180
gtacagatag	cgctgactct	ggacattgca	agtatctcta	gcatttcaga	gagtaacatg	240
gactacacag	ccaccatata	cctccgacag	cgctggatgg	accagcggct	ggtgtttgaa	300
ggcaacaaga	gcttcactct	ggatgccgcg	ctcgtggagt	tcctctgggt	gccagatact	360
tacattgtgg	agtccaagaa	gtccttctct	catgaagtca	ctgtgggaaa	caggctcatc	420
cgcctcttct	ccaatggcac	ggtcctgtat	gccctcagaa	tcacgacaac	tgttgcatgt	480
aacatggatc	tgtctaaata	ccccatggac	acacagacat	gcaagttgca	gctggaaagc	540
tggggctatg	atggaaatga	tgtggagttc	acctggctga	gagggaaacga	ctctgtgcgt	600
ggactggaac	acctgcggt	tgctcagtac	accatagagc	ggtatttcac	cttagtcacc	660
agatcgagc	aggagacagg	aaattacact	agattggtct	tacagtttga	gcttcggagg	720
aatgttctgt	atttcatttt	ggaaacctac	gttccttcca	ctttcctggg	ggtgttgtcc	780



```

tgggtttcat tttggatctc tctcgattca gtccctgcaa gaacctgcat tggagtgcacg      840
accgtgttat caatgaccac actgatgatc gggccccgca cttctcttcc caacaccaac      900
tgcttcatca aggccatcga tgtgtacctg gggatctgct ttagctttgt gtttggggcc      960
ttgctagaat atgcagttgc tcactacagt tccttacagc agatggcagc caaagatagg      1020
gggacaacaa aggaagtaga agaagtcagt attactaata tcatcaacag ctccatctcc      1080
agctttaaac ggaagatcag ctttgccagc attgaaattt ccagcgacaa cggttgactac      1140
agtgacttga caatgaaaac cagcgacaag ttcaagtttg tcttccgaga aaagatgggc      1200
aggattgttg attatttcac aattcaaac cccagtaatg ttgatcacta ttccaaacta      1260
ctgtttcctt tgatttttat gctagccaat gtattttact gggcatacta catgtatttt      1320
tga                                                                    1323

```

<210> 39  
 <211> 440  
 <212> PRT  
 <213> Homo sapien

<400> 39

```

Met Asn Tyr Ser Leu His Leu Ala Phe Val Cys Leu Ser Leu Phe Thr
 1          5          10          15
Glu Arg Met Cys Ile Gln Gly Ser Gln Phe Asn Val Glu Val Gly Arg
          20          25          30
Ser Asp Lys Leu Ser Leu Pro Gly Phe Glu Asn Leu Thr Ala Gly Tyr
          35          40          45
Asn Lys Phe Leu Arg Pro Asn Phe Gly Gly Glu Pro Val Gln Ile Ala
          50          55          60
Leu Thr Leu Asp Ile Ala Ser Ile Ser Ser Ile Ser Glu Ser Asn Met
          65          70          75          80
Asp Tyr Thr Ala Thr Ile Tyr Leu Arg Gln Arg Trp Met Asp Gln Arg
          85          90          95
Leu Val Phe Glu Gly Asn Lys Ser Phe Thr Leu Asp Ala Arg Leu Val
          100          105          110
Glu Phe Leu Trp Val Pro Asp Thr Tyr Ile Val Glu Ser Lys Lys Ser
          115          120          125
Phe Leu His Glu Val Thr Val Gly Asn Arg Leu Ile Arg Leu Phe Ser
          130          135          140
Asn Gly Thr Val Leu Tyr Ala Leu Arg Ile Thr Thr Thr Val Ala Cys
          145          150          155          160
Asn Met Asp Leu Ser Lys Tyr Pro Met Asp Thr Gln Thr Cys Lys Leu
          165          170          175
Gln Leu Glu Ser Trp Gly Tyr Asp Gly Asn Asp Val Glu Phe Thr Trp
          180          185          190
Leu Arg Gly Asn Asp Ser Val Arg Gly Leu Glu His Leu Arg Leu Ala
          195          200          205
Gln Tyr Thr Ile Glu Arg Tyr Phe Thr Leu Val Thr Arg Ser Gln Gln
          210          215          220
Glu Thr Gly Asn Tyr Thr Arg Leu Val Leu Gln Phe Glu Leu Arg Arg
          225          230          235          240
Asn Val Leu Tyr Phe Ile Leu Glu Thr Tyr Val Pro Ser Thr Phe Leu
          245          250          255
Val Val Leu Ser Trp Val Ser Phe Trp Ile Ser Leu Asp Ser Val Pro
          260          265          270
Ala Arg Thr Cys Ile Gly Val Thr Thr Val Leu Ser Met Thr Thr Leu
          275          280          285
Met Ile Gly Ser Arg Thr Ser Leu Pro Asn Thr Asn Cys Phe Ile Lys
          290          295          300
Ala Ile Asp Val Tyr Leu Gly Ile Cys Phe Ser Phe Val Phe Gly Ala
          305          310          315          320
Leu Leu Glu Tyr Ala Val Ala His Tyr Ser Ser Leu Gln Gln Met Ala

```

325 330 335  
 Ala Lys Asp Arg Gly Thr Thr Lys Glu Val Glu Glu Val Ser Ile Thr  
 340 345 350  
 Asn Ile Ile Asn Ser Ser Ile Ser Ser Phe Lys Arg Lys Ile Ser Phe  
 355 360 365  
 Ala Ser Ile Glu Ile Ser Ser Asp Asn Val Asp Tyr Ser Asp Leu Thr  
 370 375 380  
 Met Lys Thr Ser Asp Lys Phe Lys Phe Val Phe Arg Glu Lys Met Gly  
 385 390 395 400  
 Arg Ile Val Asp Tyr Phe Thr Ile Gln Asn Pro Ser Asn Val Asp His  
 405 410 415  
 Tyr Ser Lys Leu Leu Phe Pro Leu Ile Phe Met Leu Ala Asn Val Phe  
 420 425 430  
 Tyr Trp Ala Tyr Tyr Met Tyr Phe  
 435 440

<210> 40  
 <211> 289  
 <212> PRT  
 <213> Homo sapien

<400> 40  
 Met Asn Tyr Ser Leu His Leu Ala Phe Val Cys Leu Ser Leu Phe Thr  
 1 5 10 15  
 Glu Arg Met Cys Ile Gln Gly Ser Gln Phe Asn Val Glu Val Gly Arg  
 20 25 30  
 Ser Asp Lys Leu Ser Leu Pro Gly Phe Glu Asn Leu Thr Ala Gly Tyr  
 35 40 45  
 Asn Lys Phe Leu Arg Pro Asn Phe Gly Gly Glu Pro Val Gln Ile Ala  
 50 55 60  
 Leu Thr Leu Asp Ile Ala Ser Ile Ser Ser Ile Ser Glu Ser Asn Met  
 65 70 75 80  
 Asp Tyr Thr Ala Thr Ile Tyr Leu Arg Gln Arg Trp Met Asp Gln Arg  
 85 90 95  
 Leu Val Phe Glu Gly Asn Lys Ser Phe Thr Leu Asp Ala Arg Leu Val  
 100 105 110  
 Glu Phe Leu Trp Val Pro Asp Thr Tyr Ile Val Glu Ser Lys Lys Ser  
 115 120 125  
 Phe Leu His Glu Val Thr Val Gly Asn Arg Leu Ile Arg Leu Phe Ser  
 130 135 140  
 Asn Gly Thr Val Leu Tyr Ala Leu Arg Ile Thr Thr Thr Val Ala Cys  
 145 150 155 160  
 Asn Met Asp Leu Ser Lys Tyr Pro Met Asp Thr Gln Thr Cys Lys Leu  
 165 170 175  
 Gln Leu Glu Ser Trp Gly Tyr Asp Gly Asn Asp Val Glu Phe Thr Trp  
 180 185 190  
 Leu Arg Gly Asn Asp Ser Val Arg Gly Leu Glu His Leu Arg Leu Ala  
 195 200 205  
 Gln Tyr Thr Ile Glu Arg Tyr Phe Thr Leu Val Thr Arg Ser Gln Gln  
 210 215 220  
 Glu Thr Gly Asn Tyr Thr Arg Leu Val Leu Gln Phe Glu Leu Arg Arg  
 225 230 235 240  
 Asn Val Leu Tyr Phe Ile Leu Glu Thr Tyr Val Pro Ser Thr Phe Leu  
 245 250 255  
 Val Val Leu Ser Trp Val Ser Phe Trp Ile Ser Leu Asp Ser Val Pro  
 260 265 270  
 Ala Arg Thr Arg Ile Gly Asp Asn Lys Gly Ser Arg Arg Ser Gln Tyr  
 275 280 285

Tyr

<210> 41  
 <211> 265  
 <212> PRT  
 <213> Homo sapien

<400> 41  
 Met Asn Tyr Ser Leu His Leu Ala Phe Val Cys Leu Ser Leu Phe Thr  
 1 5 10 15  
 Glu Arg Met Cys Ile Gln Gly Ser Gln Phe Asn Val Glu Val Gly Arg  
 20 25 30  
 Ser Asp Lys Leu Ser Leu Pro Gly Phe Glu Asn Leu Thr Ala Gly Tyr  
 35 40 45  
 Asn Lys Phe Leu Arg Pro Asn Phe Gly Gly Glu Pro Val Gln Ile Ala  
 50 55 60  
 Leu Thr Leu Asp Ile Ala Ser Ile Ser Ser Ile Ser Glu Ser Asn Met  
 65 70 75 80  
 Asp Tyr Thr Ala Thr Ile Tyr Leu Arg Gln Arg Trp Met Asp Gln Arg  
 85 90 95  
 Leu Val Phe Glu Gly Asn Lys Ser Phe Thr Leu Asp Ala Arg Leu Val  
 100 105 110  
 Glu Phe Leu Trp Val Pro Asp Thr Tyr Ile Val Glu Ser Lys Lys Ser  
 115 120 125  
 Phe Leu His Glu Val Thr Val Gly Asn Arg Leu Ile Arg Leu Phe Ser  
 130 135 140  
 Asn Gly Thr Val Leu Tyr Ala Leu Arg Ile Thr Thr Thr Val Ala Cys  
 145 150 155 160  
 Asn Met Asp Leu Ser Lys Tyr Pro Met Asp Thr Gln Thr Cys Lys Leu  
 165 170 175  
 Gln Leu Glu Ser Trp Gly Tyr Asp Gly Asn Asp Val Glu Phe Thr Trp  
 180 185 190  
 Leu Arg Gly Asn Asp Ser Val Arg Gly Leu Glu His Leu Arg Leu Ala  
 195 200 205  
 Gln Tyr Thr Ile Glu Arg Tyr Phe Thr Leu Val Thr Arg Ser Gln Gln  
 210 215 220  
 Glu Thr Gly Asn Tyr Thr Arg Leu Val Leu Gln Phe Glu Leu Arg Arg  
 225 230 235 240  
 Asn Val Leu Tyr Phe Ile Leu Asp Leu Ser Arg Phe Ser Pro Cys Lys  
 245 250 255  
 Asn Leu His Trp Gly Gln Gln Arg Lys  
 260 265

<210> 42  
 <211> 574  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)... (574)  
 <223> n = A,T,C or G

<400> 42  
 accaacanag ctttagtaatt tctaaaaaga aaaaatgatc tttttccgac ttctaaacaa 60  
 gtgactatac tagcataaat cattcttcta gtaaaacagc taaggatatag acattctaatt 120  
 aatttgggaa aacctatgat tacaagtaaa aactcagaaa tgcaaagatg ttggtttttt 180

```

gtttctcagt ctgcttttagc ttttaactct ggaaacgcat gcacactgaa ctctgctcag 240
tgctaaacag tcaccagcag gttcctcagg gtttcagccc taaaatgtaa aacctggata 300
atcagtgtat gttgcaccag aatcagcatt ttttttttaa ctgcaaaaaa tgatgggtctc 360
atctctgaat ttatatctct cattcttttg aacatactat agctaataata ttttatgttg 420
ctaaattgct tctatctagc atgttaaaaca aagataatat actttcgatg aaagtaaatt 480
ataggaaaaa aattaactgt tttaaaaaga acttgattat gttttatgat ttcaggcaag 540
tattcatttt taacttgcta cctactttta aata 574

```

```

<210> 43
<211> 467
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(467)
<223> n = A,T,C or G

```

```

<400> 43
tttttttttt ttttttattg ccatcaattt attaaaataa acatgtatag caggtttcaa 60
caattgtctt gtagtttgta gtaaaaagac ataagaaaga gaagggtgtgg tttgcagcaa 120
tccgtagctg gtttctcacc ataccctgca gttctgtgag ccaaagggtct tgcagaaagt 180
taaaataaat cacaaagact gctgtcatat attaattgca taaacacctc aacattgctc 240
anagtttcat ccgtttggtt aanaaaacat tccttcaatt catctatggc atttgtagtg 300
gcattgtcgt ctatgaactc ttgaagaagt tctttgtatt cagtcttaga cacttggtga 360
ttgattgtct tggaaatcac attctccaat aaggggcagc cagagcctgc gtagcagtgc 420
tgggagaggg ccgccagcat gaggaccatc agcaacttca tgggtgag 467

```

```

<210> 44
<211> 613
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(613)
<223> n = A,T,C or G

```

```

<400> 44
tttttttttt ttttttttag ttttaaaata ttttcacttt attattatgc ttataatatt 60
attccaacag actgtattaa aggcagtgat cactaacaca gaacacgaca gggcgaagag 120
gcagccgggc cgattgcagg acgtggcctg tcggggccagg gtcgctgaca tgcacgctgg 180
tagctcatac actgctaccc tcagcacagg ctgcaggaaat agggacaaga cagatgccgc 240
cggactctta gaagctattt aataaatatc atccaaaaac aaaatggaaa agaaacaaga 300
aaccctccga gcacaaccac cttaggccaa ctgaatgtaa tctagtttat tcaacaaaaa 360
attgagagag aaggaaaata ttgaaacaaa caaacgaaag aaagcagttc ttaagactag 420
cagtaaataa atttatacaa cagttcggtc tgtataatat gatgaaataa atctacatct 480
tttcttattt tggngctttg aattatacat acaaacacaa attacaggga cttgttcaca 540
aagcatgtag gcctanaaaa aggcctctctg aaaccctcaa tggcaactgg tgaacggtaa 600
cactgattgc cca 613

```

```

<210> 45
<211> 334
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature

```

&lt;222&gt; (1) ... (334)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 45

accagaccaa	gtgaatgcga	caggggaatta	tttcctgtgt	tgataattca	tgaagtagaa	60
cagtataatc	aaaatcaatt	gtatcatcat	tagttttcca	ctgcctcaca	ctagttagct	120
gtgccaagta	gtagtgtgac	acctgtgttg	tcattttcca	catcacgtaa	gagcttccaa	180
ggaaagccaa	atcccagatg	agtctcagag	agggatcaat	atgtccatga	ttatcaggta	240
tgctgactat	ttccaagggg	tttttcagtt	gcttcatttg	cttgtaaagc	aggtaatcct	300
cttgttgtnt	tttctttttc	tcgatgagcc	gtgt			334

&lt;210&gt; 46

&lt;211&gt; 429

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1) ... (429)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 46

acaattttnt	taaacaagca	gaatagcact	aggcagaata	aaaaattgca	cagacgtatg	60
caattttcca	agatagcatt	ctttaaattc	agtattcagc	ttccaaagat	tggttgccca	120
taatagactt	aaacatataa	tgatggctaa	aaaaaataag	tatacgaaaa	tgtaaaaaag	180
gaaatgtaag	tccactctca	atctcataaa	aggtgagagt	aaggatgcta	aagcaaaata	240
aatgtagggt	ctttttttct	atttccggtt	atcatgcagt	ctgcttcttt	gatatgcctt	300
agggttacct	atttaagtta	gaggttgtaa	tgcaatgggtg	ggaatgaaaa	ttgatcaaat	360
atacaccttg	tcatttcatt	tcaaattgcg	gntggaaact	ttcaaaaaaa	gggtaggcat	420
gaagaaaaa						429

&lt;210&gt; 47

&lt;211&gt; 394

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1) ... (394)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 47

acgcgaantt	gtgttatgac	tgatagcctt	cagctacaaa	angataggac	tgacctgggt	60
taaagtgttc	tattttgtaa	atcattccat	ttgagtcttt	ctgatgaact	tggtctatact	120
gaaatctggt	atttttagtg	ggctccaaaa	tgagcaaagc	taggcctgat	tagagtagag	180
tgactattaa	aaaacataac	tttctaggag	ctataaatca	aagttttaaa	aagatgtttg	240
gatataattg	agtattccga	tcataaaaac	agaaattgcc	ctgcctacta	caaggacaga	300
ctgatgggaa	attatgcacc	tggtcaactt	agcttttaag	cagacgatgc	tgtaaaaaaca	360
aacggcttct	ctgatattta	ttgtaagtgt	tagt			394

&lt;210&gt; 48

&lt;211&gt; 486

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 48

acaaaggaac	cgaggggtga	ccacctctga	gatgtccttg	actttgtcat	agcctggggc	60
atattgagca	tctctctcac	agctgccttt	cttatcccca	ttcttgatgt	agacctcctt	120

ccgagtcagc	tttttctcct	cctcagacac	aaacagagct	ttgatatcct	gtgcagggag	180
cagctcttcc	ttttgttgct	ggcaagtgg	agttggagga	agcctcaaag	ctcgagttgt	240
tccctcgggtg	caggggagac	aaatgggcct	gatagtcctg	ccatatttca	gcttattctt	300
gagcttgatc	agggcaacgt	catagtcata	aaattcagga	attcctgctt	cttttttccc	360
attaatgttg	tagttggggt	gaaataggac	tacttctatc	tccaggtecc	gcttctcccc	420
tcccttgatt	gagtggttct	tgtcatccac	agtgaacaa	tgtgctgctg	tcagcacaaa	480
gtacct						486

<210> 49  
 <211> 487  
 <212> DNA  
 <213> Homo sapien

<400> 49	
acgggctgac	agagaagatt
tgtctctctg	ccaagatcca
ttctttcttt	cttaagccct
gcttctccaa	gcatcaccct
attgctgtt	ctgcttcgaa
agatttggt	tgggatcaat
aatgatatga	ccaaaatttt
tgtctggccc	gcaatactgt
ccacagt	
cccagagagta	aatcatcttt
tctaaactgg	agtgatgtta
ttgctctgga	ggaagtcttc
tgagggtttt	ctcataaatg
ccgctcagta	ttttaaatga
atgcagccaa	ccaagatgca
gtcaccctctg	ttcacttaag
atgatcttgt	tactgtgata
ttttaaatat	
	60
	120
	180
	240
	300
	360
	420
	480
	487

<210> 50  
 <211> 460  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1) ... (460)  
 <223> n = A,T,C or G

<400> 50	
acatattttg	ggtgaagaca
ttttgtaagt	aacaatatgt
tcattattta	gcaccgttta
atatcaactt	atttttcacc
aagcacactg	tatgttcagt
agcctgaaag	tttagatcta
ccattgttgt	cttcacttaa
gactaatata	acttgaaaa
ccagactgaa	gtaaacagct
ctaggtgact	tgagagtggg
catttcagtg	tattgtttat
tttaatttct	acaaaataac
atgaacactg	tcacaaatgt
tcatcaatgt	tcagttcaaa
aaaatgacaa	tatcaatcac
actattgaaa	ataagcacac
gagggggtng	
	60
	120
	180
	240
	300
	360
	420
	460

<210> 51  
 <211> 529  
 <212> DNA  
 <213> Homo sapien

<400> 51	
acacttgaaa	ccaaatttct
accataacct	aatcagtggt
tctggtttca	agtctcaagg
attcagtcct	cagcaacttg
caggttcgta	agcatagaga
gagatgggtc	aacaaacata
cagttgtttc	ataaaccaga
tattttcagc	aaacactttc
aaaacttggt	tttcttaaaa
ttccacacta	gccagtcttc
gagaggtttt	tttctttaca
tcattgtgtc	aagcaacaga
atcttccagt	gatatcggct
atcaggagaa	aggtgtttgt
tgccaatttc	tggatttctt
gactgtgtgg	gcactcatcc
aagtgatgaa	
	60
	120
	180
	240
	300
	360
	420
	480

taaatcatca aggggtttgtt gcttgtcttg gatttatata gagcttctt 529

<210> 52  
 <211> 379  
 <212> DNA  
 <213> Homo sapien

<400> 52  
 actttgccaa gcagtaaagg atccaggaga tagcactgga tgtgggtgtca tgtcctgcaa 60  
 acatgaacgt tttcacttca gcctggagat ctgcttcaga gaaatctttg gtgttttctgc 120  
 ttttggcact caaaagtatg tccagaaaat cccagcgcct tttctgagta gtatcttgtt 180  
 ttagcttatc cttaagagac tccttcgggt cctggattac tttctctgtg aactgatgaa 240  
 gttcttgggt aaatttagaa aagatttggc cttgagagct gaatttgaaa accaggctcg 300  
 tgtgatgtag aaaattgttc atgcgctggg tggagatttt gctaagggtg aacactgctt 360  
 tcaggatatga gtccagggt 379

<210> 53  
 <211> 380  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1) ... (380)  
 <223> n = A,T,C or G

<400> 53  
 acttttatct taaaagggtg gtagttttcc ctaaaatact tattatgtaa gggtcattag 60  
 acaaagtgtc tgaagtagac atggaattta tgaatgggtc tttatcattt ctcttcccc 120  
 tttttggcat cctggcttgc ctccagtttt aggtccttta gtttgcctct gtaagcaacg 180  
 ggaacacctg ctgagggggc tctttccctc atgtatactt caagtaagat caagaatctt 240  
 ttgtgaaatt atagaaattn actatgtaaa tgcttgatgg aatnntttcc tgctagtgt 300  
 gcttctgaaa ggcgctttct ccatttattt aaaactaccc atgcaattaa aagggtacctt 360  
 gccgcgacca cnctaanggc 380

<210> 54  
 <211> 245  
 <212> DNA  
 <213> Homo sapien

<400> 54  
 gcgcggcgct tcacttcttc aacttccggg ccggctcgcc cagcgcgctg cgagtgcgtg 60  
 ccgaggtgca ggaggccgc gcgtggatta atccaaaaga gggatgtaaa gttcacgtgg 120  
 tcttcagcac agagcgctac aaccagagt ctttacttca ggaagggtgag ggacgtttgg 180  
 ggaaatgttc tgctcgagtg tttttcaaga atcagaaacc cagaccaacc atcaatgtaa 240  
 cttgt 245

<210> 55  
 <211> 556  
 <212> DNA  
 <213> Homo sapien

<400> 55  
 acagaagatg aataataatg aaaaactgtg attttttgac tatcacatac attgtgttaa 60  
 aaaacaggta aatataatga ctattactgt taagaaagac aaggaggaaa actgtttcaa 120  
 tggtcagggt taaataactaa gcacaaaaat ataacaaatt ctgtgtctac aataattttt 180  
 gaagtgtata caagtgcatt gcaaatgagc tctttaaaat ttaaagtcca tttccctttt 240  
 agccaagcat atgtctacat ttatgatttc tttctcttat tttaaagtct cttctggttt 300

```

agtttttttaa aaagtttcat catggctgtc atcttggaaat ctagcctcca gctcaaagct 360
gagacttcac gcatacatat tctcctttct gggtgcatct tcacctagtt tctccaagta 420
ttcagagtta aatagcaciaa cttcttttat atgttcactt ttgtccacat gtagtggcag 480
tgctgctgct tcagtaggct ttctcacaca cccttttctt tctttcaaca gcagtcacca 540
aacgttcaca acacaaa 556

```

```

<210> 56
<211> 166
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(166)
<223> n = A,T,C or G

```

```

<400> 56
atgggccctg attacatcat tatgaactac tcaggtnaac atcccaaata ccgacctngg 60
gaaagacttg gtccgagatg tgttcaccca tacaggctac ctctccaga gncaggnc 120
caagagctgc ntnatcacct acctggccca ggtggacccc anaggg 166

```

```

<210> 57
<211> 475
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(475)
<223> n = A,T,C or G

```

```

<400> 57
acatccncat gttcctccaa atgacgtttg gggctctgct tgccaacatt ctttattgcc 60
agctgttcag gtgtcatctt atcttcttct tctacagcct tattgtaatt cttggcta 120
tccaacatct cttttaccac tgattcattg cgtttacaat gttcactgta gtccgaagt 180
gtcaaacctt ccatccaact cttcttatgc aaatttagca acatcttctg ttccagttca 240
ttttccgat agttaatagt aatggagtaa taatgtctgt ttagtccatg aattaatgcc 300
tggatagatg gcttggttaa gtgaccaga ttcgaagtgt tttgtcttgg ttcagtcc 360
aagaccatca tattagcatt gatcaatctg aaggcatcaa taacaacctt tccttttaca 420
ctctgaatgg gatccacaac cactgccaca gntctctccg ataaggcttc aaagc 475

```

```

<210> 58
<211> 520
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(520)
<223> n = A,T,C or G

```

```

<400> 58
actgttnatg tgetacttgc atttgtccct ctctctgtgc actaaagacc ccactcaett 60
ccctagtgtt cagcagtggg tgacctctag tcaagacctt tgcactagga tagttaatgt 120
gaaccatggc aactgatcac aacaatgtct ttcagatcag atccatttta tctccttgt 180
tttacagcaa gggatattaa ttacctatgt tacctttccc tgggactatg aatgtgcaaa 240
attccaatgt tcatggtctc tcccttttaa cctatattct acccctttta cattatagaa 300
aggaatgctg gaaaccacga gtccctctct tgggactctt aatgtgtatt tctaattatc 360

```



catgactctt aatgtgcata ttttcaattg cctaantgat ttcaattgtc taagacattt	420
caaagtgtcta attggggaga actgagtcctt ttatatcaag ctaatatcta gcttttatat	480
caagctaata tcttgacttc tcagcatcat agaagggggt	520

<210> 59  
 <211> 214  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(214)  
 <223> n = A,T,C or G

<400> 59	
ctggcaggaa atgcatcaaa agacttaaag gtanagcgta ttaccctctg tcacttgcaa	60
cttgctattc gtggagatga agaattggat tctctcatca aggctacaat tgctgggtggn	120
ggtgtcattc cacacatcca caaatctctg atngggaana aaggacaaca naagactgnc	180
taanggatgc ctgnatncct tggaatctca tgac	214

<210> 60  
 <211> 360  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(360)  
 <223> n = A,T,C or G

<400> 60	
gcatacaaca tggcagcagg gcctcgggaa gangggtagg aggaccgagc agcattctct	60
gtagaggaaag acaggaaagg agaccctctt ggcacacatt tatggagggt tgccctgaa	120
gagaagggca ggtgggagag gttccctgtt acttaagaga aggcaccagt ggcaaagagc	180
acaatgaaga ggatgatgat aaaaacaatc acgcagataa ggacaatcat cttcacgttc	240
ttccaccaga attttcgagc caccttctgc gatgtcgtct tgaagtgtc agatgtgggt	300
tccagatcct ctgtcttgtt gcggagatgt tccaagttt cccccgggc caggatccgc	360

<210> 61  
 <211> 391  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(391)  
 <223> n = A,T,C or G

<400> 61	
tntgggatcg tactcgatta aacagagcca cctttgttcc tgaggcaatg cataantcan	60
catttttcaa tgactgcttc tttttggaag gnttgagat gacttttatc cgcttgctga	120
ggaacacacc aatgncatca ctgttgccat agaacatctt tacagacaac atgaantgct	180
ttcgcttgtc tgagtcagat atatacaatg ttttggtgtg gcaatagtgc tttccttcca	240
agtttagctg ctgcatttct tggncactat ttcttatccc aataaatgca cacgggttag	300
actcttgntc agaacaacca tcncgttcca tttgttcttt tttntcttc catccactgc	360
ccataagata tacacannga ggtgggcaaa a	391

<210> 62

<211> 324  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)... (324)  
 <223> n = A,T,C or G

<400> 62  
 acaattttat ttttaacagat ttcaagagtc catttttttaa aaaatgagca ataaagaacc 60  
 tctatcagtg agacttctca ttttatagca aatacatttt tgcagcttaa attttcttga 120  
 attcatatac gtttctgtca ttttaacaaa cttccagaga aaactggtct ctatatattt 180  
 aagtaacaaa tttgacaaaa tacatatatta tacatatata ganctctaata ataaatatta 240  
 aatttgaaaa aatcaaattgt gaagcagaaa ctgctatata agtatattgt ntaatatcta 300  
 tntnatacat taaagnnttc cggg 324

<210> 63  
 <211> 360  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)... (360)  
 <223> n = A,T,C or G

<400> 63  
 acagannccct tgaatatgtt gtgggtccct cattatggcc cttcattccc ttctgtgtta 60  
 atagtaaagc atgttgcccta ataactacaa ccctgaccaa atttgggcct ggatctcatg 120  
 ggtcacgtgg agttttaaat acgattttta atttacttgg gtaattgagc tgaatcttta 180  
 gttttcagat tactttttta aacagatagg ctcttagaac aaattattaa aaacataata 240  
 ccccatggga ggggaatctg gattaactac ccaactgttc ccccccccc aacttttgaa 300  
 aaattttggc catatagaat gcatgaaaaa tcaggatga tcttatgagg actttatagt 360

<210> 64  
 <211> 491  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)... (491)  
 <223> n = A,T,C or G

<400> 64  
 nctgactgtg atgtccactt gttccctgat ttttacacat catgtcaaag ataacagctg 60  
 tccccacca ccagttcctc taagcacata ctctgctttt ctgtcaacat cccatttttg 120  
 ggaaaggaaa agtcatattt attcccgcac cccagttttt taacttggtc tcccagttgt 180  
 cccctcttc tctgggtgta agaagggaaa ttggaaaaaa attatatata tattctcctt 240  
 ttaatgggtg ggggctactg gagaggagag acagcaagtc caccctaact tgttacacag 300  
 cacataccac aggttctgga attctcatct tcgaacctag agaaataggt gctataaaca 360  
 gggaattaag caaaatgctg gatgctatag atcttttaatt tgncttaatt tttttctat 420  
 tattaaacta caggctgtag atntcttagg tctcacagaa cttntatcat tttaaactga 480  
 cttgtatatt t 491

<210> 65  
 <211> 484

<212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(484)  
 <223> n = A,T,C or G

<400> 65  
 accagcacac cggcgccgtc ctggactgcg ccttctacga tccaacgcat gcctggagtg 60  
 gaggactaga tcatcaattg aaaatgcatg atttgaacac tgatcaagaa aatcttgttg 120  
 ggacctatga tgcccctatc agatgtgttg aatactgtcc agaagtgaat gtgatgggtca 180  
 ctggaagtgt ggatcagaca gctaaactgt gggatcccag aactccttgt aatgctggga 240  
 ccttctctca gcctgaaaag gtatataccc tctcagtgtc tggagaccgg ctgattgtgg 300  
 gaacagcagg ccgcagagng ttggtgtggg acttacggaa catgggttac gtgcagcagc 360  
 gcagggagtc cagcctgaaa taccagactc gctgcatacg agcgtttcca aacaagcagg 420  
 gttatgtatt aagctctatt gaaggccgag tggcagttga gtatttgac ccaagccctg 480  
 aggt 484

<210> 66  
 <211> 355  
 <212> DNA  
 <213> Homo sapien  
 <220>  
 <221> misc\_feature  
 <222> (1)...(355)  
 <223> n = A,T,C or G

<400> 66  
 ngaagaaagt atgggtggag gtgaaggtaa tcacagagct gctgattctc aaaacagtgg 60  
 tgaaggaaat acaggtgctg cagaatcttc tttttctcag gaggtttcta gagaacaaca 120  
 gccatcatca gcatctgaaa gacaggcccc tcgagcacct cagtcaccga gacgccacc 180  
 acatccactt cccccaagac tgaccattca tgccccacct caggagtggg gaccaccagt 240  
 tcagagaatt cagatgaccc gaaggcagtc tgtaggacgt ggcttccagt tgactccagg 300  
 aataggtggc acgcaacagc atttttttga tgatgaagac agaacagttc caagt 355

<210> 67  
 <211> 417  
 <212> DNA  
 <213> Homo sapien

<400> 67  
 acgacacccc tcaagaggtg gccgaagctt tcctgtcttc cctgacagag accatagaag 60  
 gagtccgatgc tgaggatggg cacagcccag gggaacaaca gaagcgggaag atcgctctgg 120  
 acccttcagg ctccatgaac atctacctgg tgctagatgg atcagacagc attggggcca 180  
 gcaacttcac aggagccaaa aagtgtctag tcaacttaat tgagaagggtg gcaagttatg 240  
 gtgtgaagtc aagatatggt ctagtgcacat atgccacata ccccaaaatt tgggtcaaag 300  
 tgtctgaagc agacagcagt aatgcagact gggtcacgaa gcagctcaat gaaatcaatt 360  
 atgaagacca caagttgaag tcagggacta acaccaagaa ggccctccag gcagtgt 417

<210> 68  
 <211> 223  
 <212> DNA  
 <213> Homo sapien  
 <220>  
 <221> misc\_feature

&lt;222&gt; (1)...(223)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 68

cacttgcaag	cttgcttaca	gagacctgnt	aaacaaagaa	cagacagatt	ctataaaatc	60
agttatatca	acatatataag	gagtgtgatt	ttcagtttgt	ttttttaagt	aaatatgacc	120
aaactgacta	aataagaagg	caaaacaaaa	aattatgctt	ccttgacaag	gcctttggag	180
taaacaaaat	gctttaaggc	tcctggtgaa	tggggttgca	agg		223

&lt;210&gt; 69

&lt;211&gt; 396

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 69

accttttttc	tctccaaagg	aacagtttct	aaagttttct	gggggggaaa	aaaacttaca	60
tcaaatttaa	accatatggt	aaactgcata	ttagtgtgtg	tacaccaaaa	aattgcctca	120
gctgatctac	acaagtttca	aagtcattaa	tgcttgatat	aaatttactc	aacattaaat	180
tatcttaa	tattaattaa	aaaaaaaaact	ttctaaggaa	aaataaacaa	atgtagaccg	240
tgattatcaa	aggattatta	aagaatcttt	accaaaaatt	tcaaccctac	aacctaaaac	300
cgcaaatttc	tattttttaa	catcagaaaa	taactcttgg	ttcattactt	atgacccaaa	360
gtttttat	cactattcaa	tatctgaaaa	gtatca			396

&lt;210&gt; 70

&lt;211&gt; 402

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(402)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 70

accannccc	accaggcaa	acagctccga	catgtttngt	aagtggagaca	agccagtgc	60
agttttttt	tttttttct	ttttctttt	tttgtcttt	gcttaccttc	ttgcttaatg	120
gaattgttat	ggctaagcac	atagaaggcc	aaaaaaggag	tttttcaa	ccagcaa	180
aagtgttg	attctgaact	gccaaaagaa	aactgcactt	ccctctttaa	gtaaaacgaa	240
atgagtttct	taggtaaatg	tattcatcag	cccagataaa	aaaaaaacca	gttatgtgag	300
cgttagtcac	tgctcatttc	caggaanac	aaacaaaata	ccagcccagc	cagactcaca	360
tgtgggnata	tatatataaa	gcaagagagc	cacaccaca	ag		402

&lt;210&gt; 71

&lt;211&gt; 385

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(385)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 71

accagtagag	agtggccct	gcaggccact	tataaacag	aagctctctc	ctgagctcac	60
tgatcaacct	gcccttgga	cagacagaa	ctaccagaaa	agaacaagta	caaaacacta	120
tcattatctg	ttttctcaag	acagtcccaa	atgtccttgt	gcgatcgcca	caaactcagt	180
gattggccca	agtcattccc	gggtgccata	aacagtaact	ggtgtgcanc	attagaacaa	240
ggggacacgg	ccttgattct	cttctgagca	acatgaactg	ggatttctgc	cncctcgat	300

ctcggctgcc acctccgaag aagtcgtgac cagccacctc cacagtaaaa gattcctccc 360  
gtgagtatga tttggaatgc gncct 385

<210> 72  
<211> 538  
<212> DNA  
<213> Homo sapien  
  
<220>  
<221> misc\_feature  
<222> (1)... (538)  
<223> n = A,T,C or G

<400> 72  
caattaatta acagaggtat aattgtctca ctttcagaag tgatcattta tttttattta 60  
gcacaggcca taagaaaaat atatagaaaa ataatcaatt tcatatataa aaggattatt 120  
tctccacctt taattattgg cctatcattt gttagtgtta tttggtcata ttattgaact 180  
aatgtattat tccattcaaa gtctttctag atttaaaaat gtatgcaaaa gcttaggatt 240  
atatcatgtg taactattat agataacatc ctaaaccctc agtttagata tataattgac 300  
tgggtgtaat ctcttttgta atctgntttg acagatttct taaattatgt tagcataatc 360  
aaggaagatt taccttgaag cactttccaa attgatactt tcaaacttat tttaaagcag 420  
tagaaccttt tctatgaact aagtcacatg caaaactcca acctgtaagt atacataaaa 480  
tggacttact tattctctc accttctcca ggcctaggaa tattcttctc tggagccc 538

<210> 73  
<211> 405  
<212> DNA  
<213> Homo sapien  
  
<220>  
<221> misc\_feature  
<222> (1)... (405)  
<223> n = A,T,C or G

<400> 73  
actttatnna tgggaattttc ttctacttgt atccatttnc cggggcttat ggaccattc 60  
atactctcca tatttagaat caaagggtcc tttctgaaga gaccttaatt ttaaggtaaa 120  
acgtggtcca agttcctgaa tccaccctt cttttcactc ctgaatatgt atctgtgaaa 180  
tctgaagaat atgtaatccc gttgattgtg gaatgtggca acctgccttc cgataaattg 240  
aggattatga ggaagagag atgcaaacat acgtccaatt gaatgaccca gccgtgttgt 300  
aaaattattc agaattattt caggtatgtg ttctgtgggg tcttgctc tctcttaat 360  
ttctttacga agacgaacac tgctcattt aaaatgagca gttgg 405

<210> 74  
<211> 498  
<212> DNA  
<213> Homo sapien  
  
<220>  
<221> misc\_feature  
<222> (1)... (498)  
<223> n = A,T,C or G

<400> 74  
tgagcctgc acctgtttcc tgcacccct gccnactggt tctatggcca caaggagttt 60  
taccagtaa aggagtttga ggtgtattat aagctgatgg aaaaataccc atgtgtgtt 120  
cccttgtggg ttggaccctt tacgatgttc ttcagtgtcc atgaccaga ctatgccaag 180  
attctctga aaagacaaga tcccaaaagt gctgttagcc acaaaatcct tgaatcctgg 240

gttggtcgag gacttgtgac cctggatggt tctaaatgga aaaagcacg ccagattgtg	300
aaacctggct tcaacatcag cattctgaaa atattcatca ccatgatgtc tgagagtgtt	360
cggatgatgc tgaacaaatg ggaggaacac attgccccaa actcacgtct ggagctcttt	420
caacatgtct ccctgatgac cctggacagc atcatgaagt gtgccttcag ccaccagggc	480
agcatccagt tggacagt	498

<210> 75  
 <211> 458  
 <212> DNA  
 <213> Homo sapien

<400> 75	
agccttgac atgatactca gattcctcac ccttgcttag gagtaaaaca atatacttta	60
caggggtgata ataattctcca tagttatttg aagtggcttg aaaaaggcaa gattgacttt	120
tatgacattg gataaaatct acaaatcagc cctcgagtta ttcaatgata actgacaaac	180
taaattattt ccctagaaag gaagatgaaa ggagtggagt gtgggttggc agaacaactg	240
catttcacag cttttccagt taaattggag cactgaacgt tcagatgcat accaaattat	300
gcatgggtcc taatcacaca tataaggctg gctaccagct ttgacacagc actgttcac	360
tggccaaaca actgtgggta aaaacacatg taaaatgctt tttaacagct gatactgtat	420
aagacaaagc caagatgcaa aattaggctt tgattggc	458

<210> 76  
 <211> 340  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1) ... (340)  
 <223> n = A,T,C or G

<400> 76	
accttataacc aaaanaatgc ttattccaaa atattttttg tagctagtag ttctttcctt	60
ggaggtaaaag aaaatacacc caaactttta attaccagga ttcagaatat ttaagagaac	120
aatttttagtt aagaatcaaa tatactgaga ttcaaagagg ggaaaaaag gaaatattat	180
agaagacaaa ggtcaaactg gcattccaga tctggagcaa ttttgtaaag caggaaaaca	240
actatgacaa tctgnagctt cttagatcat tatagtgaat gtncccatct actataaggg	300
tttttataat ggtgtttcct aaataaagga acataaatgt	340

<210> 77  
 <211> 405  
 <212> DNA  
 <213> Homo sapien

<400> 77	
actccatttg tggaactcgt gtcggagtct ggtaaacagc cgaatgtctt cctcccctac	60
agtttctctt ccttgcatga gagcagtgat gtcctgatta aaggcattaa ttttatctat	120
caggaagaac attttttcat ttctgtcttc cggatgtgac acaccatact tttgtagctc	180
ctctgttatt ctctggtgag tctccttgat ttgattttct aacaggggca gagatttaca	240
gatatgtgtg atgagctcgc tggtaagttt ttctgcccag cagggaaaccg tggcctttcc	300
ttcctccagc agatccctga aatatgggtg gttctcaaag aagatcttct ctctctgcag	360
ggcttcggac aggctcagct ggtcctggat ctctgtctgg ccccg	405

<210> 78  
 <211> 410  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(410)  
 <223> n = A,T,C or G

<400> 78  
 acagcagntn tagatggctg caacaacctt ctcctaccc cagcccagaa aatattttctg 60  
 cccaccccca ggatccggga ccaaaataaa gagcaagcag gcccccttca ctgaggtgct 120  
 gggtagggct cagtgcacaca ttactgtgct ttgagaaaga ggaaggggat ttgtttggca 180  
 ctttaaaaat agaggagtaa gcaggactgg agaggccaga gaagatacca aaattggcag 240  
 ggagagacca tttggcgcca gtcccctagg agatgggagg agggagatag gtatgagggg 300  
 aggcgctaag aagagtagga ggggtccact ccaagtggca gggtgctgaa atgggctagg 360  
 accaacagga cactgactct aggtttatga cctgtccata ccggtccac 410

<210> 79  
 <211> 512  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(512)  
 <223> n = A,T,C or G

<400> 79  
 acagtgaana acaaaactaat ataaagcatt ccagnngata aaaacctcct caggcttatg 60  
 gtttggtttc caaggaaatt atgtttcaat gtaaagtttg aaatactcca gacatacatt 120  
 ccatgtaggt tttgggtgcc aatgttataa tttcaaattt tgcattgcaag gcttagcaaa 180  
 gaaacactgg cagaattcca gcatttgcaa aattctaatg tttggtgaat attgtaaata 240  
 ttacaattgg tattagaaag ccatgatgaa tccagaatta agagaaaacc catttcataa 300  
 atattttgtt tgattaaaaa ataccaggct taccatgttc taaataacac aagaaaatat 360  
 ctttaaaaaa aaaaggactg caatttaaca gtaatctgta tatcttttagc tgccattaaa 420  
 aaaagaaaaa agaacaacca aaaacaatga aaatgttaca actggtataa agtnaccna 480  
 tgatgctccc cttacgagaa aacaaaactg tc 512

<210> 80  
 <211> 174  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(174)  
 <223> n = A,T,C or G

<400> 80  
 tgattcccca gacctcaaat gggctaacac gcttctcttc tncagcagnc ttctgtccg 60  
 tgaagntncc ttccagattg gtacatggaa ctgaaaacaa agggagcctc agctggattg 120  
 aaatctggag catgccacaa agncttgac tnggcatttt cnagaagaac ccat 174

<210> 81  
 <211> 274  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(274)

<223> n = A,T,C or G

<400> 81

ttgcaacaag cacattaaat taaggcctgc tngaatttct tcttcccca	tcaggtaa	60
tttctttgcc aataaagttt gaggaggtgg catttgaaaa tctctttaaa	aaagaagtct	120
tcattctat acnagaaaaac tcaaaaaataa ttttcattat caacacacaa	actaactcaa	180
tctctgcttt aagtttctat tggccaattt ttctgattna tacgagaatt	attntcagnt	240
ntagaaaatc ctggtctttg gtcattacaa gntg		274

<210> 82

<211> 101

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(101)

<223> n = A,T,C or G

<400> 82

atggagaaga tcgaacctga gcctnntgag aattgcctgc tacngcctgg	cagccctgcc	60
cgagtggccc agcnnccattt cacnagntgg gcatgatttg	n	101

<210> 83

<211> 182

<212> DNA

<213> Homo sapien

<400> 83

tattatgggg aaagataact gagaataaag ctatcatgca gatatttgca	gagataaaag	60
taatgcagat actgagtggg gttttgatca aactatgctt gaaagccact	ctaccactag	120
ttacacaaac caataatttc ccttcgcagt ggaagtcagc ttgagttttt	tcagggtgtt	180
tt		182

<210> 84

<211> 229

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(229)

<223> n = A,T,C or G

<400> 84

actgtttgta gctgcactac aacagattct taccgtctcc acaaaggcca	gagattgtaa	60
atggtcaata ctgacttttt ttttattccc ttgactcaag acagctaact	tcattttcag	120
aactgtttta aacctttgtg tgctggttta taaaataatg tngtaatcc	ttgttgcttt	180
cctgatacca nactgtttcc cgnggttggt tagaatatat tnngttcng		229

<210> 85

<211> 500

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(500)



<223> n = A,T,C or G

<400> 85

ggggagtang	tgatttatta	aagcaagacg	ttgaaacctt	tacnttctgc	agtgaagatc	60
aggggtgcat	tgaaagacag	tggaaccag	gatgaaagt	tttacatgtc	acacactaca	120
tttcttcaat	attttcacca	ggacttccgc	aatgaggctt	cgtttctgaa	gggacatctg	180
atccgagcat	ctcttcactc	ctaacttggc	tgcaacagct	tccagagggg	catcaaattt	240
ggcaagactt	aacttgaaca	gaggttcaact	aatgaagaag	aagtctaaca	gctcagaaac	300
aagagctggg	cagaactcgg	cattggcctg	gtagcagcag	agggccagcg	tgaccagcag	360
gagacacacc	gacagcttca	tggtggcctt	ttttgctgtg	agctcagctt	tcacaaacaa	420
tgagtgattt	ggactccacc	ccaggagcct	gtggagctgc	agagcccagg	gctatttgta	480
cctgcccggg	cggncgctcg					500

<210> 86

<211> 323

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(323)

<223> n = A,T,C or G

<400> 86

ccgccagtgt	gctggaattc	gccottgccc	cccgggcagg	tactcagaag	tcatttgta	60
tttacaattg	ggtttggtg	ggatgggatn	tanggccgat	gagccagtgc	ttttgcaatg	120
aagatgcaat	antcattgtc	ctctccact	gtctcctctt	tcctcacccc	atggcagctn	180
tcatgaccca	ttcccaaagg	gtccaccgag	tcctgaactc	agcttcatca	ccaacattcc	240
tcgccttcag	ttgaattcaa	cactgncaan	ggagnagang	caaagacttg	ggtcagggag	300
agggngggaa	acacanaaca	aac				323

<210> 87

<211> 230

<212> DNA

<213> Homo sapien

<400> 87

gcagcattga	gccaccccct	tggcaggcga	tacggcagct	ctgtgccctt	ggccagcatg	60
tggagtggag	gagatgctgc	ccctgtggtt	ggaacatcct	ggggtgaccc	ccgaccagc	120
ctcgtggggc	tgtccctgt	ccctatctct	cactctggac	ccagggctga	catcctaata	180
aaataactgt	tggattagac	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaag		230

<210> 88

<211> 249

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(249)

<223> n = A,T,C or G

<400> 88

atgtgaccag	gtctaggtct	ggagtttcag	nttgacact	gagccaagca	gacaagcaaa	60
gcaagccagg	acacaccatc	ctgccccagg	cccagcttct	ctcctgcctt	ccaacgccat	120
ggggagcaat	ctcagcccc	aactctgcct	gatgcccttt	atcttggggc	tcttgtctgg	180
aggtgtgacc	accactccnt	ggtctttggc	ccggccccat	ggatcctgct	ctctggaggg	240
ggtntagat						249

<210> 89  
 <211> 203  
 <212> DNA  
 <213> Homo sapien  
  
 <220>  
 <221> misc\_feature  
 <222> (1) ... (203)  
 <223> n = A,T,C or G

<400> 89  
 tgtttacact gtcaaggatg acaaggaaag tgttcntatc tntgatacca tcatcccagc 60  
 tgttcctcct cccactgacc tgcgattcac caacattggt ccagacacca tgcgtgtcac 120  
 ctgggctcca cccccatcta ttgatttaac taacttcctg gtgcggnact cacctgtgaa 180  
 aatgangaa gatgttgcag agt 203

<210> 90  
 <211> 455  
 <212> DNA  
 <213> Homo sapien

<400> 90  
 ctctaagggg gctggcaaca tggctcagca ggcttgcccc agagccatgg caaagaatgg 60  
 acttgtaatt tgcacacctg tgatcacctt actcctggac cagaccacca gccacacatc 120  
 cagattaaaa gccaggaagc acagcaaacg tcgagtgaga gacaaggatg gagatctgaa 180  
 gactcaaatt gaaaagctct ggacagaagt caatgccttg aaggaaattc aagccctgca 240  
 gacagtctgt ctccgaggca ctaaagttca caagaaatgc taccttgctt cagaaggttt 300  
 gaagcatttc catgaggcca atgaagactg catttccaaa ggaggaatcc tggttatccc 360  
 caggaactcc gacgaaatca acgcccctca agactatggt aaaaggagcc tgccagggtg 420  
 caatgacttt tggctgggca tcaatgacat ggtca 455

<210> 91  
 <211> 488  
 <212> DNA  
 <213> Homo sapien

<400> 91  
 actttgcttg ctcatatgca ttagtcaact ttataagtca ttgtatgta ttatattccg 60  
 taggtagatg tgtaacctct tcaccttatt catggctgaa gtcacctctt gggtacagta 120  
 gcgtagcgtg gccgtgtgca tgccttttgc gcctgtgacc accaccccaa caaaccatcc 180  
 agtgacaaac catccagtgg aggtttgtcg ggcaccagcc agcgtagcag ggtcgggaaa 240  
 ggccacctgt cccactccta cgatacgcta ctataaagag aagacgaaat agtgacataa 300  
 tatattctat ttttatactc ttctattttt tgtagtgacc tgtttatgag atgctggttt 360  
 tctacccaac ggccctgcag ccagctcacg tccaggttca acccacagct acttggtttg 420  
 tgttcttctt catattctaa aaccattcca tttccaagca ctttcagtcc aatagggtga 480  
 ggaaatag 488

<210> 92  
 <211> 420  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1) ... (420)  
 <223> n = A,T,C or G

&lt;400&gt; 92

tctccggcag gctctgcccc ggctcgtagcn agnnaacct	taatcctgac cttttttgta	60
gacaaccttg gtgctgaggt taactccatc cattgtagtg	gcctgtatat caatgggacg	120
attgcatatt ttctctgggt gagctttcca gaggtctgaa	atcttctccc cacctttagt	180
ctgagatact ttatcatgat cganccactc cgtccactcc	acgtnttgaa cccactcact	240
ggacaaagaa acattgaaat attcgccatg ctctgtcttg	aacaatttga ataccgggc	300
agcagcagag cctcgatgnc caggatattc aatatggtct	tccactgaag atgatggatt	360
tcctttcaca gntagaaaac ttncnagggn gtctaaatcc	aagggtgcagg aagngngngc	420

&lt;210&gt; 93

&lt;211&gt; 241

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1) ... (241)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 93

accacgaatt ncaacatcca gatccaccac tatectaagt	ggattgtaac tgngaactgt	60
gccccgtccc tgaaagccga ccaccatgca accaacgggg	tggtgcacct catcgataag	120
gtcatctcca ccatcaccaa caacatccag cagatcattg	agatcganga cacctttgag	180
acccttcggg ctgctgnggc tgcatacagg ctcaacacga	tgcttgaagg naacggncag	240
t		241

&lt;210&gt; 94

&lt;211&gt; 395

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1) ... (395)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 94

actctattnt aattctgcct ttttatactt aattctaaat	ttttccctc taatttacia	60
caaattttgt gattttttata agaattctatg cctccccaat	tctcagattc ttctcttttc	120
tcctttatct ctttgcttaa attcagtata agctttcttg	gtatttttagg ctatcatgac	180
attcttatct cttaaaccaca gcagttcttc agagacctaa	aatccagtat aggaataact	240
gtgttagttc ttgaaaaagc attaaagaca tttttccctg	aaacatacag aacatgtcat	300
gccaaatctc ttgtttacat aataaactgg taataccggg	gaattgcaca tacagatttt	360
atctccaaga tagaataact taaatattaa aacgt		395

&lt;210&gt; 95

&lt;211&gt; 304

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1) ... (304)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 95

cgaggtagac tgatngctcc cccctgggcaa tacaatacaa	gaacngnggg ttttgtcaaa	60
ttggaacaag gaaacagaac cacagaaata aatacattgg	ttaacatcag attagttcag	120

gttacttttt	tgtaaaagtt	aaagtacgag	gggacttctg	tattatgcta	actcaagtan	180
actggaatct	cctgttttct	tttttttttt	taaatnggtt	ttaatttttt	ttaattggat	240
ctatcttctt	ecttaacatt	tcagttggag	tatgtagcat	ttagcaccac	tggetnaaac	300
ctgt						304

<210> 96  
 <211> 506  
 <212> DNA  
 <213> Homo sapien

<400> 96						
acactgtcag	cagggactgt	aaacacagac	agggtcaaag	tgttttctct	gaacacattg	60
agttggaatc	actgttttaga	acacacacac	ttactttttc	tggtctctac	cactgctgat	120
atthttctcta	ggaaatatac	ttttacaagt	aacaaaaata	aaaactctta	ttaaatttcta	180
ttttttatctg	agttacagaa	atgattactg	aggaagatta	ctcagtaatt	tgtttaaaaa	240
gtaataaaaat	tcaacaaaca	tttgctgaat	agctactata	tgtcaagtgc	tgtgcaaggt	300
attacactct	gtaattgaat	attattcctc	aaaaaattgc	acatagtaga	acgctatctg	360
ggaagctatt	tttttcagtt	ttgatatttc	tagcttatct	acttccaaac	taatttttat	420
ttttgctgag	actaatctta	atcattttct	ctaatatggc	aaccattata	accttaattt	480
attattaacc	ataccctaag	aagtac				506

<210> 97  
 <211> 241  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1) ... (241)  
 <223> n = A,T,C or G

<400> 97						
atthttctttt	taattacttt	agagagctag	ggatgcaaat	gttttcagtt	agaaagcctt	60
tattttacttt	tggaattga	acaagaaatg	catctgtctt	agaaactgga	gattatttga	120
tgtaggtaa	aacatgtaat	tgntctctg	gcaaatgtg	atcantnatt	ngaaaatgag	180
atattangaa	aaaccaattc	ttcttaaate	tagnncatct	ttctttanaa	gaacattana	240
t						241

<210> 98  
 <211> 79  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1) ... (79)  
 <223> n = A,T,C or G

<400> 98						
ggcaaacana	cttatgctgn	ancnggggtt	tancaagggt	ttcaaagnaa	aaanccatt	60
ngacttttatg	gaaaatatt					79

<210> 99  
 <211> 316  
 <212> DNA  
 <213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(316)

<223> n = A,T,C or G

<400> 99

ccacatatgt	aaaaccaga	aagaccngnt	tngcactttc	actgagagtt	gagtcacctg	60
ggctgtcnac	aggtgtctga	cgtgtaaact	tggaatcaaa	ctgacttaca	tcctcttcag	120
attgcaacag	aggtttaaag	gggggtcca	cctttcgagc	cagaagttct	tcccagttaa	180
tgtgtctaaa	gaatggatga	gcttgaactt	ctccagcgtc	cccaggacca	gctcccagac	240
gagaagcagc	atttcttttc	agcagctttt	taagcagatc	tctggcttct	tgngtgaggt	300
agggaggcaa	attgag					316

<210> 100

<211> 425

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(425)

<223> n = A,T,C or G

<400> 100

accgctttca	gaaagtttat	atgggttatt	cttcagcctc	tcttttatgc	ctttcgacct	60
ctgtttatca	accccaaacc	aattacgtat	ctggaagtta	tcaataccgt	ggcacaggtc	120
acttttgaca	ttttaattta	ttactttttg	ggaattaaat	ccttagtcta	catgttgga	180
gcacttttac	ttggcctggg	tttgcaccca	atttctggac	attttatagc	tgagcattac	240
atgttcttaa	agggncatga	aacttactca	tattatgggc	ctctgaattt	acttaccttc	300
aatgtgggtt	atcataatga	acatcatgat	ttccccaa	ttcctggaaa	aagtcttcca	360
ctggtgagga	aaatagcagc	tgaatactat	gacaacctgc	ctcactacaa	tttctggata	420
aaagg						425

<210> 101

<211> 156

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(156)

<223> n = A,T,C or G

<400> 101

actgacttgg	gaatgtcaaa	attctttatt	atgatcttcc	gagtgttgtc	ctgagctttg	60
ttggccctca	actgcaggca	gagaaccagg	agcagggtgg	cagggtggc	cctgaacagg	120
agctggagca	agcgcatgct	ngagaaaaca	gaaggc			156

<210> 102

<211> 230

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(230)

<223> n = A,T,C or G

<400> 102

actccaggcc	gggnctcagg	ttatcaaaag	tgccaggagct	ctgatcagca	tggaaccactt	60
cttccaaaga	atttcctcgc	tgcccggttg	taggggttgt	ggtaattcta	taaccagtaa	120
tgtctggggt	ggtgctcctc	ccccaggaga	ctgtgagcac	tccagtgtca	gggtttgcct	180
ccagatgcaa	gntngtnggt	ggagacaatg	gtgncaccac	tttgtnnaca		230

<210> 103  
 <211> 404  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(404)  
 <223> n = A,T,C or G

<400> 103						
actgtgaacc	ctgnggnttc	nangcgacct	acctggagct	ggccagtgtc	gtgaaggagc	60
agtatccggg	catecgagac	gagtcgcgcc	tcggggggcac	aggtgccttt	gagatagaga	120
taaattggaca	gctgggtgtc	tccaagctgg	agaatggggg	ctttccctat	gagaaagac	180
tcattgaggg	catccgaaga	gccagtaatg	gagaaaccct	agaaaagac	accaacagcc	240
gtcctccctg	cgtcatcctg	tgactgcaca	ggactctggg	ttcctgtctc	gttctggggt	300
ccaaaccttg	gtctcccttt	ggtcctgctg	ggagctcccc	ctgcctcttt	cccctactta	360
gctccttagc	aaagagaccc	tggcctccac	tttgcccttt	gggt		404

<210> 104  
 <211> 404  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(404)  
 <223> n = A,T,C or G

<400> 104						
accaggttat	ataatagtat	aacactgcc	aggagcggat	tatctcatct	tcctcctgta	60
attccagtgt	ttgtcacgtg	gttgttgaat	aaatgaataa	agaatgagaa	aaccagaagc	120
tctgatacat	aatcataatg	ataattattt	caatgcacaa	ctacgggtgg	tgctgaacta	180
gaatctatat	tttctgaaac	tggtcctctc	aggatctact	aatgatttaa	atctaaaaga	240
tgaagttagt	aaagcatcag	aaaaaaaaag	gggtattcct	acaagtcagg	acattctacg	300
tgactataat	ataatctcac	agaaatttaa	cattaatacn	ttctaagatt	taattcttag	360
antctnngta	aacaaagtag	ctcctgtgga	natgattggc	atca		404

<210> 105  
 <211> 325  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(325)  
 <223> n = A,T,C or G

<400> 105						
acagcagaag	ccagtctang	atggtgtgat	tcaatttctg	cctctagtat	ttctttgtct	60
tgtttttctc	tcaatttaga	agtgagcatt	gtgttctcag	ctatcagaac	tttaagctgc	120
ccactatatt	gagatgccct	tttagcta	gattcctctt	tcagttttag	ggtcatctga	180
agttcagcat	tcttttcttt	taaaatctta	atgtcctcaa	agtatttatt	ttccttttcc	240

tggtattggn gtttcagngt ggctatttcc agtttttagca tggcaattnc ctttttcaac 300  
atgcaatttt catgtaagag ataata 325

<210> 106  
<211> 444  
<212> DNA  
<213> Homo sapien  
  
<220>  
<221> misc\_feature  
<222> (1)...(444)  
<223> n = A,T,C or G

<400> 106  
actgtcttca atnctatgcg tgcagggtgct taccacaggc aaacagtttt ctccccattt 60  
tgtagtaatg tgatttttct attagcaaaa agaggtcacc agccctgtga gacttaaggg 120  
actcaagtca caggatgggg atttctctt aatatttttt atttngttgt ttgaactctt 180  
gatgcaacat tgtagagcag ggtgttcagg acctgctgtg cccaagggac tgataaagga 240  
aaaagctcta tttattcttt ttgtgatttg atgcacagat gaaaaactta acacacaata 300  
acagaagttg gncgttaata aatcacatcc taggctttca gcgcttnctg aagcagacga 360  
catcttcagt tttctagctc ttgnagnttc aacacngnaa catcaatgat gcatatgtnc 420  
agaatcagtt acaaagacca tccg 444

<210> 107  
<211> 287  
<212> DNA  
<213> Homo sapien  
  
<220>  
<221> misc\_feature  
<222> (1)...(287)  
<223> n = A,T,C or G

<400> 107  
acctgcactc gnacntcagg cantaggcct ccacgtcatg gccaggcact ggcattgggct 60  
ccaccacgtg caggcagtg cagtccttct gggatacatt ctggttgtaa atgtgcccac 120  
tgatgtttct ataagggtgg acagatgcat ttgcaccgga tatcttcana actcttggtg 180  
gctncagctg ggggcaccaa caaacacccg accacagcca ccaaagataa nagcttcagt 240  
cttatcangc ttgctggggc agnaaagccg gacacctaca agccnc 287

<210> 108  
<211> 478  
<212> DNA  
<213> Homo sapien

<400> 108  
acatgtgcaa gaatttggaa aagcagggca ttttccctca tctctcctag aggggaatc 60  
acagcatctg tctctactgg tccacactgg actgcagaca atgtcaaaac tctggatttg 120  
gaatgcggct gatttctttt cccctttaag gagttttcca agaatttcat aaccatcagt 180  
tgttatattt ccagcttctt tgatgtcttt ttctataatt tcatagcagt caatgtaaat 240  
cttaacactt tttgaggtca ctacaatatg aaccttggtg aaacttccat aaaataatgt 300  
ctttacttct tctgtgtcaa atgtaacagt ttgcacctcg cctcttggtat ccttggttaa 360  
gaatgataac gtcttgctag aaggatctgc aatcactcca acttggtggtt tgtagtctct 420  
gtctgtgatt tgccaaattg caaaagggc actgggagtt tctgggagaa gtctgaat 478

<210> 109  
<211> 361  
<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1) ... (361)

<223> n = A,T,C or G

<400> 109

gaatttttct tctanaataa gtattctggt gacacagact attggtaaga ttttcaacat	60
aaggtaatgc taggactggc ctcttagcat gagttgtgag taaagatctg gtctgttggt	120
tctccaaaag aagnttctta ctgcttgctc ctcagtgtt ttctgtttct gctttctctt	180
tttcatattg atatatacgg ntttttaaat ggtnattgta attaaatata tcttcatttt	240
tctcttttag gagatgatgt tgcattttcc tctcaagaaa atgaatatca attggtatct	300
tgcttttgnt gncagctttc ttatgtgcat gaactaattg ctgttgaagc cacatatttt	360
t	361

<210> 110

<211> 305

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1) ... (305)

<223> n = A,T,C or G

<400> 110

acataatgac tnncanagt aagctgattg gctgcggttc tggagtaaata ataagctctc	60
cgttcctggg aatccgcact acttgagtca cgtgcctggc ctaccaaata cttgccaaaa	120
ctatgtgcct tatccacact tnnaatctgn ctctcattt ntcagctgtt ggatcagaca	180
atgacattcc tntagatntg gcgatcaagc attccanacc tgngccaact gcaaacgggtg	240
cctncaagga gaaaacgaag gcncacacaa atgnaaaaaa tgaangnccc ttgaatgtac	300
taaaa	305

<210> 111

<211> 371

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1) ... (371)

<223> n = A,T,C or G

<400> 111

cgggggccag cggggggtat tcagccatcg atcaaactca aaacctggaa tgatatccac	60
tctcttttct ttaagctcag ggaaatatc caagtagaag tccagaaagt catcggttaa	120
gatgcttcgg aatttgaatt catgcacata ggccttgaga aaactgtcaa actgatcctg	180
atcaccaccc aagtgggcca ggtatgagac aaagcagaaa cttttctcgt aggggggtctc	240
attataggtg tegtccgggt caacgcctgg ttcaatcttc acgcggagct tgttgagtgg	300
gttttctct ccagtgatgt ccattgtgctg acgcagcaga nccgcgcccg ttgcagcctc	360
caagcaggng t	371

<210> 112

<211> 460

<212> DNA

<213> Homo sapien



&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(460)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 112

acatcttagg tttttnttcc tttantgtga agaggcggtt ccaccaaccc acagctctgc	60
gtcgagtttt tactagattg ctgcaaattt catggaatct ttgctgttgt tcagtgggtcc	120
atattattgga gccaaaaatt ctagggcgct agaattggaa caaggtagtc agccaagcac	180
aaaaacataa caaaacagga aacgccggac agaacagatg gatctagata gtagataatc	240
agaaacacca aagaaaccac acccatgatg gcaggtggaa accaggctct ttctcatcgg	300
aggactttat cagccatcag catcacttct ccccatcctt gcagctgttc ttccagactt	360
gcagctctctg cagccagcag gttgggtgct gcgattacct ccctccgcca tcgtctcggg	420
gatgcagtct ctacaagcgc aggccacctc cccaacgagt	460

&lt;210&gt; 113

&lt;211&gt; 204

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 113

gagaagacag cagagctgct ttccgcctct ttgagaccaa gatcacccaa gtccctgcact	60
tcaccaagga tgtcaaggcc gctgctaatac agatgcgcaa cttcctgggt cgagcctcct	120
gccgccttag cttggaacct gggaaagaat atttgatcat ggggtctagat gggggccacct	180
atgacctcga gggacacccc cagt	204

&lt;210&gt; 114

&lt;211&gt; 137

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(137)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 114

accgcaagaa atgggacagc aacgtcattg agacttttga catcgnccgc tngacagtca	60
acgtgacgt gggctattac tcttgagggt gtccaagcc cctgaagaac cgtgatgtca	120
tcacctccg ntccctg	137

&lt;210&gt; 115

&lt;211&gt; 278

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(278)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 115

gcgggcggct ttntggactc gctcatttac agagcatgcg tggctcttcc ccttggcattg	60
ttctccgccg gcctctcgga cctcaggcac atgcgaatga cccggagtgt ggacaacgtc	120
cagntcctgc cttttctcac cacggangtc aacaacctgg gctggctgan ttatggggct	180
ttgaaggag acgggatcct catcgtcanc aacacagtgg gtgctgcgct tcanaccctg	240
tatatctttg gcatactcgc attactgccc tcggaage	278

<210> 116  
 <211> 178  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(178)  
 <223> n = A,T,C or G

<400> 116  
 acacogtcat angtcaaaaag tncagtgtcg gccatcttgc atcaaagtgt ctttaaggcag 60  
 tgactggcta tcaaccacag nttctgtctc cccagntgca aacacaggat ccatgcaaca 120  
 gttctgagac catacactta gaaaccacng ggagatgcgg atcanatgca naactnnc 178

<210> 117  
 <211> 360  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(360)  
 <223> n = A,T,C or G

<400> 117  
 actccccaat ggnnggattta ttactattaa agaaaccagg gaaaatatta attttaatat 60  
 tataacaacc tgaaaataat ggaaaagagg tttttgaatt ttttttttaa ataaacacct 120  
 tcttaagtgc atgagatggt ttgatgggtt gctgcattaa aggtatttgg gcaaacaaaa 180  
 ttggagggca agtgactgca gttttgagaa tcagttttga ccttgatgat tttttgttct 240  
 cactgtggaa ataaatgttt gtaaataagt gtaataaaaa tccctttgca ttctttctgg 300  
 accttaaatg gtagaggaaa aggctcgtga gccatttggt tcttttgctg gttatagtgt 360

<210> 118  
 <211> 125  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(125)  
 <223> n = A,T,C or G

<400> 118  
 gcgtcgtgct atgaccggac ttngtcttga aaggggatga cagcatggga ggcaatggnt 60  
 ncacatgtaa accccacact gaaagacaag gcactctctc cacagcagcc ccaacaacta 120  
 gccct 125

<210> 119  
 <211> 490  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(490)  
 <223> n = A,T,C or G

&lt;400&gt; 119

nacaaagaaa	agcaaaaaga	atttacgaag	attgtgatct	cttattaaat	caattgttac	60
tgatcatgaa	tgtaggttag	aaaatgtag	gttttaactt	aaanaaaatn	gtattgngat	120
tttcaatntt	atgttgaaat	cngngtaata	tcctgangtt	nttttcccc	cagaagataa	180
agaggataga	caacctctta	aaatatTTTT	acaatttaat	ganaaaaagn	ttaaaattct	240
caatacnaat	caaacaattt	aaatatTTTt	agaaaaaagg	aaaagtagat	agtgatactg	300
agggtaaaaa	aaaattgatt	caattttatg	gtaaaggaaa	cccatgcaat	tttacctaga	360
cagccttaaa	tatgtctggg	tttccatctg	ctagcatttc	agacatttta	tggtcctctt	420
actcaattga	taccaacaga	aatatcaact	tctggagtct	attanatgtg	ttgtcacctt	480
tctnaagctt						490

&lt;210&gt; 120

&lt;211&gt; 361

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1) ... (361)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 120

caggtacagt	aaaattaaca	cttccgttac	aggaaatgta	tgacgcaa	aatataaaat	60
taaaagggtg	aaaaaagggtg	acactgggtt	cctaagatac	aatttactct	ttacaaccag	120
ggtecacagg	tccaggctgc	anagcgggca	tcaggaagca	gagcctncca	cctgcttctg	180
ggggacctgg	taataaaaaat	cagcccatga	tggcgctatg	gcctctcaga	caccacacgc	240
tgccataaca	cctagagctc	tggaatagtg	caacaggaga	gtgatttcca	tgggggaaat	300
tttaanaaag	atgcacatgg	gacaggcaat	agaaagtgtg	ccaaggntaa	atttgggtacc	360
t						361

&lt;210&gt; 121

&lt;211&gt; 405

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1) ... (405)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 121

acacaaaacc	ttttnacata	ttgggggctt	accgctccaa	attgctactg	atcctttaag	60
ttcacaaat	agaattttct	caccaattaa	gtaataaacc	tcattacaaa	taaagtgc	120
ctgataacca	aactcgtaag	tcccatttgc	agggactgct	tggccattta	aaggatcccg	180
tatatatgga	catgtttctc	tataacaggc	gtcatctgag	acaggtagcc	atgtatgatt	240
ccgatcaca	atagtatggg	tggcaagagg	aggtatatag	aagtatcctt	ttttacactt	300
ataatctact	cggttcacaa	tctcatagta	gggttttggg	ttaccaatga	gcctccatan	360
cttcaaatgt	tgggtggctn	ctcacaggca	tcnggcanaa	ngagt		405

&lt;210&gt; 122

&lt;211&gt; 152

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1) ... (152)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 122

accccgctcc gttgncacag atcgctgtct gccactcca tcggccattc acttggcagg	60
tgcgattggc agagccccgg agagtgtaac cgctcatagca gtggaaagag atctcatcac	120
tcacattgta gtagggagac cggggccaan ta	152

&lt;210&gt; 123

&lt;211&gt; 336

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 123

acatctgaca tatttatata gcacataaat tagggagtgc tctgaccctt gcccgaggag	60
cccaagcact gagcagggag gtgaacgcca gtccagaaag aagggtgtgg agccccgtct	120
ctgtctcttc catcacgggg ctcccctagg gcctccccag gcctccttgg ctgagtcag	180
gtgtctgcag gaggaagggt ttgtctgcat ttagtgtctg agactgggtt tgaggaggca	240
ccagataaaa ggagatacac ttgcagctat aaagtcagct tcaaacccca gggcttgtaa	300
ttccaagagg aggggtggga ggcgaggcca tagtct	336

&lt;210&gt; 124

&lt;211&gt; 253

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(253)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 124

ctgcaagagc ccagatcacc cattccgggt tcaactcccc cctccccaag tcagcagtc	60
tagccccaaa ccagcccaga gcagggtctc tctaaagggg acttgagggc ctgagcagga	120
aagactggcc ctctagcttc taccctttgt ccctgtagcc tatacagttt agaataatta	180
tttgtaatt ttattaaaat gctttaaaaa aacaaaaaaa aaaaaaaaaa aaaaaaaaaa	240
aaaaaagntt gtn	253

&lt;210&gt; 125

&lt;211&gt; 522

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 125

acaactgcaa gtctaagata atgttcattc attcccatca taaatgtaac attctaaata	60
gggtgtctct gatgtcatct gtcagaattt cttttaaact ttttcttcat cttcaacatt	120
atcaaagttc atccttattc ctcttgctt gatttcggag agtttccaat ttttcaacta	180
ttaaggcagc gattgctttt gcatctctgg tatttatctg ctcttcttga aaatttctct	240
ttgtctcttc gtagaaataa aacttaacag ttggataggc cctgatccca gctttctggc	300
atgtctgagc ataagcctga cagtctactt ttccagcttt cacttttctt ttaatcatcc	360
tagccaagag ctcaaattct ggagcaaaat tctggcaagg tccacaccaa ggagcataga	420
aatcaatcac ccaatgattt ttcccttgta gaacttttct actgaaagtc tgagggtgta	480
gatctgtgga tacttgaggt aaaaatccta gaccacagat tc	522

&lt;210&gt; 126

&lt;211&gt; 374

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

<221> misc\_feature  
 <222> (1)...(374)  
 <223> n = A,T,C or G

<400> 126  
 tttttaagat attaacttta cttttataaa tttttgtgtg aaatgaaaa aaaaatcaag 60  
 gcatacaaat ttcatgtgtg tctacatttt taaataccat cttttgtctc cgtaaaga 120  
 ttttcatcca ttattcaaa aaccttttaa gttcaactgt ccaatttaag acagagtga 180  
 gacatttttg agtatctgaa ctaagcattg tcttgactga aacgaagtaa gaactcaatg 240  
 agagtccttg tgggcctccc aggcattgct ttcgtagat aggggaacttc atctttgttg 300  
 gncatcacgc ctgctatgtc taaatgtgcc cacttaggat gagttacgaa ttctttcagg 360  
 aatgctgcag ctgt 374

<210> 127  
 <211> 130  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(130)  
 <223> n = A,T,C or G

<400> 127  
 aaagccaaga cngccattgg cactgctatg gtaaggncac agggcancca gggccttctg 60  
 gcaaaaggng atacnaccag cactatnaac agacaggaca tgggtgagag gnagnctaca 120  
 caantcctaa 130

<210> 128  
 <211> 350  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(350)  
 <223> n = A,T,C or G

<400> 128  
 aacttgattt ccgntnaaaa gaancatcat ctttaccttg acttttcagg gaattactga 60  
 acttttcttct cagaagatag ggcacagcca ttgccttggc ctcacttgaa gggctgcat 120  
 ttgggtcctc tggctctctg ccaagnttcc cagccactcg agggagaaat atcgggaggt 180  
 ttgacttctt ccggggcttt ccgagggct tcaccgtgag cctgcggcc ctcagggtg 240  
 caatcctgga ttcaatgtct gaaacctcgc tctctgcctg ctggacttct gaggcgtca 300  
 ctgccactct gtcctccagc tctgacagct cctcatctgt ggctgttga 350

<210> 129  
 <211> 505  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(505)  
 <223> n = A,T,C or G

<400> 129  
 acaataccaa agcttcataa tgctaaagaa aaccaaaca aaagacaatg gtttacacag 60

```

ggaaataacc ctaaggcaat atgaaaacag tcataattta ttactgataa agagtaaagg 120
catccttccc atagaggggg ggaattcaca gggaacacta attatatcag atgaaccacg 180
gggatagaaa ataggcccat ttttaaaatt cattgagaaa ttattacttt ttctccacaa 240
ctgtgattct atacaaaata taaaccctgc aaaccttatg tgctacctga cagataaaag 300
tagcaggagc cagactcttg aagcacttga gactgatttc tacaaagtcc aggaagagca 360
atgattccag tgtgcagtgc tgatgcatgt gtgagcctaa catgttattc agctctgggt 420
gcagcccat ctacatgggg ccagttagt ttttagggag tcacagatta ngcaggcaac 480
cgaggggcat gatttaaaaa gcaca 505

```

```

<210> 130
<211> 526
<212> DNA
<213> Homo sapien

```

```

<400> 130
acaaaagagc ctgattcttt ttaattccac aaatacctag catctcaaag taacatgtaa 60
acaaacttct atgctgctca atgaatcctt ccaatttcga taataaacta aatagtattg 120
gatctagtat atgactttca tgtgtaagtt atggttctat ccattacttt aacaatatta 180
ctgatgtaac agagaaaaat tttcaactat tgtacttatt taaaacaaac tgacaagttc 240
aagcacctgt cttcagaaaa gccagcagca tttttttttt ttttaacatac tcaaagtaag 300
atttggccta agcccttaat acctttctga acagccatgc aactaaacac cctcaggaga 360
tgttacataa gggagagaag aacatggagc aatttgcact ttttcccta gataatatta 420
acaaggtaaa gcaaattccag atctttatga atgaatggct gtcattgtta atacacttgg 480
agctctataa aactagagcc actatcatat atgtttatat agatat 526

```

```

<210> 131
<211> 477
<212> DNA
<213> Homo sapien

```

```

<400> 131
ctcagttttc ccagcaacag atgctcctga gcaatttatt agtcaagtga cgggtgctgaa 60
atacttttct cattacatgg aggagaacct catggatggg ggagatctgc ctagtggtac 120
tgatattcga agaccteggc tctacctcct tcagtggcta aaatctgata aggccctaata 180
gatgctcttt aatgatggca cttttcaggt gaatttctac catgatcata caaaaatcat 240
catctgtagc caaaatgaag aataccttct cacctacatc aatgaggata ggatatctac 300
aactttcagg ctgacaactc tgetgatgtc tggctgttca tcagaattaa aaaattgaat 360
ggaatatgcc ctgaacatgc tcttacaag atgtaactga aagacttttc gaatggaccc 420
tatgggactc ctcttttcca ctgtgagatc tacagggaac caaaagaat gatctag 477

```

```

<210> 132
<211> 404
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1) ... (404)
<223> n = A,T,C or G

```

```

<400> 132
accacacgan cgggnatcnt ttgnacatag tgagaccgg ctgattccca tacatgaatc 60
cattcatgga gtgcatttta ttagatncct gaaagtcttc atcttcttta tccacctgat 120
caggngcagt tgtaaacatn cctaataatta tcttccagga gtaaactctc attctcatca 180
aatactgtag gaaacaaata gaattccttg tctacatctt tctgtctccc atttgcata 240
aaacttcctt tcttgcatat tttcattggc ccaataagcc cagtgaatat atctttagtg 300
ggatccacag cagaataata catcttagct agacacacag ggatctgcat tacnggggtc 360
ctactttctt ggggacagcc cttcatacgn gaatgtttnt gtgg 404

```

<210> 133  
 <211> 552  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(552)  
 <223> n = A,T,C or G

<400> 133  
 accccaaatt atctctctcc tgaagtcctc aacaaacaag gacatggctg tgaatcagac 60  
 atttgggccc tgggctgtgt aatgtataca atgttactag ggaggccccc atttgaaact 120  
 acaaactctca aagaaactta taggtgcata agggaagcaa ggtatacaat gccgtcctca 180  
 ttgctggctc ctgccaaagca cttaattgct agtatgttgt ccaaaaaccc agaggatcgt 240  
 cccagtttgg atgacatcat tcgacatgac ttttttttgc agggcttcac tccggacaga 300  
 ctgtcttcta gctgttgtca tacagttcca gatttccact tatcaagccc agctaagaat 360  
 ttctttaaga aagcagctgc tgctcttttt ggtggcaaaa aagacaaagc aagatatatt 420  
 gacacacata atagagtgtc taaagaagat gaagacatct acaagcttag gcatgatttg 480  
 aaaaagactt caataactca gcaaccagc aaacacaggg acagatgang agctccacca 540  
 cctaccacca ca 552

<210> 134  
 <211> 496  
 <212> DNA  
 <213> Homo sapien

<400> 134  
 acattgatgg gctggagagc aggggtggcag cctgttctgc acagaaccaa gaattacaga 60  
 aaaaagtcca ggagctggag aggcacaaca tctccttggt agctcagctc cgccagctgc 120  
 agacgctaat tgctcaaaact tccaacaaag ctgccagac cagcacttgt gttttgattc 180  
 ttcttttttc cctggctctc atcatcctgc ccagcttcag tccattccag agtcgaccag 240  
 aagctgggtc tgaggattac cagcctcacg gagtgaattc cagaaatata ctgaccaca 300  
 aggacgtaac agaaaatctg gagaccaag tggtagagtc cagactgacg gagccacctg 360  
 gagccaagga tgcaaatggc tcaacaagga cactgcttga gaagatggga gggaagccaa 420  
 gaccagtggt ggcgcatccgg tccgtgctgc atgcagatga gatgtgagct ggaacagacc 480  
 tttctgggc cacttt 496

<210> 135  
 <211> 560  
 <212> DNA  
 <213> Homo sapien

<400> 135  
 actgggagtg atcactaaca ccatagtaat gtctaatatt cacaggcaga tctgcttggg 60  
 gaagctagtt atgtgaaagg caaatagagt catcacagtag ctcaaaaggc aaccataatt 120  
 ctctttgggtg caggtcttgg gagcgtgatc tagattacac tgcaccattc ccaagttaat 180  
 ccctgaaaaa cttactctca actggagcaa atgaactttg gtcccaataa tccatctttt 240  
 cagtagcggtt aattatgctc tgtttccaac tgcatttccct ttccaattga attaaagtgt 300  
 ggctcggtt ttagtcatctt aaaattgttt tctaagtaat tgctgcctct attatggcac 360  
 ttcaattttg cactgtcttt tgagattcaa gaaaaatttc tattcttttt ttgcatcca 420  
 attgtgcctg aacttttaaa atatgtaaat gctgccatgt tccaaacca tegtcaagtg 480  
 tgtgtgttta gagctgtgca ccctagaaac aacatattgc ccatgagcag gtgcctgaac 540  
 acagaccct ttgcattcac 560

<210> 136  
 <211> 424

<212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1) ... (424)  
 <223> n = A,T,C or G

<400> 136  
 accagcaaat ctccattagc atttctcagg ttctcatgac cttttcagat atgttggttg 60  
 attttatgta tatattgctt agaaacaaaa atccacctga tattaacaca aacacaaaaa 120  
 aatcataaaa gcaagcaaat gaacaaaaaa ccctagtttt gttgtgcttt tctttcacat 180  
 ttctacagg gagatttgta tatctcagat actttcaaaa tctaataagg aagtaaaatt 240  
 agtgccttaa ccaaacagta agataccaaa gaatcctcca tcacaagtta ctgaatcaaa 300  
 cttctcatga catttgcggt atattcagat ttgaagattt tttaaattta gaatttaaaa 360  
 caaacttttag actgctgatt ttccatattt caaagactgt agctgntgc agcatataaa 420  
 tgga 424

<210> 137  
 <211> 392  
 <212> DNA  
 <213> Homo sapien  
 <220>  
 <221> misc\_feature  
 <222> (1) ... (392)  
 <223> n = A,T,C or G

<400> 137  
 tgcgggntg aaggctagca aaccgagcga tcatgtcgca caaacaatt tactattcgg 60  
 acaaatacga cgacgaggag tttagatgc gacatgtcat gctgcccaag gacatagcca 120  
 agctgggccc taaaacccat ctgatgtctg aatctgaatg gaggaatctt ggcgatcagc 180  
 anagtcaggg atgggtccat tatatgatcc atgaaccaga acctcacatc ttgctgttcc 240  
 ggcgccact acccaagaaa ccaaagaaat gaagctggca agctactttt cancctcaag 300  
 ctttacacag ctgnccttac ttcttaacat ctttctgata acattattat gctgccttcc 360  
 tgttctcact ctganatnta aaagatgttc aa 392

<210> 138  
 <211> 284  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1) ... (284)  
 <223> n = A,T,C or G

<400> 138  
 tgctgtgca cctctttgct tgaaatatgg caagacttgg aaaaatgttt gcccttagaa 60  
 tctatctcac tacttttagtt agttgtctcc ttggggcctg ggcacagttc tggccctgat 120  
 ctggaacaga ctcccttttc taaaactgaa cttgaccaga tcaaaagntt gnaaaacaat 180  
 ctccatggta attaaacttg cattcaacac catatggnaa cagaagatgg caggaggata 240  
 anatncagat cttatgatct ttccangnan ggcagtgtac atga 284

<210> 139  
 <211> 249  
 <212> DNA



<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)...(249)

<223> n = A,T,C or G

<400> 139

```
gaggaagggg ggactgaatc tancacntg acngaactag agacagccat gggcatgac 60
atagacnnct ttacccgata ntcgggcagc gagggcagca cgcagaccct gaccaagggg 120
gagctcaagg ggctgatgga gaaggagcta ccaggcttcc ngcagagngg aaaaanacaag 180
gangccgtgg ataaattgct caaggaccta gacgccnatg gaggatgccc aggtggactc 240
cagcgagnt                                     249
```

<210> 140

<211> 390

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)...(390)

<223> n = A,T,C or G

<400> 140

```
tcataatggg tggggcagct ataatnnact acaanaatca natgtttcac atctagacct 60
cgggcagcaa cagaggtagc cacaagaagt ttgcangtcc cattcttaaa gtcatttatg 120
atgctatctc tgtcatattg atcaatgcct ccatgaagag acatgcaagg ataagatgct 180
ctcattaaat ccttaagaag accatcagca tgttctctgct tatccacaaa tataatgaca 240
gatcctgact cttgataatg gcctagaagc tcaagtaact tcaagaattt cttttcttct 300
tcaatcacia tcaattgtng ctccacatct gagcaaacca cactcctgcc tccaacttgt 360
acctgccccg ggcgggcgct caagggcgaa                                     390
```

<210> 141

<211> 420

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)...(420)

<223> n = A,T,C or G

<400> 141

```
gacactcagg gaaaagcatn ngncaaanag agcttaaaat gcatcgccaa cggggtcacc 60
tccaaggtct tctcgcgat tccgaggtgc tccactttcc aaaggatgat tgctgaggtg 120
caggaagagt gctacagcaa gctgaatgtg cgcancatcg ccaagcggaa cccngaagcc 180
atcactgagg tcgtgcagct gcccaatcac ttctccaaca natactataa cagacttggn 240
cgaagcctgc tggaatgnga tgaanacaca gggcagcaca atcaggagac agcctgatgg 300
anaaaantgg gcctancatg gccaggcctc ttccacatcc tngcangaca gaccactgtg 360
cccaaacaca cccnctgagc tgacttnnac aggagacgca cnaaggagcc cggcagangc 420
```

<210> 142

<211> 371

<212> DNA

<213> Homo sapiens

<400> 142

```

gggttcgaca atgctgatcc gcaattagaa gacactggta agctgtgtta cactgggctt 60
cattgaaatc ttcaaggata tagccagctc ctgctcgaag ctgggattct gtatactgct 120
tggtgaaagg aggaatttcc aaaaattcct cctcttcttc actgcttcct gtaggacat 180
ctggcagttt ggagcggctg gccaacttgt cactggttgt ggccatggta aggagaaatg 240
cgtagcccag aaacaaggctc ttgttgagag gcaaaggccc tctctgctct tccagggcag 300
agggttcacc ggtgtgtctc ccactctcac aggggctcac aaactctcct gcccctactt 360
gcaccaggtt t                                     371

```

```

<210> 143
<211> 270
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (1)...(270)
<223> n = A,T,C or G

```

```

<400> 143
ggtggctgtg atnaccttn ttagtttaca aataaaaaag ntaaaaagaa atactgtgtt 60
tagggtaagg taacannttc atctaatacag aggagagtga agangaggcn ctgccttcta 120
ggngctgtga ccttctcctt ttcgngattc ttcnccacct tgggnaacat cttccccgct 180
atgctggaan tacttcgng ttctgcggtg gccatgntga acatctgatg aactgaaant 240
ncatccnaat gcacacgaag anatagncna                                     270

```

```

<210> 144
<211> 259
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (1)...(259)
<223> n = A,T,C or G

```

```

<400> 144
ttctctttgc tttttataat tttaaagnaa ataacacatt taactgtatt taagtctgtg 60
caaataatcc ttcagaagaa atatccaaga ttctgtttgc agaggtcatt ttgtctctca 120
aagatgatta aatgagtttg tcttcagata aagtgtcctc gtccagnaga actcaaaagg 180
ccttcaagct gttcagtaag tgtaggttca gataagactc cgcatacga attccagctt 240
cccgtgccca ctgtacctc                                     259

```

```

<210> 145
<211> 433
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (1)...(433)
<223> n = A,T,C or G

```

```

<400> 145
accacatnta ccatagtgtg attagtttta attttcacat gaatcaaagg tttcctttca 60
tgtctattta cagtccaatt gtgccaaact cttacttgtg tgctgactaa caaggcattt 120
agggtgtgcag catcctagag tgctccaggg cagtgtcagc gttctcggga gtaaaagggtg 180
ccacttggtg gcaatgatat tccagaatta aatgggtttt tgttgccatg gagactgcat 240
ttatataaat gtagcctgta gcttaagtta actaaaccta atgctgctgt taaaaacagt 300

```

ttattttaat attaaaatac agttgattag caacagcggt gctgtatttt aagagacact 360  
ttattggaag tgcaatcata gttatttggt ttcacaattt tacagngcat tctaattact 420  
gatgggtgca att 433

<210> 146

<211> 576

<212> DNA

<213> Homo sapiens

<400> 146

acctcaggcc tgtgcacctc tttgcttgaa atatggcaag acttggaana atgtttgccc 60  
ttagaatcta tctcactact ttagtttagtt gtctcctttg ggcctgggca cagttctggc 120  
cctgatctgg aacagactcc cttttctaaa actggacett gaccacatca aaagtttgta 180  
aaacaatctc catggtaatt aaacttgcat tcaacacat atggtaacag aagatggcaa 240  
aggataagat tcagatctta gatctttcca agtagggcat gttagatgat agaaggatta 300  
gttgcaagct ggatctgagc tcaggcttgg gcatgaagga aactgtctcc catgtgggtt 360  
ggaagagtta ggggtcctct gagctctatt gtgaactata cgggtttcat ccaaggaatg 420  
gtatgatgtg ggcataaaac cattcttcag acaactgaag atgggtccct tctgtagcca 480  
gaaacactag ctgtcctgca ttgccatttc ctttacccca ggcggtctgc agaaggaaag 540  
gccataatta attaaaaggc ttaatgaagt tttgga 576

<210> 147

<211> 300

<212> DNA

<213> Homo sapiens

<400> 147

ccagccccca ggaggaaggt ggggtctgaat ctagcaccat gacggaacta gagacagcca 60  
tgggcatgat catagacgtc tttaccgat attcgggcag cgagggcagc acgcagaccc 120  
tgaccaaggg ggagctcaag gtgcttatgg agaaaggagc taccaggctt ctgcagagtg 180  
gaaaagacaa ggatgccgtg gataaattgc tcaaggacct agacgccaat ggagatgcc 240  
aggtggactt cagtgaagtc atcgtgttcg tggctgcaat cacgtctgcc tgtcacaagt 300

<210> 148

<211> 371

<212> DNA

<213> Homo sapiens

<400> 148

acataatcct cataatggtt ggggcagcta taatttacta caagaatcag atgtttcaca 60  
tctagacctc gggcagcaac agaggtagcc acaagaagtt tgcagggtccc attcttaaag 120  
tcatttatga tgctatctct gtcattatga tcaaatggcc tccatgaaga gacatgcaag 180  
gataagatgc tctcattaaa tctttaagaa gaccatcagc atgttctctgc ttatccacaa 240  
atataatgac agatcctgac tcttgataat ggcctagaag ctcaagtaac ttcaagaatt 300  
tcttttcttc ttcaatcaca atcacttggt gctccacatc tgagcaaacc acactcctgc 360  
ctccaacttg t 371

<210> 149

<211> 585

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1) ... (585)

<223> n=A,T,C or G

```

<400> 149
cgaggtacan cactgctaaa tttgacactn anggaaaagc attcgtcaaa gagagcttaa 60
aatgcatcgc caacgggggc acctccaagg tcttcctcgc cattcggagg tgctccactt 120
tccaaaggat gattgctgag gtgcaggaag agtgctacag caagctgaat gtgtgcagca 180
tcgccaagcg gaacctgaa gccatcactg aggtcgtcca gctgcccaat cactttctcca 240
acagatacta taacagactt gtccgaagcc tgctggaatg tgatgaagac acagtcagca 300
caatcagaga cagcctgatg gagaaaattg ggcctaacat ggccagcctc ttccacatcc 360
tgcagacaga cactgtgccc caaacacacc cacgagctga cttcaacagg agacgcacca 420
atgagccgca gaagctgaaa gtccctcctca ggaacctccg aggtgaggag gactctccct 480
cccacatcaa acgcacatcc catgagagtg cataaccagg gagaggntat tcacaacctc 540
ccaaactagt atcatttttag gggnggttga cacaccagtt ttgag 585

```

```

<210> 150
<211> 642
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (1)...(642)
<223> n=A,T,C or G

```

```

<400> 150
acttnccgggt tcgacaatgc tgatccgcaa ttagaagaca ctggtaagct gtgttacact 60
gggcttcatt gaaatcttca aggatatagc cagctcctgc tcgaagctgg gattctgtat 120
actgcttggt gaaaggagga atttccaaaa attcctcctc ttcttccactg cttcctgtat 180
gaccatctgg cagtttgagg cggttgccca acttgteact ggttggtggc atggtaagga 240
gaaatgcgta gcccgaaaac aaggctctgt tgagaggcaa aggccctctc tgctcttcca 300
gggcagaggg ttcaccgggtg ttgtctccac tctcacaggg gctcacaac tctcctgcc 360
ctactgcacc aggttttact gtggcagact tgcgacctcg cttggcaggg gaccgttct 420
cttcagaagt gataagtttt cttttgcctg agagaactcc catggaggca cgaggacttt 480
ctgtgatctt tcgggtaggg gttgtgctgc tactggaggc agtangggtg gctggggagc 540
tgacgttact gcgcggttcc cgttctcttc caccaaattg ctaagctgat atctgctgcc 600
tttgaagaa gnggtactgc ttcatanggg ccaagcccat ac 642

```

```

<210> 151
<211> 322
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (1)...(322)
<223> n=A,T,C or G

```

```

<400> 151
nttggacaac atcttccccg ctatgctgga attacttcgg tgttctgcgg tggccatgg 60
gaacatctga tgaactgaaa ttccatcgga atgcacagga agatatagtt gatcttcaa 120
aatgtccttt ccaggaccac catactgggg aagttctttc gggcgcctgc naatgggctg 180
caccctgggg ctggggccga gctctagctc tgcctagcca tcgccactga aatcggtttn 240
cagatgatta gtctcttcat gccccgtcca ttttctcggt tttctccagt gttcagaaat 300
tcaaattgatt aacttctggg aa 322

```

```

<210> 152

```

<211> 262  
<212> DNA  
<213> Homo sapiens

<400> 152  
acaaagtctt ctctttgctt ttataaattt taaagcaa ataacattta actgtattta 60  
agtctgtgca aataatcctt cagaagaa atccaagatt ctgtttgcag aggtcatttt 120  
gtctctcaaa gatgattaaa tgagttgtc tttagaataa agtgtcctg tccagcagaa 180  
ctcaaaaggc cttcaagctg ttcagtaagt gtagttcaga taagactccg tcatacgaat 240  
tccagcttcc cgtgcccact gt 262

<210> 153  
<211> 284  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)  
<223> n=A,T,C or G

<400> 153  
ctcgggagta aaagggtgcca cttggtagca atgatattcc agaattaaat gggtttttgt 60  
tgccatggag actgcattta tataaatgta gcctgtagct taagttaact aaacctaattg 120  
ctgctgttaa aaacagttta ttttaattatt aaaatacagt tgattagcaa cagcgggtgct 180  
gtattttaag agacacttta ttggaagtgc aatcatagtt atttgttttc acaattttac 240  
ngtgcattct aattactgat gggngcaatt acttttaatc gngg 284

<210> 154  
<211> 531  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(531)  
<223> n=A,T,C or G

<400> 154  
accacacctt aatttgaact cttatcaaga ggctgatgaa tctgaccatc aaataggata 60  
ggatggacct ttttttgagt tcattgtata aacaaatttt ctgatttgga cttaattccc 120  
aaaggattag gtctactcct gctcattcac tctttcaaag ctctgtccac tctaactttt 180  
ctccagtgtc atagataggg aattgctcac tgctgtccta gtctttcttc acttacctgg 240  
cctctgatag aaacagttgc cctctcatt tcataaggtc gaggacttgt gaccctggat 300  
ggttctaaat ggaaaaagca ccgccagatt gtgaaacctg gcttcaacat cagcattctg 360  
aaaatattca tcaccatgat gtctgagagt gtccggatga tgctgaacaa atgggaggaa 420  
cacattgccc aaaactcagc tctggagctc tttcaacatg tctccctgat gaccctggac 480  
agcatcatga agtgtgcctt cagccaccag ggcagcatcc agttngacag t 531

<210> 155  
<211> 353  
<212> DNA  
<213> Homo sapiens

<220>

<221> misc\_feature  
 <222> (1)...(353)  
 <223> n=A,T,C or G

<400> 155  
 tcttgacaag actgagagag ttacatgttg ggaaaaaaaa agaagcatta acttagtaga 60  
 actgaaccag gaggattaag ttctgaaatt ttgaatcatc tctgaaatga agcagggtga 120  
 gcctgccctc tcatcaatcc gtctgggtgc cagaactcaa gggtcagtgg acacatcccc 180  
 ctgttagaga cctcatggg ctaggacttt tcatctagga tagattcaag acctttacct 240  
 canaattatg taaactgtga ttgtgtttta gaaaaattat tatttgctaa aaccatttaa 300  
 gtctttgtat atgtgtaaat gatcacaaaa atgtatttta taaaatgttc tgt 353

<210> 156  
 <211> 169  
 <212> DNA  
 <213> Homo sapiens

<400> 156  
 agtttgttct actacatttg tggccacta gttcactttg ctgtgttgat aagcggtacc 60  
 accaattgca ctttctatag cctcttttac aatgttgctc acttcatcaa caacaaaagc 120  
 agtctcctcc gcagcctggt agtcttccat ctttctctcg gcgcgtccc 169

<210> 157  
 <211> 402  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(402)  
 <223> n=A,T,C or G

<400> 157  
 gtttaactacc cgctccgaga cgggattgat gacgagtcct atgaggccat tttcaagccg 60  
 gtcattgtcca aagtaatgga gatgttccag cctagtgcgg tggctttaca gtgtggctca 120  
 gactccctat ctggggatcg gttaggntgc tttaatctac tatcaaagga cagcceaagt 180  
 gtgtggaatt tgtcaagagc tttaacctgc ctatgctgat gctgggaggc ggtggttaca 240  
 ccattcgtaa cgttgcccgg tgctggacat atgagacagc tgtggccctg gatacggaga 300  
 tccctaataa gcttccatac aatgactact ttgaataact tggaccagat ttcaagctcc 360  
 acatcagtcc ttccaacatg actaaccaga acacgaatga gt 402

<210> 158  
 <211> 546  
 <212> DNA  
 <213> Homo sapiens

<400> 158  
 actttgggct ccagacttca ctgtccttag gcattgaaac catcacctgg tttgcattct 60  
 tcatgactga ggttaactta aaacaaaaat ggtaggaaag ctttcctatg cttcgggtta 120  
 gagacaaatt tgcttttgta gaattggtgg ctgagaaagg cagacagggc ctgattaaag 180  
 aagacatttg tcaccactag ccaccaagtt aagttgtgga acccaaagggt gacggccatg 240  
 gaaacgtaga tcatcagctc tgctaagtag ttaggggaag aaacatattc aaaccagtct 300  
 ccaaatggat cctgtggtta cagtgaatga ccactcctgc tttatttttc ctgagattgc 360  
 cgagaataac atggcactta tactgatggg cagatgacca gatgaacatc atcatcccaa 420  
 gaatatggaa ccaccgtgct tgcataata gatttttccc tggtatgtag gcattcctgc 480  
 catccattgg cacttggtc agcacagtta ggccaacaag gacataatag acaagtccaa 540

aacagt

546

&lt;210&gt; 159

&lt;211&gt; 145

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(145)

&lt;223&gt; n=A,T,C or G

&lt;400&gt; 159

acttttgcta taagtttctt aaaaatattt aatacttttt tttttcaatt taaattaaat 60  
ctnttgatga acaggggggg gntggcaaaa tttccaagcn ctggactgga attttganan 120  
aggcatttac ngaccctnat aactt 145

&lt;210&gt; 160

&lt;211&gt; 405

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 160

tgtaaategc tgtttgatt tcctgatttt ataacagggc ggctgggtta tatctcacac 60  
agtttaaaaa atcageccct aatttctcca tgtttacct tcaatctgca ggcttcttaa 120  
agtgcagta tcccttaacc tgccaccagt gtccccctc cgcccccggt cttgtaaaaa 180  
ggggaggaga attagccaaa cactgtaagc ttttaagaaa aacaaagttt taaacgaaat 240  
actgctctgt ccagaggctt taaaactggt gcaattacag caaaaaggga ttctgtagct 300  
ttaacttgta aaccacatct tttttgcact ttttttataa gcaaaaacgt gccgttttaa 360  
ccactggatc tatctaaatg ccgatttgag ttcgcgacac tatgt 405

&lt;210&gt; 161

&lt;211&gt; 443

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(443)

&lt;223&gt; n=A,T,C or G

&lt;400&gt; 161

tttgctttta atgaaggaca agggattaag acncatagag actggccana caaatgggaa 60  
accgaccaga ccagcccatg accaaaatat cacaggcaga ccaccacaaa atgcagaggc 120  
ctcagagtcc acagtggcgc gttggaaccc agggccccag ggaatctttc agctgcattc 180  
cggctgtgat cggcgggcaa caggtagagg tgctggaggg ggctgagtcg tgattttcgg 240  
tgtctgtcat attcgatcaa gtgtgtcata gagcttctctg tttcatctcc cagttattca 300  
aggagaggct ggtggctcca cctcccagg aactgtgctg tgaagatctg aagacaggca 360  
cgggctcagg caccgcttgt ctggaatgtc aatttgaaac ttaaaaagca gcgaccatcc 420  
agtcatttat ttccctccat tcc 443

&lt;210&gt; 162

&lt;211&gt; 228

&lt;212&gt; DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)...(228)

<223> n=A,T,C or G

<400> 162

```
tcgttatcaa aatggaagac accaaaccat tactggcttc taagctgaca gaaaaggagg 60
aagaaatcgt ggactagtgg agtaaatttt atgcttnctc aggggaacat gaaaaatgcg 120
gacagtatat tcagaaaggc tattccnagc tcaagatata tnattgtgaa ctanaaaata 180
tagcanaatt tgagggcctg acagacttct canatacntt caagttgt 228
```

<210> 163

<211> 580

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)...(580)

<223> n=A,T,C or G

<400> 163

```
acccaaggct acacatcctt ctgtgaaaca gtctcacgga gactctcaga atcccaagaa 60
ttttcttcaa ctttcttttg ttttgattct gaagggaaca tctgatctgc tctcaatggt 120
tgttcattct tcaattccaa ggctttattt ggaacagact ttgcatttca atggcaggct 180
cgaaggcaga tggcttctcg ggaggctctg ctttgaaagt ttgcntgtcc atcaattcta 240
aggctttagn tggaaatagaa actttcattc tgcagggagc cttcagaaaa ccatcattat 300
caggagactc ttctaatttt ccatattatt tatctatttc tttttgatgc gcagccttgg 360
gtanacacac atccttctgt gaaacagtct cacagagact ctcagaatcc caagaacttt 420
cttcatagtc cttttgtttg gattctgatg ggagtatctc atctgctctc aatgtttgtt 480
cattcttcaa ttccaaggct ttatttgaa cagacttttg catttcaatg gcaggctcga 540
aggcagatgg cttctcggga ggctctgctt tgaaaagtgt 580
```

<210> 164

<211> 140

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)...(140)

<223> n=A,T,C or G

<400> 164

```
acttatatct tttggncttg ggcttctcaa agttcacgac agacataggc actctcacag 60
tatcaagccc atttacgnc acctcacacc aatactcgcc ccaccgngng ataggntctg 120
ctggnaactt taatgnatgn 140
```

<210> 165

<211> 370

<212> DNA

<213> Homo sapiens



<220>  
<221> misc\_feature  
<222> (1)...(370)  
<223> n=A,T,C or G

<400> 165  
acatggagcc actgccacca gtggtgatgg aaagcactgc cttcttactc cggaaggggc 60  
ctttgtcata catggcagcg taagtgtgaa caaactctcc tatgaacact cgctcaaacc 120  
agcctttcag aatggcaggg actccaaacc actgcnnngg ggaactggaa tatcacaagg 180  
tctgcggctt ccagcttctt ttgttcagcc acaatatctg ggctcanatg gncttcttta 240  
taagccagaa cagactcggg aggatactga aagttcgcag ggnccctcan ttacactgng 300  
atgncccttn tggaaatgat gggattgaag ntcatggnat aaaggncgga ctnccaccac 360  
tccattcttt 370

<210> 166  
<211> 258  
<212> DNA  
<213> Homo sapiens

<400> 166  
gtcaaaagtc atgattttta tcttagttct tcattactgc attgaaaagg aaaacctgtc 60  
tgagaaaatg cctgacagtt taatttaaaa ctatgggtgta agtctttgac aagaaaaaaa 120  
aacaacaaaa cacttctttc catcagtaac actggcaatc ttctgttaa ccactctcct 180  
tagggatggg atctgaaaca acaatgggta cctcttgag attcgtttta agtgtaattc 240  
cataatgagc agaggtgt 258

<210> 167  
<211> 345  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(345)  
<223> n=A,T,C or G

<400> 167  
ggtcagccaa acaccagga tctctgtaaa actgaagaac aggncaatgc caccaacaaa 60  
tctcaaaacc tctccagcat attctcttat gattggagca catggngagc acnantgggc 120  
acttttaaca canctagcca gacaggngnc atttgggtta acacttcgga acccacagca 180  
ntttanantt ctctggatgt catttcgagc acttgattt attgggcann tttctgtatc 240  
tngcgcttgg ttagccctga accaggagca acaggngcag cttctggagg ntggttggaa 300  
caatacggca agtgntngaa atgacatcca acctncngaa atgac 345

<210> 168  
<211> 61  
<212> DNA  
<213> Homo sapiens

<400> 168  
gatagtgtgg tttatggact gaggtcaaaa tctaagaagt ttcgcagacc tgacatccag 60  
t 61

<210> 169

<211> 344  
<212> DNA  
<213> Homo sapiens

<400> 169  
acattggtgc tataaatata aatgctactt atgaagcatg aaattaagct tcttttttct 60  
tcaagttttt tctcttgtct agcaatctgt taggcttctg aaccaagacc aaatgtttac 120  
gttcctctgc tgcataccaa cgttactcca aacaataaaa aatctatcat ttctgctctg 180  
tgctgaggaa tggaaaatga aacccccacc ccctgacccc taggactata cagtggaaac 240  
tgttcattgc tgatgaatgc agcagtcacc aaaaaatata cccaatcttc cagataacct 300  
cagtgcactt taggaaatca aaaattacct ggaagcaatt tagt 344

<210> 170  
<211> 114  
<212> DNA  
<213> Homo sapiens

<400> 170  
agcagtgtgt cctccatgaa taaacaggag ttctggagge ccattctctg catcttctgc 60  
tgattgttct tccccaattt tacttaaate ccacacattc aggcggcggt cagt 114

<210> 171  
<211> 150  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(150)  
<223> n=A,T,C or G

<400> 171  
actgagagca ttataaatct gaccaaattc ataggcatta ttaggcttgg ctatcggaag 60  
tttctcaggg tcttctggng acctgctgct tttgcctccc ttctcanaag caaggcatcc 120  
catggagacc tccctgcag ggttccagg 150

<210> 172  
<211> 435  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(435)  
<223> n=A,T,C or G

<400> 172  
atgtgttttc cactgcctca cactagttag ctgtgccaa tagtagtgtg acacctgtgt 60  
tgtcatttcc cacatcacgt aagagcttcc aaggaaagcc aaatcccaga tgagtctcag 120  
agagggatca atatgtccat gattatcttc tggtttaggt ctacagtcaa tgtgatgggtg 180  
gtctttgtct cccagtctgc cagaatatct ttgtgcttct ctaatcattg gctttaaagc 240  
taatcaatgt gttggcagca tctctgtcac tcttgtttaa cacgtgaaga aatcaggtag 300  
atgtttttct gtggcattgt tttcgacct aaaatcaggt atgctgacta tttccaaggg 360  
gtttttcagt tgcttcattt gcttgtaaag caggaatcc tcttgntgct tttctttttc 420  
tcgatgagcc cgtgt 435

<210> 173

<211> 622  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(622)  
<223> n=A,T,C or G

<400> 173  
actgntttcc cccaagtcca tgacatgtat acataattaa tggtttgcct ccttgattgt 60  
tttctccaac atccagacat agaggctgac caacgctttt aatgtatcca gatataacag 120  
gattaaggctc tggcacatac acctctggat aaatgttggt cagataccat gtaaaatttt 180  
tacctgaag gcggtgtttt atttcaaatac tttttgaaag atcaccaaata gctttttgtt 240  
taacaatttt tgctgcatct gtatttctcc tataaaatat ttccttgat tcatccatcc 300  
agacttctgc aaggcgaact tggtttctag caatcacctg agtgcctttt ggaaagctat 360  
gagggctttt gctgcgaaaa acatgtccaa caacagagca aggcataatc tccaactgcc 420  
caccacattg ccatactctg aaagacattt ctatattttc acctccccag atttccattt 480  
cttcatcata gcttccaata tactcaaaat attcttttga tatggaaaaa agtctctctg 540  
caaaagtggg tgttttaatt gggtagggtt catctttcct tctttgcttc tcatgatcag 600  
gaagcgactt ccaccaatg aa 622

<210> 174  
<211> 362  
<212> DNA  
<213> Homo sapiens

<400> 174  
acgggtgcagt tgaccactg ttggctctcc ttgcagttcc tgatatgtca tcttttagcat 60  
gtggctactt acgtaatctt acctggacac tttctaatct ttgccgaac aagaatcctg 120  
cacccecgat agatgctgtt gagcagattc ttcctacctt agttcagctc ctgcatcatg 180  
atgatccaga agtgtttagca gatacctgct gggtattttc ctaccttact gatggccaa 240  
atgaacgaat tggcatgggt gtgaaaacag gagttgtgcc ccaacttgtg aagcttctag 300  
gagcttctga attgccaat gtgactctg ccctaagagc catagggaa attgtcactg 360  
gt 362

<210> 175  
<211> 486  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(486)  
<223> n=A,T,C or G

<400> 175  
acagntnctc tactacactc agcctcttat gtgccaaagt tttctttaag caatgagaaa 60  
ttgctcatgt tcttcatctt ctcaaatac cagaggccga agaaaaacac tttggctgtg 120  
tctaaaactt gacacagtca atagaatgaa gaaaattaga gtagttatgt gattatttca 180  
gctcttgacc tgtccctctt ggctgctctt gagtctgaat ctcccaaaga gagaaaccaa 240  
tttctaagag gactggattg cagaagactc ggggacaaca tttgatccaa gatcttaaat 300  
gttatattga taaccatgct cagcaatgag ctattagatt cattttggga aatctccata 360  
atttcaattt gtaaaatttg ttaagacctg tctacattgt tatatgtgtg tgacttgagt 420  
aatgttatca acgtttttgt aaatatattac tatgttttct tattagctaa attccaacaa 480  
ttttgt 486

<210> 176  
<211> 461  
<212> DNA  
<213> Homo sapiens

<400> 176  
accctggcca ctcttttctt tttggttggc caatgtctcc tctgtaggct ccagaaggct 60  
ctcagggatg caggcggcct cctgcagggt tgagttgcaa tgggaacaaa gacagctgtg 120  
gtcccatagc accctcatct ggtgacatcc tgctactgac agtcaaaaga agccttccca 180  
gatgaaattt tagtctcttg cgagccatg ctcttcttcc agcaaaagag ccatgtgcag 240  
tcgggtctgc tcccatggg ggctttgatg tgggcccagc agtggatcag ccttccagac 300  
acgtcaact ctgcacactc ttcttgcgc ctcaggcttt ccaggaccct cccgagcctt 360  
atcagagtcc ttaccctcag ggctactgat accttgcctg gtgacctgg acagattcac 420  
ttacctggac tcagtttcat aatatgaaaa tgatagggtt g 461

<210> 177  
<211> 234  
<212> DNA  
<213> Homo sapiens

<400> 177  
acacattttg taattacctt ttttgttgtt ttgtagcaac catttgtaaa acattccaaa 60  
taattccaca gtctgaagc agcaatcgaa tccctttctc acttttggaa ggtgactttt 120  
caccttaatg catattcccc tctccataga ggagagggaaa aggtgtaggc ctgccttacc 180  
gagagccaaa cagagccag ggagactcgg ctgtgggaaa cctcattgtt ctgt 234

<210> 178  
<211> 657  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(657)  
<223> n=A,T,C or G

<400> 178  
gagctcgan ccctagtaac ggccgcccagg gtgctggat gngcccttgc gagcgnngncg 60  
cccgggcagg nacttttnatc cccctcatc ttctgttagc tcatttgtnt ctctcatttt 120  
ttggcatatt tttcaagtca cacttaaaaa ctcttccatg tattcaactc tcatcacttg 180  
gtctacatgc cgaacctaa gtcaggatc caaaaagatg agtatcctc caaacgcctc 240  
ctaagcctct ggtatacatg actttggctg tgcacttcat ttagacttca cctttttgtt 300  
tgctgttgtt ttttactacta gattcctttg tcttcattaa agataatgaa agattcacat 360  
cacagtgcag ctcttcgctt tgtcctttcg taagtcgta gcaactgccg agagttcttg 420  
tctgctaggc atgtgtgaaa tccgctttgt ggctctctgt gatttgttcc gcttaacgtt 480  
tttatttgc ttatttacac atgccaaagg ggcaacgtga aaaatgtctc tgacgtatt 540  
ttccgactgt aaagctgagc attcgatata agtagctgct ccaatctgtt tggccatact 600  
tgccccctgg tcataggaca ctggcgtctg cctgtgattg gagagctcta ctaatgt 657

<210> 179  
<211> 182  
<212> DNA  
<213> Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(182)

&lt;223&gt; n=A,T,C or G

&lt;400&gt; 179

```

acaaaanctt ttaaatttta tattattttg aaactttgct ttgggtttgt ggcaccctgg 60
ccaccccatc tggctgtgac agcctctgca gtccgtgggc tggcagtttg ttgatctttt 120
aagtttcctt ccctaccag tccccathtt ctggttaagg ttctaggagg tctgttaggt 180
gt 182

```

&lt;210&gt; 180

&lt;211&gt; 525

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 180

```

acacgctttt ggccccgacc aatgaggcct tcgagaagat ccctagttag actttgaacc 60
gtatcctggg cgaccagaa gccctgagag acctgctgaa caaccacatc ttgaagtcag 120
ctatgtgtgc tgaagccatc gttgcggggc tgtctgtaga gacctggag ggcatgacac 180
tggaggtggg ctgcagcggg gacatgctca ctatcaacgg gaaggcgatc atctccaata 240
aagacatcct agccaccaac ggggtgatcc actacattga tgagctactc atcccagact 300
cagccaagac actatttgaa ttggctgcag agtctgatgt gtccacagcc attgaccttt 360
tcagacaagc cggcctcggc aatcatctct ctggaagtga gcggttgacc ctcttggttc 420
ccctgaattc tgtattcaaa gatggaaccc ctccaattga tgcccataca aggaatttgc 480
ttcgaacca cataattaaa gaccagctgg cctctaagta tctgt 525

```

&lt;210&gt; 181

&lt;211&gt; 444

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 181

```

acaccacaat gtgcatcaag gagacgtgcc gattgattcc tgcagtcccg tccatttcca 60
gagatctcag caagecactt accttcccag atggatgcac attgcctgca gggatcaccg 120
tggttcttag tatttggggt cttcaccaca atcctgtgtg ctggaaaaac ccaaaggtct 180
ctgacctctt gaggttctct caggagaatt ctgatcagag acacctctat gcctacttac 240
cattctcagc tggatcaagg aactgcattg ggcaggagtt tgccatgatt gagttaagg 300
taaccattgc cttgattctg ctccacttca gactgactcc agacccacc aggcctctta 360
ctttcccaa ccatatttat ctcaagccca agaatgggat gtatttgcac ctgaagaaac 420
tctctgaatg ttagatctca ggg 444

```

&lt;210&gt; 182

&lt;211&gt; 441

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 182

```

acaaccttta ttgcttctcc agcattttcc agaagaatgg tgcattaga gggccacagg 60
ggatggggga gtaaaaaata acataaacga actgaacaga aatgcaggag ggtggcaaga 120
ggggccgaga ttgggtgttc agggcagaga ggtggaagac caggggcagt cagtgttct 180
tagctttcag ccaccagagt ggagaattcg tcaaccccaa ttttgccgtc cccatctttg 240
tctccagcag ccatcagcat cttggtttct ttagcagaca ggtctctggc atctggggag 300
aagcctttta ggatgaatcc cagctcatcc tctcgatga agccactttg tccttggtcca 360
gcatgtgaaa caccttcttc acatcatccg cactcttttt cttcaggccg accatttggg 420
agaacttttt gtggctgaag g 441

```

<210> 183  
<211> 339  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(339)  
<223> n=A,T,C or G

<400> 183  
tgtntcatcn taaggggatt gggctctaga tctgtcgacg ggcattgag gatttgcnat 60  
cggttangtg gtccgcgagt catgaatttt tgctctggag cgttattgtt tgtgaagttt 120  
atccaggaga gaactatgat tgtgtcgatg cgtttactgc aggaagantc acgggtctcag 180  
tcacggaggt gtaaggggtg actgactgan tgagacaagg gatatntngt tnttatannc 240  
ttgtgatgaa cctgcctacc gtttatgtct ctttgctaat gggctctcng tncgtgnatt 300  
cncncaagct gcgggggctt ccncgggtctt gggctctga 339

<210> 184  
<211> 490  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(490)  
<223> n=A,T,C or G

<400> 184  
atatagcaag cttgtacgac cgacacatac ggcgcattgt gctggattgc ttatcttgtc 60  
gcgcgacgtc tatataancg anactacata gtctcggaaa tccactcant ttcaagttcc 120  
caaaanacng ganaaaaacc catgccttat ttaactaanc atcagctcgc ttctccttct 180  
gtaaccgcgc ttntngctcc cagcctatag aagggtaaaa ccacactcgc tgcgncagtc 240  
atcnataaac tgattcgccc gggactgcc gggcggcgct cganaccaat tngcanaatt 300  
cacacattgc ggcgctcnan aagctctaga aggccaatcg ccatattgat ctatacatta 360  
tgcccgctgt tnacacgtcg tgacgggana ncctggngta ccattaatcg ctgcacantc 420  
ccttcgcagc tggggtntac aaaagccgcc catcnctcca cgttgcgncc gatggcaagg 480  
acnccctnat 490

<210> 185  
<211> 368  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(368)  
<223> n=A,T,C or G

<400> 185  
ctnnanatag cangcttgta cgaccgacac aatacggcca ntgtgctgga ttcgcttcag 60  
cgccgcccgg gcagtaccgg cgctcatcta tcngatgatg gcgcaccaat gtgggggttt 120  
aaccttttta tatggctggg gacanaaagc gcggttacnn aaccnataac gagctgatgg 180  
tcatttaaaa atgcttgggg ttttcccggc cttttgggga attgaaactg agtgggactt 240

canaaactgt gctacttttcg cttatctaag tactcgcccg caacacctag ccgaatccgc 300  
 anatatcatc acnctgggcg gcgtcancat gcntctaaag ggccaattcn cctanatgag 360  
 tcttatac 368

<210> 186  
 <211> 214  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(214)  
 <223> n=A,T,C or G

<400> 186  
 ngggagatcg cagcttgtag gactcgatc ataacgnnca atgtgctgga tcgcttcanc 60  
 gccgcggcg gtctaactcg gtcgggattn tgtgtgtntt gtctntntta canggtgcta 120  
 tcccttctt cctcctctc tgccatctc atcctttatc tcctttttgg acaagtgtca 180  
 nancagacag angcagggtg gtggcaccgt tgaa 214

<210> 187  
 <211> 630  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(630)  
 <223> n=A,T,C or G

<400> 187  
 cagctgggac gagtcgatca tatacggcgc atgtgttgna tcgctatcgt gtcgggcgag 60  
 tanttattan attactgtta tttctgctcc tactggatat gatctcttga nggcangtct 120  
 gtgtcgtctg gtcacacat gttctcagcg tgggcaaata ccttcctata atagtattatg 180  
 gataatgaat gacgactang tctanaaana cgctagctaa ataacacact cagggaaaga 240  
 gtcttaaata ttgtgaaggt gtttttanta tacaacnttt gtttacataa taggaaataa 300  
 ttttttagact tttaaacaga cacttgagcc agatttgta atgttaccat ctatagtgtc 360  
 ttgaaaatat tcctcttagt ttccaatatg aatgaatcta aaatccatct tttcaattat 420  
 gcccgcccc gtgggtcaatg cncctcnac acttcattaa cggattatac cttgggaaac 480  
 cataatctgg cntaggacga atcgctggc ncangctaan aactgccctg tattgagggg 540  
 ttatnntga ttgcnaggt gcctctccag gtccccaag ggtcgtactg ttgaanctgg 600  
 ctctaanttt ntcttgccn acagggtctc 630

<210> 188  
 <211> 441  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(441)  
 <223> n=A,T,C or G

<400> 188  
 cnnccaanac anggtcggat tccngtgagg naanaattcc ctnatagggc tcgcccccta 60

```

ttcaccaaac caancngaaa ctcttgcggt caaatctaag ctatnncaca accccactct 120
gnagggtatg cgccccgccc ctgcaatgaa atcaatanca tatttgagaga cagagagata 180
gagagagaga gggttcctggc cttnnctatt ctgctcttac ttggnagatn tcaganatag 240
aaaaacctat cctagggtccn nccaatgatn gcggcttneg aatcccgngg tggccantcc 300
ccggatcgga ctaaatcaaa gaagatcctc cgtcttcctg ttcctccaca ctggagtcctc 360
attgtatgca tgggtntttc actggctnat cataccnnag gatctgtcca ccttnaactc 420
ttctctngga antccctncc c 441

```

<210> 189

<211> 637

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)...(637)

<223> n=A,T,C or G

<400> 189

```

aggnggtata taccacttg tacnactcga tcatanacgc gcatntctga atcgcttntc 60
ggcgcgatg tactgtgggc acttaagcac tgagtactgt ttgcgtcatg ccnggtcana 120
agatgctgct gcaaggagac tccaacnaaa tacactgtct tcaacaggag ttaacacctc 180
acacttggtg ganaanagaa ctactgggtg gtgatgcaca cgactgnatc catcaagtgc 240
gtttgcctgt tgactgctaa ccaaggctct ggcagtacct gcccgggcgg cgtcogaaac 300
caaactcgca aatatcatca cactggcggn cgtcagcat catctanaag gccatcgctc 360
atagtgcgtc tatacatcat ggccgcnttt acactcctac tggaaaacct gcgtaccact 420
taatcgcttc acacatcccc ttctcgngtn gcttatancn aaaagcccac gatgcctcca 480
cattgcncnc tgatggcatg anccccctac gcgcataccc gcggtntgtg taccncangt 540
accgtntctg acgtacnctn tcttctctct cctcttcccc ttcctgttcc tcaccattcg 600
gggccttagg tcnatatctc gnccacccaa atntagg 637

```

<210> 190

<211> 653

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)...(653)

<223> n=A,T,C or G

<400> 190

```

agggggtata taccacttg tacgactgna tcatatacgc gcatgtctgg aatcgcttnc 60
gtggctgcc a tgtattgaca ctacttctaa gaactacaaa agtgatactg angatacatt 120
acacagaang gctnacattc tncagatcc tcatttntca tgatatgtgg acatcangan 180
cacgtggata agtgtatcta aanaatggct ttcaaaatat ttccacttta ttaaggtttg 240
acatganatt cataaaatgt cttaatacta tttctnaaaa taacatctaa tcggaaacta 300
tgccnaact gcacnttttn tgtgtanata atcntanttg tacgcccggc ggcgccaaag 360
ccnaatctgc gattctcac ctggcgccgc tcaacatcat ctaaaggcca atcgccata 420
ntantctata cactctggcc gcgtttacac gtctaattgg aaaccggcgt accacttatc 480
gcttgacgca ctecccttcc cactgggtta tacnaagcc gcncgatgcc tcccacattc 540
canctgatgc aatgacctt gtctgcctta ncccgcggtt tgtgtaccca ntnaccacnt 600
cagcgtcgcn cntcttctt ctctcttctt gccttncgt tccctcactc nng 653

```

<210> 191



<211> 663  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(663)  
 <223> n=A,T,C or G

```
<400> 191
angnggtata taccactgt ncgactcgat catatacgcg catgtcggat cggctccanc 60
gcgcggcat gtactatatac tacatcaact gtattatcat ttanatatg atnaagaca 120
aatcatatac tccatctgct cactgatgat aattactatg atacatgatc atgtaaacgt 180
atcaatataa caatggaaga tccctctgac tatgcaagcc taattttcca atencatgca 240
ctctcatagc tcaaanatnt cacngacatc ctgatgaaac tatnatacan tttccacaca 300
aatcacttcg cttagatct ctccattatt ctgtcttttc ccccttaaca actacaaatc 360
ctcntgggat gggaagaata tatatcatct actaaaaata atatataatc ccctgcanat 420
ttgtggnaaa tcnggtgtct caanagccac aggagnacaa gggggnacca actaggactt 480
ttgtatgctt atctctgtac tcgcgcacac ctaagcgatt ctgcnattct ccctggcggc 540
gtcacanctc tanaggccat cncnatatga tctatacatc ntggcgtctt tacactctga 600
cggaaccggt gtnccantta ccctggacca tcccttcgcn ctgntataca aagccccga 660
ncc 663
```

<210> 192  
 <211> 361  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(361)  
 <223> n=A,T,C or G

```
<400> 192
antttttata taccactgg tacaactcga nccatacgg cgcanttneg gaatcanctt 60
cancggcgcc ggcattgtacc ggtnatcacc atcngatgat ggcgctcnaa tgtgggtttt 120
acctnttata cggctgagat canatcgct acataacaaa nncaactgat ggtnaatnta 180
aatnccgttg ggttctcccn ntctgttggg gaacttgana ctgagtngga cntccatana 240
cgtgctattn tcggctanct antcctcagc gnacacctat ngnagtgcgc naattcatcc 300
atgntggcct cgactnttcc aaaangccnt ncgcccacnt gntcgenana cantctcggc 360
c 361
```

<210> 193  
 <211> 314  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(314)  
 <223> n=A,T,C or G

```
<400> 193
aggngnata taccaactgg tncgactcga tccatacgc gcatttcgga ttcgcttcaa 60
cggcgccggc atgtacacaaa cctcaatccc aaccgtctca nttngacggg ctcagttctg 120
tcacagccac cccacatttc tttgttttg tctgccactt caaaagaatt ccaaataaga 180
```

attctgtctgc agctccgtac aaggatatgg gcagcacagc acacacagag tngtgctcct 240  
cacacttctc tggnaatgtc tcgtgaatat ctcaacagtc angaagtggg gcgttatcaa 300  
aaacaatcag ggcc 314

<210> 194  
<211> 550  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(550)  
<223> n=A,T,C or G

<400> 194  
aggngngata taccactg tncgactcga tcctatacgc gcatgtcgga ncgctatgtg 60  
gtcncgcaag tacctcttct gcagtgatgg tctgtntcct ctatgatnag tgatcgaata 120  
atcatcgaat tcancgaaag ttattcgagt gatatntgtg gcttgtagaa tctatgctcc 180  
atgggtgtgt cactgtcaag attaacacag aatggaagan ncngcactgc ataaaagatg 240  
ttgtcaaatt ggggtgcgtt atcngatagc tcntcccaag aggtcantgg tgttcaggat 300  
tncnacataa gatnttggat caccngacga ccagangata ccngtgcaaa ctgtgaancn 360  
ngtaatctgc ctatncctgc cctctcggan gatccctcgg ggacgacgag atcattctgg 420  
aaacagcnan tgatagtcca gtnnangatt gatgancgac ganacgcntg atanatgtct 480  
gacgtgagat tnggatgtga atcttccent gtgtgacctg cncntaccn aanggtgcgn 540  
ctccactcnn 550

<210> 195  
<211> 452  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(452)  
<223> n=A,T,C or G

<400> 195  
nngcgggnat gataccaact ggtacgaact cganctctat nacggcgctn tttcnngatc 60  
tgctatgtgg tctcggcaat gtacattata acngggcana catataatct acntctgtct 120  
ttntctcccc cngagagcgc aancatctcc aaatcgggtt ctgggtcatc caatggctctc 180  
cantaatcac acaactcata tatatttatg gaangtgtct gtcacgtcc ccacgangga 240  
agtnnecgtc ctgtntgtct gtcactaggt gngtactctc cagtacttga aanctggtna 300  
nngctgtctg tngtactggc cggcgccctc gaaancgaat ctgtnnatat catcacatng 360  
cgncgcccga ncatcactna gggncanttc gcctatactg atcgtntgcg annctgcgn 420  
cncttacacg tcgnacggga naccggcctt cc 452

<210> 196  
<211> 429  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(429)  
<223> n=A,T,C or G

```

<400> 196
gcggggnnnat gataccagct ngtagcactc gatcctataa cggcgcatgt gngtatcggc 60
tacgtgtctc ggcatgttac atataacggg gcaacatata atnatacant ctgtcttttt 120
ctcccccgga aacggcaacc atctccaata tcggctctggg tctccaatgg tctccaacta 180
aatcacacaa gtcaaata nttanggaaa gtgtctgtct cntccccaga aggagtancg 240
ttagctgttg tctgtcatta ggttggtacc tccagtnaca tgaaaactgg tgaggggtgtc 300
cttggtacaag ctctgcctca ccagatccta tactattagg gggcccacgg ttatctatct 360
taagggtctn aaaacctgga cttcatctgc tccggcggan gaatgtcccg cttacttacg 420
ntgttccac 429

```

```

<210> 197
<211> 471
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (1)...(471)
<223> n=A,T,C or G

```

```

<400> 197
atgatacgca gctngtacga gccgtcacta tnacggcnca ttgtgtggat tcngetntga 60
tcggcgcccc ggcatgtcca tcnagagcgc atcatgggan tgnactcccc atatnntgac 120
caangttcgc gcaaggagcc naganccgat actacctgag ctgtcgtctn gttatacacg 180
tttctggcca angancaact ccacatncaa caagttggtg ttgaaatgtt gtttatnagt 240
ccaccaaccg gccgtctgtt ccttccccga tgatccgaag ataagcttcc tgtccggaan 300
acgaacggcg tgggtgtgngg acatantgat atgtgcgggt caggaagtac tcgncgcaac 360
ncgcaagcna atctgcnata tcatcacctg gcggcgctcg agctgccana ngcccnttcg 420
cctatatgag tctatacatt cctggcgctc tnttactc ngacgggaaa c 471

```

```

<210> 198
<211> 643
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (1)...(643)
<223> n=A,T,C or G

```

```

<400> 198
tngtncgacc gtcactatac gccatgtgtt ggatccgntc caccggcgccg ggcangtacg 60
anactatatt gatcctctga tattgaaagt tggctctanca ataaccttta angcaaatca 120
ctcantgagt tttgaccaga agtcaccaca tcatgaatca cagtctatgg caaatgatac 180
cagtgctctt aagtcctatg ctcaaggtaa gagcatgcta ttccgtttta catttactgg 240
aatttactgt tcattcatna ttaaaatctc tagttttcat cctcaactgt ctaanaccag 300
tgtgcacaga cttaagactc tgttctcttc attttctcca acagaaacat tctcagtgtc 360
tactgttcta aaaggaatt tccgaggtgg cacttctcgg aatatcgacc ctonggctct 420
atcaggcggtt acttcnngca ctcgctcattt gggcttggtc anttgtctta tctgtccagt 480
cacttcattt taagaaaaca attgatcgct ggtcacatgt nattcattgg cagccgggtgt 540
gactgctgag tctcgcgcac acnctagcaa tcggnattct ccatggngcg tcaactctcta 600
naggccatcc cctatatgat ctataatctg gcgtctttac act 643

```

```

<210> 199

```

<211> 292  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(292)  
<223> n=A,T,C or G

<400> 199  
nccggcnggag ttcgcagttg nacgaccgat cctatacgc gcatttctga tccgctacnt 60  
gtccggcgag tctatgctat ttatttntga ttaaatcaat attttcttc tgaatattaa 120  
tcttatctnt acttttatac tattgaccta gctatatgta ttganctttt tgaactocta 180  
tcagtntttt tcatgctatc gtatattttc cacttgggtac ctntngctga ntcctagata 240  
tcgtaaaaca tctctnnatc ntcacacnga gnccagggt ctgtatngaa tt 292

<210> 200  
<211> 275  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(275)  
<223> n=A,T,C or G

<400> 200  
atacgcaagc ttggtaccga gctnngatcc ctattaaccg gccgcaatat tctggaattc 60  
tgcttanctg ggtcncggcc gaagtactat gctatnttac ttttttggga tataaaatca 120  
atatatttct ttctnaagta tataaatctt atccnctgat cnttcnatac ctntctgaca 180  
ntaagcttat angtatntga tctntgttga actcctatca agtgntttcn catgctatcg 240  
tganntcttc cacnttggtg ccttttacgc tgaat 275

<210> 201  
<211> 284  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(284)  
<223> n=A,T,C or G

<400> 201  
cgnnnatcca gtgtanaccg tcnttacgcg cattctgac gtccacgccc gcgtctttat 60  
atctatctcg actgattcac ctgtcattgt aaanaattcg tgtcagctgt ctaccnctta 120  
nacatcatct aatcnaacta ncctgataaa tttcttcaat agggatanac ntntagtaca 180  
tacgnttcca ttgagntacn tccgcggacc cncatcgcaa acnnatcgcg gtcagtcnna 240  
gcatcctcta tcttaatccg tctttacct ntgaacgctc cact 284

<210> 202  
<211> 448  
<212> DNA  
<213> Homo sapiens

<220>

<221> misc\_feature  
 <222> (1) ... (448)  
 <223> n=A,T,C or G

<400> 202  
 atgatacgca agcttgtagc actcggatca tataacggcc gcaatgtgct ggaattccgc 60  
 ttgcacggac gccgggcagc tacttttata atnctactcc tcagacctg catctcnacc 120  
 gctnnggtcca gtttgtaaaa acnnacttcc gtngtgcagc cctgggtctg ancantctct 180  
 atcacnctct atcctcnat ccncaanact anategcgtg aattcatatt tattcatttt 240  
 ccataatgat gggggaanga ctatcnctna tnatgcttan cacnctngct gcanttcgnc 300  
 natctcgna ngcntgaaac gattactctg tcgcgaaccc tctangntga attctgcnaa 360  
 atatctntna cncctggcngg cgctcnangn atgcctctcg anggccaatc cgccnngcat 420  
 gattctaatt anatccntng gtcccntt 448

<210> 203  
 <211> 321  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1) ... (321)  
 <223> n=A,T,C or G

<400> 203  
 ggggtgcnaga tcgcagtngt acgaatcgnt catatacggc gcatgtgntg antcgctacg 60  
 tgtccggcga ngtagcatat aatcgaanta ncatagttct ggangccnc tcattttcaa 120  
 ttccccaaa nacgggaaaa ccnaagcctt atttaactaa ctatctgctc gcttctcgct 180  
 tctgtaccgc gctatntgct nccagcctat aanaagggtg aaaccacac tcggtgcgctc 240  
 agtctccnat atantgagtc nccgggtact ggccgggcgg tcgttcnaaa ncaattcncg 300  
 aanttacta ctggcggcgc c 321

<210> 204  
 <211> 369  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1) ... (369)  
 <223> n=A,T,C or G

<400> 204  
 ntgtngtatg taccagtggt tacgactcga tcctagtacg gcgcagtggt ctgaatcggt 60  
 acttgctcgc gccaaagtatc tataaagcaa actatcacag ttctgaaagt ccattctcant 120  
 tttagtccc aaaagancgg gaaaacccaa gccttattaa actaacaatc agtcgctctc 180  
 gcttctgtac cgcgcttttg gccccagcc tataaaaggg taaaaccac actcgggtgcg 240  
 ccagtcacgc ataactgaat cgcccgttac tgcccggggc gcgctcnann ccaaactctgc 300  
 agatatcaca cactggcggc gctcancatg ctctagaagg ccaattcncc tatantgatt 360  
 ctattacaa 369

<210> 205  
 <211> 2996  
 <212> DNA  
 <213> Homo sapien

&lt;400&gt; 205

cagccaccgg	agtggatgcc	atctgcaccc	accgccctga	ccccacaggc	cctgggctgg	60
acagagagca	gctgtatttg	gagctgagcc	agctgacca	cagcatcact	gagctgggcc	120
cctacaccct	ggacagggac	agtctctatg	tcaatggttt	cacacagcgg	agctctgtgc	180
ccaccactag	cattcctggg	acccccacag	tggacctggg	aacatctggg	actccagttt	240
ctaaacctgg	tccctcggct	gccagccctc	tccctggtgct	attcactctc	aacttcacca	300
tcaccaacct	gcggtatgag	gagaacatgc	agcacccctg	ctccaggaag	ttcaaacacca	360
cggagagggg	ccttcagggc	ctggtccctg	ttcaagagca	ccagtgttgg	ccctctgtac	420
tctggctgca	gactgacttt	gctcaggcct	gaaaaggatg	ggacagccac	tggagtggat	480
gccatctgca	cccaccaccc	tgaccccaaa	agccctaggc	tggacagaga	gcagctgtat	540
tgggagctga	gccagctgac	ccacaatatc	actgagctgg	gcccctatgc	cctggacaac	600
gacagcctct	ttgtcaatgg	tttcaactcat	cggagctctg	tgtccaccac	cagcactcct	660
gggacccccca	cagtgtatct	gggagcatct	aagactccag	cctcgatatt	tggcccttca	720
gctgccagcc	atctcctgat	actattcacc	ctcaacttca	ccatcactaa	cctgcggtat	780
gaggagaaca	tgtggcctgg	ctccaggaag	ttcaacacta	cagagagggt	ccttcagggc	840
ctgctaaggc	ccttggttcaa	gaacaccagt	gttggccctc	tgtactctgg	ctgcaggctg	900
acctgtgctc	ggccagagaa	agatggggaa	gccaccggag	tggatgccat	ctgcaccac	960
cgccctgacc	ccacaggccc	tgggctggac	agagagcagc	tgtatttggg	gctgagccag	1020
ctgaccacaca	gcatactga	gctgggcccc	tacacactgg	acagggacag	tctctatgtc	1080
aatggtttca	cccatcggag	ctctgtaccc	accaccagca	ccgggggtgg	cagcgaggag	1140
ccattcacac	tgaacttcac	catcaacaac	ctgcgtaca	tggcggacat	gggccaaccc	1200
ggctccctca	agttcaacat	cacagacaac	gtcatgaagc	acctgctcag	tcctttgttc	1260
cagaggagca	gcctgggtgc	acggtacaca	ggctgcaggg	tcategcact	aaggctctgtg	1320
aagaacgggtg	ctgagacacg	ggtggacctc	ctctgcacct	acctgcagcc	cctcagcggc	1380
ccaggctctgc	ctatcaagca	ggtgttccat	cagatggacc	agcagacca	tggcatcacc	1440
cggtcggggc	cctactctct	ggacaaagac	agcctctacc	ttaacggtta	caatgaacct	1500
ggtccagatg	agcctcctac	aactcccaag	ccagccacca	cattcctgcc	tcctctgtca	1560
gaagccacaa	cagccatggg	gtaccacctg	aagaccctca	cactcaactt	caccatctcc	1620
aatctccagt	attcaccaga	tatgggcaag	ggctcagcta	cattcaactc	caccgagggg	1680
gtccttcagc	acctgctcag	acccttggtt	cagaagagca	gcattggccc	cttctacttg	1740
ggttgccaac	tgatctccct	caggcctgag	aaggatgggg	cagccactgg	tgtggacacc	1800
acctgcacbt	accacctga	ccctgtgggc	cccgggctgg	acatacagca	gctttactgg	1860
gagctgagtc	agctgacca	tgggtgcacc	caactgggct	tctatgtcct	ggacagggat	1920
agcctcttca	tcaatggcta	tgcaccccag	aatttatcaa	tcggggcgga	gtaccagata	1980
aatttccaca	ttgtcaactg	gaacctcagt	aatccagacc	ccacatcctc	agagtacatc	2040
acctgctga	gggacatcca	ggacaaggtc	accacactct	acaaaggcag	tcaactacat	2100
gacacattcc	gcttctgcct	ggtcaccaac	ttgacgatgg	actccgtgtt	ggtcactgtc	2160
aaggcattgt	tctcctccaa	tttggacccc	agcctgggtg	agcaagtctt	tctagataag	2220
acctgaatg	cctcattcca	ttggctgggc	tccacctacc	agttggtgga	catccatgtg	2280
acagaaatgg	agtcacagt	ttatcaacca	acaagcagct	ccagcaccca	gcacttctac	2340
ctgaatttca	ccatcaccaa	cctaccatat	tcccaggaca	aagcccagcc	aggcaccacc	2400
aattaccaga	ggaacaaaag	gaatattgag	gatgcgctca	accaactctt	ccgaaacagc	2460
agcatcaaga	gttatttttc	tgaactgtcaa	gtttcaacat	tcaggctctgt	ccccaacagg	2520
caccacaccg	gggtggactc	cctgtgtaac	ttctcgccac	tggctcggag	agtagacaga	2580
gttgccatct	atgaggaatt	tctgcggatg	accgggaatg	gtacccagct	gcagaacttc	2640
acctgggaca	ggagcagtgt	ccttggtggat	gggtattttc	ccaacagaaa	tgagccctta	2700
actgggaatt	ctgaccttcc	cttctgggct	gtcactctca	tcggcttggc	aggactcctg	2760
ggactcatca	catgcctgat	ctgcggtgtc	ctggtgacca	cccgcggcg	gaagaaggaa	2820
ggagaataca	acgtccagca	acagtaccac	ggctactacc	agtcacacct	agacctggag	2880
gactctgcaat	gactggaact	tgcgggtgcc	tggggtgctt	ttccccagc	cagggtccaa	2940
agaagcttgg	ctggggcaga	aataaacctt	attggtcgga	cacaaaaaaa	aaaaaa	2996

&lt;210&gt; 206

&lt;211&gt; 914

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

<400> 206  
Met Ser Met Val Ser His Ser Gly Ala Leu Cys Pro Pro Leu Ala Phe  
1 5 10 15  
Leu Gly Pro Pro Gln Trp Thr Trp Glu His Leu Gly Leu Gln Phe Leu  
20 25 30  
Asn Leu Val Pro Arg Leu Pro Ala Leu Ser Trp Cys Tyr Ser Leu Ser  
35 40 45  
Thr Ser Pro Ser Pro Thr Cys Gly Met Arg Arg Thr Cys Ser Thr Leu  
50 55 60  
Ala Pro Gly Ser Ser Thr Pro Arg Arg Gly Ser Phe Arg Ala Trp Ser  
65 70 75 80  
Leu Phe Lys Ser Thr Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu  
85 90 95  
Thr Leu Leu Arg Pro Glu Lys Asp Gly Thr Ala Thr Gly Val Asp Ala  
100 105 110  
Ile Cys Thr His His Pro Asp Pro Lys Ser Pro Arg Leu Asp Arg Glu  
115 120 125  
Gln Leu Tyr Trp Glu Leu Ser Gln Leu Thr His Asn Ile Thr Glu Leu  
130 135 140  
Gly Pro Tyr Ala Leu Asp Asn Asp Ser Leu Phe Val Asn Gly Phe Thr  
145 150 155 160  
His Arg Ser Ser Val Ser Thr Thr Ser Thr Pro Gly Thr Pro Thr Val  
165 170 175  
Tyr Leu Gly Ala Ser Lys Thr Pro Ala Ser Ile Phe Gly Pro Ser Ala  
180 185 190  
Ala Ser His Leu Leu Ile Leu Phe Thr Leu Asn Phe Thr Ile Thr Asn  
195 200 205  
Leu Arg Tyr Glu Glu Asn Met Trp Pro Gly Ser Arg Lys Phe Asn Thr  
210 215 220  
Thr Glu Arg Val Leu Gln Gly Leu Leu Arg Pro Leu Phe Lys Asn Thr  
225 230 235 240  
Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr Leu Leu Arg Pro  
245 250 255  
Glu Lys Asp Gly Glu Ala Thr Gly Val Asp Ala Ile Cys Thr His Arg  
260 265 270  
Pro Asp Pro Thr Gly Pro Gly Leu Asp Arg Glu Gln Leu Tyr Leu Glu  
275 280 285  
Leu Ser Gln Leu Thr His Ser Ile Thr Glu Leu Gly Pro Tyr Thr Leu  
290 295 300  
Asp Arg Asp Ser Leu Tyr Val Asn Gly Phe Thr His Arg Ser Ser Val  
305 310 315 320  
Pro Thr Thr Ser Thr Gly Val Val Ser Glu Glu Pro Phe Thr Leu Asn  
325 330 335  
Phe Thr Ile Asn Asn Leu Arg Tyr Met Ala Asp Met Gly Gln Pro Gly  
340 345 350  
Ser Leu Lys Phe Asn Ile Thr Asp Asn Val Met Lys His Leu Leu Ser  
355 360 365  
Pro Leu Phe Gln Arg Ser Ser Leu Gly Ala Arg Tyr Thr Gly Cys Arg  
370 375 380  
Val Ile Ala Leu Arg Ser Val Lys Asn Gly Ala Glu Thr Arg Val Asp  
385 390 395 400  
Leu Leu Cys Thr Tyr Leu Gln Pro Leu Ser Gly Pro Gly Leu Pro Ile  
405 410 415  
Lys Gln Val Phe His Glu Leu Ser Gln Gln Thr His Gly Ile Thr Arg  
420 425 430  
Leu Gly Pro Tyr Ser Leu Asp Lys Asp Ser Leu Tyr Leu Asn Gly Tyr  
435 440 445  
Asn Glu Pro Gly Pro Asp Glu Pro Pro Thr Thr Pro Lys Pro Ala Thr

450 455 460  
 Thr Phe Leu Pro Pro Leu Ser Glu Ala Thr Thr Ala Met Gly Tyr His  
 465 470 475 480  
 Leu Lys Thr Leu Thr Leu Asn Phe Thr Ile Ser Asn Leu Gln Tyr Ser  
 485 490 495  
 Pro Asp Met Gly Lys Gly Ser Ala Thr Phe Asn Ser Thr Glu Gly Val  
 500 505 510  
 Leu Gln His Leu Leu Arg Pro Leu Phe Gln Lys Ser Ser Met Gly Pro  
 515 520 525  
 Phe Tyr Leu Gly Cys Gln Leu Ile Ser Leu Arg Pro Glu Lys Asp Gly  
 530 535 540  
 Ala Ala Thr Gly Val Asp Thr Thr Cys Thr Tyr His Pro Asp Pro Val  
 545 550 555 560  
 Gly Pro Gly Leu Asp Ile Gln Gln Leu Tyr Trp Glu Leu Ser Gln Leu  
 565 570 575  
 Thr His Gly Val Thr Gln Leu Gly Phe Tyr Val Leu Asp Arg Asp Ser  
 580 585 590  
 Leu Phe Ile Asn Gly Tyr Ala Pro Gln Asn Leu Ser Ile Arg Gly Glu  
 595 600 605  
 Tyr Gln Ile Asn Phe His Ile Val Asn Trp Asn Leu Ser Asn Pro Asp  
 610 615 620  
 Pro Thr Ser Ser Glu Tyr Ile Thr Leu Leu Arg Asp Ile Gln Asp Lys  
 625 630 635 640  
 Val Thr Thr Leu Tyr Lys Gly Ser Gln Leu His Asp Thr Phe Arg Phe  
 645 650 655  
 Cys Leu Val Thr Asn Leu Thr Met Asp Ser Val Leu Val Thr Val Lys  
 660 665 670  
 Ala Leu Phe Ser Ser Asn Leu Asp Pro Ser Leu Val Glu Gln Val Phe  
 675 680 685  
 Leu Asp Lys Thr Leu Asn Ala Ser Phe His Trp Leu Gly Ser Thr Tyr  
 690 695 700  
 Gln Leu Val Asp Ile His Val Thr Glu Met Glu Ser Ser Val Tyr Gln  
 705 710 715 720  
 Pro Thr Ser Ser Ser Thr Gln His Phe Tyr Leu Asn Phe Thr Ile  
 725 730 735  
 Thr Asn Leu Pro Tyr Ser Gln Asp Lys Ala Gln Pro Gly Thr Thr Asn  
 740 745 750  
 Tyr Gln Arg Asn Lys Arg Asn Ile Glu Asp Ala Leu Asn Gln Leu Phe  
 755 760 765  
 Arg Asn Ser Ser Ile Lys Ser Tyr Phe Ser Asp Cys Gln Val Ser Thr  
 770 775 780  
 Phe Arg Ser Val Pro Asn Arg His His Thr Gly Val Asp Ser Leu Cys  
 785 790 795 800  
 Asn Phe Ser Pro Leu Ala Arg Arg Val Asp Arg Val Ala Ile Tyr Glu  
 805 810 815  
 Glu Phe Leu Arg Met Thr Arg Asn Gly Thr Gln Leu Gln Asn Phe Thr  
 820 825 830  
 Leu Asp Arg Ser Ser Val Leu Val Asp Gly Tyr Phe Pro Asn Arg Asn  
 835 840 845  
 Glu Pro Leu Thr Gly Asn Ser Asp Leu Pro Phe Trp Ala Val Ile Leu  
 850 855 860  
 Ile Gly Leu Ala Gly Leu Leu Gly Leu Ile Thr Cys Leu Ile Cys Gly  
 865 870 875 880  
 Val Leu Val Thr Thr Arg Arg Arg Lys Lys Glu Gly Glu Tyr Asn Val  
 885 890 895  
 Gln Gln Gln Cys Pro Gly Tyr Tyr Gln Ser His Leu Asp Leu Glu Asp  
 900 905 910  
 Leu Gln



<210> 207  
<211> 2627  
<212> DNA  
<213> Homo sapiens

<400> 207  
ccacgcgtcc gccacgcgt ccggaaggca ggggcagctc cactcagcca gtaccagat 60  
acgctgggaa ccttccccag ccatggcttc cctggggcag atcctcttct ggagcataat 120  
tagcatcatc attattcttg ctggagcaat tgcactcatc attggctttg gtatttcagg 180  
gagacactcc atcacagtca ctactgtcgc ctgagctggg aacattgggg aggatggaat 240  
cctgagctgc acttttgaac ctgacatcaa actttctgat atcgtgatac aatggctgaa 300  
ggaaggtgtt ttaggcttgg tccatgagtt caaagaaggc aaagatgagc tgtcggagca 360  
ggatgaaatg ttcagaggcc ggacagcagt gtttgcctgat caagtgatag ttggcaatgc 420  
ctctttgcgg ctgaaaaacg tgcaactcac agatgctggc acctacaaat gttatatcat 480  
cacttctaaa ggcaagggga atgctaacct tgagtataaa actggagcct tcagcatgcc 540  
ggaagtgtta gtggactata atgccagctc agagaccttg cgggtgtgagg ctccccgatg 600  
gttccccag cccacagtgg tctgggcata ccaagttgac caggagacca acttctcggg 660  
agtctccaat accagctttg agctgaactc tgagaatgtg accatgaagg ttgtgtctgt 720  
gctctacaat gttacgatca acaacacata ctctgtatg attgaaaatg acattgccaa 780  
agcaacaggg gatatacaag tgacagaatc ggagatcaaa aggcggagtc acctacagct 840  
gctaaactca aaggcttctc tgtgtgtctc ttctttcttt gccatcagct gggcacttct 900  
gcctctcagc ccttacctga tgctaaaata atgtgccttg gccacaaaaa agcatgcaaa 960  
gtcattgtta caacagggat ctacagaact atttcaccac cagatatgac ctagttttat 1020  
atttctggga ggaaatgaat tcatactctag aagtctggag tgagcaaaca agagcaagaa 1080  
acaaaaagaa gccaaaagca gaaggtctca atatgaacaa gataaatcta tcttcaaaga 1140  
catattagaa gttgggaaaa taattcatgt gaactagaca agtgtgttaa gagtgataag 1200  
taaaatgcac gtggagacaa gtgcatcccc agatctcagg gacctcccc tgctgtcac 1260  
ctggggagtg agaggacagg atagtgcagt ttctttgtct ctgaattttt agttatatgt 1320  
gctgtaatgt tgctctgagg aagcccctgg aaagtctatc ccaacatata cacatcttat 1380  
attccacaaa ttaagctgta gtatgtacct taagacgctg ctaattgact gccacttcgc 1440  
aactcagggg cggctgcatt ttagtaatgg gtcaaatgat tcacttttta tgatgcttcc 1500  
aaaggtgcct tggcttctct tcccaactga caaatgccaa agttgagaaa aatgatcata 1560  
attttagcat aaacagagca gtgcggcaga ccgattttat aaataaactg agcaccttct 1620  
ttttaacaa acaaatgcgg gtttatttct cagatgatgt tcatccgtga atgggtccagg 1680  
gaaggacctt tcaccttgac tatatggcat tatgtcatca caagctctga ggcttctcct 1740  
ttccatcctg cgtggacagc taagacctca gttttcaata gcatctagag cagtgggact 1800  
cagctggggg gatttcgccc cccatctccg ggggaatgtc tgaagacaat tttggttacc 1860  
tcaatgaggg agtggaggag gatacagtgc tactaccaac tagtggataa aggccaggga 1920  
tgctgtctca cctcctacca tgtacaggac gtctcccat tacaactacc caatccgaag 1980  
tgtcaactgt gtcaggacta agaaaacctg gttttgagta gaaaagggcc tggaaaaggg 2040  
ggagccaaca aatctgtctg ctctctcaca ttagtcattg gcaaataagc attctgtctc 2100  
tttggctgct gcctcagcac agagagccag aactctatcg ggcaccagga taacatctct 2160  
cagtgaacag agttgacaag gcctatggga aatgcctgat gggattatct tcagcttgtt 2220  
gagcttctaa gtttctttcc ctctattcta ccttgcaagc caagttctgt aagagaaatg 2280  
cctgagttct agctcaggtt ttcttactct gaatttagat ctccagaccc ttcttgcca 2340  
caattcaaat taaggcaaca aacataatcc ttccatgaag cacacacaga cttttgaaag 2400  
caaggacaat gactgcttga attgagacct tgaggaatga agctttgaag gaaaagaata 2460  
ctttgtttcc agccccctt ccacactctt catgtgttaa ccaactgcct cctggacctt 2520  
ggagccacgg tgactgtatt acatgttgtt atagaaaact gattttagag ttctgatcgt 2580  
tcaagagaat gattaaatat acatttctta caccacaaaa aaaaaaa 2627

<210> 208  
<211> 282  
<212> PRT  
<213> Homo sapiens

&lt;400&gt; 208

Met Ala Ser Leu Gly Gln Ile Leu Phe Trp Ser Ile Ile Ser Ile Ile  
                                   5                                  10                                  15

Ile Ile Leu Ala Gly Ala Ile Ala Leu Ile Ile Gly Phe Gly Ile Ser  
                                   20                                  25                                  30

Gly Arg His Ser Ile Thr Val Thr Thr Val Ala Ser Ala Gly Asn Ile  
                                   35                                  40                                  45

Gly Glu Asp Gly Ile Leu Ser Cys Thr Phe Glu Pro Asp Ile Lys Leu  
                                   50                                  55                                  60

Ser Asp Ile Val Ile Gln Trp Leu Lys Glu Gly Val Leu Gly Leu Val  
                                   65                                  70                                  75                                  80

His Glu Phe Lys Glu Gly Lys Asp Glu Leu Ser Glu Gln Asp Glu Met  
                                   85                                  90                                  95

Phe Arg Gly Arg Thr Ala Val Phe Ala Asp Gln Val Ile Val Gly Asn  
                                   100                                  105                                  110

Ala Ser Leu Arg Leu Lys Asn Val Gln Leu Thr Asp Ala Gly Thr Tyr  
                                   115                                  120                                  125

Lys Cys Tyr Ile Ile Thr Ser Lys Gly Lys Gly Asn Ala Asn Leu Glu  
                                   130                                  135                                  140

Tyr Lys Thr Gly Ala Phe Ser Met Pro Glu Val Asn Val Asp Tyr Asn  
                                   145                                  150                                  155                                  160

Ala Ser Ser Glu Thr Leu Arg Cys Glu Ala Pro Arg Trp Phe Pro Gln  
                                   165                                  170                                  175

Pro Thr Val Val Trp Ala Ser Gln Val Asp Gln Gly Ala Asn Phe Ser  
                                   180                                  185                                  190

Glu Val Ser Asn Thr Ser Phe Glu Leu Asn Ser Glu Asn Val Thr Met  
                                   195                                  200                                  205

Lys Val Val Ser Val Leu Tyr Asn Val Thr Ile Asn Asn Thr Tyr Ser  
                                   210                                  215                                  220

Cys Met Ile Glu Asn Asp Ile Ala Lys Ala Thr Gly Asp Ile Lys Val  
                                   225                                  230                                  235                                  240

Thr Glu Ser Glu Ile Lys Arg Arg Ser His Leu Gln Leu Leu Asn Ser  
                                   245                                  250                                  255

Lys Ala Ser Leu Cys Val Ser Ser Phe Phe Ala Ile Ser Trp Ala Leu  
                                   260                                  265                                  270

Leu Pro Leu Ser Pro Tyr Leu Met Leu Lys  
                                   275                                  280

&lt;210&gt; 209

&lt;211&gt; 309

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 209

His Ala Ser Ala His Ala Ser Gly Arg Gln Arg Gln Leu His Ser Ala  
                                   5                                  10                                  15

Ser Thr Gln Ile Arg Trp Glu Pro Ser Pro Ala Met Ala Ser Leu Gly  
                                   20                                  25                                  30

Gln Ile Leu Phe Trp Ser Ile Ile Ser Ile Ile Ile Ile Leu Ala Gly  
                                   35                                  40                                  45

Ala Ile Ala Leu Ile Ile Gly Phe Gly Ile Ser Gly Arg His Ser Ile  
                                   50                                  55                                  60

Thr Val Thr Thr Val Ala Ser Ala Gly Asn Ile Gly Glu Asp Gly Ile  
   65                                  70                                  75                                  80

Leu Ser Cys Thr Phe Glu Pro Asp Ile Lys Leu Ser Asp Ile Val Ile  
                                   85                                  90                                  95

Gln Trp Leu Lys Glu Gly Val Leu Gly Leu Val His Glu Phe Lys Glu  
                                   100                                  105                                  110

Gly Lys Asp Glu Leu Ser Glu Gln Asp Glu Met Phe Arg Gly Arg Thr  
                                   115                                  120                                  125

Ala Val Phe Ala Asp Gln Val Ile Val Gly Asn Ala Ser Leu Arg Leu  
   130                                  135                                  140

Lys Asn Val Gln Leu Thr Asp Ala Gly Thr Tyr Lys Cys Tyr Ile Ile  
  145                                  150                                  155                                  160

Thr Ser Lys Gly Lys Gly Asn Ala Asn Leu Glu Tyr Lys Thr Gly Ala  
                                   165                                  170                                  175

Phe Ser Met Pro Glu Val Asn Val Asp Tyr Asn Ala Ser Ser Glu Thr  
                                   180                                  185                                  190

Leu Arg Cys Glu Ala Pro Arg Trp Phe Pro Gln Pro Thr Val Val Trp  
                                   195                                  200                                  205

Ala Ser Gln Val Asp Gln Gly Ala Asn Phe Ser Glu Val Ser Asn Thr  
                                   210                                  215                                  220

Ser Phe Glu Leu Asn Ser Glu Asn Val Thr Met Lys Val Val Ser Val  
  225                                  230                                  235                                  240

Leu Tyr Asn Val Thr Ile Asn Asn Thr Tyr Ser Cys Met Ile Glu Asn  
                                   245                                  250                                  255

Asp Ile Ala Lys Ala Thr Gly Asp Ile Lys Val Thr Glu Ser Glu Ile  
                                   260                                  265                                  270

Lys Arg Arg Ser His Leu Gln Leu Leu Asn Ser Lys Ala Ser Leu Cys  
                                   275                                  280                                  285

Val Ser Ser Phe Phe Ala Ile Ser Trp Ala Leu Leu Pro Leu Ser Pro  
 290 295 300

Tyr Leu Met Leu Lys  
 305

<210> 210  
 <211> 742  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(742)  
 <223> n=A,T,C or G

<400> 210  
 cattgggtac gggccccctc gagtcgacgt atcgataagc ttgatatcga attcgggcacg 60  
 aggccccgacc gctccctgag agccagcaac gggcagtgat gtttagcccc gaggaataat 120  
 tacatgcgga atggaaagca ggcgctcagg gtggctcctg ctggaatgag agctggagtg 180  
 caggctccgt ggttcctggg catgcgggtg tggctcagtt ctcacctgc agatggagtg 240  
 ggactgttga cccaggccag cctggggact gcctcctcac ctccctgcgc aggtgacct 300  
 tgtcaccttg cctcttgagc ttgcctctct cctgcccaga ngctcttga gcaaatgga 360  
 ggtcgagagg catttggcac tcacgcctca ccacggacac tgggtgcatc ttgggtacct 420  
 cttggcctca atctattgct gggggangga ngactganc ccattgctgg ggccctgaat 480  
 gcagggactg taaccaccca tcccctctc agggcacctc tccctctcca gcacncttgc 540  
 tttgctatta atgtaccta atttctact gangtggctc agaagctcct ccgccattgc 600  
 ccttgccgcc agcaaatttt tatccctagg gttaagataa cagaaggcan ccttgggcct 660  
 tgcctgccac attctcaggt ntncactgaa gcacagtatc tatttctcca aaaatagggg 720  
 ctgtnaactt gttactaccc cc 742

<210> 211  
 <211> 946  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(946)  
 <223> n=A,T,C or G

<400> 211  
 ggcacgaggc acatcgctgg atttctcatt gccaaagtctc attaatcat tctttttcat 60  
 aacctcttat tcttatttca tggatgcaac attttctttg tctctcaggg aataataatt 120  
 attctactt ttaaaggtct aatttcttta ttactttatt tctctgggag tgagtttttc 180  
 ctaaagggat aatgagatgg aaaatgaaaa aacaaagttg agacatggag ataccttctg 240  
 aaactcaagc attcctctac gtggatgtgc cagagggaaa gaacagaaca aaggagggtg 300  
 gacactattt aaataaaaa atataagaat attacataac aaacaaaaaa gcccaaatcc 360  
 tcaggttgaa aaggaggaga aaatgtcaag caagacaaaa acagatgaag caaccaaaa 420  
 agtgacatag ctgggtcacct atattgaaat ttcagaacat gagtgataaa ggactcccag 480  
 aaaaaaaca aacccaaact aaaaaacaga aaaaaaggac tttaccacn aaaacttgan 540  
 gaatcaggaa gactcagtct ctcattaaga aaantgctat aggggatggg ggcaaggcct 600  
 tcaaagtngc aggggatacc aataacctct ctgaagtttt ggaacttcat actccaaat 660  
 ngaatttttg tttgaatagc cccggttagg ggccaatttt aggacttaga aaggaccng 720  
 gnaaatcatt ccnncttgc ccccccgaa agaaattaat agaaggggtt tattcccgcc 780  
 attannaaaa aaggaatcca ggaattnccg nttttttcca gtgttangnt gggngtgan 840

aaactgaggg cttagcaagg gcggnattaa ccaccnnggg tcccacccca aaantggngng 900  
gggtgggccc caaattcggg nttntnctt ttaangcgtt aaaccc 946

<210> 212  
<211> 610  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(610)  
<223> n=A,T,C or G

<400> 212  
ggcaccgaggt ttctggctgg agcctcggac actggctcac tgcagttggt ggtgtcgaca 60  
gtggtangag ggcaaccagt aacgggagct tctcctgccaggaggaga cgagtagaag 120  
ggagcggcat gctggaggct ggagcctgag ccctcggggc tcgccttgct gtgtttggtg 180  
gtgacgtggg acactgcagc tcggccagag tggtaaaaaa tgcctggtg tacgcttttc 240  
tggttttgcc cgtctatctg ctccaagcca ggctgganga ngagganaag gaatcacctg 300  
tggtacgtg gagcctgcat gtggcgtgac tctgcaactc gcctcgtgtg actgatggca 360  
gccacggaga ctgcagctcg acagggagtg aggccttctca ntggcttgaa agctcagctg 420  
actcccacga aatttgccgg aaactcaagg ctgtcagtg cnttcgtggc gccaaagactt 480  
aancangcgc gttgcatgca tccggccagt gtctgtgcc cgtgccctga cnccaccttg 540  
anataancac ccggaacgcg cncgcgcgag gccgcgcgca cagncceggg cancaacttg 600  
gctggcttcc 610

<210> 213  
<211> 438  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(438)  
<223> n=A,T,C or G

<400> 213  
ccganagcgg tttaaacggg ccctctagac tcgagcgggc gccctttttt tttttttttg 60  
aaataaattt ctagattatt tattacataa gcagaccact gaaacattta ttcaaaaagta 120  
ttccattgag agtcaaaaac atattgatat gattattatt ggtctgttaa agaaaacaaa 180  
ataaaaagaa caaactggga attatcaata aacaaatcaa aacttagatg taattataac 240  
ctaaagggct cacagggcaa atgtgaagca agcttctgtc tcagagcctg catatggaag 300  
acatgtagta cttagctttg gcattcttct ttccctctct tgggtgagtt taagtattaa 360  
taaaagggtg actgagaaaa ccttttttta caatcttatg ggtattttt agtggaacg 420  
ttttaagat aggaatat 438

<210> 214  
<211> 906  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(906)  
<223> n=A,T,C or G

&lt;400&gt; 214

```

gccctctaga tcgngcggcc gccctttttt tttttttttt gaaataaatt tctagattat 60
ttattacata agcagaccac tgaaacattt attcaaaagt attccattga gagtcaaaaa 120
catattgata tgattattat tggctctgta aagaaaacaa aataaaaaga acaaactggg 180
aattatcaat aaacaaatca aaacttagat gtaattataa cctaaagggc tcacagggca 240
aatgtgaagc aagcttctgt ctgagagcct gcatatggaa gacatgtagt acttagcttt 300
gncatctttc tttcctcttc ttgnttgagt ttagtattaa taaaagttgg actgagaaaa 360
ccttttttta caatcttatg ggttattttt agtggaaacg tttagaagta gaatatacat 420
attaaaactg cncagaacaa atgnggtgca tctcaaatgg nggtccattt tcaaaatatg 480
aacacatatg ggcagcantt ttttttttaa aaagtcagaa ggggcctnct catgcccctt 540
tccacttctt cactcattgg nccttcaacc caagcttaac tactntcctg acctccaaca 600
tcataaacta gtttccnagc tttgaaactt ttttccaatg agtcntaccg gaatagatgn 660
tcacagaanc ctcttaaaaa ttttggaacc tgcccgggnt ntaaaaaggg tgcaataaac 720
ccaccaacat cttggctggg ggggcagggg ccaaaagaan ttcccaaac cgtttttgat 780
naaaaaaggg gacttttgaa aaaaaatta aaatttttgc cagnaaagca tgggnccccc 840
cccttgaana aaccccctgc atnaaaccaa cnttntggga ntttttngg tanggttttt 900
ctggct                                     906

```

&lt;210&gt; 215

&lt;211&gt; 312

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(312)

&lt;223&gt; n=A,T,C or G

&lt;400&gt; 215

```

ggcacgagga aaccaggttg gctgggtttt ggggtgtaac ttáaaatga caatcagcat 60
gagctggccg tgggctgtgg gggttgtagg ggcattcttg taagggaacc ctgcctcagt 120
ccctctctgt tctggtgggg aggacaagga gggccaatag gggccaatag ggaggctgct 180
gctaggangg tttcctaaaa gaacaggtgt agggctaggg ctggttctta gttcaggttg 240
ctctgggcag tgatttatat ccacacacct ttctgcaaag tgtcctaagg aganggcagg 300
gataggagtg tc                                     312

```

&lt;210&gt; 216

&lt;211&gt; 341

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(341)

&lt;223&gt; n=A,T,C or G

&lt;400&gt; 216

```

taagcctntc gaanataatg aatgagtcn ggagaggctn atgangaaat nccaaacacc 60
tgactaatng gtgccacatg attncaatgg nctanacatg ggtagatct cntcngngga 120
atgagcaata acacnttaa antcntcaat tgacctagac acttcacact tgaaanataca 180
tcacttttna ngaccacgaa tgatgcttaa gaatcacatt ttgtgnngaa ntggantctg 240
gctacttaca cgaacagatt cttattcctg ttcatgagcc agtagaccg gaanaagact 300
taagagcttc tganccttct cttagctcca nngcttgaan g                                     341

```

&lt;210&gt; 217

<211> 273  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(273)  
 <223> n=A,T,C or G

<400> 217  
 nnccttcncc ccttnacnga catgaacaaa acagcngtct ngaaatttta ttaacattnn 60  
 aaggggttacn ctccctnctt ntgttttccg ntaaaanncta nacctgcgcn ggggcggccg 120  
 atncagccct atagtggagaa gcctaattnc agcacactgg cggccgttac tanngnatcc 180  
 cgactcggtta ncaanttttg gngtaaagat ggacatanct ctatccnnga gnactcgtca 240  
 nccntttctct atntttacatg cnctaacgna gac 273

<210> 218  
 <211> 687  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(687)  
 <223> n=A,T,C or G

<400> 218  
 ttttcagtgc tgttttggtc tcaattttga tgtcaaaatc tctgggttct tctaancnng 60  
 ttatgttctt ccancaaate cttccagttt ttgtaatatt tttctatatc agaagcgcct 120  
 gancecaatg cccaattnat acaccgggtc tctccggaac gcttggtcna aagggtntag 180  
 tcnattnggc tcttggaagc atctnaaatg ctccaggtta ctcccangnc cctggannac 240  
 ttcanttgc tanacgaatc ctgggttttcg agcggtcctt gatatcgcaa ggaaatacgg 300  
 taataaattat ccaagctctc tttccactna gganttcgga tctcatcagc cgggtaaagg 360  
 aaaactctc angaagtttg ggcttccctt cgggtctacc ggctaagtgt aggaattact 420  
 tctggctctc ttccgataca tctctcttc aaagtnaaga aggttaaaag aatnttaacn 480  
 tctccagtg gctaattggtc aaacaccatc ctcatnagtc agactggggt ttcgaaagga 540  
 ggatataacc tctttgcag ttnnaattaa aagggattaa ccanatggac tanccctcnc 600  
 cccgggattt nctctctcac aggagaagggt gtctcncnc ttgggtcatc cgaagcatag 660  
 gcaaaccnccn ggggaattttc agaaacc 687

<210> 219  
 <211> 247  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(247)  
 <223> n=A,T,C or G

<400> 219  
 gggcccttcn cctttnaatc gagagatcca aggttcaagg catgaaatac cagnctataa 60  
 aatgtctcaa gacntaaata atacggatng ngatagagag gttgaataat aaatgaanaa 120  
 anatgaaagn nattatgngg gaatacnaaa aaancngact aanggcggca ctgctgggca 180  
 tggnaaaatc ggattaattc ctcataggac agccnaacc cttaaaatct cantttccgt 240  
 nacccga 247

<210> 220  
 <211> 937  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(937)  
 <223> n=A,T,C or G

```
<400> 220
cgggctcgag tgcggccgca agcttttttt actatagacc aatattaaag tcagttaagt 60
tccaaataca ganttggaag actaaagtaa aatatttaaat gggagaatat ctgcatctga 120
atatgtcaac tgtttgctat ttttcagcta tttaatcctt ctacctgtat ctcagaaaca 180
aatttaaaaa ttaatagatt tgacagcaaa atcattcagc actttactta ctccatcagc 240
aaggatatta tgtagtcatt tccatccatg tggccaaact gaaaatccct aaccaccacc 300
aaccaaaaat aaataaataa aaggagaggg ggtgggggga gagagagaga gaaagctcat 360
taaatagtaa aaaagtaaat aaaacaatga agttaaattc aggcctcagt aggccagaa 420
actgtaaaaca tttcacatgt aaatcatata caataaacac tgctaaaagt gtaaattcta 480
ctggcttctg agatacaaat acacgagtag aggaaattct aagacatttc tacttggttt 540
atgcatattt aaaattcagg gaaatatcag ctattctacc tgaaatatgt ttaagaaaaa 600
ttcctatttt ctctaaaaaa aggaataatc agaagacgct acatactatg taagaaaact 660
atacaatgac ccatcattag aagattcaga ataggaaaga aataataatt cactaataaa 720
atatatttat attgactgtc tttttttatg atagcaacaa tgattcagca taaagtaaaa 780
atatatgtat ttccgatgcc attttttatt cagttattct tttgagtttc tgttagaata 840
attatctgcc tatctctgac ttctgancag tcatttatgt ccaattataa gtacatgtgc 900
atattttatt accttaaacg cctctcaaat cctttca 937
```

<210> 221  
 <211> 353  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(353)  
 <223> n=A,T,C or G

```
<400> 221
ggctatnna tnnntntaan atcntgncnn ccttgacgct gttantaaan aaaaacaaac 60
gaatatcctt tttttgctcc cccctgtncg gatactaata tcacactaat acttacagta 120
taactnttcc tttcaactac caatattaag ttccaagcca cctgggctta agtatcccaa 180
caacttaggt aatttgttgc taaccaccat actatatgct aattataaca ctctaagccc 240
caaggaattt ttgttcagat ttcttatant ttccacttat aaatatnatt ccncctctat 300
gggtatatnn nncctctagn cccatatnnc ccacngggat ttgttgaggg ggc 353
```

<210> 222  
 <211> 813  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(813)



<223> n=A,T,C or G

<400> 222

```

ggcaccgaggc tttactaagg ccagactcac tatccccgct tctgttctgt ggtacactgt 60
tcaactcctca gtccatccta acctgacttc ctggccactg cagctcttcc gataaggggc 120
agcagtggct tagttattgc taaataataa ggcacatgc actccctctt tcctgaaaca 180
ttgtccctcc ttgggttctg ttccttccta ggtctcctat cactcctcct tagtcttctg 240
tgccgacttc tgttccttct gccctttaaa agttggtatt ttccaggatt ctgtcctagg 300
cccacttact tctcattctg cacgttcttg ttggatgatt ctatcacatc cctaaacttct 360
gctgcccagt atgcacttaa aattcccaaa tctgtatatc tggatctggc ctgtgtctct 420
agcctagaag tgtgctttat ccagaagca cctcaaacac tgcactttgg aaattaagct 480
tactgagtct cgagtctcaa gtcccaaaact gacttctttt tctctatttt ggtagtgac 540
aacactattht attcagtcac gcaaaccaga gccctgagaa ccatcttaca ttctctttct 600
ccctttactc agttcttgct tctgttcttt ctctccncc tctcctgcct gtgggcctag 660
nggncattaa ctgggtggca ctgctttact ttcnattttt ttggctganc taaccnaag 720
ancctnttgt aggggccttt ctntcaggcn tnacttctnn caagancccc cgaaaccaga 780
tccnggggan tgctatggnn tggaaatatt ttg
813

```

<210> 223

<211> 882

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)...(882)

<223> n=A,T,C or G

<400> 223

```

tcacactact gagaagcagg gaaaccact gaaagggcac gtttcttaac ctcagaatgg 60
ggctactagc ctctaaagca ggaattgcgt tttgtttagt atttccatgg tctgctgcaa 120
ggcgtggcct ttacccaatg gataaatgct tacaaggctc ttgtgagcag tcaagtttct 180
cgaggtttac agttgaaggg aagtgggatt gttttcctgc gcatttaaatt gaaggtaggt 240
gggtgatcac ctttccttaa atgtgtgaag ggatgagata aagagatagg catcttaatt 300
gccactgatg gccttcaggt gaggacaggc atgagccaac tgaagctttg acaattgtgc 360
tgaaccctaaa acttcaaaaa caagaaaaaa catagactgg ctgaaatgat ctaagtcaac 420
agagcatggc cagcgttca tacaaggcag gaccacaggg gaacactgac agcccaggag 480
gcactgagac agaggcagtg ggaagaagt acagacccca gggactcccc accaacagca 540
gctgctgttg attaggaacc ccagtagac tgtcaggcac ctggtagtagg agaggctacc 600
aaggcccggg ctggagagga gccaaaggaa gaaacagtgc agtgcttaga cccctctggg 660
tctgcccgtg tccatacccc tagggagatt ccattccaga agtggacata ttcccacaga 720
gtgcctgggg ctactcatc acagctgccc ctncatgaag gcattctcac tgcagcctta 780
ncagggaaca gggtcatttg cattagggcan cttgctgtcc tagaaggcnt cggngtccc 840
tactctgcc atgttcccaa ngnggttcaa nctcnaaaan tn
882

```

<210> 224

<211> 660

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)...(660)

<223> n=A,T,C or G

<400> 224

```

gattaaacte aatcattcac cggggtcga gtgcgccgc aagctttttt tttttttttt 60
tttttttttt ttttggncc tggggttgt gcccggaagg ggantgctgg gccacntggg 120
tgtccgtgtt tgattttctg ggacctgccc ccccgntcc cgcgccgnt gccgcgtctc 180
actccccgcc gcggtgcnag gggccccgtg tgccgcgcac ccttccacc gtgttttctt 240
gtttttttga ctntggggtg cccaggggtg cancgccgt ggggccctgg tttgctttca 300
cctcttcac tgcacttg cgcnantgn gtcttnttca aacaaacgt tgaaggncaa 360
nccctgggct cctgtgaacc cggcgtctt tgccgcaaan tctgaggctc cttcgttatt 420
ctggatccgg cctntggtcg gangcgtgct ctgcaggcac tgctccatt gctggcanc 480
ttttctcccc gtggccgcc ggcgcccat naaaggcgtt gcaaacgcc gccctcgcca 540
gcgcaaagtc aaacnccggt ggcccgcgga ccccccggcg gncgggaaca cccancagg 600
cgggcaccac aanaagcgcg gncctccggc gtctaaaact nccatgtggc nccccccgn 660

```

&lt;210&gt; 225

&lt;211&gt; 438

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1) ... (438)

&lt;223&gt; n=A,T,C or G

&lt;400&gt; 225

```

aaaaaaaaag gaaaagtacc cagtgtctct agcttctgag cctcctctac agccctgttg 60
gnttttaaac ctgtgccctg tgtctgtgtc cccacttaat atatatagta cacagctgga 120
gagatggctc agccaggaga gggaccata ggtctgtgaa ttccagagga naggcaggna 180
tttatagggt gntctgtcag gtgaaatcng aggagccaaa gctattgtat gtgcatatgt 240
cagccgggct ctgtgggagg tgggtgaaga cctatggnat gggacangtg tncacgctgg 300
gatctctggc cggttccgaa aagtgaggat caggtagtgg gtggctgatt gcacaagttt 360
anaaccagg attagggaca cacaggtcag cacctgcttc tcagcatcct gactgggtgt 420
gatgggcata ctcaaggc 438

```

&lt;210&gt; 226

&lt;211&gt; 480

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1) ... (480)

&lt;223&gt; n=A,T,C or G

&lt;400&gt; 226

```

aaaattaaaa ccaaaaggat cttagaggct ctttacttca gtggttctca atgtcagagg 60
atgttatgat acctaataa aatctccagg ggaactgttt tgaactcaac agactctctc 120
ctgttctgag agactctggc aaagttggga gagctgccag gtactgtcca catgaccctg 180
actgcccatg attcaattac cttgaatggc ttatccagtc caataccttc atttcttaca 240
tgaggaaact gaagcacgta tcacatagtg atacaatgaa aacttggcct taatcgattt 300
tcagtgtgct cagtacaatg tcttgagcat atcaatttct tccaaccctt gacaacataa 360
ggtacgacca tcaaattttt tatttctgct aatttattag accaaaaaaa aagggnatct 420
cnccatttgt tttacaggga tgattttatt ncagaggatt tcatcntggn gctgattcnt 480

```

&lt;210&gt; 227

&lt;211&gt; 423

&lt;212&gt; DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)...(423)

<223> n=A,T,C or G

<400> 227

```
cattgtgttg ggctctgctt agcacatcac atcggagcac agaggtgacc tgttctgcc 60
cagggatgtt caccttagtc acctgattga ttcctcttca ctttggtcac gtgattcctc 120
caggaggatg ttcaccttgg tcgcctgatt cctccaggag gatgttcacc ttggtcgcct 180
gaccacacag gcatttatca ggctttctca ctgcagccac tatgtcccca taatggatga 240
gtgtcttggt gagagatagt ccaaatgaca ctgatacctt ttgcctcata cggcctcacc 300
ccccaacaat cnaccactaa tgactgcctc atagcagttt ttccatttcc acagtccctt 360
ctatatgtat taattgtcat tctactataa agaanacttt ttctttttaa aaaaaaaaaa 420
aag 423
```

<210> 228

<211> 249

<212> DNA

<213> Homo sapiens

<400> 228

```
cattgtgttg ggctgtagta aaatatgtgt ctggtaagat atgtgaagaa ataaaaaag 60
atcaattaaa tctggcccat tgaatgacac attaatgtga tattaatatg taatgttaa 120
gatattagga gatgggtggga cattatggca aactaaattt gggaggagggt tgaattgtat 180
aatttatgaa atcctaaagt ctagtacatt aacactctct actgtcaact tttcaaagca 240
gtgagaaac 249
```

<210> 229

<211> 436

<212> DNA

<213> Homo sapiens

<400> 229

```
cattgtgttg ggatgttatt tgaccatcac aatatgattt ataatatgga ggcattgaagt 60
catttctcat tggggcagga gtgtggcaag ggggaagaag agctttacca attaactcaa 120
gattatttgg tgacatttct cttacctttt aggtgaggag aaagagacag aggatggaga 180
attggtgctt ttagtatgct gatacattaa gctgcctgga agcagatgct aaatcctatt 240
gaaaataatt ttatttgcgt tttgcttagg gcattgttta gcaaaatact acacaaaaag 300
tcttgacctg tgtgtttgaa atggcagatg ttcacagtga ggactgagcc ttggggcaac 360
atcaatcttc acaattctgc acctatttgc tcaataactg gcttggtttg aaaaaaagg 420
aaaaaaaaa aaaaag 436
```

<210> 230

<211> 760

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)...(760)

<223> n=A,T,C or G

&lt;400&gt; 230

```

cattgtgttg ggnngtggaa ggaaaanttt gaggcaatga agctaaacat aaaagaggaa 60
aagcanatgt tacctcaatg accacaatct acaaagtcca aatanaaaac ctgggagtat 120
gataggatga aactataacc tccagcaaag agcttaacag caattaaaat aaagacaaat 180
ttctgggatg gatnagacaa agtagcatat attacaaagg aaaatanact agtatcatnt 240
acgtttgatt aagtaactgc tttcaaataa ttgaatcata aacaatgatt tctgcggttt 300
taagctcatt attttggttc cctggtttct cctaggatgc agtatagaat ctccatgcct 360
gatgtttatg taccaacaga agctgctgct tctttctttc attatttcct ttttaagtga 420
aagttaatac ctttttatatg ttacagagaa gaggcagaaa aagccacact cccactatgc 480
tattaaatgc cctgaggatc aactgaggga tgattatacn catggctgaa tacagtntat 540
tcatttgttt ctttggattg tanataacaa aagggtggtat tctgtaacat cttgtgncaa 600
ttanccaaat gttaaggcga aaatggaatc tttcaaacaa gtgttntaaa caggttttga 660
ttttccaaaa tttantatta gaacntttc aattctggaa gttncccaat ttccangttg 720
tgttttctct tccaattctt ctttcctttg naaatccccc 760

```

&lt;210&gt; 231

&lt;211&gt; 692

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(692)

&lt;223&gt; n=A,T,C or G

&lt;400&gt; 231

```

cattgtgttg ggggggtgctn tgggggagaac acgcttatgt tganatnggg ctccccgaga 60
aagcctcatt gacacnttcg aataaggacc cntngggaaa ttcangtgag ttgtggacat 120
ncntagataa natcaaaggc cttgangaag tccgcctggc acctccngt ctgcgaggag 180
gttgatacca aatgctaagg ggtccagntg cantgtanta tctgtgagatc agagtgatgg 240
gcagggtgtg gcacgcgggc cctcaanang aagtgccag gatgactcag acttatgcct 300
atatccattc antcctgttc attattttta ncnttccctc naaggacccc caatttnaac 360
catttgttat tcanggctat acttataaaa gtcatttgtt ttnagtctgg gtgatattaa 420
aaccatttgg acgccangca tgggtggetcn nggcctataa tccnttccac cttggggaag 480
ccgaagctgg tnnaatccct naaggtcngg aatttgaaaa ccatcctggg ncaacattgg 540
gngaaaccct gtctctactn caaaaaacan aaaattttct ggggcctngg ttngcaggtn 600
gcctgaaaat tcccancnt tactccggga aggccgaatg ccntaaaaaa nnnaccttta 660
acccccccga angggcgga agtttccatt tn 692

```

&lt;210&gt; 232

&lt;211&gt; 518

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(518)

&lt;223&gt; n=A,T,C or G

&lt;400&gt; 232

```

actcaaatgn ccncttgaag gtcacccaga ctcanaangt gtcaagcttt ggggtgggtn 60
gtaatnaata nctcggnctc ctgattagtn ctccatagctc gatcnetggc tgagatnngt 120
tcgagacccc ttcctttgat cccgtcaaac nccnggnaaa agcngcctgc gtagtcncct 180
nagccgaatc tgnnttcccg acaccctccg ctcggtcggc tgccctggtn aagcngcntc 240
ctnaaanaaa aaagngaagt ctccccngtc tcncccnant cctngggaaa acngcctgaa 300
ccaatatgnt cccccaaggc cnccccaggc cacntaaccg gttaggaggg cccccnctg 360

```

gcgttttggc cnaaagcccn gccccngnaa taaccccnct anaaccacgn aaaaatgcaa 420  
agtcccaaag ggtaaagaat cteccnacc cccgggtccc tcgcaanctt cccctnngna 480  
cttgtgttcc gggaaaaccc ttancccgan cctttcca 518

<210> 233  
<211> 698  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1) ... (698)  
<223> n=A,T,C or G

<400> 233  
gcacgagttt ctgtctgtct gtctctctct ctctctctct ctctctctgt ctctctctca 60  
cagttagaat ttggctctgt tctttattca ataccccaat atatgttcat taggggtata 120  
ctgtatacac tacacataac agttttgttt tttgttttgg atattatttg ataataagaa 180  
ttttaccaca tcattaaaaa aagtttcccc aagctataat ttttgataat tgcaactctc 240  
cactattcaa atgtttattt aactctttct ctctctggag aggtttacat tccatttttag 300  
ctatgatact gctttaagag aaattgtttt aagataaatt tccatagaca ggtcaaagga 360  
gggtgaatata tgtaagcttt tcgatgcctg ttactgaatc tcattctgga aaacataact 420  
gtcaatgccc tctttttctc atggtaaaaa aatacataac aaaatttacc atcttaatcg 480  
tttttaaatg ttacagtacg atagtgttna ctgtatgtac cttgtgcaac agattctctg 540  
aaaacttttt catttttcaa aatgaaaact ctgtactcat tgaacaggca gcttcccaac 600  
ttccccattc ctcccanncc ctacccctgg ttaanagtct nacaaaaccc gggaatttta 660  
tgaaatttga aacactttta naataccnct tattaggg 698

<210> 234  
<211> 773  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1) ... (773)  
<223> n=A,T,C or G

<400> 234  
ggcacgagcg cagcttttct aaagctgtaa tttgttttgt atcaaaagtc ctgcagtata 60  
ttagtctcat tgcattttta agagtttcca agtgatcagt gatggttgct tgttttttag 120  
tattacggtc ttatgtaatg ttcgaaaact agtcagtttg gtgctgtcgt acggggcgga 180  
aagatcaggc caggcaaagt actctggccg ccaaagtaaa tgcttaaggc cgccaacgga 240  
ttatgtcctg gggttcgatg agggccgtaa ttagggttag ctggtgtang ctaacctcgc 300  
agccatgtcg gagagagatg agagacataa natttttaaag taggggcgta ttttacgaag 360  
ttctgancca tttcctttgt tatcggtccc ggcaaaagca actgagataa atgtgttaaa 420  
agactcgatg attttttcga cttcagcaac gtactcagcc ttgggttctc gtagtttttc 480  
aaaggcagct atttgctgag attcatgaaa agtttgactt ganctgcttg tcaatttctg 540  
cagcncgggc ttcaactgtt attgaatttg tttgattaag cncaatacgt tgcnggtcac 600  
caagggtttc catgttttga ctncacctgg tcgaaccaat ttgaattatg tntttttgcc 660  
tgnctgttc cccnccctt aaatccatct cttttttnga aacctttgng nggttgaatt 720  
cngccgccc gttcccaacn tttggttcna ccttggaaaa aaanatgggt agt 773

<210> 235  
<211> 849

<212> DNA  
 <213> Homo sapiens  
 <220>  
 <221> misc\_feature  
 <222> (1)...(849)  
 <223> n=A,T,C or G

<400> 235  
 attgggtacg ggccccccctc gagcagcctc cactgcaatg ccgctgaatc aagagacttt 60  
 tcaatacgtt ttatcagtga aaatgatgtg atctgaagag tcctatcttg agcactttgc 120  
 atgacatcca aggttaaatgt ccacaacgtt cttagctgcc caacccttt atcggcaagc 180  
 tccaaagggtg tgtgcaaacg ttctacggcg tcatgaaaag ctgaaaaatg ctgtgtcaac 240  
 actgcaccgc tgcgcatctt caaaagcagc gcccttatag tctccgcatt cgaagacgat 300  
 aaccgcgcta gaatagcctc ataatacatt ttgtagaaat caatcagagc tgtgctagga 360  
 acctttccat ccaaaacata cgactgtgcg accacgtctg caaaagcaga cgtcacatta 420  
 tgcataatgcc ctcttaccgt cagccgatca tcctcactca tagcgacgcg agaaagctct 480  
 tgttccagct cgtgcacggt atccaattca gtaatcctac gcaacgccgt ctgaatcgtg 540  
 ttcataagtt cagtttttaa gctcaaaact tcgtctctta ntttaccctt tgtgactttc 600  
 aaactgggcy antcttcacc attttattaa tcgtcttttt gangganggc ccagcgtag 660  
 atctgcatcg ccagcggaat cgttactccc tccattcct cctccgggta acgcanntag 720  
 tttctccgaa gccttaaaat tagccgggga aagggaantt atttgcccca acaangnat 780  
 cgcggnctcg gtggttaaaa ggaactgaaa taaaattaaa ncccncttgg gggaaangcc 840  
 cgcatactg 849

<210> 236  
 <211> 310  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(310)  
 <223> n=A,T,C or G

<400> 236  
 ggggtgggtt gcttccgaaa nccggggccc ggccaacttg ttggcttggg aatattctgg 60  
 caagaaaatt tccagggcgg cgccaatttn atcaagcccg ggcggcctta aaccgaaaac 120  
 tctggcaggg tcaaccctt tcatgggcn ttgaaagctt gaagcgcgcc aagttactcc 180  
 caagcttggt gcgnttgcgg ttgggggcgg gggaaaagtt gaaaacacgg gcgntttgtt 240  
 gcccgccccg cgggcggttt nttacgcat cctgggaaaa ctttcagggt tggctgctta 300  
 cnaaacggg 310

<210> 237  
 <211> 315  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(315)  
 <223> n=A,T,C or G

<400> 237  
 gcacgagntt ttgttattta natnttgctt tgtttaangg aagaacacaa naatgccctg 60  
 ctaaagggat tctgttttgg tgcangctgc nagggggaa aaaatcnaa tgtatnttgc 120

```

acaacangat tttttagaan tcagaactat gacatgaagt canncagggc actctacgac 180
tgaatttgcg gtgctgcctt cacangctcc ttntctcgctc tntnctggca ncngtgactc 240
ntacacgtcc tgganantan cctccctana aggaacgact cgcacacccc cccnntaccc 300
ctnaangttc atcng 315

```

```

<210> 238
<211> 510
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (1)...(510)
<223> n=A,T,C or G

```

```

<400> 238
ngcacgagtn tttgttattt atatattgct ttgtttaaag gaagaacaca aaaatgccct 60
gctaaaggga ttctgttttg ttgcaggctg cnngcgggga aaaaatcaaa gtgtattttg 120
cagaaaatga ttttttanaa gtcagaacta tgacatgaag tcaagcaggg cactctagga 180
ctgaatttgc tgtgctgcct tcatatgctc cttgctcgct cttttctggc agctgtgact 240
cncacaggtc atggaganta tcattcccta aaaggaacaa cnccgatatt catctttatc 300
cattaagtnc atctgtccca ttctatgtng tggatgctaa cttttgatca ttgatngtga 360
tnccatggac atntancatc anctttcana ncctnnggac tttgacnagt cttattantn 420
agantccaac tantacgatg ccganttana aatgctggnt ntccaattcc tactcaaata 480
nccnacatga acttccantc cccttgcnna 510

```

```

<210> 239
<211> 209
<212> DNA
<213> Homo sapiens

```

```

<400> 239
ggtgcttttc ccttctactc gtcttctctg ctggcaggag aagctcccgc tactggttgc 60
ccttctacca ctgtcgacac caccaactgc agtgagccag tgtccgaggc tccagccaga 120
aacaggtagc agccatgccg gataccaaac gccacacatt aagagcctga aatgacctga 180
cgccacctcc gcatgcttta cctactgag 209

```

```

<210> 240
<211> 610
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (1)...(610)
<223> n=A,T,C or G

```

```

<400> 240
ggcacgaggt ttctggctgg agcctcggac actggctcac tgcagttggt ggtgtcgaca 60
gtggtangag ggcaaccagt aacgggagct tctcctgccg ggcaggaaga cgagtagaag 120
ggagcggcat gctggaggct ggagcctgag cccctggggc tcgcttgct gtgtttggtg 180
gtgacgtggg acactgcagc tcggccagag tggtaaaaaa tgccttggtg tacgcttttc 240
tggtcttgcc cgtctatctg ctccaagcca ggctgganga ngagganaag gaatcacctg 300
tggtacgctg gagcctgcat gtggcgtgac tctgcaactc gcctcgtgtg actgatggca 360
gccacggaga ctgcagctcg acagggagtg aggccttctca ntggcttgaa agctcagctg 420

```

```

actcccacga aatttgccgg aaactcaagg ctgtcagtga cnttcgtggc gccaaagactt 480
aancangcgc gttgcatgca tccggccagt gtctgtgcca cgtgccctga cnccaccttg 540
anataancac ccggaacgcg cncgcgcag gccgcgcgca cacgnccggg cancaacttg 600
gctggcttcc                                     610

```

```

<210> 241
<211> 474
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (1) ... (474)
<223> n=A,T,C or G

```

```

<400> 241
ggcacgaggt ttctggctgg agcctcggac actggctcac tgcagttggt ggtgtcgaca 60
gtggtangag ggcaaccaat aacgggagct tctcctgccca ggcaggaaga cgantagaan 120
ggancggcat gctggangct ggancctgan cccttggggc tcccttgctg tgtttggtgg 180
tgacgtggga cactgcagct cggccagant ggtaaaaatg tcctgggtga cgcttttctg 240
gctttgcccg tctatctgct ccaagccacg ctggaagang agganaagga ntcacctgtg 300
gtacgccgga gctgcatgt gggngtgact ctgcaactcg cctcgtgtga ctgatggcac 360
ccacggacac tgccactcta cagngaataa ggcttctecn tggactngaa agctcanctt 420
nactccncc aagtttgncg gaactcaagg ctntcactna acttcgtggc gccca 474

```

```

<210> 242
<211> 415
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (1) ... (415)
<223> n=A,T,C or G

```

```

<400> 242
ngcgggggnt tccaccagct cgtgtgcaca agtngcgcca cacaacatg cgcaggcact 60
gcatgtcatc natgtgcttc gccgtggttc tggaacagcg agtagaagat ggcgttcggg 120
tcgcgaccaa attcgacgct ntggatgctc ttgcgcaaga angtcacgta cgggatcggc 180
ccgatggatc cgctnaagcg ccgaaaggcc ctgacttgca aaccgcggct cacagaaccg 240
gcaccaccgg cgccctccgc cnacaaaagt cgagcggcct ccgacacaca ctccctcaca 300
tcccgtcnc gcacttcggc ngtttctagc tccgccacgg ttgtcagcgg caccgcgggc 360
gccnagctgc cggcggcatc cgttgcacac agcacacacg gatccgctct cgtgc 415

```

```

<210> 243
<211> 841
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (1) ... (841)
<223> n=A,T,C or G

```

```

<400> 243

```



```

aacgaggtgt cgatgagcgc gaacaatcgc cctccttcat ctctacctga tggatgaactt 60
cgctcctaca gccgagccaa tgaagacgaa ttggtgctgc cgaggatggg agtctcacta 120
gagcacgcgg cgctggacaa ctcatcgact ttgtacgcttc cggtagctta gcccattcag 180
ctccactgac gacagagacg gagctggcca ctgccatctc gacgcagcgg gacaaggagc 240
agcttcgggc gccgtatgca tcaactgaag agaaccagga gcagccgga gaggangcg 300
ctgcacggta caggcacttt cggcgcttca gcggatccat cgggcccgat ccgtacgtca 360
ccttcttgcg caagaacatc caggacgtcg aattcggtcg cgaaccgaat gccatcttct 420
actcgctctt ccaggaccgc gcgaagcaca ttgatgacat gcagtgcctt gcgcagtgtt 480
gtgcggcgct accttggtgc acacgaacga nggcaaccaa cccgcccag gtgcccgtct 540
atgcattcct gttctgttcc ggtgtgcatg gccggatgtg gaccgtganc ttggtgaatc 600
ggctggtgca tgaagactta ccgctctent caaggcgaa cgcncctcan ttcgganaag 660
gaacaaaacc ccccnnaag aacggcantt gcancntttt ccccgctgc cggtcttct 720
ccattcgggn attctctntc tcchaaant ccgnaaatc ttcttcggt ttctccctg 780
tttttatttg cccttccgc cacttgggtt gttttacatc ctacaancct ttttttctc 840
c

```

841

&lt;210&gt; 244

&lt;211&gt; 761

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(761)

&lt;223&gt; n=A,T,C or G

&lt;400&gt; 244

```

aacgaggtgt cgatgagcgc gaacaatcgc cctccttcat ctctacctga tggatgaactt 60
cgctcctaca gccgagccaa tgaagacgaa ttggtgctgc cgaggatggg agtctcact 120
agagcacgcg gcgctggaca actcatcgac ttgtacgctt cggtagctt agcccattca 180
gctccactga cgacagagac ggagctggcc actgccatct cgacgcagcg ggacaaggag 240
cancttcggg cgccgtatgc atcaactgaa gagaaccagg agcagccgga agcaggagc 300
gctgcacggt acaggcactt tcggcgcttc agcggatcca tcgggcccga cccgtacgtc 360
accttcttgc gcaagaaaca tccaggacgt cgaattcggt cgcgaccga atgccatctt 420
ctactcgctc ttccaggacc cggcgaagca catttgatga actgcagtgc ctgcgcatgt 480
ttgttcgggc gctacctggt tgcaacngan cgaangcaac aaccgcgccc angttgccg 540
tctatgcatt ccctgtctgt ccggtgttgc atggccggat gtggancgtg ancttgtgaa 600
tccgctgggt gcatgaagga cttaccgctc tcgtcaaggg cgaacgcgcc atcaattccg 660
gaaaagggaac naaaaccccc cccaangac ggnaatttgc ancttttccc ncncctgccg 720
gctcttctcc antnccgggt tctctttctc anaaaattcc c

```

761

&lt;210&gt; 245

&lt;211&gt; 710

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(710)

&lt;223&gt; n=A,T,C or G

&lt;400&gt; 245

```

aacgaggtgt cgatgagcgc gaacaatcgc cctccttcat ctctacctga tggatgaactt 60
cgctcctaca gccgagccaa tgaagacgaa ttggtgctgc cgaggatggg agtctcact 120
agagcacgcg gcgctggaca actcatcgac ttgtacgctt cggtagctt agcccattca 180
gctccactga cgacagagac ggagctggcc actgccatct cgacgcagcg ggacaaggag 240

```

```

cagcttcggg cgccgtatgc atcactcgaa gagaaccagg agcagccgga agcaggaggc 300
gctgcacggt acaggcactt tcggcgcttc agcggatcca tcgggccgat cccgtacgtc 360
accttccttg gcaagaacat ccaggacgtc aaattcggtc gcgaccgaat gccatcttct 420
actcgctctt ccaggaaccg gcgaagcaca ttgataacat catgcctgcc catgtttgtt 480
gcggccctcc tggttgcncg cgaancgaag ggcaacaaac ccgcgccagg tngccgctct 540
tatgcattcc ttgtctgttc cggtnntgca tggcccggan nttggaaccg tnancttggg 600
nnaatcggtt ggtgcattga aggaacttac cgctctcgtc aagggccgaa cgcnccttcc 660
agttcgkana aaggancgaa aacccccccn naaggaacgg ccnttgcnng 710

```

&lt;210&gt; 246

&lt;211&gt; 704

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(704)

&lt;223&gt; n=A,T,C or G

&lt;400&gt; 246

```

aacgaggtgt cgatgagcgc gaacaatcgc cctccttcat ctctacctga tgggtgaactt 60
cgctectaca gccgagccaa tgaanacgaa ntggctgctg ccgaggatgg gagtctcact 120
aaagcacgcg gcgctggaca actcatcgac ttgtacgctt ccggtagctt agccatttca 180
gctccactga cgacaganac ggagctggcc actgccatct cgacgcagcg ggacaaggga 240
gcagcttcgg gcgcggtatg catcactcga agagaacagg agcagccgga agcaggaggc 300
gctgccccgt acaggcactt tcggcgcttc ancgatcca tcgggccgat cccgtacgtc 360
accttccttg gcaanaacat ccaggacgtc gaattcggtc gcgaccgaa ttgccatctt 420
ctactcgctc ttccaggac cggcgaagca cattgatnaa attgcattgc ctgcgcattg 480
ttgtgcgggg ctctctgggt ccccgancga agggcnacaa ccccgcgcca ggggtgccnt 540
ctatgcattc ctntctgttc cgggtgttgc tgggcgggat ttgaaccgtg aancttgggt 600
aatccgnttg gtgcattaag aacntaaccg ttntctgtca ggggcnnacc ggncccttnc 660
aatttcggaa aaangaacca aaanccccc cnccaagga aacn 704

```

&lt;210&gt; 247

&lt;211&gt; 618

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(618)

&lt;223&gt; n=A,T,C or G

&lt;400&gt; 247

```

ggccgccagt gtgatggata tcgaattcaa cgaggtgtcg atgagcgcg acaatcgccc 60
tccttcatct ctacctgatg gtgaacttcg ctctacagc cgagccaatg aagacgaagt 120
ggctgtgccg gaggatggga gtctcactag agcacgcggc gctggacaac tcatcgactt 180
gtacgcttcc ggtagcttag cccattcagc tccactgacg acagagacgg agctggccac 240
tgccatctcg acgcagcggg acaaggagca gcttcgggcg ccgtatgcat cactcgaaga 300
gaaccaggaa gcagccggaa gcaggaggcg ctgcacggta caggcacttt cggcgcttca 360
gcggatccat cgggcccgat ccgtacgtca ccttcttgcg caagaacatc caggacgtcg 420
aattcggtcg cgaccggaat gccatcttct actcgctctt ccaggaccgg gcgaaagcac 480
attgatgaca tgcagtgcct gcgcatgttt gtngcggcgc tacctgggtg acacgagcga 540
nggcaacaaa cccgcgcccc ggtgcccgtc tatgcattcc tgttctgtcc ggggtgtgcat 600
ggcccggatg tggaaccc 618

```

<210> 248  
 <211> 622  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(622)  
 <223> n=A,T,C or G

<400> 248  
 gcacgagagc ggatccgtgt gtgctgtgtg caacggatgc cgcgggcagc ttggcgcccg 60  
 cggtgccgct gacaaccgtg gcggagctag aaactgccga agtgcgcgac ggggatgtga 120  
 gggagtgtgt gtcggaggcc gctcgacttt tgttgccgga gggcgccggt ggtgccggtt 180  
 ctgtgagccg cggtttgcaa gtcagggcct ttcggcgctt cagcggatcc atcgggccga 240  
 tcccgtagct gaccttcttg cgcaagagca tccacnacgt cgaatttggt cgcgaaccga 300  
 acgccatctt ctactcgctc ttccagaacc cggcgaagca cattgacaac atgcnntgcc 360  
 tgcgcatggt tgtgcccgcg tncctgntgc acacgaccga gggtagcaac ccgcgccagg 420  
 ntgcncctct acgcattcct gtctgcccgg tgtgctgtgg cnggatgtgg accntgagcn 480  
 ggngantccg ctggtgcntg aagacnttgc cgctctcgtc aaggccnacc gccntcgcg 540  
 gcggaaaaag gancaaaanc cccccgcaa gaaccggcnc tgcaccgttn tcgcgccctt 600  
 gctgggctct tctccttac gg 622

<210> 249  
 <211> 517  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(517)  
 <223> n=A,T,C or G

<400> 249  
 cattcgagct cggtagccgg gatccgattg gtaaaggagg tgccggaacag ccagctggtg 60  
 ttttcgggtg ggcgggggca gccacatcg ctgtggctgt tggcgtagtg gatgcgatgt 120  
 gccgggacaa acgcgttttc caccacgatg tcatgactgc ctgtgccgcy caggcccagc 180  
 acatcccagt tgtcctcaat gcggtagtcc gccttgggca ccagaaaagt cacatgctcc 240  
 aggccaggcg tgccatcacg cttgggcagc agaccgccta gaaacagcca gtcgcaatgc 300  
 ttggagccgg tggaaaagct ccagcgaccg ttgaacctga atccgccttc cacgggctcg 360  
 gccttgccag taggcatata ggtcgaggcg atgcgcacgc cgttatcctt gccccacaca 420  
 tcctgctggg cctggtcggg gaaaaancgc cagctgcaa ggggtgaacg ccgaccaccc 480  
 cgtaaatcca ggccgtggac atgcagccct ttaccaa 517

<210> 250  
 <211> 215  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(215)  
 <223> n=A,T,C or G

&lt;400&gt; 250

nntncattgg gccgacgtcg catgctcccg gccgccatgg ccgcgggatt accgcttgtg 60  
accgcttgtg accgcttgtg accgcttgtg accgcttgtg accgcttgtg accgcttgtg 120  
accgcttgtg accgcttgtg accgcttgtg accgcttgtg accgcttgtg accgcttgtg 180  
accgcttgtg acnggggggtg tctgggggac tatga 215

&lt;210&gt; 251

&lt;211&gt; 231

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(231)

&lt;223&gt; n=A,T,C or G

&lt;400&gt; 251

ngcgcccacc tngtgattga tggctggtta ctatcaagta tgtacatctt gctctagaca 60  
actccnattc agtgggaagaa attgggaaag tatccccgat aagtaatagg nattaggtct 120  
nccttantgc ttgggtgggat attccncaac tgntccngat cggatcagnc tctgtctcngn 180  
gaatgtgctc gatcgttatt ctactnctga gcttctatcc nnacgtggcc t 231

&lt;210&gt; 252

&lt;211&gt; 389

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(389)

&lt;223&gt; n=A,T,C or G

&lt;400&gt; 252

atgtatcanc nctgttggtg ttncatcttt tgcagtcngt tctaagggn gataantatc 60  
agagatgcta atgcatnttc tgccaggcca ncattggtg cctatgcgta ctcttcttat 120  
cttctgaag agtcatctct ggnggatgtg tccccccctc tccacagtgt ttgcaagcgt 180  
taccacacgn tgcggnggcc gggaaggtcn ncacatccgg gnagaactcc ccncgtntga 240  
atcgtntctn gaatctccgg cgtctccct naacctcttg actnggacaa ngncctgtnt 300  
tccccntgt gaactngtan ccgccccctc tccccccctc agcctaancg ggaangaaga 360  
cnggggtcnat ctngggcncc acaagaant 389

&lt;210&gt; 253

&lt;211&gt; 289

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(289)

&lt;223&gt; n=A,T,C or G

&lt;400&gt; 253

nggggcnna tgagcgcgcg taatacnatc actatngggc gaattgggta cgggcccccc 60  
tcnagcggcc gccttttntt nttttttnt tntttttnt caaaacaccc tccncntgg 120  
atgganacgt nacctttctc taaccanac ttcacaatnc nantctcagg cagccgcctc 180

aaanccgatg tcangttggn atntcaantn caatcttatt ttngnaatta anctganatt 240  
gtggatggtn naccaatcan atacttggn tccgttgaac cctgtgga 289

<210> 254  
<211> 410  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(410)  
<223> n=A,T,C or G

<400> 254  
attgtgttgg gaacttgtag acagctatat caattgcagt gctatttctc tgaggtattg 60  
aatctcantt attataattt tgaaatccaa ttggcttgga cttcattatt ttccaactaa 120  
aaagatgatt gaaggattta ttgaaatgt gtaaagagta atatagattt tatgcttatg 180  
tttccttgaa aaaagtaggt aaaattcttc tggaaagtgt actcctaaaa tacaaatgaa 240  
catgtcaaga attacataaa ttctttaaac tatccttaan aannaatggc tctatgtann 300  
gagngaccct tacagactat taagaattaa cttgcatggc anagactcat ttanattcat 360  
gaaatggntc tcactttctt ggtaagatct ggcttggacg tttttggtaa 410

<210> 255  
<211> 668  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(668)  
<223> n=A,T,C or G

<400> 255  
tttttttttt ttttcctgtg ccaggcacta taccactgtg ctaggtgect tctttgcatt 60  
acttcatttc ctcataagct ttctgaggan acagaaagct tgaggttcac gtagctagca 120  
tctacataaa ttagttgcta aaaacataca atacgtcttc cggcaggctg tcattagtaa 180  
ctgatactac tagttgataa tctcataaac ctgacanaan ctaccattta agctgaaaca 240  
actgtcaata tctaanta aaacttaaat ccataaatca actatattct aaaatctgac 300  
ttcagttcaa ttaaaaaatc actagttggt acctacctcc ttctgaaagc cagtacaagt 360  
taaatgaaca actcccaggt ttaacaaaca agtggcatct aaaaaaaga tttaaaaaat 420  
aatccactta catatattta aaatggcatt aataaaacaa aatttatcca ataacnaant 480  
ggcaaaggaa ggtgtccaat tattacatgt tataaatctt taaattaaac ttttcttngg 540  
tttttcntcc ctanaataaa tacaancctt tccccgcna accagaaaaa agcaaaaaac 600  
aaaacccaaa aactcccagc nngcttaaa aaacncaaaa aaaataaaan ctctattaaa 660  
tgcccnaa 668

<210> 256  
<211> 487  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(487)  
<223> n=A,T,C or G

&lt;400&gt; 256

```

cgnaaccgtn cntttttnat gtgcgcccgc cncagnacca gngccgctac aggccaaggc 60
cggaagcacg ggagaggntt nggaaaaaaa agagtgccta caaagagcat attcgcagag 120
ttgggatgag tgaaggggac cagaaggngc agcggtaggg acgcgtgaaa ggangcngcg 180
gagaaatgac agcaagaagg gganaagcac acgaaaaggc agtatcctcc tcccccttt 240
tcgaggactg ccgcatcttt gttttctgcc cattccagtc accgaanaag atcccaana 300
aagaagaaaa gaancagagg tgcacttcgc ttcataattc nctcgctttc ttttctgnct 360
tcacnagttc tgcaggattg cccttgctct ctcccgagca catctacgca cgnatgaggc 420
tcggcaggtc aagccnaca aacnctcgca ctctctttt tctttgcnnng tctgngtggt 480
angngg 487

```

&lt;210&gt; 257

&lt;211&gt; 502

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(502)

&lt;223&gt; n=A,T,C or G

&lt;400&gt; 257

```

cctttgaaag ncnngctnaa ttengnganc cccngatca gcaccaggga gctacaacna 60
aggccggaag caggggattt ngccggaaaa aaaagagtg ttaaaaagag nttatccnca 120
nagatgggat gagtgaagg gacgagaagg tgcagcggtg gggacgcgtg aaaggaggca 180
gcgagaaaat gacagcaaga aggggagaag cacacgaaaa ggcagtatcc tctcccccc 240
ttttcgagga ctgccgcac tttgttttct gccattcca gtcaccgaaa aagatcccaa 300
agaaagaaga aaagaaacag aggtgcactt cgcttcatat ttcgctcgct ttctttctg 360
tcttcacaag tctgcaggat tgccttgct ctctccgag cacatctacg cacgtatgag 420
gctcgagggn caagccaaaa aaacgcttgc actcctcttt ttctttgcgt gtctgtgtgt 480
atgtggaatt ccgcggncc gc 502

```

&lt;210&gt; 258

&lt;211&gt; 510

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(510)

&lt;223&gt; n=A,T,C or G

&lt;400&gt; 258

```

actcgncact cgatncanta caagagnnta tgnattcgaa ngtgcccccg catcagcacc 60
aggagctac aacgaaggcc ggaagcaggg gagagggccg gaaaaaaaag agtgcttaca 120
aagagcatat ccgcagagtt gggatgagtg aaggggacga gaaggtgcag cggtaggagc 180
gcgtgaaaag aggcagcgga gaaatgacag caagaagggg agaagcacac gaaaaggcag 240
tatcctctct ccccttttgc gaggactgcc gcatctttgt tttctgcccc ttccagtcac 300
cgaaaaagat cccaaagaaa gaanaaaaga aacagagggt cacttcgctt catatttcgc 360
tcgctttctt ttctgtcttc caagtctgca ggattgcctt tgcctctctc cgagcacatc 420
tacgtcacgta tgaagctcgg aggtcnnngc aaaaaaacgc ttgcactcct ctttttcttt 480
cgnagtctgt gtgcatngg gaaatnctna 510

```

&lt;210&gt; 259

<211> 292  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(292)  
 <223> n=A,T,C or G

<400> 259  
 gannngagtc acgaaaaggc agtatccctcc tccccctttt tcgaggactg ccgcaccttt 60  
 gttttctgcc cattccagtc accgaaaaag atcccaaaga aagaagaaaa gaaacagagg 120  
 tgcacttcgc ttcataatttc gctcgctttc ttttctgtct tcacaagtct gcaggattgc 180  
 ccttgctctc ttccgagcac atctacgcac gtatgaggct cggagggtcaa gccaaaaaaa 240  
 cgcttgcaact cctctttttc tttgcgtgtc tgtgtgtatg tgggaattcct tg 292

<210> 260  
 <211> 582  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(582)  
 <223> n=A,T,C or G

<400> 260  
 gcacgagggt ggggtggtact gtgtataata actccagatc cttgaccaag tttggagagt 60  
 cacttatggc catttgaaac caaatgaagg atcaaaggac taattatattt gaatacctct 120  
 gagtgttttc cccaagcttg agaagagttt cattcagcta taaaatgctc attgtgcaaa 180  
 tgagtgggtt ccatgctgta taattaaagc attgccttta ataataatttt attaccttta 240  
 gcttgctctt ttaatttgag gaaaatccaa acaattttaa gtaaaacgtg ataaagacag 300  
 tttttcngga gananaaggg nagatcgcta tgtttattcc acttaatatc tatatcaa 360  
 atttgatca aaagcagact ctcaacttta aaatattctt ctaatggcna gaatcttttn 420  
 cctagattga ggtcagagc tcacatagna tnaactgctg taaatagaca cttagactat 480  
 agagctnagc tnaagttcca actanccaac tgcatttctg aatatgcttt ttattnaaag 540  
 gccagnnctt ttgccttttt nccnccctaa tnccttctat tg 582

<210> 261  
 <211> 783  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(783)  
 <223> n=A,T,C or G

<400> 261  
 gcacgaggca aaatacagag ggtattttac catggacagg caaccatttt ttccaggaca 60  
 actcttttgc gcagagagct attctctttc ttttgcttta cactctcaac ctcaactctc 120  
 gagtgtctgc atcctanttt tccatggcca taagataagg aaccatgagt gttactctag 180  
 atgaggctgt ttcatgtgtg gagctcatcc aggatccaag gtagattcat cagaagggtta 240  
 agtataggag tgggaaccca aatctctact tttattttga ggccttctct cctcaatttt 300  
 aaattgtaaa atcaaactta aaactgggta tctgatggcc agttaaaga ctgggtatct 360  
 gattgccagt taagagatgg tcatttatgc tcaccacat tctcaagacg cagggtaggt 420  
 gacangcttg ctggggaatg ctgancgaat cccccaatgc cttcaggatt ctggggaatg 480

```

tggctctgnt ttaaactggn tgactttttac aaagagccta cccgtcatgg ggggactggg 540
aagaaaaccc anangcagnt tctggcccan gggttacacc ccanggn tac cttgaaggnt 600
ttttggacat acctnttnc cccctnttac tgnttcatta gggcntcnnc aacccaant 660
tccaagttnt ggccttcena aaantttttt nttttcctt tccanggacc cccctggnt 720
cctggnnccc cctttttata nccaaccttg ccnggnattt tttcncttn aaagggaat 780
aat 783

```

```

<210> 262
<211> 741
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (1)...(741)
<223> n=A,T,C or G

```

```

<400> 262
tgaaccctan tgggcccggc cccctcgagt cgacggatc gataagcttg atatcgaatt 60
cggcacgagt gtatatctg ttattatacc ccagattnaa gtgtatattc ttaggcagta 120
gttctggtta acatccttac tacataaaat ccacttacta tttaagtatt attctaacag 180
gaggtagaat agctgcctta aaaaatgtag tgatcgaatg gcagtttttc tgctgaatgg 240
aaattactga cacaaaattt ggttttggga gacattttcc tccttggtgt tgagttttcc 300
cattcacgga tagggcataa agcttggttt atagttgagg ggtgcaaaag ggggaatagga 360
ttgggaaaaat acagtgttcc agcaaagggtc tgacaaggta catcttgag aggattccta 420
ttctgctang tggcactgta ngcttgaaa tactgtgtac tttccagaca aaggatagag 480
aaaaagacct tcactgggtg ggggagaaga aaaccctgt tcctagaaaa atcacaaaaa 540
aggcatcctt tancctatat tcccagnttt actggngcat ttgcttgatg tgactgacnc 600
ngattatttc ctttnactgg naaaaattcc tgcctcttg gatatnaang ggggnaccng 660
gaaaatnggg ggcnttgggg aaggaaanaa aaaaaattgg agggaccnaa ctttggaana 720
tgggntgctt nangcctaa g 741

```

```

<210> 263
<211> 437
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (1)...(437)
<223> n=A,T,C or G

```

```

<400> 263
ggcacgagag aatgtgttca cagacactat tttatannta tctgatgtgt actgtgtctg 60
gtggatgtga aagccatact tcttaaactc gatttgaaaa gcaaatctga ttatcacagc 120
cataattaaa tttggccagc cttccttctt cctcctctcc ttcacttctt tccttccttc 180
cgctcgtgc cgaattcggc acgagcctga cctcactacc aaaaaaaaaa aaattcaaag 240
tgctgaggt ttccaggcat tcttagctct atttacttac ttcccacctc aaatggcctt 300
agaattcaaa ttctgnanaa aatggattgc catanataat ccaatgaaaa tgggtcatat 360
tttgccatta atagaatcac agtcnacaag ggactaatag aattagtcac ttangtactn 420
ttagatttgg gagacnn 437

```

```

<210> 264
<211> 706
<212> DNA

```



<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)...(706)

<223> n=A,T,C or G

<400> 264

```
gcacgagcac cccaagggtt taggacaaaa tgggatgagt gaattcatgg cttgacagac 60
tgaacagaaa aatgaggctc cgtgctccat attcatgtgc atctgcccct catggtgaca 120
tgctaattgg ttggccggtg cacaagacaa ggaagtgcag gtttctgtt gctcacacag 180
tgcttcctgt ctgctgtggc aggagccggg aggaaggagg cgagccaaga ggggtgctgc 240
ccaccggaaa cgtggcgcg aggccgcaga gctaaatggg ggccctctcca gggagtgtgc 300
tgttcacggc tccatcgctg ttagtaagta tcttgtgatt tcggaattta aatgagggtg 360
tgtttaacct gcataacatc tggcttttaa aatctgactt tattttcctt ttatttctgt 420
gcatcggttc aggcacactt agtggtggtc taggtgttga agtcagggtta ccaaacagca 480
cgccctctct ttattctcag gctgcgtgtt tcattgattc tgaaggtcag atggctgtgt 540
tcaagttctg ttagtatatt ggtgtcagaa atgaaaagat gatgtaacct ttataactt 600
cttaaaggct catatcatgt caggaaatta acctgtacga gttatggaca aatgcccatc 660
ctgatgattt tcanccatga aaatgaatna aagggganaa gggcca 706
```

<210> 265

<211> 717

<212> DNA

<213> Homo sapiens

<400> 265

```
ggcagcagca gcattacggt ttatacacat gtccacaact cagcattgct ttcaaaatag 60
gaacacttta ttagtaaaga ggaagaaatt gcctaaacag actcagtgtc tttcccataa 120
caatcatctg ccaagccgca ggccaaacca ggaaatccca tttccttttg gcgttggtgc 180
ctccaccaac agatacaacc ctgatgccaa atggtgtatg gtttgtaggt gttgtgagcc 240
aatgagggca tgccatgggc caaaggctgc cctttggaat gagggcaagg tcgtagactc 300
catcaaaca ccaatgcatc ctctccaaa atcaaatgct caacacatgc agcctttcgt 360
atgcccatct cccctttact cattttcatg gctgaaaatc atcaggatgg gcatttgtcc 420
ataactccta caggttaatt tcttgacatg atatgagcct ttaagaagtt ataaagggtt 480
acatcatctt ttcatttctg acaccaatat actaacagaa cttgaacaca gccatctgac 540
cttcagaatc aatgaaacac gcagcctgag aataaagaga gggcgtgctg tttggtaacc 600
tgacttcaac acctaaagca ccactaagtg tgccctgagcc gatgcacaga aataaaagga 660
aaataaagtc agatttttaa aagccagatg ttatgcaggg taaacacaac ctcat 717
```

<210> 266

<211> 362

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)...(362)

<223> n=A,T,C or G

<400> 266

```
ggcagcaggt tagatttaac ttccacagat gactcagcag aggataacta ctaatcagag 60
tacaacatca aaactgtaac cagtataatc actggattat gagcaactca aaatagctcc 120
agtttccaaa gggccataaa ctgcacatat cagtactatg tgcaattaac acataattta 180
ttatgaaaat gtggacatgc caggtaagta aggggattta ggttgacttt ttataatact 240
ttaaatttga aatgccattt ctgtggattg gatgacatct tccagggtgt ntaatnctgg 300
```

gntacctnct gatanatcct gananaaaga ggtancacca gcgtctatca nacctcaata 360  
ca 362

<210> 267  
<211> 692  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(692)  
<223> n=A,T,C or G

<400> 267  
ggcacgaggt tagatttaac ttccacagat gactcagcag aggataacta ctaatcagag 60  
tacaacatca aaactgtaac cagtataatc actggattat gagcaactca aaatagctcc 120  
agtttccaaa gggccataac tggccctttt aanacttttn gcaattaaca cataatttat 180  
tatgaaaatg tggacatgcc aggtaagtaa ggggatttag gttgactttt tataatactt 240  
taaatttgaa atgccatttc tgtggattgg atgacatctt ccaggtgctt taatttggtt 300  
tacctcctga tagatcctga cagaaagagg nagcaccagc gtctatcaaa cctcaatata 360  
gngtgtgaaa cacangagag cctgcttttg tcnacacggg gaaacacatt gttatcaca 420  
cacacaaaag gcaanctncc aatggggnan ncttacctgn cctctcatat tgggggcaan 480  
gaaaangggg ccccanatg gctgagtana tccccaaaaa ccnccactan tggtcagnnt 540  
gcttccccan acagccagat gactgaattt agcccaagct gcagtctcaa aaccagcttt 600  
ctgacaatca gtaacaagaa catactgggc tgttcgagtg agctcaagtg ttgggtgttc 660  
agtcaaaaanc catggatgcc aatcatctcc ca 692

<210> 268  
<211> 605  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(605)  
<223> n=A,T,C or G

<400> 268  
cgtgccgaat tcggcacgag ngcacatatc agtactatgt gcaattaaca cataatttat 60  
tatgaaaatg tggacatgcc aggtaagtaa ggggatttan gttgactttt tataatactt 120  
taaatttgaa atgccatttc tgtggattgg atgacatctt ccaggtgctt taatttggtt 180  
tacctcctga tagatcctga cagaaagagg tagcaccagc gtctatcaaa cctcaatata 240  
gttgtaaaac acagagagcc tgcttgccca cacatggaga aacattgtta tcacaagaca 300  
cagaaggcaa acttccaatc tggcatactt nctgtctctc tcatatttgg ggcaatgaga 360  
atgggtggacc agatggcttg antagatgcc aaagaacacc canactgggc agcatgcttn 420  
cccagacagc cngaagactg aaatttantc ccagctgcag ncttaaacc cttttttgac 480  
nttccgtaac cagaccatac tttttttctc gatgcttttc ttaacttcat cttttccaat 540  
taaattcatt agtnnaaccc taaanggggc ccgttttccg aaaaatttcc nttntntntt 600  
cccn 605

<210> 269  
<211> 535  
<212> DNA  
<213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(535)  
 <223> n=A,T,C or G

<400> 269  
 gcacgaggng caaccccagg gtggggtctc tgggatgaac ctggagacct gagcttgcac 60  
 agcttccttg gtaaattgag gaggcattga ccacaagatt gccaaagctcc ttctatcca 120  
 aacttgatat tgtagattc catgatccag ttcattcacg ttgatggctg aatctcatgc 180  
 actanaaaaa ggtaatatata aaganaaaaa tanaangatn ttcaagttag tataaanacc 240  
 tttaatctca ntctttctag ttcaaagaga cggacaacat agagatgctg gttcatanag 300  
 ctgntanatt taacttcac agatgactca ncagaggata actactaatc anagtacaac 360  
 atcaaaactg taaccagtat aatcactgga ttatgagcaa ctcaaatag ctccagtttc 420  
 caaagggccca taaactgccca tatcaantac tatgtgccat taaccataa tttattatga 480  
 aaatgtggac atgccangtn agtaagggga tttagggtga ctttttatna tactt 535

<210> 270  
 <211> 803  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(803)  
 <223> n=A,T,C or G

<400> 270  
 gcacgagggc aaccccaggg tggggtctct gggatgaacc tggagacctg agcttgca 60  
 gcttccttg taaattgagg aggcattggc cacaagattg ccaagctcct ttctatcca 120  
 acttgatatt gtagattcc atgatccagt tcatcacggt tgatggctga atctcatgca 180  
 ctgaaaaaag gtaatatata agaaaaaat aaaaagatat tcaagttagt ataaagacct 240  
 ttaatctcag tctttctagt tcaaagagac ggaacaatga gagatgctgg ttcataagac 300  
 tgtagattt aacttcacac gatgactcag cagaggataa ctactaatca gagtacaaca 360  
 tcaaaactgt aaccagtata atcactggat tatgagcaac tcaaaatagc tccagtttcc 420  
 aaagggccat aaactgcaca tatcagtact atgtgcaatt aacacataat ttattatgaa 480  
 aatgtggaca tgccaggtaa gtaaggggat ttaggttgac tttttataat actttaaatt 540  
 tgaaatgccca tttctgtgga ttggatgaca tcttcagggt gctttaattt gggttacctc 600  
 ctgatagatc ctgacagaaa gaggtagcac cagcgtctat caaacctcaa tacagttgta 660  
 aaacacagag agcctgnttt gcctacncat ggagaacatt gttatcaca gacacagaag 720  
 ggaacttcca tctggctact tacctggctt tatttttggg gcaatganaa tngggggacc 780  
 aatgntgan tanatgccaa aaa 803

<210> 271  
 <211> 836  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(836)  
 <223> n=A,T,C or G

<400> 271  
 gcacgagggc aaccccaggg tggggtctct gggatgaacc tggagacctg agcttgca 60  
 gcttccttg taaattgagg aggcattggc cacaagattg ccaagctcct ttctatcca 120  
 acttgatatt gtagattcc atgatccagt tcatcacggt tgatggctga atctcatgca 180

```

ctagaaaaag gtaatatataa agaaaaaat aaaaagatat tcaagtgagt ataaagacct 240
ttaatctcag tctttctagt tcaaagagac ggaacaatga gagatgctgg ttcataagagc 300
tgtagatttt aacttccaca gatgactcag cagaggataa ctactaatca gagtacaaca 360
tcaaaactgt aaccagtata atcactggat tatgagcaac tcaaaatagc tccagtttcc 420
aaagggccat aaactgcaca tatcagtact atgtgcaatt aacacataat ttattatgaa 480
aatgtggaca tgccaggtaa gtaaggggat ttaggttgac tttttataat actttaaatt 540
tgaaatgccca tttctgtgga ttggatgaca tcttccagggt gctttaattt gggtttacctc 600
ctgatagatc ctgacagaaa gangtagcac cagegtctat caaacctcaa tacagttgta 660
aaacacagag agcctgcttt gnctacacat ggagaaacat tgtatcacia gacacagnaa 720
ggcaacttcc atctgggata ctacctgtct ctctatttgg ggcatganat ggggacaatg 780
ntgananatg caanacacca atgngagctg nttccnacag cnatatgatt ntccat 836

```

&lt;210&gt; 272

&lt;211&gt; 203

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(203)

&lt;223&gt; n=A,T,C or G

&lt;400&gt; 272

```

ggagaattgg gcccgtcang ggtgcattct gcatcacctg antttnaaat ctngagtcaat 60
cnncgtacta atantatcaa catnatttna acctgatctc cactgcttng tnattttcnn 120
ttcactgncc ctntcactng aacntctntt cacacagcca cccccatta tctggntggc 180
acctccncca aatnccnct naa 203

```

&lt;210&gt; 273

&lt;211&gt; 594

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(594)

&lt;223&gt; n=A,T,C or G

&lt;400&gt; 273

```

attcgggccn ctggatnctg gctcgagcgg ccgcccgtgt gatggatata tgcanaattc 60
ggcttctgga gagagctttn tttttgatgg ttgcangtac tctcgatgga gttgggtgggt 120
gtggttatct ctctctggtt gtctttctgt ataaanttct tgcnctgact nctanctcn 180
cctccccctg gtccttcct tagngtaaca nctggtaate cctntcttct ttgctctcct 240
tncttctcct gancgatttc ctctntttgt ccactctcag gnanaaccct gntggtcagt 300
gttcatgact tcnngaagnt cgaccgcna aatagggncn cacggatnat gttgaancng 360
ggaagggagn gtccaanttc tctgttccan aggcctnagcc tagaganaat gatgggagan 420
ggtttactga gatcatngnn tcttctcgaa gatatnnttt aggggtgggcc ccataagng 480
aatttctcan cttcaaatct tctaatacat tactgaacan ctgncatttg ttacgccaca 540
nattgnaatt ctccatntct ttttagaaac nattncaagg tcatttattt ccct 594

```

&lt;210&gt; 274

&lt;211&gt; 229

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

<221> misc\_feature  
 <222> (1)...(229)  
 <223> n=A,T,C or G

<400> 274  
 ctactcactg tccggccatt tggncctctg natgcatnct caagcagcnc gccantatga 60  
 tnnatatctg cacanttcag cttctngaga aaactatggt ttaaacagtt gcntanactt 120  
 anaatanaaa tcgagtaagg tntagatnan tctctaacga tngaattatt ntacanaggg 180  
 gtanncgatn accaggagta nctaganttg ancancancc taggtcnga 229

<210> 275  
 <211> 651  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(651)  
 <223> n=A,T,C or G

<400> 275  
 atatctgntg aatacggntt cctgnaaaaa ggtntnattt agatggttga gtccgactca 60  
 gcgatgcgac ttggtgggtg tggtcantct cttatgggtg agattgttca tgatatcatg 120  
 ccctgagatg cctggactnn cctcaccgga gatcctagac ggtgntancc cctgagagtc 180  
 tctctcntcc tgcctcctca acttctocta atgatccctc cnattgtcta ctgtccnatt 240  
 gaacccttct tgcctatgta tncaatcntt nacggtgtcc ctgctnantt tttganacga 300  
 ngctcataat ggacngggga aggatagtnt gaataatntc ctgtataccc acgccnacnt 360  
 ctacnctntg atctgacacg gtatactgat ttgtgctggt cncttcacca ttccantttc 420  
 taccttccgc tcatatgtc tgtangctac accctctgtg actgctttct cagttacgtg 480  
 caacaaggtn ttcatatctn gaactcttac accattctag anggatcncc cctcgganaa 540  
 antttggaan aacaagcaag ancanaatnc ctctctngtg ntacacnanc cggcttnctg 600  
 atcctcgtn aaggaattcc ccgctttcct gggctttaan tctcctaaac t 651

<210> 276  
 <211> 392  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(392)  
 <223> n=A,T,C or G

<400> 276  
 acccccccg aattacgntg gccnatntaa aagtncatca ngcctccang caacntatcn 60  
 tttcattacc acccacactc ctgttnnggg anggangtgg naatccttca ccatnctaata 120  
 gtatgtggtg ctctcatgcn ggtacgtata atctannctg cccctnaaat cggatgcttc 180  
 tgtaatcnn agtcacnaaa ccacanggan caactgaaac angatttggc taacagccaa 240  
 tgtctggggc ctcncaaatc cctnnaatat ctctacacc tgtagtanna atnaactacn 300  
 ctacnctatt nnacacacgn tttaggttgt annaccaagc cntatttgag tgaaatcggt 360  
 tnatngtat naaatgccaa aagntgcggt aa 392

<210> 277  
 <211> 212  
 <212> DNA  
 <213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(212)  
<223> n=A,T,C or G

<400> 277  
ggtttgccggg natgaanttt gnaanaatna actttagnga taaccacccc accaatncct 60  
nctnagtatt tgncaacctn aaaactacag ctctctccag atagactntn ccttnctgat 120  
ttcaactctc cttggactgg tcagcctgaa ggggtggtaat gactcaccaa cgctactaat 180  
nccttnttna ctgtgccttn attttttcgc ct 212

<210> 278  
<211> 269  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(269)  
<223> n=A,T,C or G

<400> 278  
nnntccatcc taataccact cactatcggg ctcgaaacgg ccgcccgggc acgtntcttn 60  
tgngacagga tctgaatnaa ggggtggttg taacttnact naaaattctg aaatgatcct 120  
gcatcagaca gggttctccg tntanaatan agtttccctg ttagttatcn agcctgggca 180  
ggggangana gattcgagga cntntgaaat gaaggnatta tttaggatgg gtgactcatt 240  
ccnaccnttc ncgctnacca gnccganga 269

<210> 279  
<211> 266  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(266)  
<223> n=A,T,C or G

<400> 279  
gttggtgant cngtttgngg tcttctcgtt gntnggtgtt tgggtgtgtg nnttggtgtn 60  
gggtngtntt tntggagaga gttgtagttc gtgagggttg cagtgtactt actatggagc 120  
ctaaggangt gngctaactt anantgatna ctttgetcat actgccctgc cctnaatgcc 180  
nngcttgect caccctgggtg ccnaaccnna tcgaacacct aacagtctag taggcttctt 240  
gctntancag actnctcttg aggatc 266

<210> 280  
<211> 317  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(317)  
<223> n=A,T,C or G

```

<400> 280
acactgttnag gtgtntggaa ntgntgtagg catagncttt ntggcacaga gttggagccg 60
tgaggcatag cntgtactta ctatggagcc taaggangga gctaaacttat antnatnact 120
ttgctcatac tgccctgctc tnaatgccta ngcttgccct accctgntgc cttacnnnat 180
cgaacaccta cgcggtctat aggccttcttg ctctatcagg actnctcttc nagcttcttc 240
gcctcanttg actcactgtg ctcggtcggt ctactngat ccagncgctc atnaacctna 300
cttnggacgc aggtcat 317

```

```

<210> 281
<211> 174
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (1)...(174)
<223> n=A,T,C or G

```

```

<400> 281
gnggtcatat tatacatcta aggcattggcc aactccacgc cattatnaat tccatcgtag 60
tgtccgcagt cactacttat aacctagatt aatagtgcct ggccccggac ngctctgtgca 120
atctnccgcc ataccaattn cgatccnca accncgatna cactcctcct tact 174

```

```

<210> 282
<211> 169
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (1)...(169)
<223> n=A,T,C or G

```

```

<400> 282
atcgagcgtt gtacgatcgt catataacgc gcatgtgcgg atcgcttcag cgccgccga 60
ctgtcagaag gangagatct tttttatcac ttgtttgttt gactatanat aanancgact 120
acagcattga tgtgtgtcct caaganttgt ctgggtctga naaagctga 169

```

```

<210> 283
<211> 157
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (1)...(157)
<223> n=A,T,C or G

```

```

<400> 283
ggntntctaa gatcgaggtt gtacgatcgt catatnacgc gcatgtgcgn atcgcttcac 60
gtcgccnggc tgtccaggan atgcatntca acataatgtg cactctatat gggtattgat 120
taatacgagn tangagcana tatcngatc aacacaa 157

```

```

<210> 284
<211> 133
<212> DNA

```

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)...(133)

<223> n=A,T,C or G

<400> 284

ggngtggtgt nagatacgca ngctgggacg aatcgnntca tagtacggcg catgtgttga 60  
tcaattctga aaatccatcc cggcgcgctc ancatgcact anagggcaat cgcctatatg 120  
antcgtatta caa 133

<210> 285

<211> 194

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)...(194)

<223> n=A,T,C or G

<400> 285

ntntgngtga tgatacccaa gctggntacc nactngantc caattaccgg ctcantntgc 60  
tngaaaacngc ttgatngnc tcctggcatg tacttgaaac aggntanata tctaatagnn 120  
tacngtgnnn ttttcnatca tacagnttnt atattncact nectnccatt cntttctant 180  
ctctctctcc ntat 194

<210> 286

<211> 134

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)...(134)

<223> n=A,T,C or G

<400> 286

gagggnttat gataccaagc tggtagcanc ccgtcactat nacggcccag tgtgtggatc 60  
cgctanctgg tcncgcgatg tctacncaca cgngaactgc ctctcgcnaa gatctcctct 120  
cctctccnaa gaga 134

<210> 287

<211> 119

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)...(119)

<223> n=A,T,C or G

<400> 287

tngggatatat ccagttgtac actggncata tacgggcatt atgatcgttt cacgcccgga 60  
gtacggcatc attacganat ggnctcattc gtttaccttt ntcgctggac acaagcgtc 119

<210> 288



<211> 170  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(170)  
<223> n=A,T,C or G

<400> 288  
gggntgagat acncaagttg gtacgagtcg gatcatatna cggncgccat tttctggaat 60  
ccgcttacgt ggtcccggcg aagtactttt tcatgccttg caaaatngcg ttactgcact 120  
ancttgctta acctatgagt ggggtctttc atacccttc tntcatggaa 170

<210> 289  
<211> 126  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(126)  
<223> n=A,T,C or G

<400> 289  
ggccaattgg ggcctctana tgcntgctcg aacgggcgcc aatttnatgg atatctccaa 60  
aattcggtt accntggteg cggncnaagt acttaactca atccatctnt cactcaggat 120  
naatgc 126

<210> 290  
<211> 126  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(126)  
<223> n=A,T,C or G

<400> 290  
ggccaattgg ggcctctana tgcntgctcg aacgggcgcc aatttnatgg atatctccaa 60  
aattcggtt accntggteg cggncnaagt acttaactca atccatctnt cactcaggat 120  
naatgc 126

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 June 2001 (07.06.2001)

PCT

(10) International Publication Number  
**WO 01/40269 A3**

(51) International Patent Classification<sup>7</sup>: **C07K 14/47**,  
16/30, A61K 38/00, 39/39, 45/00, G01N 33/53, 33/531,  
33/574

Jennifer, L. [US/US]; 16677 NE 88th Street, Redmond,  
WA 98052 (US). WANG, Aijun [CN/US]; 3106 213th  
Place SE, Issaquah, WA 98029 (US).

(21) International Application Number: PCT/US00/32520

(74) Agents: POTTER, Jane, E., R.; Seed Intellectual Prop-  
erty Law Group PLLC, Suite 6300, 701 Fifth Avenue, Seat-  
tle, WA 98104-7092 et al. (US).

(22) International Filing Date:  
29 November 2000 (29.11.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/451,651 30 November 1999 (30.11.1999) US  
09/510,662 22 February 2000 (22.02.2000) US  
09/523,586 10 March 2000 (10.03.2000) US  
09/545,068 7 April 2000 (07.04.2000) US  
09/571,025 15 May 2000 (15.05.2000) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): CORIXA  
CORPORATION [US/US]; Suite 200, 1124 Columbia  
Street, Seattle, WA 98104 (US).

Published:  
— with international search report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): DILLON, Davin,  
C. [US/US]; 18112 NW Montreux Drive, Issaquah, WA  
98027 (US). DAY, Craig, H. [US/US]; 11501 Stone Ave.  
N., C122, Seattle, WA 98133-8317 (US). JIANG, Yuqiu  
[CN/US]; 5001 South 232nd Street, Kent, WA 98032  
(US). HOUGHTON, Raymond, L. [US/US]; 2636 -  
242nd Place SE, Bothell, WA 98021 (US). MITCHAM,

(88) Date of publication of the international search report:  
13 December 2001

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: COMPOSITIONS AND METHODS FOR THERAPY AND DIAGNOSIS OF BREAST CANCER

(57) Abstract: Compositions and methods for the therapy and diagnosis of cancer, such as breast cancer, are disclosed. Composi-  
tions may comprise one or more breast tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions.  
Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a breast tumor protein, or a T cell  
that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of  
diseases such as breast cancer. Diagnostic methods based on detecting a breast tumor protein, or mRNA encoding such a protein, in  
a sample are also provided.

WO 01/40269 A3

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/32520

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/47 C07K16/30 A61K38/00 A61K39/39 A61K45/00  
 G01N33/53 G01N33/531 G01N33/574

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 33869 A (CORIXA CORP) 8 July 1999 (1999-07-08) Example 2 in connection with pages 15 to 17	35,36
Y	Example 1	1-34, 37-59
X	WO 99 37775 A (GENQUEST INC) 29 July 1999 (1999-07-29) See the whole document, in connection with page 21 -page 28	35,36
Y	Page 5 et sequentia	1-34, 37-59
Y	WO 97 25431 A (CORIXA CORP) 17 July 1997 (1997-07-17) the whole document	1-59
	-/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

20 April 2001

Date of mailing of the international search report

09.07.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Bretherick, J

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 00/32520

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>DIATCHENKO L ET AL: "SUPPRESSION SUBSTRUCTIVE HYBRIDIZATION: A METHOD FOR GENERATING DIFFERENTIALLY REGULATED OR TISSUE-SPECIFIC CDNA PROBES AND LIBRARIES" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 93, 1 June 1996 (1996-06-01), pages 6025-6030, XP002911922 ISSN: 0027-8424 Abstract, discussion, page 1520 et sequentia</p>	1-12, 57-59
Y	<p>LEE S W ET AL: "POSITIVE SELECTION OF CANDIDATE TUMOR-SUPPRESSOR GENES BY SUBSTRUCTIVE HYBRIDIZATION" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 88, 1 April 1991 (1991-04-01), pages 2825-2829, XP002048608 ISSN: 0027-8424 Abstract page 2826, column 2, paragraph 6 -page 2828, column 1, paragraph 1</p>	1-59
Y	<p>BURGER A ET AL: "BREAST CANCER GENOME ANATOMY: CORRELATION OF MORPHOLOGICAL CHANGES IN BREAST CARCINOMAS WITH EXPRESSION OF THE NOVEL GENE PRODUCT DI12" ONCOGENE,GB,BASINGSTOKE, HANTS, vol. 16, 22 January 1998 (1998-01-22), pages 327-333, XP002914258 ISSN: 0950-9232 the whole document</p>	1-59
Y	<p>SCHLOM J ET AL: "STRATEGIES FOR THE DEVELOPMENT OF RECOMBINANT VACCINES FOR THE IMMUNOTHERAPY OF BREAST CANCER" BREAST CANCER RESEARCH AND TREATMENT,US,NIJHOFF, BOSTON, vol. 38, no. 1, 1996, pages 27-39, XP000578043 ISSN: 0167-6806 the whole document</p>	1-59
Y	<p>WO 99 14230 A (FLEMING TIMOTHY P ;WATSON MARK A (US); UNIV WASHINGTON (US)) 25 March 1999 (1999-03-25) the whole document</p>	1-59

# INTERNATIONAL SEARCH REPORT

national application No.  
PCT/US 00/32520

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 20, 21, 28-30, 33, 34, 36-38 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-59 (party)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-59 (partly)

Invention 1.

Isolated polypeptide comprising at least an immunogenic portion of a breast tumour protein, variants thereof such that the ability of variant to react with antigen-specific antisera is not substantially diminished, wherein the tumour protein comprises an amino acid sequence that is encoded by polynucleotide sequence SEQ. ID. NO: 2. or its complement; isolated encoding polynucleotide, expression vector, host cell transformed therewith; antibody specifically binding thereto; fusion proteins; pharmaceutical compositions and vaccines; therapeutic methods and methods of inhibiting growth/development of and removing tumour cells from a biological sample; methods of stimulating and/or expanding T cells specific; T cell populations prepared according to method; use thereof in therapy; diagnostic methods, Kits; oligonucleotides comprising 10-40 contiguous nucleotides that hybridise to SEQ ID NO: 2, kits containing same.

2. Claims: 1-59 (partly)

Inventions 2-284

As above, but respectfully referring to sequences 1,3-38, 42-204,205,207,210-290.

Note that sequences

1,6,8,9,11,12,14,17-20,22-24,26,27,29,31,32,34,36,37,38,42-62,64-71,74-80,82-102,105,106,110-117,119-127,130-133,135,137-158,162,163,165-180,182,205-207 are only mentioned in claims 24-52 per se.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.2

Present claims 1(b),57..... relate to an oligonucleotide comprising 10 to 40 contiguous nucleotides that hybridise under moderately stringent conditions to a polynucleotide (SEQ ID NO:2)

The claims cover all oligonucleotides having this property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of same. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the oligonucleotide by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the SEQ ID NO:2 per se.

Present claims 1,3..... relate to a variant encoded by SEQ ID NO 2 defined by reference to a desirable characteristic or property, namely "variants of said isolated polypeptide, the ability of the variant to react with antigen-specific antisera not being substantially diminished"

The claims cover all variants having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such products. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the variants by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the SEQ ID NO: 2 per se, mentioned in the exemplification, sequence listing and claims. The claim set has been searched with this in mind.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/32520

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9933869 A	08-07-1999	AU 2010699 A EP 1042360 A ZA 9811800 A	19-07-1999 11-10-2000 23-06-1999
WO 9937775 A	29-07-1999	AU 2342299 A	09-08-1999
WO 9725431 A	17-07-1997	AU 1575697 A	01-08-1997
WO 9914230 A	25-03-1999	US 5922836 A AU 9373798 A BR 9812472 A CN 1277614 T EP 1037901 A HU 0004022 A NO 20001358 A PL 340689 A TR 200001646 T	13-07-1999 05-04-1999 19-09-2000 20-12-2000 27-09-2000 28-03-2001 12-05-2000 26-02-2001 23-10-2000